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Abstract 
The processes of proliferation, differentiation, and apoptosis are tightly 
regulated during haemopoiesis with aberrations resulting in the uncontrolled clonal 
growth of non-functional haemopoietic cells, a disease state known as leukaemia. 
Approaches that target cellular growth and differentiation pathways to alter the 
proliferative potential of leukaemia cells while limiting cytotoxicity to healthy cells 
have recently undergone a revival in clinical interest. Known as differentiation 
therapy, the immature cancer cells undergo terminal differentiation culminating in the 
ultimate removal of these cells by apoptosis. 
The sphingomyelin signalling pathway, and its second messenger ceramide, 
has emerged as an important regulator of cellular growth, differentiation and 
apoptosis. Whilst numerous studies have addressed the apoptogenic properties of 
ceramide signalling, very few have investigated the mechanisms underlying ceramide 
mediated terminal differentiation. 
The aim of this study was to investigate the potential for the ceramide 
signalling pathway to be utilised in differentiation therapy for the treatment of human 
leukaemia. 
A range of haemopoietic cell lines were treated with the synthetic ceramide 
analogue, C2-ceramide. Growth inhibition, cell cycle arrest, activation of the 
retinoblastoma (Rb) tumour suppressor protein, expression of the cyclin-dependent 
kinase inhibitor p21 aP I/Waf1  and apoptosis were shown to be common outcomes of 
ceramide treatment. Myeloid cells exposed to ceramide differentiated into a mature 
phenotype. Taken together, these results show that ceramide is inducing terminal 
differentiation in the treated cell lines. 
Phosphatases have a well characterised function in Rb activation and their 
potential as an effector mechanism for ceramide-induced Rb activation and 
differentiation was examined. Inhibitor studies revealed that ceramide-mediated Rb 
activation resulted from protein phosphatase activity, and that the contribution of 
p2 Cip 1/Waft was not significant, at least in the early phases of cell cycle arrest. 
Interestingly, inhibition of protein phosphatase activity did not impact on the ability 
of ceramide signalling to induce myeloid cell differentiation. This lead to the 
conclusion that Rb activation and ceramide-induced differentiation occur by two 
independent pathways. 
Gene expression profiling using a cDNA filter array was performed to 
elucidate the involvement of genetic mechanisms involved in the ceramide response. 
1 
Genes that prevent progression through the cell cycle and genes involved in 
differentiation were upregulated whereas the expression of proliferation-related genes 
were downregulated. These findings are consistent with the hypothesis that ceramide 
reduces the proliferative potential of leukaemic cells by inducing terminal 
differentiation. 
This thesis presents a comprehensive study into the biological effects of the 
ceramide signalling pathway, and has in part defined the molecular mechanisms 
responsible for ceramide-induced growth arrest and differentiation. Ceramide was 
shown to mediate the terminal differentiation of leukaemia cells into mature, non-
dividing cells that die by apoptosis. Manipulation of the ceramide-signalling pathway 
may present a novel therapeutic target for the treatment of diseases that lack control 
of growth and differentiation processes. 
Y". 
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Chapter 1: Literature Review 
Haemopoiesis 
The circulatory system contains a variety of mature blood cells, each with a 
unique set of specialised properties and functions. However, mature blood cells are 
destined to live for only a short period of time, ranging from hours (granulocytes) to 
weeks (erythrocytes) before being destroyed (Testa & Dexter, 1999). To account for 
this steady-state loss of haemopoietic cells, a new cell must be produced to replace 
every cell that dies. This process, by which the cellular elements of the blood are 
produced in order to maintain a homeostatic system, is defined as haemopoiesis. 
Haemopoiesis not only provides new blood cells throughout adult life, but also 
provides a remarkable degree of cell specialisation, ultimately originating from a 
relatively small pool of pluripotent progenitor cells. 
Within the bone marrow (the main haemopoietic organ post-birth), various 
types of blood cells in different stages of development can be identified. These 
include very primitive cells that act as the precursors for the various mature cell 
lineages. Each of these precursor cells are originally derived from a common cell, 
termed the pluripotent haemopoietic stem cell (HSC). Currently, stem cells are 
broadly defined as any cell capable of reproducing itself, and also possess the ability 
to differentiate along one or more pathways (Metcalf, 2001, Schwarzenberger et al., 
2002). As stem cells differentiate into more mature cells, the self-replicating abilities 
and differentiation options are increasingly exchanged for functional capacity (Boggs 
& Boggs, 1984). The exact definition of a true stem cell is still debatable. The status 
of current research involving haemopoietic stem cells and future implications of this 
work has been reviewed in detail by Chu & Gage (2001), Lazner et al. (2001), 
Lovell-Badge (2001), Metcalf (2001) and Scwarzenberger et al. (2002). Figure 1.1. 
presents a schematic model of haemopoiesis, illustrating the cell hierarchy from the 
most primitive precursor cells leading to the trilineage production of the formed 
elements of the blood (erythroid, myeloid, lymphoid). This seemingly complex 
system is in fact highly simplified in this diagram. 
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Figure 1.1.: Representation of the cell hierarchy in the process of haemopoiesis (adapted from Eaves, 
1996 and Testa & Dexter, 1999). The progenitor cells [colony-forming units (CFU) and burst-forming 
units (BFU)] are defined by the following prefixes: E = erythroid; Meg = megakaryocyte; Eo = 
eosinophil; G = neutrophilic granulocyte; M = macrophage/monocyte; Ba = basophil. Cells which 
form colonies containing cells from three or more cell lineages are denoted CFU-GEMM (colony-
forming units - granulocyte, erythroid, megakaryocyte, and macrophage). HSC = haemopoietic stem 
cells, CFU-S = colony-forming units - spleen. 
As shown in Figure 1.1., the different levels of the haemopoietic hierarchy 
have been historically defined by functional growth characteristics in specific ex vivo 
culture assays, not by morphologic or cell surface marker characteristics. 
Furthermore, distinct subsets of haemopoietic precursor cells have been defined by 
their ability to form specific types of colonies (single lineage versus multilineage) 
and their ability to give rise to further colonies if serially replated (Pluznik & Sachs, 
1965, Bradley & Metcalf, 1966, Senn et al., 1967). The most mature precursor cell 
subset are those that exhibit lineage restricted colony growth (single lineage) and 
essentially have no self-renewal capacity and a very limited secondary plating 
efficiency (e.g. CFU-G, CFU-M, CFU-Meg, and, CFU-E). The more immature 
precursor cell subset includes CFU-GM, which have more capacity for differentiation 
(multilineage colony growth) into neutrophilic granulocytes or macrophages 
(Metcalf, 1977, Till, 1980). An even more primitive level of progenitor cell has the 
4 
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potential to give rise to several lineages. An example of such a myeloid progenitor is 
the CFU-GEMM which can differentiate into colonies composed of granulocytic, 
erythrocytic, megakaryocytic, and macrophage lineages (Fauser & Messner, 1979). 
CFU-S cells form a population of even more primitive progenitor cells and were the 
first described candidate stem cell. They were originally shown to be able to generate 
visible colonies in the spleen of mice (Till & McCulloch, 1961), which can only 
produce one lineage of cells and do not undergo self-renewal (Magli et al., 1982) as 
originally proposed (Siminovitch et al., 1963). Pluripotent haemopoietic stem cells 
comprise the most primitive level of the progenitor cells and are characteristically 
positive for the cell surface cell marker CD34. The most mature of the blood cells are 
those that have entered terminal differentiation, that is, they are irreversibly blocked 
in their ability to proliferate, although they may perform their specialised function for 
a period of time prior to their eventual destruction. Inhibiting haemopoietic 
differentiation (i.e. preventing the passage of cells from an immature to mature state) 
permits an accumulation of immature cells, seen in diseases such as leukaemia and 
lymphoma, which leads to a dramatic disruption of many physiological processes. 
A moderate alteration in the haemopoietic process can be life threatening, 
which demonstrates that haemopoiesis must be a tightly regulated physiological 
function that allows the appropriate number and types of blood cells to be produced 
at any one time. An understanding of the regulatory mechanisms that control the 
production of new blood cells has progressed dramatically within the past two 
decades. Diseases such as leukaemia and lymphoma are results of a dramatically 
disrupted haemopoietic process, leading to clonal overproduction of immature cells 
that are unable to carry out their normal role. Ironically, inhibition of haemopoiesis 
represents the most common serious toxicity associated with conventional cytotoxic 
cancer therapies. Clearly, a better understanding of the haemopoietic system would 
prove beneficial to improving the therapeutic index of cancer treatments and 
regaining control of abnormal blood cell populations (Demetri, 1997). By preventing 
the occurrence of alterations to haemopoiesis, it is possible that haematological 
neoplastic diseases could be effectively treated, if not prevented. 
The complex and essential process of haemopoiesis has captured the interest 
of clinicians and scientific researchers for many years. An ability to manipulate the 
haemopoietic system has potential for the treatment of diseases arising from 
alterations that affect haemopoiesis and have already been achieved for conditions of 
insufficient haemopoiesis. The cytokine erythropoietin (EPO) is licensed for use as a 
physiological regulator of erythropoiesis for the treatment of anaemia (Kojima, 
5 
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1996). Granulocyte/macrophage colony-stimulating factor (GM-CSF) and 
granulocyte colony-stimulating factor (G-CSF) are cytokines that influence the 
production of neutrophils while mobilising peripheral blood stem cells, and are used 
in the treatment of chronic neutropaenia following myeloblative chemotherapy (Jones 
& Millar, 1989, Steward & Scarffe, 1989, Dempke et al., 2000). Consequently, a 
more complete understanding of the exact mechanisms involved in blood cell 
proliferation, differentiation, and subsequent death, will provide strategies for 
reversing excessive haemopoiesis, which will inevitably prove beneficial for 
potential cancer therapies. 
6 
Chapter 1: Literature Review 
1.1. Human Leukaemia 
1.1.1. General Information 
Leukaemia is a neoplastic proliferation of cells of haemopoietic origin which 
arises following somatic mutation in a single haemopoietic stem cell, the progeny of 
which form a clone of leukaemic cells (Bain, 1999). The term leukaemia, meaning 
white blood, was introduced in the 19 th  century by Rudolf Virchow (Virchow, 1845) 
because of the enormous accumulation of white blood cells found in a patient with 
far-advanced chronic myeloid leukaemia and originally reported by Velpeau in 1827. 
Similar cases were soon reported by Craigie (1845) and Barth (1856). The 
subsequent disordered differentiation and proliferation of these neoplastic cells leads 
to their accumulation, thus suppressing the differentiation and proliferation of normal 
haemopoietic cells. Leukaemia leads to disturbances principally in marrow, blood, 
and spleen (Lichtman, 1990). Accumulation in the marrow results in the diminished 
production of normal erythrocytes, granulocytes, and platelets, leading to 
manifestations of the disease including weakness, fatigue, and pallor as a result of 
anaemia; infection arising from granulocytopenia; and haemorrhage as a result of 
thrombocytopenia (Henderson, 1990). Although less common, other manifestations 
of the disease are produced by infiltration of leukaemic cells into sites other than the 
marrow, principally leading to disturbances in the lungs (Green & Nichols, 1959), 
heart (Roberts et al., 1968), bone (Thomas et al., 1961), gastrointestinal tract 
(Steinberg et al., 1973), kidney (Uno, 1967), skin (Gunz & Baike, 1974), central 
nervous system (Davies-Jones et al., 1980), or virtually any other organ. 
1.1.2. Classification and Diagnosis of Human Leukaemia 
The human leukaemias have been historically divided into two categories, 
determined clinically by the observed duration of patient survival; 1) acute 
leukaemia, which generally comprises populations of immature proliferating cells 
and if untreated usually causes death in weeks or months, and 2) chronic leukaemia, 
which consists of more mature cells and if untreated causes death in months to years 
(Goasguen et al., 1996, Bain, 1999). They are further divided into lymphoid, myeloid 
and biphenotypic (both lymphoid and myeloid) leukaemias. This broad classification 
system has remained in use to the present day, however elaborate methods of sub-
classification of the human leukaemias have been introduced, in turn improving the 
management of this disease. 
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Leukaemias are a heterogenous group of diseases that vary in aetiology, 
pathogenesis and prognosis. The need for identification of leukaemic sub-classes is 
important for three reasons: 1) some leukaemias have clinical features that influence 
therapeutic approaches; 2) response rates and survival differ, so that classification is 
necessary for estimating prognosis [for example, curative therapy is well established 
for acute leukaemias (Gillis & Goa, 1995, DeLoughery & Goodnight, 1996), but 
remains elusive for chronic leukaemias]; and 3) classification facilitates 
communication and cooperation throughout the world. 
One system, a morphological classification first proposed by the French-
American-British (FAB) Cooperative Group in 1976, has stood the test of time and 
remains in use throughout the world in the present day. The FAB classification 
system was first applied to the acute leukaemias (Bennett et al., 1976), and was 
subsequently applied to the pre-leukaemic syndromes (Bennett et al., 1982) and 
chronic leukaemias (Bennett et al., 1989) and has been under continual revision as 
knowledge has developed (Nielsen et al., 1984, Bennett et al., 1985, LiHeyman et al., 
1986, van Eys et al., 1986, Zafar, 1992, Laurencet et al., 1994, Wong & Chan, 1995, 
Budde, 1996). The features that are taken into account in the FAB system include the 
degree of maturation of the abnormal proliferating cells and the lineage involved. 
The presence of membrane and cytoplasmic antigens or enzymes by cytochemical, 
immunologic, cytogenetic, and molecular genetic methods provide supplementary 
information allowing a more precise classification in this system. 
Rapid advances in monoclonal antibody production, cytogenetic and 
molecular biology techniques soon lead to the derivation of a number of new 
leukaemia and lymphoma classification systems throughout the world with a great 
deal of controversy, including the Kiel classification (Lennert, 1981, Stansfeld et al., 
1988, Lennert & Feller, 1992), the Lukes-Collins classification (Lukes & Collins, 
1974, 1975 & 1977), and the Working Formulation (Non-Hodgkin's Lymphoma NCI 
Working Formulation, 1982). 
The International Lymphoma Study Group, comprising of 19 expert 
haemopathologists, proposed a new classification system in 1993 in Berlin, Germany 
(published in 1994) known as the Revised European-American Classification of 
Lymphoid Neoplasms (REAL), in an attempt to arrive at a consensus regarding the 
categories of lymphoid neoplasia that were readily recognisable at that time, based on 
morphological, immunological and genetic techniques, and also provides features of 
lymphoma diagnosis not catered for in previous classification schemes (Harris et al., 
1994). The REAL classification has since proven to be the desired system of 
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lymphoma classification and is used worldwide. Since 1995, minor modifications 
were made to the REAL system, thus deriving a new system using principles of the 
REAL system named the World Health Organisation classification (Society for 
Hematopathology Program, 1997, Jaffe et al., 1998 & 1999, Harris et al., 2000a, 
2000b & 2000c). 
The following section presents the various human leukaemias, and for the 
purpose of this thesis are grouped in accordance with the classification system 
proposed by the FAB Cooperative Group (Bain, 1999). As the content of this thesis 
deals with chronic and acute leukaemias, the myelodysplastic syndromes and 
lymphomas will not be discussed in detail. 
A) Acute Leukaemia 
Acute Myeloid Leukaemia (AML) 
Having correctly diagnosed an acute disease from chronic disease and 
established myeloid involvement, AML can be further classified based on two 
features: cell attributes that identify the specific myeloid lineage, and the presence of 
more than 30% blast cells among all nucleated cells in peripheral blood and bone 
marrow differential counts (Goasguen et al., 1996). These can be supplemented with 
cytochemical analyses and lysozyme levels. The acute myeloid leukaemias are 
broadly divided into 8 subtypes according to the FAB system (summarised in Table 
1.1.): The first four types (MO, Ml, M2, and M3 and M3var) correspond to a 
predominant granulocytic proliferation; one (M5) is of a monocytic lineage only; M4 
represents a mixture of granulocytic and monocytic lineages; M6 and M7 
corresponds to dysplastic erythroid and megakaryocytic proliferation respectively. 
Rare cases in which granulocytic maturation cannot be demonstrated by standard 
methods, and its myeloid nature is only revealed by exclusive expression of myeloid 
antigens are now designated AML MO, and is the most recent to be added (Bennett et 
al., 1991). Interestingly, certain clinical, haematological, and prognostic features 
correlate with the AML FAB classes. For example, patients with the MO subtype 
have a poorer than average response to combination remission induction therapy (Lee 
et al., 1987, Goasguen et al., 1996), and patients with M3 AML are younger than 
average, usually have disseminated intravascular coagulation (DIC) (Velisco et al., 
1992, Randolf, 2000) and often have a relatively low white cell count. The FAB 
category with the best prognosis is M2, followed in order by M4, Ml, M3 (and 
M3var), M5, and M6 (Bloomfield etal., 1984). 
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Table 1.1.: Classification of the Acute Myeloid Leukaemias according to the FAB classification 
system proposed by the French-American-British (FAB) Cooperative Group in 1976 (Bennett et al., 
1976), and still applying today (taken from Bain, 1999). 
Cell Clone Abbrv. 
Name 
FAB 
Subtype 
Common Terms 
Myelogenous AML MO Myeloblastic w/o cytologic maturation 
M1 Myeloblastic with minimal maturation  
Myeloblastic with significant maturation  
Acute promyelocytic leukaemia (usual form) 
M2 
APL M3 
M3 variant APL unusual hypogranular form 
Myelogenous 
and monocytic 
AMML M4 Acute myelomonocytic leukaemia 
M4eo M4 with eosinophilic maturation 
M4baso M4 with basophilic maturation 
Monocytic AMoL M5a Acute monoblastic leukaemia (poorly differentiated) 
M5b Acute monocytic leukaemia 
Erythroid AEL M6 Acute erythroid leukaemia 
Megakaryoblastic M7 Acute megakaryoblastic leukaemia 
Despite extensive morphological characterisation of these subtypes, there 
remains only one cytochemical marker in AML, the Auer rod, which demonstrates 
that a blast cell is definitely myeloid and of leukaemic origin (Auer, 1906, Jain et al., 
1987). Auer rods have been shown to be abnormal azurophilic crystalline-like 
granules that result from the concentration primary peroxidase containing lysosomal 
granules of myeloid precursors (Ackerman, 1950, Bainton et al., 1977). These 
structures are demonstrable by Wright-Giemsa staining or with the use of a 
cytochemical detection technique using benzidine base or 3, 3'-diaminobenzidine 
(Goasguen et al., 1996). 
In addition to the distinctive clinical and morphological features of M3 and its 
variant (M3var), acute promyelocytic leukaemia (APL) can be characterised by a 
t(15;17)(q22;q12) translocation (Larson et al., 1984) which fuses portions of the 
PML gene on chromosome 15 to the retinoic acid receptor alpha (RARa) gene on 
chromosome 17 (Borrow et al., 1990, de The et al., 1990, Alcalay et al., 1991, de 
The et al., 1991, Kakizuka et al., 1991, Chang et al., 1992a & 1992b, Goddard et al., 
1992, Grignani et al., 1993). This specific translocation is present in nearly 100 
percent of APL cases (Van Den Berghe et al., 1979, Sheer et al., 1985, Dong et al., 
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1993), making it a novel target for molecular diagnosis and treatment. Although the 
PML-RARoc comprises the most diagnostically significant translocation, other 
cytogenetic aberrations have also been reported in AML cases (Le Beau et al., 1983, 
Heim et al., 1987, Mitelman, 1991, Soekarman et al., 1992). 
Acute Lymphoblastic Leukaemia (ALL) 
ALL is the most common malignancy in children (Brincker, 1982). It was one 
of the first malignancies to respond to chemotherapy (Farber et al., 1948) and was 
later among the first that could be cured in a majority of cases (George et al., 1979). 
ALL is currently curable in 60-70% of children and 20-35% of adults (Cortes & 
Kantarjian, 1995). Patients with ALL have lymphadenopathy in up to 80% of cases 
and hepatomegaly and/or splenomegaly in up to 75% of cases (Henderson, 1990). 
Other organs have also been shown to be involved including the kidney (Henderson, 
1990), lungs (Corbaton et al., 1984), heart (Mancuso et al., 1985), and eyes (Ninane 
et al., 1980). Diagnosis of ALL is made from a combination of morphological 
features and with the use of immunophenotyping. The cell surface marker CD10, 
initially known as the common ALL antigen (cALLA), was identified as one of the 
earliest markers expressed by leukemic cells of the lymphoblastic lineage, and 
remains a useful subclassification tool for B-lineage leukemias (Bene & Faure, 
1997). Cases of ALL can be categorised into three FAB subgroups (summarised in 
Table 1.2.): Childhood type ALL (L1), adult type ALL (L2), and Burkitt-like ALL 
(L3). Recognition of cases of L3 is regarded as generally straightforward, however 
the distinction of a case of Li or L2 is considered more difficult (Bain, 1999). 
Distinction between the ALL subtypes is made by morphological considerations 
including cell size, nucleocytoplasmic ratio, and nuclear shape. ALL of L3 subtype 
has a prognosis worse than that of the other ALL subtypes, although it is rapidly 
improving with the introduction of modern treatment protocols (Bain, 1990). 
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Table 1.2.: Morphological characteristics of the ALL subtypes according to the FAB classification 
system (adapted from Bain, 1999). 
Feature Li L2 L3 
Cell size Small, homogenous  
Regular  
Not visible or small 
Large, heterogeneous  
Heterogenous  
Usually visible, large  
Variable, often abundant  
Variable 
Large, homogenous  
Regular  
Usually noticeable  
Moderately abundant  
Strong 
Nuclear shape 
Nucleolus 
Cytoplasm Scanty  
Slight to moderate Cytoplasmic 
basophilia 
Cytoplasmic 
vacuoles 
Variable Variable Often prominent 
B) Chronic Leukaemia 
Chronic Myeloid Leukaemia (CML) 
The FAB group have not yet proposed a classification for CML. CML cells 
display more mitotic divisions than normal in the maturing compartment, and the life 
span of CML cells is longer than normal, and thus these cells have been described as 
having an inability to die (Goasguen et al., 1991). These two factors combined, result 
in a characteristic malignant proliferation in the bone marrow of cells of the 
granulocytic and megakaryocytic series (Strife & Clarkson, 1988). The four 
recognised forms of CML are chronic granulocytic leukaemia (CGL), atypical CML, 
chronic neutrophilic leukaemia, and juvenile CML. 
CML usually has a biphasic, and sometimes triphasic course. The initial phase 
is a benign chronic phase, in which the disease is frequently asymptomatic. Patients 
with symptoms usually have a gradual onset of fatigue, weight loss, increased 
sweating, and early satiety due to splenic enlargement (Bain, 1990, Cortes et al., 
1996). The disease may then progress through a transitional phase called the 
accelerated phase (Kantarjian et al., 1988 & 1990a) in which some patients develop 
fever and night sweats, and progressive enlargement of the spleen. However at least 
20% of patients progress directly to an acute blastic phase without evidence of an 
accelerated phase (Kantarjian et al., 1993, Goasguen et al., 1996). It is in this phase 
that patients are most likely to have symptoms including those described above, and 
generally also includes bone pains (Hughes & Goldman, 1991). Symptoms of 
anaemia, infectious complications, and bleeding are also commonly seen in the 
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blastic phase (Cortes et al., 1996), and signs of CNS leukaemia can be identified 
(Hughes & Goldman, 1991). 
The most distinguishing feature of CML is the Philadelphia (Ph) chromosome 
(Nowell & Hungerford, 1966, Rowley, 1973), t(9;22)(q34;q11), a shortened 
chromosome resulting from a chromosomal translocation consequently generating 
the fusion gene known as bcr-abl, that is, a relocation of the abl proto-oncogene 
(which codes for a tyrosine kinase domain) adjacent to the bcr gene (Melo, 1996). 
This juxtaposition greatly enhances the kinase activity of ABL (Goldman, 2000). The 
resultant protein BCR-ABL, denoted p210, perturbs stem cell function, resulting in 
the chronic phase of CML (Goldman, 1997), transforming the ABL tyrosine kinase 
into a constitutively expressed kinase. The Ph chromosome can be found in 95% of 
typical CGL cases (Bain, 1999). However in approximately 5% of CGL cases in 
which patients display otherwise typical clinical features of CML, the Ph 
chromosome is absent (Kantarjian et al., 1990b). Ph-negative CGL must be 
distinguished from atypical CML which are also frequently Ph-negative. 
Chronic neutrophilic leukaemia is a rare form of CML and is predominantly 
confined to the elderly. It is characterised by a considerable increase in the neutrophil 
count, with few granulocyte precursors in the peripheral blood, anaemia, 
splenomegaly and sometimes hepatomegaly (Bain, 1990). This disease is also Ph-
negative, and blastic transformation is uncommon. 
Juvenile CML is a disease that mainly affects children less than five years of 
age, and is associated with a reversion to some characteristics of foetal erythropoiesis 
(Castro-Malaspina et al., 1984). It is generally readily distinguishable from CGL, 
which is very rare in children. The concentration of haemoglobin F has been 
proposed as a useful marker in diagnosing juvenile CML (Bain, 1999). 
Chronic Leukaemias of Lymphoid Lineage 
A classification system for chronic T and B lymphoid leukaemias was first 
proposed by the FAB group in 1989 (Bennett et al., 1989). Under this proposal, 
chronic lymphoid leukaemia is separated into B lineage and T lineage leukaemias, 
and subsequent classification is based on clinical features, cell morphology, 
membrane markers and histology. The introduction of immunological methods and 
flow cytometry for detecting membrane antigens has permitted accurate distinction 
between true chronic lymphoid leukaemia (B-CLL: CD5+, CD20+, ic/X+) and the 
appearance of abnormal circulating lymphocytes found in non-Hodgkin's lymphoma 
cases (CD5-, CD20+), and has enabled the distinction of the abnormal T or B-cell 
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subpopulations involved in the disease. In addition, cytogenetic techniques have 
revealed an association between some B-CLL subtypes and particular chromosome 
translocations, thus even further clarifying these subclassifications (Goasguen et al., 
1996). The translocation t(14;18), common to most follicular lymphomas which 
juxtaposes the IgH gene to the 3' region of bc1-2 (deregulating bc1-2), has been 
reported to occur in a significant fraction (approximately of 10%) of B-CLL and is 
proposed to function in leukemogenesis (Adachi & Tsujimoto, 1989, Adachi et al., 
1990). 
The chronic B-cell leukaemias include B-cell chronic lymphocytic leukaemia 
(B-CLL), B-cell prolymphocytic leukaemia (B-PLL), hairy cell leukaemia (HCL) and 
plasma cell leukaemia. CLL is the most common of these and is typically a disease of 
the elderly, characterised by lymphadenopathy, hepatomegaly and splenomegaly, and 
eventual impairment of bone marrow function (Bain, 1990). A demonstration of a 
monoclonal population of B-cells with characteristic markers allows early diagnosis 
of the disease. B-CLL cells are typically small with more uniform morphology 
compared with normal peripheral blood lymphocytes (Bennett et al., 1989). Nuclear 
chromatin is often highly condensed in course blocks, and the leukaemic cells are 
more fragile than their normal counterparts, therefore the formation of smear cells 
during blood film preparation can be helpful in diagnosis (Bain, 1999). Another form 
of CLL, CLL with mixed cell types (Bennett et al., 1989), appears as typical B-CLL 
but with an increase in prolymphocytes (designated CLL/PL) (Enno et al., 1979), or 
an increase in a spectrum of cells from small to large lymphocytes. PLL is diagnosed 
on the basis of a high white cell count, and the presence of more than 55% PLL cells 
(easily demonstrated due to high surface Ig density surrounding these cells) (Galton 
et al., 1974). Patients with PLL generally have a shorter survival than that of patients 
with either CLL or CLL/PL (Goasguen etal., 1996). 
Hairy-cell leukaemia (HCL), a rare B-cell disorder affecting males 4-5 times 
more frequently than females (Golomb et al., 1983), involves cells with distinctive 
morphological features. They are generally of medium size with an abundant, lightly 
basophilic cytoplasm of 'fluffy' appearance, and 'hairy' cytoplasmic projections 
extending from an irregular cytoplasmic border (Kroft etal., 1995). Hairy-cell variant 
(HCV), also a very rare malignancy, is characterised by cells with morphological 
features intermediate between hairy-cells and prolymphocytes (Bennett et al., 1989). 
In contrast to HCL, HCV patients present with a high white cell count and lack 
monocytopenia (characteristic of HCL). 
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Chronic leukaemias of the T-cell lineage are uncommon. Abnormal 
proliferations of mature T-cells are easily identified by immunophenotyping and 
specific morphology. T-cell morphology can be variable, and may include large 
granular lymphocytes with an abundant cytoplasm containing azurophilic granules 
(as in T-CLL), or typical prolymphocytes (found in T-PLL). Twenty percent of PLL 
cases are reported to be of the T lineage (Catovsky et al., 1974). Adult T-cell 
leukaemia/lymphoma (ATLL) is a chronic T-cell disease, first reported in Japanese 
adults (Uchiyama et al., 1977), and is the only human leukaemia to have been linked 
to infection with the human retrovirus HTLV (Blattner et al., 1982, Bain, 1990). 
1.1.3. Diagnosis of Human Leukaemia 
Diagnosis of human leukaemia has previously been based on cell morphology 
and cytochemical staining to provide rapid identification of the involved lineage 
(Bennett et al., 1976, Shibata et al., 1985). These include the detection of 
myeloperoxidase and naphthol ASD chloroacetate esterase to demonstrate myeloid 
involvement and to provide prognostic evaluation significance (Bennett & Begg, 
1981, Matsuo et al., 1989), and the Sudan black B and Periodic Acid-Schiff 
reactions. However, these techniques have been superseded by immunophenotyping 
and molecular biology procedures. 
Current immunophenotyping protocols require the preparation of a viable cell 
suspension by red cell lysis (AFCG, 1997) and subsequent analysis using monoclonal 
antibodies directed against cluster of differentiation (CD) antigens found on the cell 
surface, or intracellular enzymes (MPO and TdT), using flow cytometry. Major 
progress made in the last decade in flow cytometry and the computer technology used 
to acquire and process the data, has allowed for simultaneous detection of four or 
more fluorochromes which include FITC, PE, PerCP and PE-Cy5. Flow cytometry 
allows the enumeration of leukocyte subsets within the peripheral blood, lymph node 
and bone marrow aspirate cell populations and is now considered an essential 
technique in the diagnosis of leukaemias and lymphomas (Macey, 1993). Distinction 
of cells is based primarily on their forward and 90° light-scattering properties, and 
subsequently the binding (depending on the cell type) of fluorochrome-labelled 
monoclonal antibodies to the cell (Carter & Myer, 1994). The main application for 
flow cytometry in leukaemia diagnosis is in the detection of abnormal patterns of cell 
surface marker expression. To provide examples, Tables 1.3. & 1.4. have been 
included to illustrate the patterns of reactivity with antibodies commonly observed in 
FAB categories of AML and chronic B-cell leukaemias respectively. 
15 
Chapter 1: Literature Review 
Loken et al. (1990) established a protocol using a combination of 
fluorescence associated with CD45/CD14 and forward and side light scatter, to 
accurately distinguish lymphocytes from other leukocyte populations in peripheral 
blood. Having identified the cell population of interest based on 
immunofluorescence, a light scattering window was then drawn to include all of the 
lymphocytes, a process called 'gating'. The reactivity of monoclonal antibodies on 
monocytes and granulocytes can be accounted for once the nonlymphocytes have 
been identified as being within the acquisition gate (Loken et al., 1990). Gating of 
leukocyte subpopulations is now routinely used for the diagnosis of leukaemia and 
lymphoma using flow cytometry. 
Table 1.3.: Patterns of reactivity with antibodies observed in a selection of AML FAB subtypes 
(adapted from Bain, 1999). 
Markers of precursor cells Myeloid Markers Monocyte 
Markers 
TdT HLA-Dr CD34 CD13 CD33 CD117 CD15 CD 1 lb CD14 
MO + or- mainly + + or - often + mainly - mainly - mainly - 
M1 + or- . in 	+ 1111106 often + main! - + or - matn1 	- 
M2 
- MI 111111 + or - Effill 
often + 
MEM M3* - - - Illarrillg + or- + or - 
M4 + or - 
M5 mainl 	- + or - + or - + or - often + 
M6** + or- + or - + or - + or - =fitly - + or - mainly - 
- 
1\47*** 
- mainly - + or - often + mainly - - 
AML 
overall 
10-20% 
•ositive 
About 70% 
•ositive 
30-40% 
positive 
60-90% 
positive 
70-90% 
positive 
60-70% 
positive 
40-70% 
positive 
50-60% 
positive 
15-40% 
positive 
Also CD9 positive 
Also CD36 and glycophorin positive 
Also CD9, CD36, CD41, CD42a, CD42b, CD61 positive 
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Table 1.4.: Immunophenotype patterns commonly observed in some chronic B-cell leukaemias 
according to the FAB classification system (adapted from Bain, 1999). 
Marker B-CLL B-PLL HCL Plasma cell leukaemia 
surface membrane Ig weak strong mod.-strong negative 
cytoplasmic 1g - -1+ -1+ ++ 
CD5 ++ - - - 
CD19, 20, 24, 79a ++ ++ ++* - 
CD79b - ++ -/+ - 
CD23 ++ - - - 
FMC7, CD22 -7+ ++ ++ - 
CD10 - -/+ - -/+ 
CD25 - - - - 
CD38 - - -7+ ++ 
HLA-DR ++ ++ ++ - 
* 	HCL cells are negative with at least some antibodies of the CD24 cluster 
Many significant advances have emerged in the underlying knowledge of 
cellular and molecular biology of leukaemias. Traditionally, cytogenetic techniques 
utilising metaphase chromosomal spreads have been used to detect specific deletions, 
additions and translocations, a number of which are diagnostic. Metaphase spreads 
are however becoming replaced with fluorescent in situ hybridisation (FISH) which 
employs multicolour nucleotide probes. FISH is superior to traditional techniques in 
that it provides unambiguous results, in a relatively short period of time (Ekong & 
Wolfe, 1998, Neri et al., 2000). 
Although now superseded because of lengthy protocols, Southern blotting has 
previously been an important molecular biology technique for the detection of 
specific gene rearrangements. More rapid techniques however, including the 
polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), and real-
time RT-PCR are now becoming routinely used for leukaemia diagnosis. The list of 
chromosome changes and gene mutations in leukaemia is now very extensive and 
include changes that are leukaemia subtype specific. Detection of the PML-RARa 
translocation which predominates in APL, the bcr-abl fusion gene and the Ph gene in 
CML, and similarly many other reported translocations are now routinely diagnosed 
by PCR, RT-PCR, and becoming more routinely diagnosed by real-time RT-PCR 
(Borrow et al., 1992, Castaigne et al., 1992, Hussey et al., 1999, Otazu et al., 1999, 
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Preudhomme et al., 1999, Kurahashi et al., 2000, Otazu et al., 2000). RT-PCR and 
real-time RT-PCR are emerging as useful techniques because they allow rapid 
detection of actively expressed fusion gene transcripts. Other diagnostic alterations 
reported in leukaemia are more broadly based, including mutations in the n-ras 
proto-oncogene and the p53 tumour suppressor gene. Although not routinely 
performed, many flow cytometers have the ability to sort which are proving to be 
useful in collecting malignant cells for analysis by PCR and obtaining chromosomes 
for FISH studies (Rasmussen et al., 1998). 
A fundamental feature of leukaemia is its clonal nature. Clonal polymorphism 
of immunoglobulin and T-cell receptor genes have provided valuable markers of 
clonality in lymphoid neoplasms (Baruchel et al., 1995, Gong et al., 1999, Moreau et 
al., 1999, Wickham et al., 2000). Other acquired markers linked to the leukaemic 
process (chromosomal alterations, rearrangements and mutations) have also been 
exploited as clonal markers. Advances in our understanding of the cellular and 
molecular biology of leukaemia coupled with progress in the use of stem cell biology 
and growth factors is likely to contribute to more successful treatment and 
management of leukaemic patients (Greaves, 1996). 
1.1.4. Treatment of Human Leukaemia 
Arsenous oxide (Fowler's solution) was first administered by Lissauer in 1865 
to treat a patient with CML, resulting in a complete remission (Lissauer, 1865). 
Roentgen rays, discovered in 1895, were first applied to the treatment of leukaemia 
in 1902 (Pusey, 1902) and quickly replaced arsenicals as the treatment of choice for 
leukaemias. However, both arsenicals and radiotherapy were shown to be ineffective 
in acute cases, and leukaemia remained incurable until the 1940's. The discovery of 
the haematological effects of alkylating agents, naturally occurring cytotoxic 
antibiotics, and the development of antimetabolite therapy has provided the basis for 
therapeutics used in the current day. 
For a chemotherapeutic to be effective, it must have differential cytotoxic or 
cytostatic effects on the malignant cell. Current chemotherapeutic agents rely on 
differences between the sensitivity of leukaemic cells and normal cells, or 
specifically target the genetic apparatus and the cell division mechanism of malignant 
cells (Creaven etal., 1996). 
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Conventional Therapies 
Folate antagonists, including methotrexate (MTX) and aminopterin have 
played an important role in treatment of acute leukaemia. These agents act by 
interfering with biosynthetic pathways involving the folate coenzyme dihydrofolate 
reductase (Osborne et al., 1958), and specifically target neoplastic cells due to their 
increased metabolic rate. Dihydrofolate reductase inhibition in turn prevents the 
synthesis of thymidylate, an essential factor in the DNA replication process 
(Fridland, 1974, Tattersall et al., 1974). Aminopterin was initially used as a single 
agent to induce remission in children with acute leukaemia (Farber et al., 1948) and 
subsequently is now used in combination with MTX to treat this disease (Bertino et 
al., 1997). In addition to treatment of ALL, MTX used in combination with other 
chemotherapeutics has been shown to be of value as part of the treatment of AML 
(Hudson et al., 1990, Rots, 2001). 
Having established that nucleic acid synthesis was an essential factor in cell 
growth control, purine and pyrimidine analogues were developed, which function to 
inhibit DNA and RNA polymerase enzymes (Pizzorno et al., 1997). These include 
fluorouracil, cytosine arabinoside, 5-azacytidine (pyrimidine analogues), 6- 
mercaptopurine, deoxycoformycin, 2-chlorodeoxyadenosine, and 6-thioguanine 
(purine analogues). Cytosine arabinoside (araC) and 5-azacytidine (5-AC), both 
cytidine analogues, are the most commonly used of these in human leukaemia 
treatment. Since its introduction in 1963 (Talley & Vaitkevicius, 1963) araC has 
remained as one of the most important drugs in the treatment of AML (Bishop, 
1997), and is also effective against ALL and, to a lesser extent, CML and non-
Hodgkin's lymphoma (NHL) (Chabner, 1990). 5-AC is primarily used in the 
treatment of AML and myelodysplastic syndrome (MDS) (Saiki, 1978, Pizzorno et 
al., 1997). The purine analogue deoxycoformycin has been useful in the treatment of 
CLL, prolymphocytic leukaemia, and ATLL (Dearden et al., 1987), although 
demonstrating high toxicity in some patients (Pizzorno et al., 1997). Similarly, 2- 
chlorodeoxyadenosine is beneficial in CLL, NHL, and in children with AML (Piro et 
al., 1988, Santana et al., 1994). The most successful use of these two purine 
analogues however has been in the treatment of HCL, where complete remissions of 
the disease are now available, which raises the issue of detection and significance of 
minimal residual disease (Piro et al., 1988, Kroft et al., 1995). 
In addition to nucleotide analogues, other agents that inhibit biosynthetic 
reactions leading to nucleic acid precursors have been developed, including acivicin 
and hydroxyurea (HU). The oral chemotherapeutic HU, which functions to inhibit 
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DNA synthesis by inhibition of the enzyme ribonucleotide reductase, has been an 
initial therapy of choice for the treatment of CML to relieve symptoms or retard their 
progression (in combination with alkylating agents and interferon-a) (Hehlmann et 
al., 1994). Although HU does not markedly prolong survival (Mughal & Goldman, 
1995) it remains a popular choice for CML treatment because of its rapid action, low 
level of adverse effects (Kennedy, 1972, Simonsson, 1998), and specificity for 
myeloid cells (Goldman, 1997). 
The alkylating agents comprise a large therapeutic component of human 
leukaemia treatment. These agents form covalent chemical bonds with nucleophiles 
such as sulphur in proteins and nitrogen in DNA, and appear to employ cytotoxicity 
primarily by inhibition of DNA replication and cellular division (Colvin, 1997). 
Sulphur mustard was first recognised as an antitumour agent following its use in 
weapons in World War IL The closely related, but less toxic, nitrogen mustard was 
chosen for further study. Five remain in common use in cancer therapies today, and 
include mechlorethamine, cyclophosphamide, ifosfamide, melphalan, and 
chlorambucil. Chlorambucil has been used extensively in the treatment of CLL and is 
well tolerated by patients compared with cyclophosphamide or melphalan, and results 
in a remission rate higher than that achieved with CHOP (combined therapy which 
incorporates cyclophosphamide and other chemotherapeutics) (Han & Rai, 1990, 
Catovsky & Murphy, 1995). The alkyl sulphonate class of drugs include one of the 
earliest alkylating agents, busulphan, is relatively inexpensive and has selective 
toxicity for early myeloid precursors (Frei Ill & Antman, 1997), making it a useful 
drug in CML therapy. Busulphan however has a higher toxicity profile than HU 
(Weatherall et al., 1969, Vicariot et al., 1979, Bolin et al., 1982), and therefore is 
now reserved for CML patients whose disease is resistant to HU (Goldman, 1997). It 
is now commonly used as a component of bone marrow ablative therapy for bone 
marrow transplantation (BMT) of AML (Zander etal., 1997). 
Anthracyclines are included in a class of drugs which become inserted 
between successive DNA base pairs (DNA intercalators), and hence alter the function 
of polymerase enzymes. Actinomycin D was the first anthracycline to be used in 
cancer treatment, followed by doxorubicin (Adriamycin) and others, most commonly 
daunorubicin, and idarubucin. Doxorubicin was found to possess very broad 
antitumour properties, and subsequently has been used in combination with araC in 
the treatment of AML (Myers, 1997, Bishop, 1999), and in combination with 
vincristine (a Vinca alkaloid) and prednisone (a corticosteroid) for ALL treatment 
(Cortes & Kantarjian, 1995, Myers, 1997). Daunorubicin, in combination with araC, 
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has been a standard AML therapy for many years, but is now often replaced by 
idarubicin (Bishop, 1999). Similar to doxorubicin, daunorubicin and idarubicin have 
proved useful in the treatment of ALL when combined with vincristine and 
prednisone (Myers, 1997). 
The epipodophyllotoxin etoposide (VP-16) is a semisynthetic derivative of 
podophyllotoxin, a compound found to exhibit a wide antitumour activity spectrum 
extracted from the Podophyllum plant. These agents have a unique interaction with 
the DNA topoisomerase H enzyme, leading to DNA damage by preventing DNA 
resealing (Wozniak & Ross, 1997). Etoposide is a front-line therapy for treatment of 
a vast array of cancers, including AML, AMML, and NHL (Issell et al., 1984). 
Etoposide also plays a very important role in ablative protocols for both autologous 
and allogeneic BMT (Wozniak & Ross, 1997). 
Also plant derived, the Vinca alkaloids represent one of the most important 
anticancer drug classes. The most commonly used Vinca alkaloids include 
vinblastine, vincristine, and vinorelbine (Navelbine), and as opposed to the 
anticancer drug classes discussed previously, do not target DNA. Their anticancer 
properties arise because of their ability to interact with intact microtubules 
(components of the cellular cytoskeleton) or microtubule subunit molecules. These 
agents were first discovered to be useful following studies into the hypoglycaemic 
properties of the periwinkle plant extract (Johnson et al., 1963). Although unable to 
show any antidiabetic effects, researchers found that the extract prolonged the life of 
mice with transplantable lymphocytic leukaemia. Vinca alkaloids are mainly used in 
combination therapies due to their unique mode of action. Although the Vinca 
alkaloids play a crucial role in leukaemia treatment (in particular, VCR in the 
treatment of ALL and CLL) their role is somewhat limited in comparison to their 
uses in other forms of human cancers including Hodgkin's lymphoma and NHL 
(Tesch et al., 1998, El Helw et al., 2000, Takenaka et al., 2000). 
First introduced in 1985, Interferon-a (IFN-a) has become a well established 
first-line treatment for patients with early-stage CML. IFN-a has been reported to 
improve survival by a median of 20 months in chronic-phase CML patients, 
compared to those treated with the standard HU or busulphan therapy (Silver et al., 
1999). Treatment with IFN-a is demonstrated to lead to a complete, or partial, return 
of Ph-negative cells in a significant number patients (Giralt et al., 1995). In fact, it 
has been reported to result in a complete haematological remission (CHR) in 50-80% 
of CML patients and a complete cytogenetic response (CCR) in up to 60% 
(Simonsson, 1998). This is of significance as an association has been found between 
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IFN-a treatment and a 10-year survival of 90% in patients who achieve a CCR, 
which compares favourably to allogeneic BMT (Kantarjian & Giles, 1999). IFN-a is 
highly effective in CML patients when used in combination with other agents, most 
commonly araC, further increasing the number of patients with both a CI-IR and CCR 
(Kantarjian et al., 1998). Recently, another combination yielding promising results is 
the use of IFN-a and homoharringtonine (HHT), another novel plant alkaloid, with or 
without araC (Kantarjian et al., 1998). Results from these studies suggests that HHT 
acts in synergy with IFN-a, and even further increases the number of patients with a 
CHR and remarkably accelerates the time to CCR compared with lFN-a/araC 
treatment (Kantarjian & Giles, 1999). Unfortunately, lFN-a is known to cause 
pronounced side effects including adverse neurological symptoms (Quesada et al., 
1986), thus limiting the duration and dosage of therapy in some patients (Kantarjian 
et al., 1993). Another more recent approach to IFN treatment has arisen with the 
development of pegylated IFN-a (PEG-IFN-a) which allows more sustained serum 
IFN-a levels by reducing the peak serum levels, which is expected to reduce 
toxicities, allowing higher and more effective doses to be delivered (Kantarjian & 
Giles, 1999). 
Combination therapies have been derived in part from studies of the 
development of drug resistance (Law, 1956, Schnipper, 1986). Combination 
regimens incorporating a mixture of two or more antineoplastic and other drugs are 
frequently used in patients with leukaemia; the combination of which drugs being 
varied according to the type of leukaemia being treated. Essentially all curative 
cancer chemotherapy involves a combination of agents (Frei DI & Antman, 1997). 
The most widely used regimens include chlorambucil with prednisone in CLL 
treatment (Montserrat & Rozman, 1993), IFN-a and araC or HU in CML treatment 
(Cortes et al., 1996), COP (cyclophosphamide, vincristine and prednisone) for 
treatment of CLL (Liepman & Votaw, 1978, Oken et al., 1979, Catovsky & Murphy, 
1995), CAP (cyclophosphamide, doxorubicin and prednisone), CHOP (COP + 
doxorubicin), POACH (COP + doxorubicin and araC), and M2 (COP + BCNU and 
melphalan). Combination therapy is highly effective in the treatment of cancers 
because the therapeutic effect of each of the drugs used is additive (Frei III & 
Antman, 1997). As such, combination regimens allow for achievement of a high 
Summation Dose Intensity (SDI) (Freireich et al., 1959). Careful selection of drugs 
must be made, to ensure that each agent has independent non-additive, non-
overlapping toxicity, while maintaining a high SDI (Frei III & Antman, 1997). 
Studies have been performed to investigate the possibility of applying combination 
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chemotherapy for inhibiting metabolic pathways by blocking sequential or concurrent 
points in two metabolic pathways such that the final metabolic product is ineffective 
(Sartorelli & Caresy, 1982), and for simultaneously synchronising cells in vivo, and 
exploiting this with a cell cycle phase-specific agent (Allegra, 1990, Ruiz-Cabello et 
al., 1995). 
Over the past fifteen years there has been increasing interest in the use of 
bone marrow transplantation for the treatment and potential cure of human 
leukaemia. BMT relies on intensive cytoreductive therapy to reduce the number of 
leukaemic cells, incurable by conventional-dose therapies, followed by the 
administration of healthy cells from the same patient (autologous) or from a matched 
related or unrelated donor (allogeneic), capable of producing complete trilineage 
haemopoietic engraftment (Thomas & Storb, 1970). Cytoreductive therapies vary 
depending on the leukemia subtype being treated, but include the use of 
cyclophosphamide and busulphan for CML (Cortes et al., 1996), and etoposide 
combined with busulphan and cyclophosphamide for AML treatment (Zander et al., 
1997, Kroger et al., 2000). It is now clear that BMT remains as one of the only 
curative leukaemia treatments. A better understanding of imrnunogenetics of 
histocompatibility and the cellular events leading to graft rejection and graft-vs.-host 
disease (GvHD), has led to the evolution of allogeneic BMT for leukaemia treatment 
and has been extensively reported to cure CML (Thomas & Clift, 1989, Litzow & 
Tefferi, 1994, Mughal & Goldman, 1995), with relapse rates occurring in less than 
10-20% of patients (Goldman, 1997). While the chance of GvHD is increased in 
patients receiving an allogeneic BMT (second leading cause of death in these patients 
in Australia after relapse [ABMTRR, 2000]),. allogeneic transplants offer an 
advantage over autologous transplants in that there is resistance towards the 
leukaemic cells through adoptive immune cell transfer from the healthy donor, a 
phenomenon termed the graft-vs.-leukaemia (GvL) effect (Antin, 1993). Despite 
improvements in tissue typing techniques and supportive care, procedure-related 
mortality rates are increased in allogeneic BMT recipients, especially during the first 
year after transplantation. However, the long-term outcome for these patients is better 
than those receiving conventional chemotherapy (Simonsson, 1998). Data collected 
in Australia by the Australasian Bone Marrow Transplant Recipient Registry 
(ABMTRR, 2000) over seven years (1992-1999) reveals a survival rate of 65% in 
related allogeneic transplants and 52% in unrelated transplants for CML patients. The 
indications for autologous BMT are similar to that for allogeneic transplants in the 
treatment of leukaemia. Autologous transplants, however, do not possess the added 
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benefits of GvL effects, but do essentially eliminate the chance of early morbidity 
due to GvHD. ABMTRR data show a 68% survival rate after seven years in CML 
patients receiving an autologous transplant (ABMTRR, 2000). 
Differentiation therapies which utilise agents known to induce lineage 
maturation in the immature leukaemia cell have been used previously, although with 
limited efficacy to date. These agents, which include vitamin D3 and all-trans retinoic 
acid, will be discussed in detail in Chapter 1.4., and therefore will not be dealt with 
here. 
New and Arising Therapies 
Although many patients achieve a complete remission following conventional 
chemotherapy, a large proportion will eventually relapse with a disease that is 
resistant to a broad spectrum of chemotherapeutic agents (Nooter & Sonneveld, 
1993, McKenna & Padua, 1997). A significant number of studies have been 
conducted into the mechanisms of multidrug resistance (MDR) in an attempt to 
establish their prognostic importance and to develop a means to overcome such 
resistance. The most extensively studied form of MDR is due to the membrane 
transporter protein P-glycoprotein (PgP), which is capable of actively excluding a 
range of anticancer drugs including anthracyclines, Vinca alkaloids, and 
epipodophyllotoxins, thus lowering their intracellular concentration to sublethal 
levels (McKenna & Padua, 1997). A reported 10-50% of ALL patients at diagnosis 
and 15-60% at relapse express the PgP MDR gene (List, 1993). Hence, there is an 
increasing need for the development of new drugs with the ability to target novel 
cellular mechanisms. 
The cellular immune response is thought to have evolved to recognise and 
eliminate clones of tumour cells. T cells, NK cells, dendritic cells and activated 
macrophages have all been proposed as candidates for maintaining tumour 
surveillance (Kane et al., 1986). However, many types of tumour cells lack the 
expression of immunogenic cell surface antigens and so are able to evade the 
immune response. Attention has recently been directed towards the hypothesis that 
differentiation of immature clones of tumour cells into a mature phenotype will lead 
to increased immunogenic antigen expression and their subsequent removal from the 
population by immune surveillance. A significant number of these studies have 
focussed on the CD80 antigen (the product of the B7 gene), which is required for co-
stimulation through CD28 binding and activation of T cells. Most human leukaemic 
cell lines, and other types of cancer cells, have been shown to express low or 
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undetectable levels of CD80 protein, suggesting that CD80 plays a critical role in 
tumour immunity (Wollenberg et al., 1998, Jia et al., 2002). Increased CD80 
expression has been seen following treatment of in vitro cell populations with human 
IFN-a (Hakem et al., 1989) and following gamma-ray irradiation (Vereecque et al., 
2000). Transfection of the B7 gene into human cell lines deficient in CD80 
expression increases their antigen presentation potency for activation of anti-tumour 
T cells and NK cells (Zhao et al:, 1998, McCarthy et al., 2000, Jia & Ke, 2002, Ke et 
al., 2003). Conversely, inhibition of CD80 in CD80-expressing CHO cells using anti-
B7 monoclonal antibodies leads to T cell anergy (Wang et al., 2002). Thus, enhanced 
expression of the CD80 antigen in cancer cells that lack expression of this co-
stimulation factor may provide a novel immunotherapeutic approach for treating 
human haemopoietic malignancies. 
Recently, attention has been directed towards the retinoids, in particular all-
trans retinoic acid (ATRA) as an alternative therapy for patients with APL (Huang et 
al., 1988, Gillis & Goa, 1995). ATRA has long been known to induce APL cell 
differentiation and reduce proliferative activity both in vitro and in vivo (Chen et al., 
1991, Fenaux & Degos, 1996, Shiohara et al., 1999, Hansen et al., 2000). Since its 
introduction into clinical use, ATRA has proved to be highly effective, inducing 
remission in up to 94% of patients with APL (DeLoughery & Goodnight, 1996), 
while resolving the coagulopathic problems that arise in conventionally-treated 
patients (Kawai et al., 1994). Unfortunately, retinoic acid therapy has been strongly 
linked to an increased leukocyte count due to the release of several cytokines by the 
maturing blast cells in about 25% of treated APL patients (Fenaux & De Botton, 
1998). This phenomenon has been termed the ATRA syndrome and is often fatal in 
the absence of prophylactic measures. However, with measures in place 
(dexamethasone and occasionally antineoplastic therapy to relieve the white cell 
count), the incidence of ATRA syndrome has decreased to about 15% and has 
reduced mortality to 1% of ATRA-treated patients (Fenaux & De Botton, 1998). 
ATRA has been used in combination with araC in the treatment of myelodysplastic 
syndrome, but results from recent retrospective studies suggest that this combination 
is no more effective than ATRA or araC therapy alone (Nair et al., 1998, Letendre et 
al., 1999). 
Monoclonal antibody therapy has recently emerged as a promising 
antileukaemia treatment. With the use of Mab Thera, an anti-CD20 therapy, in 
common use today for the treatment of low grade NHL, new monoclonal antibodies 
are being developed as a target-specific therapy. Preliminary results using two anti- 
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CD33 (HuM195 and CMA-676) antibodies conjugated with calichearnicin 
(combination chemotherapy), recently developed and tested for use against AML for 
targeted therapy, appear very promising (Bernstein, 2000, Jurcic, 2000, Maslak & 
Scheinberg, 2000, Radich & Sievers, 2000, Ruffner & Matthews, 2000). HuM195 
has also been tested with an 1L-2 conjugate (Kossman et al., 1999). While 
demonstrating antileukaemic activity this combination produced significant toxicity. 
Also being considered is the use radiolabelled HuM195 for targeted alpha and beta 
particle therapy which is suggested to minimise radiation exposure to normal tissues 
(Jurcic, 2000). Another monoclonal antibody which has recently been introduced, 
Campath-1H (alemtuzumab), has been used with promising results in the treatment 
of T- and B-CLL (Schulz et al., 2000, Kennedy et al., 2002) and NHL (Khorana et 
al., 2001, Uppenkamp et al., 2002). Campath-1H is directed against CD52, a cell 
suface antigen present on the lymphocytes of almost all patients with B and T cell 
lymphocytic leukaemia (Sorokin, 2001). The most significant response to Campath-
1H has been in the treatment of T-PLL (Dearden et al., 2001). A rationale for this has 
been proposed by Ginaldi et al. (1998), who have reported that T-PLL cells show the 
greatest expression of CD52. The effectiveness of Campath-1H, and the summary of 
results from its use in clinical trials to date, have been reviewed by Dyer (1999), 
Flynn & Byrd (2000), Pangalis et al. (2001) and Sorokin (2001). 
The aberrant bcr-abl fusion gene found in nearly every CML cell, and its 
protein product, a constitutively active tyrosine kinase p210 BCR-ABL, have been 
successfully targeted recently. By inhibiting BCR-ABL it has been possible to reverse 
the leukaemic phenotype (Goldman, 1997). Labelled as the most promising agent to 
emerge to date by leading researchers for the treatment of CML is a specific inhibitor 
originally known as CGP 57-148B, and recently renamed signal transduction 
inhibitor 571 (STI571 , Gleevec/Glivec - Novartis Pharmaceuticals) (Kantarjian & 
Giles, 1999, Mauro & Druker, 2001) which competes with the ATP-binding site of 
the enzyme, preventing subsequent phosphorylation of a substrate (Goldman, 2000). 
Introduced into clinical trials in 1998, STI571 has been given to chronic-phase CML 
patients who had failed 1FN-a therapy. CHRs have been achieved in up to 96% of 
patients after four weeks, and a CCR was achieved in 33% of patients within two 
months of treatment (Kantarjian & Giles, 1999). A recent clinical trial by Druker et 
al (2001) demonstrated minimal toxicities with STI571. A long term follow-up is 
required for a full evaluation of the efficacy of 5T1571. Another approach to inhibiting 
BCR-ABL has been with the use of antisense oligonucleotides directed against bcr-
abl transcripts. Early studies demonstrated that these oligonucleotides could in fact 
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suppress colony formation of CML cells (and not normal cells) in vitro, however 
later studies have been less encouraging; the main problem being difficulties in 
delivering oligonucleotides into the cells (Mughal & Goldman, 1995, Kantarjian & 
Giles, 1999). Of the anti-sense bcr-abl mRNA oligonucleotides constructed, none has 
definite clinical efficacy (Goldman, 2000). 
Due to existing problems associated with drug resistance and toxicity as a 
result of drug non-specificity, there continues to be a need for the development of 
new leukaemia therapies. Much research is currently being undertaken into novel 
therapies targeting cellular growth and differentiation pathways in an attempt to 
induce the immature leukaemia cells to mature, whilst limiting cytotoxic effects to 
surrounding healthy cells. Current studies into differentiation therapies appear 
promising, and may prove to be of great clinical significance over the next decade for 
the treatment of haematological disorders. 
Significance of Apoptosis in Leukaemia Treatment 
Unregulated apoptosis (programmed cell death) has been associated with a 
number of diseases. Excessive apoptosis has been linked to neurodegenerative 
disorders including Alzheimer's disease and Huntington's disease, which 
demonstrate an increase in caspase activity. Other examples of excessive apoptosis 
resulting in disease include insulin-dependent diabetes mellitus, Hodgkin's disease, 
ischaemic disease and transplant rejection (Fadeel et al., 1999). A defective Fas 
antigen, which is normally responsible for the deletion of autoreactive T cells, has 
been shown in mice to exist in cells involved in a lymphoproliferative disorder and 
its associated autoimmune disease, systemic lupus erythematosus (SLE) (Watanabe-
Fukunaga et al., 1992). 
Overactivation of the pro-survival protein Bc1-2 leads to a failure of cells to 
die. Overexpression of Bcl-2 has been reported in B-cell precursor ALL cells, 
resulting in prolonged survival of leukaemic cells in vitro (Campana et al., 1993), 
and has been shown in all patients with ALL by Gala et al. (1994), except those 
patients with Burkitt's phenotype. Similarly, Bc1-2 protein levels are elevated in 
primary CML cells (Handa et al., 1997, Maguer-Satta, 1998). 
Agents modulating apoptosis at the levels of initiation, mediation, and 
execution show potential for the treatment of diseases affected by overactive or 
underactive apoptosis, including leukaemia. Some current strategies in apoptosis-
related drug development are discussed below with particular reference to leukaemia 
and cancer in general. The use of Fas-specific Abs have been shown to induce 
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apoptosis in cancer cells, and treatment with anti-Fas Abs has been successfully 
applied to mice bearing human haemopoietic tumours (Debatin et al., 1993). 
Additionally, Rensing-Ehl and colleagues (Rensing-Ehl et al., 1995) have shown 
elimination of the Fas expressing lymphoma YAC-1 cells in mice following 
treatment with a soluble Fas-L. 
Treatment with the glutathione-depleting agent buthionine sulfoximine 
increases the level of reactive oxygen species, thus producing a decrease in 
mitochondrial transmembrane potential, which has been recently shown to have anti-
leukaemic activity in patients (Hedley et al., 1998). It is likely that inhibitors of NF-
KB and AP-1 will find application for increasing the pro-apoptotic efficacy of 
chemotherapeutics and anti-cancer drugs (Deigner & Kinscherf, 1999). 
Chemotherapeutic-mediated cell death involves the activation of caspase-9 (Hakem 
et al., 1998), while caspase-3 has been shown to be activated by a number of agents 
including the protein kinase inhibitor staurospine and the DNA-damaging agent 
etoposide (Zhivotovsky et al., 1995, Weil etal., 1996). 
Cell lines expressing elevated levels of Bc1-2 show an increased resistance to 
apoptosis-inducing agents including etoposide, methotrexate and doxorubicin, and an 
increased resistance to y-irradiation (Zhan et al., 1993, Ascaso et al., 1994, Datta et 
al., 1995). It has therefore been postulated that agents which restore a normal level of 
Bc1-2 expression or reduce Bc1-2-mediated effects should enhance apoptosis and 
improve the anti-tumour effects of conventional chemotherapeutics (Deigner & 
Kinscherf, 1999). Bc1-2 is constitutively expressed in the promyelocytic leukaemia 
cell line NB4, and treatment of these cells with As203 produced downregulation of 
Bc1-2 protein resulting in cell death (Chen et al., 1996). In addition, human B-cell 
lymphomas bearing Bc1-2 translocation can be specifically inhibited by antisense 
oligonucleotides (Reed etal., 1990). 
1.1.5. Experimental Models of Human Leukaemia 
The study of human leukaemias has been aided greatly by the establishment 
of immortal human haemopoietic leukaemic cell lines, which are blocked at different 
stages of maturation. Leukaemic cell lines provide a simplified study of leukaemic 
cell responses following drug addition (e.g. differentiation), and allow the convenient 
investigation of a homogenous population of neoplastic cells (Koeffler, 1983). They 
provide a renewable source of material for characterisation of cell surface markers 
and receptors, and of mRNA for molecular analysis. Cell lines usually become 
independent of growth factors during adaptation to tissue culture conditions 
28 
Chapter 1: Literature Review 
(Markham et al., 1984), in some cases due to the constitutive production of 
autostimulatory factors (Schrader, 1986). It is important to remember that all 
haemopoietic cell lines, being leukaemic in origin, are abnormal in a variety of ways. 
Thus responses observed in these cells (e.g. the response to addition of a given 
substance) may not always result in the acquisition of all the traits of a normal cell 
response (Lyons & Ashman, 1989). Over the last decade, a majority of the 
established cell lines have been comprehensively studied for the presence of 
particular adhesion molecules, differentiation antigens, cytochemical properties, and 
for growth behaviour, in an attempt to characterise each individual cell line for 
further research applications. Table 1.5. provides a brief account of common human 
haemopoietic cell lines used in leukaemia research, with emphasis on those cell lines 
used in this thesis. Expression profiles and differentiation capacity for the various 
myeloid cell lines have been extensively reviewed by Lubbert et al. (1991). 
Leukaemic cell lines have provided the opportunity for studies to be 
performed into the induction of leukaemia cell differentiation. Many agents possess 
the ability to induce maturation of these cells from their previously blocked state. 
These include phorbol diesters (e.g. 12-0-tetradecanoyl-phorbol 13-acetate [TPA]) 
for induction of differentiation in KG-1, HL60, U-937 and THP-1 cells, teleocidins 
(indole alkaloids) for HL60 and KG-1 differentiation, polar-planar drugs (e.g. DMSO 
and acetamide) for HL60 differentiation, and some chemotherapeutic agents 
including actinomycin-D, methotrexate, 5-AC, bromodeoxyuridine, 6-thioguanine, 
araC and vincristine, for HL60 cell differentiation (Koeffler, 1983). The use of 
leukaemic cell lines as a model for research into potential treatments for leukaemia in 
vivo is well accepted in the scientific community, hence the use of leukaemic cell 
lines in this current study. 
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Table 1.5.: A summary of commonly used haemopoietic cell lines and accompanying characteristic 
features (Hb = Haemoglobin, DMSO = dimethyl sulphoxide, IL-2 = Interleukin-2, EBNA = Epstein-
Barr virus nuclear antigen). 
Cell Line Diagnosis of Disease Cell Lineage Characteristic Features 
K562 blast crisis of CML erythromyeloid, 
early granulocytic 
precursor 
- 	strongly glycophorin positive ) 
- 	carry the Ph chromosome ) 
- 	can 	induce 	to 	produce 	Hb 	in 
presence of haemin(I '2) 
- 	spontaneously 	differentiate 	into 
erythroid, 	granulocytic 	and 
monocytic precursors (3) 
KG-1 AML myeloblastic 	and 
promyeloblastic 
- 	strongly CD34 positive ) 
- 	spontaneously 	differentiate 	into 
granulocytes (3) 
- 	differentiate 	into 	macrophages 	in 
presence of phorbol esters (5) 
- 	rely on CSF in soft-gel culture ) 
KG-la AML very 	young 
myeloblasts 
(KG-1 variant) 
- 	strongly CD34 positive ) 
- 	do not spontaneously differentiate ) 
or respond to phorbol esters (5) 
- 	do not express Dle ) or respond to 
CSF (6) 
HL60 PML promyelocytic - 	highly 	responsive to 	a 	range 	of 
differentiation agents 
- 	differentiate 	into 	granulocytes 	in 
presence of DMS0(1), and 
macrophages in presence of phorbol 
esters (7) 
THP-1 AML Monocytic - 	differentiate 	into 	macrophages 	in 
presence of phorbol esters (8) 
- 	lack 	prominent 	chromosomal 
abnormalities (9) 
U-937 Histiocytic Lymphoma Monocytic - 	differentiate 	into 	macrophages 	in 
presence of phorbol esters (I°) 
Jurkat ALL T lymphocytic - 	produce large amounts of IL-2 in 
presence of phorbol esters (3) 
- 	CD3 positive ) 
MOLT-4 ALL T lymphocytic - 	have rosette-forming ability° I) 
Raji Burlcitt's Lymphoma B lymphocytic - 	EBNA positive ) 
List of References Provided in Table 1.5.: (1) Koeffler & Golde, 1980, (2) Lozzio & Lozzio, 1975, 
(3) ATCC® , 2001, (4) Pasternak & Pasternak, 1994, (5) Koeffler etal., 1981, (6) Koeffler & Golde, 
1978, (7) Rovera et al., 1979, (8) Tsuchiya et al., 1980, (9) Koeffler, 1983, (10) Sundstrom & Nilsson, 
1976, (11) Minowada etal., 1972. 
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1.2. The Cell Cycle 
1.2.1. Role of the Cell Cycle 
The cell cycle describes the life cycle of a cell. Essentially, the role of the cell 
cycle is to ensure that the DNA is accurately replicated once every cycle, and that 
identical chromosomal copies are distributed equally to the two resulting daughter 
cells (Heichman & Roberts, 1994). 
The cell cycle is depicted in Figure 1.2., and consists of four main phases: 
Gap 1 (G1), Synthesis (S), Gap 2 (G2), and Mitosis (M). On recognition of a growth 
signal, which usually originates outside the cell and sensed by receptors in the cell 
membrane, a cell will enter into G1 phase of the cell cycle. In G1 phase, RNA and 
protein synthesis occur but the cellular DNA content remains constant. DNA 
synthesis, or S phase, begins with replication of DNA and continues until the entire 
complement of DNA is replicated, and the DNA content has doubled. It is just prior 
to the transition from G 1 to S phase (known as the Restriction Point) that a number of 
key regulatory events takes place, and the cell must overcome checkpoints to allow 
continued progression through the cell cycle. A diagrammatic representation of the 
events that occur at the Restriction Point of the cell cycle is presented in Figure 1.3., 
and the key events will be discussed in detail. Having progressed through S phase, 
the cell then prepares for division as it enters G2 phase. Division takes place in M 
phase where the cell splits into two new daughter cells each containing half the DNA 
content of the parental cell (Fingert et al., 1997). 
After completing M phase, a cell can re-enter the cycle in G 1 phase, or can 
exit the cell cycle and enter a resting state denoted as Go. Cells may stay in this 
quiescent state for days, weeks, or years, until the cell is stimulated to divide again. 
The cell then becomes active, and re-enters the cell cycle in G 1 (Fingert et al., 1997). 
Because cells in Go and G1 both contain the same amount of DNA, they are 
indistinguishable and are often noted together as G0/G1 (Mangiarotti etal., 1998). 
DNA content distribution has long been analysed by staining with a hypotonic 
solution of propidium iodide, a dye which intercalates into the DNA molecules and is 
excited at 536nm, fluorescing at 617nm (Krishan, 1975, Nicoletti et al., 1991). Using 
flow cytometry, cycling cells can be gated and DNA content depicted in a resulting 
DNA histogram (shown in Figure 1.4.). Analysis of DNA distribution allows the 
detection of differences in ploidy between cell populations, and detection of the 
relative proportions of cells in each phase of the cell cycle. This technique is 
invaluable in analysis of the cell cycle (Crissman & Steinkamp, 1973, Krishan, 1975, 
31 
New Daughter Cell 
Go 
Mit0SiS 
(cell division) 
CDKs 
active 
Synthesis 	 S 
(Doubling of 
DNA) 
Restriction Point 
Regulation by p53, Rb, CKIs 
Figure 1.2.: Diagrammatic representation of the cell cycle (illustration by George Eade) Following a 
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Fried et al., 1976) and apoptosis (Nicoletti et al., 1991, Ormerod et al., 1993, Belloc 
et al., 1994, McCloskey et al., 1994) in mammalian cell populations and has proved 
to be useful in the clinical setting for detecting abnormal aneuploid populations 
(Valet et al., 1984, Dressler et al., 1988). 
1.2.2. Key Regulators and Kinetics of the Cell Cycle 
A number of regulatory proteins have been found to be involved in 
controlling the cell cycle. These involve both proteins that promote cell cycle 
progression, including cyclin-dependent kinases which are activated by their cyclin 
protein subunits, and proteins that negatively regulate the cell cycle which include 
cyclin-dependent kinase inhibitors and tumour suppressor proteins. The important 
cell cycle regulatory elements are discussed in detail below. 
A) Cyclins and Cyclin-Dependent Kinases 
Progression through the cell cycle is mediated by a phylogenetically 
conserved family of protein kinases known as cyclin-dependent kinases (CDKs), 
whose activity requires interaction with their positive regulatory subunit proteins 
termed cyclins (Pines, 1995). A vast number of cyclin and CDK members have been 
identified to play a role in mammalian cell cycles which appear to be conserved 
among multicellular eukaryotes, but are distinct in yeast. The A-, B-, D- and E-type 
cyclins have been shown to be critical in cell cycle progression, along with their 
CDK partners CDK1, CDK2, CDK4, and CDK6. Both are present in Drosophila and 
vertebrates (Edgar & Lehner, 1996). As positive regulation of CDK activity is 
mediated by the level of cyclin accumulation within the cell (Morgan, 1995, Nigg, 
1995), the expression levels of the cyclins vary as the cell progresses through the 
phases of the cell cycle (as shown in Figure 1.5.) 
Passage through the Restriction Point is dependent on levels of cyclins D, E, 
and A. D-type cyclins are proposed to act as growth factor sensors as their expression 
and assembly with their respective catalytic CDK partners (CDK4 and CDK6), have 
been shown to be regulated according to extracellular cues (Sherr, 1993 & 1994). 
Expression of the D-type cyclins (D1, D2, and D3) is increased as the cell moves 
through the Restriction Point (Sherr, 1994). Interestingly, a loss in cyclin Dl-
dependent kinase activity prior to the Restriction Point results in a cell which is 
unable to enter S phase, while its absence later in the cell cycle is without effect 
(Baldin et al., 1993). This would suggest that cyclin D-dependent kinases must 
phosphorylate a key substrate whose modification is essential for G 1 exit. 
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Figure 1.5.: Diagrammatic representation showing the fluctuations in expression of cyclins, and the 
cyclin-dependent kinase inhibitor p27'41 , as the cell progresses through the cell cycle (taken from 
Sherr, 1996). Expression of E-, A-, and B-type cyclins is periodic, while D-type cyclins (DI, D2, and 
D3) are expressed throughout the cycle following initiation by mitogenic stimuli. The cyclins associate 
with cyclin-dependent kinase enzymes to regulate their activities (cyclin D forms complexes with 
CDK4 and CDK6; cyclin E with CDK2; cyclin A with CDK2 in S phase and CDK1 in late S and G2 
phases; and cyclin B with CDK1). p27 1(1131 levels are high in quiescent cells, and rapidly fall in 
response to mitogenic stimulation, remaining at low threshold levels in proliferating cells, and increase 
again when mitogenic stimulation is withdrawn. It appears to be most directly involved in Restriction 
Point control (G 1 to S phase transition). 
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Cyclin E expression is maximal at the Restriction Point and complexes with 
CDK2, which irreversibly commits the cell to entering S phase. The cyclin E-CDK2 
complex (in addition to cyclin D-CDK4) has been shown to be essential for the 
transition from G 1 to S phase (Resnitzky et al., 1994). Expression of cyclins A and B 
peak as the cell enters S phase, when cyclin E expression begins subsiding. During 
the early stages of cyclin A expression, cyclin E also associates with CDK2 until late 
S phase and in G2 phase where it forms complexes with CDK1 (also known as 
Cdc2). Cyclin B only complexes with CDK1 (Sherr, 1996), a complex historically 
known as the maturation promoting factor (MPF). Cyclins A and B in association 
with CDK1 regulate entry into M phase (Sherr, 1994) where a series of proteolytic 
reactions are required to trigger transition from metaphase to anaphase (reviewed by 
Yu et al., 1996). Cyclin A and B expression ceases as the cell moves towards the end 
of M phase. Expression levels of cyclin A mRNA have been previously proposed as a 
new marker of proliferation for human haematological malignancies (Paterlini et al., 
1993), and has been shown to be a powerful early indicator of clinical response 
(growth arrest) to tamoxifen therapy in breast cancer patients (Maas etal., 1995). 
B) Cyclin-Dependent Kinase Inhibitors 
Activity of CDKs that govern cell cycle progression require strict 
coordination and regulation. As mentioned above, the level of cyclin accumulation 
within the cell generally mediates positive regulation. Negative regulation can be 
achieved either by phosphorylation of the catalytic subunit, or via the binding of 
CDK inhibitory proteins known as cyclin-dependent kinase inhibitors (CKIs) 
(Morgan, 1995). Increases in the levels of CKIs, which bind in place of the cyclin 
subunit of cyclin-CDK complexes, render these complexes inactive. Two families of 
CKIs have been described (Elledge & Harper, 1994, Sherr & Roberts, 1995): the 
INK4 (inhibitors of CDK4 and CDK6) inhibitors, and the Cip/Kip inhibitors. 
lNK4 proteins have been shown to directly block cyclin D-dependent kinase 
activity, causing G 1 cell cycle arrest (Serrano et al., 1993, Kamb et al., 1994, Hirai et 
al., 1995). The four known INK4 proteins p16 INK4a (Sherr & Roberts, 1995), p15 INK4b 
(Hannon & Beach, 1994), p18 INK4c (Guan et al., 1994, Hirai et al., 1995), and 
p 9iNkad (Hirai et al., 1995) (15-19kDa) bind and inhibit CDK4 and CDK6 only, 
revealing that they play a role specifically at the Restriction Point of the cell cycle. 
The Cip/Kip family of inhibitors target a broader spectrum of CDKs, 
including CDK2, CDK4, CDK6 and possibly CDK1 (Harper et al., 1995). The 
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family consists of three members: p21 Cipl/Wafl , prKipl , and  p57kip2 (Sherr & Roberts, 
1995). 
Using a subtractive hybridisation approach, el-Deiry et al. (1993) identified a 
gene in rodents which became known as WAF1 (wildtype p53-activated fragment 1), 
whose expression induction was found to be associated with p53 expression (a 
tumour suppressor — to be discussed in more detail in Chapter 1.2.2(C)) and could 
suppress growth of a variety of tumour cells in culture. At the same time, Harper et 
al. (1993) identified a gene in mammalian cells, named OP1, whose expression was 
also induced by p53 and whose product inhibited the function of CDKs, specifically 
CDK2. It is now known that the sequence of WAF1 is identical to that of ClP1 (el-
Deiry et al., 1993, Harper et al., 1993). In addition an identical gene sequence was 
associated with human melanoma cells by Jiang et al. (1995) and was named MDA6 
(melanoma differentiation-associated gene 6). Being regulated by the p53 tumour 
suppressor, it is commonly regarded to play its major role at the Restriction Point, but 
has been shown to accumulate in the cell nucleus at the onset of mitosis (Dulic et al., 
1998). Many reports have revealed that p21 Cip1/Waf1 expression can be induced by 
DNA damaging agents that trigger G 1 arrest in cells with wildtype p53 (el-Deiry et 
al., 1994, Akashi et al., 1995, Russo et al., 1995), as well as p53-independent 
mechanism involving activation by mitogens (Michieli et al., 1994), 
immunosuppressive agents (Khanna & Hosenpud, 1999), cytokines (Datto et al., 
1995, Robson et al., 1999), and by a variety of differentiating agents in fibroblasts, 
haemopoietic, and hepatoma cells (Jiang et al., 1994, Steinman et al., 1994, Zhang et 
al., 1995, Liu et al., 1996a, Zeng & el-Deiry, 1996, Brown et al., 1997, Ragg et al., 
1998). Additionally, p53-independent expression of p21 Cip 1/Wafl  has been shown in 
muscle and other terminally differentiating cells (Steinman et al., 1994, Halevy et al., 
1995, Parker et al., 1995, Flink et al., 1998), thus emphasising an important link 
between p21 CipliWafl and a proposed role in terminal differentiation. Furthermore, 
Taniguchi et al. (1999) have shown that the expression of p21 CiP ilWan is regulated in 
a lineage-specific manner during normal haemopoiesis, and p21 ciP 1/wan protein levels 
are particularly high in megakaryocytes, leading to the proposal that it must be 
involved in terminal exit from the cell cycle. These findings further imply that 
differentiation agents that can activate p21 ciP 1/wan via a p53-independent mechanism 
may have significant potential for use in cancer therapies (Manfredi et al., 1996). 
Interestingly, p2l ci P liwel is not coupled to apoptosis (Steinman et al., 1994, 
Freemerman et al., 1997). 
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Several reports have suggested that p21 Cip1/Warl may also have a role in 
blocking the action of the proliferating cell nuclear antigen (PCNA), which functions 
by direct binding both in DNA replication and repair as a subunit of DNA 
polymerase 8 (Dietrich, 1993, Flores-Rozas et al., 1994, Henderson etal., 1994, Li et 
al., 1994, Waga et al., 1994, Luo et al., 1995). This further potentiates the ability of 
p2l ciP uwan to induce G 1 cell cycle arrest when overexpressed. 
p2716P 1 , first described by Toyoshima & Hunter (1994), appears to be most 
directly involved in the Restriction Point of the cell cycle, and interacts with CDK4. 
The level of p27 1(iP 1 is high in quiescent cells (antisense inhibition of p27 1(i)1 in 
cycling cells can prevent them from becoming quiescent [Coats et al., 1996, Rivard 
et al., 1996]) but fall once the cell enters the cell cycle (Figure 1.4.) (Kato et al., 
1994, Nourse et al., 1994). Residual p27 1cP 1 is believed to be sequestered into 
complexes with excess cyclin D-CDK complexes (Kato et al., 1994, Nourse et al., 
1994, Polyak et al., 1994), alleviating p27 1(iP 1 repression in cycling cells. p27 1(iP 1 is 
fundamental in regulating both cell number and cell size as mice nullizygous for the 
p27KiP 1 gene grow faster and exhibit tissues containing increased numbers of smaller 
cells than littermate controls (Nakayama et al., 1996). 
p57KiP2 , along with its counterparts p21 Cip1/Waf1 and pr icipi , inhibits several 
cyclin-CDK complexes at the Restriction Point, as its overexpression blocks cells in 
G 1 phase of the cell cycle (Lee et al., 1995, Matsuoka et al., 1995). Like p21 CiplAVan , 
p57IGP 2 is expressed in terminally differentiated cells suggesting an involvement of 
this CKI in the cell cycle exit of specific cell types (Grana & Reddy, 1995). 
C) Tumour Suppressor (TS) Proteins 
The existence of tumour suppressors was first suggested in 1969 by Harris 
and colleagues following experiments using normal cells fused with tumour cells, 
which resulted in suppression of the neoplastic properties of the tumour cell (Harris 
et al., 1969). Inactivation of tumour suppressor proteins contributes significantly to 
the neoplastic phenotype by preventing critical cell cycle checkpoints and DNA 
repair mechanisms. The transcription factor p53 and the retinoblastoma TS protein 
are the two TS proteins most worthy of consideration, and will be detailed in this 
review. 
p53 Tumour Suppressor 
The p53 gene, the most commonly mutated tumour suppressor gene in human 
cancer (Nigro et al., 1989, Levine et al., 1991, Hollstein et al., 1991 & 1994, 
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Greenblatt et al., 1994), was originally discovered in 1979 by Arnold Levine, David 
Lane, and William Old. In 1989 Bert Vogelstein, Ray White and colleagues revealed 
that p53 was actually a TS, and that it was altered in most colon cancers. Since then, 
many mutant forms of the gene have been reported in a variety of tumour types. In 
the wildtype form, p53 acts to stop cell division whenever DNA damage is detected 
in the cell, thus allowing the cell to repair the DNA prior to duplication, and 
subsequent transfer to daughter cells. This is emphasised by reports identifying the 
ability of p53 to protect against UV-B radiation-induced skin cancer (Jiang et al., 
1999). The p53 protein also becomes stabilised and activated in response to other 
stressful stimuli including hypoxia, nucleotide depletion, and oncogene activation 
(reviewed by el-Deiry, 1998). It is normally expressed at low levels and has a rapid 
turnover mediated by ubiquitination and proteolysis, and is activated by 
phosphorylation, dephosphorylation, and acetylation to yield a potent sequence-
specific DNA-binding transcription factor (Levine, 1997, el-Deiry, 1998). 
p53 acts specifically at the Restriction Point. More explicitly, p53 has the 
potential to induce expression of the p21 CipliWafl CKI (as discussed previously), thus 
resulting in G0/G 1 cell cycle arrest. In fact, it has been identified that the promoter of 
the p21 Cipl/Wari gene possesses a binding site for p53, and as such p53 functions as a 
transcription factor to activate expression of p2l ciP uwail (Kim, 1997). p53 expression 
has also been coupled to activation of a number of other target genes that result in 
growth controlling endpoints including apoptosis, senescence, differentiation, and 
antiangiogenesis (el-Deiry, 1998). Specifically, these targets include the growth arrest 
and DNA-damage inducible gene 45 (GADD45) (Zhan et al., 1998), 14-3-3a 
(Hermeking et al., 1997), Bax and Bc1-2 (Miyashita et al., 1994 & 1995), and Fas 
(Owen-Schaub et al., 1995). 
An important negative regulator of p53 at the protein level is the MDM2 
oncoprotein, which is itself responsive to p53 levels within the cell (Kubbutat et al., 
1997, Kubbutat et al., 1998). MDM2 binding to p53 conceals its transactivation 
domain thus inhibiting p53-dependent effects (Kubbutat et al., 1998). It is also 
believed that MDM2 can target the p53 protein for ubiquitin-mediated proteolysis 
(Haupt et al., 1997, Kubbutat et al., 1997, Kubbutat et al., 1998). MDM2 binding to 
p53 can be alleviated by phosphorylation of serine residues 15 and 37 on p53 by the 
ATM and DNA-dependent protein kinases, thus stabilising p53 and reducing its 
degradation (Shieh et al., 1997, Woo et al., 1998, Banin et al., 1998). This is 
highlighted by the fact that both ATM- and DNA-PK-deficient cells have defects in 
p53 activation following DNA damaging ionising radiation (el-Deiry, 1998). The 
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ability to enhance the function of p53 by phosphorylation modifications to specific 
target serine residues may have very significant implications in the future treatment 
of cancer. 
Retinoblastoma Tumour Suppressor 
Retinoblastoma is a childhood disease that results from the loss of function of 
the retinoblastoma (Rb) gene (Godbout et al., 1983, Sparkes et al., 1983). Given this 
information, it was later suspected that Rb might play a role in restraining or 
controlling cell growth, a hypothesis supported by the finding of Rb gene mutations 
in a variety of human cancers including osteosarcomas, and cancers of the lung, 
breast, bladder and prostate (reviewed by Weinberg, 1991, Budillon, 1995, and 
Brown, 1997). Abnormalities to the Rb gene have been shown to occur in 10 to 30 
percent of all types of acute leukaemia, especially those with monocytic character 
(Ahuja et al., 1991). The widespread tissue distribution of Rb mutations, and its 
involvement in such a wide array of tumours emphasises the biological importance of 
the Rb gene in normal cell proliferation (Ewen, 1994). The Rb gene may have an 
important function in the control of neoplastic growth, which is supported by 
evidence revealing that Rb associates with the transformation proteins of several 
viruses including El A of adenovirus (Whyte et al., 1988), large T antigen of SV40 
(DeCaprio et al., 1988), and the E7 protein of human papillomavirus type 16 (Dyson 
et al., 1989). The retinoblastoma tumour suppressor protein was the first tumour 
suppressor system to be studied in humans (Riley et al., 1994). 
The retinoblastoma family of proteins include the retinoblastoma protein (Rb 
or p105), and other Rb-like proteins (p107, p130) (Riley et al., 1994). These proteins 
are differentially regulated during the various stages of cell proliferation and 
differentiation (Garriga et al., 1998) and are considered to serve as mediators for 
extracellular signals for growth and differentiation (Chen et al., 1995a). The product 
of the RB1 gene, the Rb protein, is a nuclear phosphoprotein, predominantly 
regulated by phosphorylation on serine and threonine residues (Ludlow et al., 1989, 
Shew et al., 1989). It plays an essential role at the Restriction Point of the cell cycle, 
where it functions to moderate a family of heterodimeric transcription factors, 
collectively termed the E2Fs (Nevins, 1992, Helin et al., 1993, Lees et al., 1993), 
which can transactivate genes whose products are important for S phase entry 
(Neuman et al., 1994, Buchmann et al., 1998). In its hypophosphorylated state Rb is 
inactive, binding to E2F complexes and converting them to repressors that prevent 
expression of E2F target genes (Weintraub et al., 1992). When Rb is phosphorylated 
37 
Chapter 1: Literature Review 
(hyperphosphorylated or active state), the bound E2Fs are released and are 
subsequently able to transactivate their gene targets. It is now well established that 
Rb is the key target for phosphorylation by cyclin D-dependent kinase complexes 
(Ewen et al., 1993, Kato et al., 1993, Sherr, 1994). The finding that cyclin D-
dependent kinases are dispensable for passage through the G 1 to S phase in cells that 
lack functional Rb (Lukas et al., 1994) further supports this notion. 
The process of E2F release by cyclin D-dependent-mediated phosphorylation 
of Rb is further accelerated by the formation of the cyclin E-CDK2 complex (Hinds 
et al., 1992, Mittnacht et al., 1994), because the cyclin E gene is itself E2F-
responsive. That is, cyclin E-CDK2 acts through positive feedback, which in turn 
facilitates progressive rounds of Rb phosphorylation and subsequent E2F release 
(Weinberg, 1995) (refer to Figure 1.3.). It is at the G1-S boundary that the cell 
undergoes irreversible commitment to enter S phase, and Rb inactivation shifts from 
being mitogen-dependent (cyclin D-driven) to mitogen-independent (cyclin E-driven) 
(Sherr, 1996). Rb is then maintained in its hyperphosphorylated state by cyclin A-
and cyclin B-dependent kinases, and remains dephosphorylated until the cell 
completes mitosis and re-enters G0/G1 phase. 
The phosphorylation status of Rb during cell differentiation has been 
extensively studied in a variety of cell types. Whyte and Eisenman (1992) found that 
PMA-induced macrophage differentiation of HL60 cells resulted in the reduction of 
phosphorylated Rb, concurrent with cells undergoing G 0/G 1 cell cycle arrest. 
Additionally, Juan et al. (1998) have reported that terminal differentiation of HL60 
cells involves both an increase in content of Rb and dephosphorylation of Rb already 
present in the cell. 
Two mechanisms of Rb dephosphorylation have been noted to date in the 
literature: indirectly via activation of the CKIs p21 Cipl/Wafi and p271(41 which inhibit 
cyclin D-dependent kinases from phosphorylating Rb (Harper et al., 1993, 
Toyoshima & Hunter, 1994), and, by direct removal of phosphate groups by protein 
phosphatase (PP) activity. A number of reports were initially made by Durfee et al. 
(1993) and Ludlow et al. (1993), and more recently by Nelson et al. (1997), showing 
that PPs are involved in Rb dephosphorylation during mitosis and back into G0/G 1  
phase. Schonthal & Feramisco (1993) and Dou et al. (1995) were fundamental in 
advancing the role of PP-mediated Rb dephosphorylation, culminating in G 0/G 1 cell 
cycle arrest. Many investigators have since reported on the involvement of PPs, and 
all are in agreement that serine/threonine phosphatases belonging to the PP1 
(Schonthal & Feramisco, 1993, Dou et al., 1995, Ludlow & Nelson, 1995, Berndt et 
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al., 1997, Nelson, 1997, Rubin et al., 1998, Kishikawa et al., 1999, Edwards & 
Thomas, 2000) and PP2A (Schonthal & Feramisco, 1993, Dou et al., 1995, 
Voorhoeve et al., 1999) sub-families of protein phosphatases are involved. This was 
determined in each case using specific PP1 and PP2A inhibitors including okadaic 
acid, calyculin A, and phosphatidic acid (Ishihara et al., 1989, Kishikawa et al., 
1999). 
Rb has been implicated in apoptosis by a number of investigators who have 
reported findings implying that Rb is cleaved by Interleukin 113-converting enzyme-
like proteases and other caspases, thus contributing to the activation of the cell-death 
pathway (An & Dou, 1996, Janicke et al., 1996, Chen et al., 1997, Tan & Wang, 
1998, Fan & Steer, 1999, Schrantz et al., 1999). Further to this, Song and colleagues 
(Song et al., 1992, Song & Lavin, 1993) have reported an involvement of PPs in 
apoptosis. That is, by inhibiting PP activity, y-irradiation-induced apoptosis was 
prevented. More recently, Morana et al. (1996) and Wolf et al. (1997) have drawn a 
link between phosphatase activity, Rb dephosphorylation, and etoposide-induced 
apoptosis in ML-1 human haemopoietic cells, suggesting that Rb dephosphorylation 
is a critical regulator of apoptosis. 
A thorough understanding of the p53 pathway, which controls activation of 
negative regulatory elements of the cell cycle, and the Rb pathway and its 
components, forms the basis for understanding how to regain control of the cell cycle 
in neoplastic cells. 
1.2.3. Abnormalities in Cancer Cell Cycles 
The hallmark of cancer is uncontrolled proliferation, which typically arises 
due to acquired damage to genes that directly regulate the cell cycle (Sherr, 1996). 
The result is an uncoupling of normal proliferative and differentiation events 
culminating in neoplastic proliferation, that is, cancer. It is now clear that the 
development of cancer is not the result of a single oncogenic event, but rather a 
combination of events proceeding in a step-wise fashion, likely to be influenced by 
the cellular environment (Ho & O'Neill, 1995). Consequently, transformed immature 
cells can give rise to a spectrum of diseases depending on the growth factors 
available, and indeed studies by O'Connor et al. (1990) and Kurtzberg et al. (1989) 
have shown that growth factors are capable of dictating the lineage commitment of 
immature ATLL cells. 
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A myriad of genetic alterations has been reported in cancer. Of the more than 
100 proto-oncogenes and TS genes identified, most function to uncouple cells from 
their environmental controls by mimicking the effects of persistent mitogenic 
stimulation (Sherr, 1996). Alterations to pivotal cellular components (for example 
DNA replication and chromosome segregation) are highly debilitating, if not fatal, to 
cells. The uncontrolled proliferative nature of cancer implies that genes commanding 
these processes are not 'ideal' candidates for targets of mutation, deletion, or 
amplification in cancer. Instead, a significant majority of genes altered in cancer are 
those that govern control of the cell cycle, in particular genes that regulate exit from 
the G1 phase of the cell cycle. In fact, such alterations are so frequent in human 
cancers it has been proposed that inactivation of such genes (p53, Rb, CDKs and 
CKIs) may well be necessary for tumour development. 
The p53 gene is reported to be the most frequently mutated gene in human 
cancer (Nigro et al., 1989, Hollstein et al., 1991, Hollstein et al., 1994, Greenblatt et 
al., 1994). Loss of p53 predisposes cells to aberrant chromosomal segregation during 
mitosis (Fukasawa et al., 1996), leading to changes in chromosome number and 
ploidy. Rb inactivation is of course a feature of retinoblastomas (Knudson, 1971), 
and is most often targeted in adult cancers, particularly osteosarcomas and small-cell 
carcinomas of the lung (Hall & Peters, 1996). As it is a significant target protein for 
p53, loss of Rb function can bypass p53-mediated G1 arrest. Overexpression of E2F 
genes has not yet been reported in human cancers. 
Mutations affecting the cyclins, CDKs and CKIs have been extensively 
reported in human cancers. Overexpression of cyclin D1 has been noted in a variety 
of different human cancers including squamous cell carcinomas, oesophageal 
carcinomas, bladder cancer, breast carcinoma, small-cell lung tumours, 
hepatocellular carcinomas, colorectal tumours, melanomas, and B-cell leukaemias 
(Motolcura et al., 1991, Hall & Peters, 1996). Alterations in the cyclin E and A genes 
appear to be rare (Hall & Peters, 1996). In fact, there is only one instance in which 
the cyclin A gene was found to be altered in a hepatoma (Wang et al., 1990). A 
mutation in CDK4 preventing its interaction with p16 has been found in melanoma 
(Wolfel et al., 1995). While p16 INK4a mutations have been associated with familial 
melanomas and occur in high frequency in billiary and oesophageal carcinomas (Hall 
& Peters, 1996, Elledge & Harper, 1994, Sherr & Roberts, 1995), mutations or 
, deletions of p15 INK41' 	18iNk4c , p or pi 9 INK4d  have not been reported in tumours. 
Interestingly, inactivation of p27 KI P 1 and p21 Cip1iWafi genes have not been reported 
either, however a reduction in their levels has been noted (Sherr, 1996). This may 
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suggest that p53 probably activates additional, critical tumour suppressor pathways 
(Shiohara et al., 1997). 
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1.3. The Sphingomyelin Pathway 
1.3.1. Introduction 
The sphingomyelin (SM) pathway is a ubiquitous, cellular signalling system 
that is highly conserved from yeast to humans (Harmun, 1996, Spiegel et al., 1996, 
Mathias et al., 1998) and is responsible for conveying signals throughout the cell in 
response to cellular stress, cytokines and ligation of a number of receptor types , 
(Hannun & Luberto, 2000). The SM pathway involves a number of different 
sphingolipids which result from the hydrolysis of the sphingophospholipid, 
sphingomyelin, which is confined to both the inner and outer leaflets of cell 
membranes, although there is still uncertainty as to which of these pools is important 
in signalling (Perry & Hannun, 1998). SM consists of a sphingosine backbone base 
linked to a fatty acid by an amide bond, and has a hydrophilic headgroup that extends 
into the aqueous environment (Saba et al., 1996). Figure 1.6. details the key 
components of the SM pathway. SM and its associated sphingolipid hydrolysis 
products were long regarded as metabolically inactive, and stable structural 
components of the membrane, and are considered only minor components of cell 
membranes (Ghosh et al., 1997) compared with the more familiar glycerolipids 
which were known to produce active second messengers such as diaglycerol and 1P 3 
(Igarashi, 1997). The notion that sphingolipids were biologically inactive was first 
challenged by Okazaki and colleagues (1989), who reported Vitamin D 3-induced 
turnover of SM in HL60 cells. Sphingolipids are a diverse class of molecules, a 
number of which have been shown to play an important role as second messengers 
within the cell (Kolesnick et al., 1994), producing a diverse range of stress-related 
cellular responses including cell cycle arrest, apoptosis, and cell senescence 
(Kolesnick and Golde, 1994, Hannun, 1996). 
Sphingolipid signal transduction has become a dominant theme in biology 
today. As more research is conducted into elucidation of the molecular events that 
occur to elicit an intracellular response, the more it is recognised that sphingolipid 
signalling is crucial for normal cell behaviour. Furthermore, aberrant sphingolipid 
signalling consistently results in a diverse range of pathological consequences 
(Ghosh et al., 1997). 
1.3.2. Ceramide Synthesis in the Sphingomyelin Pathway 
Ceramide is the central molecule in the SM pathway. Two mechanisms have 
been shown to generate ceramide: hydrolysis of SM by enzymes termed 
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sphingomyelinases (SMases), and, de novo synthesis by the ceramide synthase 
enzyme (Kolesnick, 1991, Spiegel et al., 1996, Spiegel & Merrill, 1996, Merrill et 
al., 1997). Both synthesis pathways are presented in Figure 1.6. and are described in 
some detail below. Interestingly, enzymes involved in ceramide generation are 
located in different subcellular compartments, and this significantly affects the final 
ceramide-mediated outcome (Mathias etal., 1998). 
The de novo synthesis of ceramide is initiated by the condensation of serine 
and palmitoyl-CoA resulting in the formation of 3-oxosphinganine, which is 
subsequently reduced to sphinganine. An amide linkage of fatty acyl groups to 
sphinganine yields dihydroceramide, and the introduction of a trans-4,5-double bond 
results in the formation of ceramide. The early stages of the de novo pathway occur at 
the endoplasmic reticulum and proceeds to the Golgi network where the newly 
generated ceramide can act as a precursor to other SM members (Perry & Hannun, 
1998). 
Ceramide generation resulting from hydrolysis of SM at the cell membrane 
involves the action of one of a number of SMase isoforms, with at least seven having 
been identified to date (Levade & Jaffrezou, 1999). SMases are classified according 
to their pH optima and divalent ion dependence (Levade & Jaffrezou, 1999). The 
most well characterised of the SMases include the following: the lysosomal acid 
SMase (A-SMase), the acid Zn2±-dependent SMase, the neutral membrane bound 
Mg2+-dependent SMase (N-SMase), the neutral Mg-independent SMase present in 
myelin sheath and the cytosol of leukaemic cells, and the alkaline SMase present in 
bile and the digestive tract (Fowler, 1969, Rao et al., 1976, Nyberg et al., 1996, 
Schissel et al., 1996, Chakraborty et al., 1997). The best characterised of these 
SMases is the lysosomal A-SMase, as it has been found to be deficient in patients 
affected with the autosomal recessive condition, Niemann-Pick disease (NPD), a 
lysosomal SM storage disorder (Levade et al., 1986, Levade & Jaffrezou, 1999). The 
properties, tissue distribution, subcellular localisation, and regulation of SMase 
activity associated with ceramide generation are outside the scope of this thesis, but 
are reviewed by Liu etal. (1997 & 1999a) and Levade & Jaffrezou (1999). 
Kinetic studies have shown that ceramide can be generated within minutes or 
hours, depending upon the extracellular stimuli. The most dramatic change in 
ceramide generation has been found to occur after deprivation of serum in leukaemia 
cell cultures (Hannun, 1996). The magnitude of ceramide generation, the site and 
source of generation, and the phase of the cell cycle and state of activation of 
transmodulating signals all appear to play a role in the final biological effect 
43 
Chapter 1: Literature Review 
mediated by ceramide (Mathias et al., 1998). As well as having a role in cellular 
function (discussed below), ceramide serves as a precursor for all other complex 
sphingolipids such as galactosylceramide, glucosylceramide, acyl ceramides and 
ceramide phosphate through the action of a direct kinase (Kolesnick & Hemer, 1990). 
1.3.3. Inducers of Ceramide Generation 
A number of substances can induce hydrolysis of SM by SMases. Okazaki et 
al. (1989) found that addition of the differentiating agent 1a,25-dihydroxyvitamin D3 
to HL60 human leukaemia cells caused early and reversible hydrolysis of SM and 
subsequent generation of ceramide. INF-a and y-interferon have also been shown to 
induce SM hydrolysis in HL60 cells (Kim et al., 1991, Mathias et al., 1991, Dressler 
et al., 1992). These studies defined the basic components of the SM pathway, and it 
was later shown that ceramide generation as a response to treatment with these agents 
involved activation of the neutral cytosolic SMase (Okazaki et al., 1994). Serum 
withdrawal has also been shown to induce ceramide production through activation of 
this SMase, resulting in Go/G1 cell cycle arrest (Jayadev et al., 1995). Interestingly, 
other differentiating agents including retinoic acid, dibutyl cyclic AMP, dimethyl 
sulfoxide and phorbol esters failed to induce SM hydrolysis (Kiss et al., 1988, Kim et 
al., 1991). Ceramide levels have been shown to be significantly elevated following 
retinoic acid treatment, but this has been proposed to be due to de novo synthesis and 
not SMase activation (Kalen et al., 1992). Ligation of the Fas receptor has also been 
reported to induce SM hydrolysis to increase cellular ceramide levels (Jarvis et al., 
1996). Additional inducers of SM hydrolysis include IL-113 (Ballou et al., 1992, 
Mathias et al., 1993), dexamethasone (Ramachandran et al., 1990), and complement 
components (Niculescu et al., 1993). 
Chan & Ochi (1995) have shown that ligation of the CD28 membrane 
glycoprotein of T cells with its ligand initiates SM hydrolysis and generated 
ceramide. Furthermore, treatment of T cells with either exogenous SMase or a 
ceramide analogue resulted in the proliferation of these cells and transcription of the 
IL-2 gene, thus mimicking the CD28 signal. They concluded that the ceramide-
signalling pathway is a candidate for mediating the costimulatory signal. 
Ceramide synthesis can therefore be induced during periods of cellular stress 
(for example, during serum withdrawal) on the one hand, and during periods of 
cellular proliferation or differentiation on the other hand. This suggests therefore, that 
ceramide is a multi-functional molecule within the cell, and its role as a second 
messenger varies markedly depending upon the extracellular circumstances. 
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1.3.4. Cellular Targets of Ceramide 
Ceramide has been shown to mediate a diverse range of cellular responses. 
The resulting response depends on the initial stimulus, cell type and the phase of the 
cell cycle when stimulated (refer to Figure 1.7.). To allow for such a vast array of 
cellular responses, it has become clear that ceramide has multiple molecular targets 
within the cell. Studies performed over the last decade to investigate the targets of 
ceramide signalling and the resulting cellular response have used cell-permeable, 
biologically active ceramide analogues including C2-ceramide and C6-ceramide, or 
ceramide produced in the plasma membrane by incubation of cells with a bacterial 
SMase. These models effectively mimic the action of an extracellular stimulus 
(Levade & Jaffrezou, 1999). Ceramide has been shown to activate a plethora of 
downstream targets including kinases and phosphatases, members of the stress-
response kinase cascade (SAPK/JNK) and components of the mitogen-activated 
protein kinase cascade (MAPK) (reviewed by Testi, 1996, Riboni et al., 1997 and 
Gomez-Munoz, 1998). 
One such target of ceramide is a Mg 2+-dependent proline-directed 
serine/threonine specific kinase, exclusively confined to the cell membrane, which 
has been named the ceramide-activated protein kinase (CAPK) (Mathias et al., 1991, 
Dressler et al., 1992, Joseph et al., 1993). CAPK has been shown to phosphorylate 
the Raf-1 kinase, coupling the SM pathway with the MAPK cascade. Raf-1 activation 
in turn activates the extracellular-signal-regulated kinase 2 (ERK-2), a type of 
MAPK, via phosphorylation of MAPK/ERK kinase (MEK) (Yao et al., 1995). 
Additionally, a direct target of ceramide is a guanine nucleotide exchange factor, 
Vav, which is able to activate Ras, indicating that ceramide may interact at different 
levels with MAPK signalling (Gulbins etal., 1994). 
Ceramide activates a cytosolic heterotrimeric protein phosphatase, which has 
been named the ceramide-activated protein phosphatase (CAPP) (Dobrowsky & 
Hannun, 1992 & 1993, Dobrowsky et al., 1993, Hannun, 1996). CAPP has been 
shown to belong to the PP2A subfamily of protein phosphatases (Dobrowsky et al., 
1993, Galadari et al., 1998), and is believed to mediate c-myc downregulation and 
apoptosis in HL60 cells (Wolff et al., 1994), c-jun phosphorylation in A431 human 
epithelial tumour cells (Reyes et al., 1996), PKCa inactivation in MOLT-4 and 
Jurkat T cells (Lee et al., 1996), and among other effects is also considered a key 
mediator for dephosphorylation of Rb (discussed previously in Chapter 1.2.2.) thus 
resulting in G0/G 1 cell cycle arrest (Schonthal & Feramisco, 1993, Dbaibo et al., 
1995, Voorhoeve et al., 1999, Lee et al., 2000). In addition, another protein 
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Figure 1.7.: Mechanisms of ceramide generation and targets of ceramide action (modified from 
Mathias et al., 1998). Ceramide is generated by hydrolysis of sphingomyelin (SM) by 
sphingomyelinases (SMases), or by the de novo synthesis pathway. Ceramide is pleiotropic in nature, 
capable of activating a number of different molecular targets depending on specific circumstances. 
Downstream effects of ceramide generation include cell cycle arrest, cellular senescence, 
differentiation, and/or apoptosis. 
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phosphatase, belonging to the PP1 subfamily of protein phosphatases, is also 
believed to be activated by long chain ceramides (Chalfant et al., 1999) and is 
associated with Rb dephosphorylation and cell cycle arrest (Dou et al., 1995, Ludlow 
& Nelson, 1995, Berndt et al., 1997, Nelson et al., 1997, Rubin et al., 1998, 
Kishikawa et al., 1999, Liu et al., 1999b, Edwards & Thomas, 2000). 
Ceramide has also been shown to activate transcriptional targets including c-
fos and c-jun. In the stress-response kinase cascade, ceramide activates MEK kinase 
(MEKK) to activate Jun kinase 1 (JNK-1) by phosphorylation via stress-activated 
protein kinase/ERK kinase (SEK) (Westwick et al., 1995, Verheij et al., 1996, 
reviewed by Liu et al., 1999a). Corresponding with this, the levels of the 
transcription factor complex AP-1 increase following ceramide treatment (Okazaki et 
al., 1998), which is important in ceramide-induced apoptosis in HL60 cells (Sawai et 
al., 1995). In addition, ceramide has been shown to suppress the expression of the c-
myc proto-oncogene by interfering with transcription elongation (Wolff et al., 1994). 
The protein kinase C 4 isoform (a DAG and phorbol ester-insensitive 
isoenzyme of PKC) is known to be a target of ceramide signalling (Muller et al., 
1995). A number of investigators have suggested that ceramide rapidly induces the 
translocation and activation of NF-KB (Schutze et al., 1992, Yang et al., 1993, 
Wiegmann et al., 1994), most likely through phosphorylation of the cytosolic IKBoc 
inhibitor by PKC4 (Lozano et al., 1994, Limatola et al., 1997). The subsequent 
induction of degradation of NF-KB critically controls the expression of a number of 
genes that are dependent on this factor (Testi, 1996). 
In the same way that ceramide synthesis can be activated during distinctly 
different extracellular circumstances, the targets of ceramide signalling are markedly 
varied. This indicates that ceramide synthesis and the interaction of ceramide with its 
different target molecules, will give rise to a multitude of cellular responses. This 
further supports the notion that ceramide is multi-functional (although able to initiate 
a specific response depending on the target activated), as opposed to having a single, 
defined function within the cell. 
1.3.5. Ceramide-Mediated Cellular Effects 
The transduction of extracellular signals is mediated by transient molecules 
termed second messengers (McGovern et al., 1995), of which ceramide is regarded to 
be an important member. Second messenger molecules are generated from a pre-
existing precursor (sphingomyelin, in the case of ceramide) strictly in response to a 
specific signal, and function to elicit a specific biological response, thus forming a 
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tight coupling of the intracellular reaction to the extracellular signal (Ghosh et al., 
1997). 
The second messenger ceramide, the central component of the SM pathway, 
has a highly pleiotropic nature, capable of instigating a range of anti-proliferative 
cellular responses. These include proliferation, differentiation, growth arrest and 
apoptosis (Mathias et al., 1998), depending on the cell type and the initial stimuli 
presented to the external surface of the cell, and also the amount and location of 
ceramide generation (Perry & Hannun, 1998). This is due to the fact that ceramide 
signalling is linked to a variety of cell receptors. Furthermore, Spiegel and colleagues 
describe the "ceramide/sphingosine-l-phosphate rheostat" to propose that a balance 
exists between cellular ceramide levels that favour death and sphingosine-1- 
phosphate levels that inhibit death, and strongly suggest that this is a critical factor 
that ultimately determines the fate of cells (Van Brocklyn et al., 1998). Some of the 
downstream cellular functions of ceramide signalling are detailed below. 
A) Cell Cycle Regulation and Senescence 
Treatment of HL60 with the cell permeable ceramide analogue, C2-ceramide, 
was sufficient to induce specific and potent antiproliferative effects even at 
concentrations as low as 1-10 1.1M (Okazaki et al., 1990). Ceramide has now been 
shown to induce these effects in a number of different human leukaemia cells and in 
normal fibroblasts in logarithmic phase of growth (Hannun, 1994). Similarly, a 
considerable increase in ceramide levels has been noted in WI-38 human diploid 
fibroblast cells entering senescence (Venable et al., 1995). Ceramide-induced cell 
cycle arrest occurs specifically in the G0/G1 phase of the cell cycle, thus preventing 
progression into S phase (Jayadev et al., 1995). Extensive research has been 
performed into the mechanisms by which ceramide induces cell cycle arrest, and it 
now appears that ceramide-induced cell cycle arrest certainly involves the 
dephosphorylation (activation) of Rb (Chao et al., 1992, Jayadev et al., 1995, Dbaibo 
et al., 1995). Cells partially deficient in Rb or expressing proteins that sequester the 
Rb protein were resistant to ceramide-induced cell cycle arrest (Mathias et al., 1998). 
As previously discussed, two mechanisms exist for Rb activation: activation of 
expression of the CKI p21 CipliWafl, and activation of protein phosphatases, both of 
which are shown to occur following ceramide treatment (Dobrowsky et al., 1992, 
Dobrowsky et al., 1993, Kolesnick & Golde, 1994, Wolff et al., 1994, Hannun, 1996, 
Ragg et al., 1998, Lee et al., 2000). 
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Therefore, ceramide has the ability to control significant components of the 
cell cycle, such as the phosphorylation status of Rb at the G 1 to S phase transition. 
This in turn implies that manipulation of the ceramide signalling pathway may be 
beneficial in the treatment of proliferative disorders such as leukaemia, where 
regaining control of the cell cycle is of extreme importance. 
B) Differentiation 
Ceramide was first postulated to be an intracellular modulator of 
differentiation following the finding that treatment of HL60 cells with a ceramide 
analogue results in differentiation of these cells along the monocytic lineage 
(Okazaki et al., 1990, Kim et al., 1991). This response mimics the effect of TNFa, 
1 a,25-dihydroxyvitamin D3, IL-l3 and y-interferon treatment previously noted in 
HL60 cells (Okazaki et al., 1989, Ballou et al., 1992, Kim et al., 1991, Mathias etal., 
1993, Kolesnick & Golde, 1994). Ragg et al. (1998) have demonstrated ceramide-
induced terminal differentiation (passage from the G o/G 1 phase into the S phase of 
the cell cycle is prevented) accompanied by concomitant cell cycle arrest in U-937 
monoblastic cells. Similarly, studies on the rat neuronal T9 cell line have revealed 
that these cells form neurite processes, a marker of differentiation in T9 cells, four 
days after ceramide addition (Dobrowsky et al., 1994). In addition, Prinetti et al. 
(1997) have linked ceramide-mediated protein phosphatase activation with 
differentiation of a neuroblastoma Neuro2a cells. 
C) Apoptosis 
The involvement of ceramide in inducing apoptosis (programmed cell death) 
was first demonstrated by Obeid et al. (1993) in U-937 cells and has since been 
extensively studied. Jarvis & Grant (1998) have demonstrated an association between 
ceramide signalling and chemotherapy-related apoptosis. Ceramide levels are 
increased in HIV-infected T lymphocytes, which are known to undergo apoptosis 
(Van Veldhoven et al., 1992). Ligation of the Fas and TNFcc receptors, which results 
in apoptosis, has been associated with SM hydrolysis and the subsequent generation 
of ceramide (Kim et al., 1991, Mathias et al., 1991, Dressler et al., 1992, Jarvis et al., 
1994a, Verheij et al., 1996, Kolesnick & Kronke, 1998). Addition of exogenous 
ceramide results in apoptosis in a number of cell lines. These two findings were used 
to postulate the hypothesis that ceramide was directly responsible for Fas- and 
TNF'a-induced apoptosis (Obeid et al., 1993, Cuvillier et al., 1996, Verheij et al., 
1996, Mathias etal., 1998). 
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More recent studies have shown that ceramide is not the primary second 
messenger responsible for Fas-induced apoptosis. Instead, ceramide generation as a 
result of Fas receptor ligation may be merely accentuating the apoptotic signal, or 
may be a coincidental finding, or a redundant secondary pathway of Fas signalling 
(Gamen et al., 1998, Hsu et al., 1998, Tepper et al., 1999). In fact, a study by Watts 
et al. (1997), and a similar study by Sillence and Allan (1997), has dissociated the 
link between ceramide signalling and Fas-induced apoptosis, after showing that Fas-
induced apoptosis in Jurkat T cells was not accompanied by a detectable increase in 
ceramide production. The role of ceramide in TNFa-induced apoptosis is also not 
universally accepted. Some authors suggest that ceramide generation is a 
consequence of TNFa-mediated apoptosis and that ceramide and TNFa can induce 
the apoptotic pathway via separate means (reviewed by Liu et al., 1999a). As 
ceramide-induced apoptosis relies on activation of the transcription factor c-jun, and 
TNFa-induced apoptosis occurs independent of c-jun activation, Liu et al. (1996b) 
suggest that ceramide production and TNFa-mediated apoptosis are separate events. 
Although not directly related to the Fas or TNFa studies, Jayadev et al. (1995) 
showed that activators of PKC, known antagonists of ceramide-induced apoptosis 
(Obeid et al., 1993, Jarvis et al., 1994b), had no effect on ceramide-induced cell 
cycle arrest. This suggests that ceramide regulates the outcomes of apoptosis and cell 
cycle arrest independent of one another. Mengubas et al. (1999) have shown that 
ceramide-induced death of malignant cells from patients with B-CLL and normal B 
lymphocytes occurs via a non-apoptotic mechanism. 
The mechanism by which ceramide causes apoptosis has remained elusive, 
and is still regarded to be somewhat controversial. There is a lack of data 
demonstrating a direct interaction between ceramide signalling and the primary 
components (the caspase and Bc1-2 families) of the apoptotic machinery (Perry & 
Hannun, 1998). There is some, although limited, support for the involvement of 
ceramide-induced apoptosis by activation of caspases (Smyth et al., 1996, Spinedi et 
al., 1998), while other authors present conflicting arguments to say that ceramide-
mediated apoptosis occurs independently of caspase activation (Belaud-Rotureau, 
1999). Recent reports now indicate that the mitochondria may be central in ceramide-
induced apoptosis. Modulation of mitochondria function by ceramide in mainly cell-
free systems has been shown in a number of studies (Arora et al., 1997, Garcia-Ruiz 
et al., 1997, Ruvolo et al., 1999, Di Paola et al., 2000). More specifically, ceramide 
can induce the release of cytochrome c from isolated mitochondria (Ghafourifar et 
al., 1999) and enhances cytoplasmic cytochrome c levels prior to caspase activation 
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(Ito et al., 1999, Cuvillier et al., 2000). These findings provide the link between 
ceramide signalling and execution easpases. Recent studies have revealed that there 
is a reduction in the transmembrane potential of the mitochondria during chemically-
induced apoptosis (Scarlett et al., 2000), and during ceramide-induced apoptosis in 
Jurkat T cells (Hearps et al., 2002). A reduction in mitochondrial transmembrane 
potential is consistent with compromised permeability of the organelle, which allows 
for the release of cytochrome c and its subsequent activation of effector caspases in 
coordination with a protein called Apaf-1 (Zou et al., 1997). 
As mentioned in Chapter 1.2.2(C)., the retinoblastoma protein, known to be 
activated by ceramide, has been implicated to play a role in apoptosis. It has been 
suggested that Rb is cleaved by Interleukin 1P-converting enzyme-like proteases, 
accentuating the apoptotic response (An & Dou, 1996, Janicke et al., 1996, Chen et 
al., 1997, Tan & Wang, 1998, Fan & Steer, 1999, Schrantz etal., 1999). There is also 
some evidence to suggest that ceramide mediates apoptosis via activation of protein 
phosphatases (Song et al., 1992, Song & Lavin, 1993). Protein phosphatase 
inhibition has been shown to prevent drug-induced caspase activation (Morana et al., 
1996). Some members of the Bc1-2 family are regulated by phosphorylation and it is 
possible that these are likely targets for ceramide effectors in apoptosis (Perry & 
Hannun, 1998). 
A better understanding of the molecular basis of ceramide action may be 
useful in providing greater insights into the pathogenesis of disease and may 
potentially offer novel strategies for therapeutic intervention. Further elucidation of 
the mechanisms of ceramide-induced cellular effects is paramount to releasing this 
potential. 
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1.4. Differentiation Therapy 
1.4.1. Current Proceedings in Differentiation Therapy 
Current conventional therapies for cancer treatment are not tumour specific 
and are often associated with considerable toxicity (Mokyr & Dray, 1987, Pai & 
Nahata, 2000). Furthermore, the emergence of drug resistant cells, despite the use of 
combined therapies as an attempt to overcome this, is one of the main obstacles for 
successful chemotherapeutic treatment of haematological malignancies (Nooter & 
Sonneveld, 1993, Sikic, 1999, Bunn & Kelly, 2000). As such, there is a need for the 
development of new drugs or treatment strategies for leukaemia and related diseases. 
A potentially less toxic approach is to target cellular growth and differentiation 
pathways to modify the state of differentiation and growth of cancer cells, while 
limiting cytotoxicity to healthy neighbouring cells, a strategy termed 'differentiation 
therapy' (Sachs, 1978, Fisher et al., 1985, Waxman, 1996, Leszczyniecka et al., 
2001). Differentiation therapy is based on the assumption that many neoplastic cells 
show reversible defects in normal differentiation and cell growth programs, and with 
the appropriate treatment, these tumour cells can be reprogrammed to result in loss of 
proliferative capacity, induction of terminal differentiation (Sachs, 1978, Fisher et 
al., 1985, Waxman 1996), and ultimately apoptosis (Martin etal., 1990). 
The three major fates of haemopoietic cells (proliferation, differentiation and 
death) are closely interconnected. Induction of differentiation is generally associated 
with reduced proliferative capacity, and cell death regularly accompanies the latter 
stages of differentiation (Leszczyniecka et al., 2001). Therefore, it is not surprising 
therefore that in disease states which exhibit haemopoietic deregulation, such as 
leukaemia, there is a disruption to the processes of cellular proliferation, 
differentiation and/or apoptosis. To fully appreciate the close inter-relationship 
between proliferation, maturation, and death, it is necessary to understand the factors 
affecting haemopoietic cell differentiation, and how deregulation leads to enhanced 
proliferation and/or a block in differentiation. 
Differentiation is initially triggered by the binding of haemopoietic growth 
factors to their appropriate receptor on the external surface of the cell. Several growth 
factors have been shown to be involved during the early stages of haemopoietic 
proliferation and differentiation, including stem cell factor, IL-1 and IL-3, while other 
growth factors such as GM-CSF and G-CSF have been associated with this process 
during the latter stages (Leszczyniecka et al., 2001). The binding of growth factors to 
cell surface receptors activates a variety of signal transduction pathways, and it is the 
51 
Chapter 1: Literature Review 
components of these pathways (in particular, the modulation in activity) that have 
attracted significant attention in recent differentiation studies. The final cellular 
response is dependent upon the specific pathway activated. For example, activation 
of ERK MAPK pathway is associated with proliferation, whereas SEK/JNK 
activation is associated with an antiproliferative response (growth arrest, 
differentiation and apoptosis) (Szabo et al., 1994, Xia et al., 1995, Pyne et al., 1996, 
Verheij et al., 1996). That ERK is hyperexpressed in human breast cancer and may 
be a critical element in initiation and metastatic potential of this disease (Johnson, 
1997, Sivaraman et al., 1997, Mueller et al., 2000) is further evidence that aberrant 
intracellular signalling can be a causative factor in cancer. Interestingly, the finding 
that inhibitors of PKC and MEK/MAPK can block phorbol ester- and retinoic acid-
induced leukaemic cell maturation (Ragg et al., 1998, Yen et al., 1998, Hu et al., 
2000) implies that this pathway also has the potential to regulate terminal 
differentiation. 
Stimulation of signal transduction pathways results in the activation of 
transcription factors (TFs), which permit the transcription of specific genes, whose 
protein products promote the differentiation response. TFs triggered by 
differentiation stimuli in haemopoietic cells include PU.1 (Olson et al., 1995, Simon 
et al., 1996, Bellon et al., 1997, DeKoter et al., 1998, Anderson et al., 1999, Oikawa 
et al., 1999), c-jun (Adunyah et al., 1992 & 1995), AP-1 (Liebermann et al., 1998, 
Rosson & O'Brien, 1998), substance P-1 (Laurenzi et al., 1989, Bost & Pascual, 
1992, Pascual et al., 1992), and c-Myc (Lerga et al., 1999, Lin et al., 2000). It is not 
unexpected to note that TFs that are involved in cell differentiation have also been 
linked to regulation of apoptosis, emphasising the close relationship that exists 
between differentiation and cell death (Leszczyniecka et al., 2001). 
A crucial prerequisite for haemopoietic cell terminal differentiation is cell 
cycle arrest (Freytag, 1988, Furukawa, 1997, 1998, & 2002), a process that has been 
tightly linked with the activation of TFs factors via differentiation-associated 
signalling. A consequence of cells escaping this regulation process is seen in disease 
states such as melanoma (Platz et al., 1996) and leukaemia (Drexler, 1998). Myeloid 
cell exposure to phorbol esters results in an increase in p21 ciP UWan expression via 
MAPK (Jiang et al., 1994, Kharbanda et al., 1994, Zeng & el-Deiry, 1996), a well-
noted feature in terminally differentiated cells (Halevy et al., 1995, Liebermann et 
al., 1995, Parker et al., 1995, Flink et al., 1998). The ability to link activation of the 
MAPK signal transduction pathway and p21 c1P uwan expression is important from a 
therapeutic perspective, as studies by Park et al. (1999), Niibe et al. (1999), Tian et 
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al. (2000), and others have shown that p21 cIP liwan null cells or cells expressing p21 
antisense have increased sensitivity to chemotherapy and radiotherapy-induced 
apoptosis. Thus the ability to control expression of p21 CiP IAVan is of dual importance, 
as upregulated expression is essential for reducing the proliferative capacity via 
terminal differentiation, whereas downregulated expression may increase 
susceptibility of the cancer cells to apoptosis-inducing agents. These studies highlight 
that manipulation of intracellular signalling pathways may represent a potential 
strategy for the induction of terminal differentiation or the sensitisation of cells to 
chemotherapeutic agents or radiation. 
1.4.2. Differentiation-Inducing Agents 
To date, differentiation therapy has had the greatest impact in haematological 
malignancies, most notably leukaemia (Leszczyniecka et al., 2001). In vivo, the 
majority of tumour cells, regardless of their lineage, appear to be refractory to the 
most extensively studied inducers of differentiation (Manfredi et al., 1996). 
Considerable research over the last decade has concentrated on finding suitable 
differentiation-mediating drugs. Two, in particular, have emerged as showing 
promise in the clinical setting in their ability to overcome maturation defects in 
leukaemia cells; vitamin D3 and all-trans retinoic acid, although the use of these 
agents are associated with clinical limitations. Examples of various differentiation-
inducing agents that have been investigated to date are discussed below. While each 
of these agents have been shown to be effective in vitro, only a minority have been 
applied to the clinical treatment of patients with haematological malignancies. 
A) Vitamin D3 
The hormonal form of vitamin D, 1 a,25-dihydroxyvitamin D3 (or vitamin 
D3), plays a role in calcium ion homeostasis, and was first demonstrated by Koeffler 
et al. (1984) to induce human normal and leukaemic myeloid cells to terminally 
differentiate into macrophages/monocytes. Likewise, vitamin D3 induced 
macrophage differentiation of leukemic colony-forming cells taken from patients. In 
fact, 80% of CML and approximately 50% of AML colony-forming cells 
differentiated to macrophage-like cells. The authors concluded that these findings 
suggested that vitamin D3 may play a role in haemopoiesis and that the compound or 
a related analogue may possibly have a therapeutic role in some leukaemias (Koeffler 
et al., 1984). 
53 
Chapter 1: Literature Review 
Differentiation has been demonstrated following vitamin D3 treatment of 
human promyelocytic cells HL60, and human monocytic leukaemia cells U-937 (Bar-
Shavit et al., 1983, Olsson et al., 1983, Mangelsdorf et al., 1984, Koeffler et al., 
1985, Taimi et al., 1993). Accompanying differentiation was a noted impediment to 
cell cycle progression, believed to be due to a GI, and possibly a G2/M block (Godyn 
et al., 1994). This has also been reported following treatment in U-937 cells (Oberg 
et al., 1991), murine myelomonocytic leukaemia cells WEHI-3 (Abe et al., 1986), 
and human T lymphocytes activated to proliferate (Rigby et al., 1985). The exact 
mechanism by which vitamin D3 induces leukaemic cell differentiation is not known, 
but it has been related to induction of CKIs including p21 Cipl/Waft , prKipl , 15, and 
p18 (Liu et al., 1996a, Kawa et al., 1997, Park et al., 2000, Hager et al., 2001, 
Zenmyo et al., 2001), and perturbations in the subcellular distribution of protein 
phosphatases (Song & Norman, 1998). This further demonstrates the close link 
between cell cycle arrest and terminal differentiation, and supports the hypothesis 
that p21 cIP liwafi expression is directly coupled with terminal differentiation (Liu et 
al., 1996a). 
Clinical trials using vitamin D3 are still in their infancy. The use of vitamin 
D3 in the clinical setting for the treatment of malignancies has been hampered by its 
associated toxicity, namely hypercalcaemia, at a concentration required to suppress 
cancer cell proliferation (Laubenthal et al., 1975, Nagpal et al., 2001, Mehta & 
Mehta, 2002). In an attempt to overcome the hypercalcaemic effects of vitamin D3, 
and exploit the ability of vitamin D3 to inhibit the growth of neoplastic cells, nearly 
400 structural analogues have been synthesised and evaluated for their efficacy and 
toxicity. Among these are EB1089, R024-5531, 1 alpha-hydroxyvitamin D5, and 
calcitrol, which have been evaluated in Phase I clinical trials for dose tolerance in 
advanced patients (Smith et al., 1999, Mehta & Mehta, 2002). Vitamin D3 acts 
synergistically in a sequence-dependent manner with the cytotoxic drug cytosine 
arabinoside (araC) to induce apoptosis in human leukaemia cells (Studzinski et al., 
1991), and with other drugs in solid tumours (Moffatt et al., 1999). As such, it has 
been proposed that the role of vitamin D3 in leukaemia therapy may be as a 
potentiator of cytotoxic drug action (Leszczyniecka et al., 2001). 
B) All-Trans-Retinoic Acid 
The retinoid All-trans retinoic acid (ATRA) is a vitamin A-related compound, 
and binds to the retinoic acid receptor (RAR) which belongs to a superfamily of 
transcription factors. Early in vitro studies demonstrated that ATRA induces 
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granulocytic differentiation of HL60 cells (Drach et al., 1994), and it has been 
described to be a regulator of macrophage functions and cytokine production 
(Dillehay et al., 1988). Subsequent studies revealed that treatment of HL60 cells with 
ATRA also resulted in apoptosis, presumably secondary to the differentiation process 
(Gianni et al., 2000). 
Over the last decade, the molecular basis for ATRA-induced maturation has 
been elucidated. It was the finding that APL cells exhibit a t(15;17) chromosomal 
translocation which has lead to the clinical use of ATRA (Borrow et al., 1990, de 
The et al., 1990, Alcalay et al., 1991, de The et al., 1991, Kakizuka et al., 1991, 
Warrell et al., 1991, Chang et al., 1992a & 1992b, Goddard et al., 1992, Grignani et 
al., 1993). This translocation encodes for the PML-RAR fusion promyelocytic 
leukaemia protein (Degos, 1992, Li et al., 1997). Under normal conditions, retinoids 
bind to the RAR which leads to its dissociation from a histone deacetylase co-
repressor complex, ultimately resulting in transcriptional activation of a variety of 
genes involved in haemopoietic cell maturation (Grignani et al., 1998). In APL cells, 
this process is disrupted by the PML-RAR fusion protein, but can be reactivated with 
supraphysiologic concentrations of ATRA (Grignani et al., 1998). 
Since its introduction into clinical trials in 1988 (Chen et al., 1991), ATRA 
has proved to be a safe and effective agent, inducing complete remission in excess of 
80% of APL patients based on the results of several clinical trials (Castaigne et al., 
1990, Warrell et al., 1991, Warrell et al., 1993, Warrell et al., 1997, Lo Coco et al., 
1998, Slack et al., 2000). ATRA therapy exerted rapid improvement in abnormal 
haemostatic markers in APL patients without the need for anticoagulant therapies 
(Kawai et al., 1994), a problem commonly seen in conventionally treated APL 
patients. Rb has been proposed to be a downstream target or effector of ATRA 
(Brooks et al., 1996, Dimberg et al., 2002), and this is consistent with the 
demonstration of G 1 cell cycle arrest (following ATRA treatment) and an increase in 
expression ofp2I CIPI/Wafi and p27KiP 1 
ATRA treatment has however been associated with a potentially fatal 
increased leukocyte count in a proportion of patients, due to the release of several 
cytokines by the maturing blast cells (Fenaux & Debotton, 1998). This phenomenon 
has been termed the ATRA syndrome. The incidence of ATRA syndrome has been 
reduced however with prophylactic measures such as dexamethasone and 
occasionally antineoplastic therapy to relieve the white cell count (Fenaux & 
Debotton, 1998). 
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Other problems have also previously existed with ATRA therapy. Because 
ATRA therapy fails to eradicate the malignant clone, a high percentage of patients 
who were in complete remission from APL following ATRA treatment relapsed 
within a few months (Castaigne et al., 1990, Chen et al., 1991, Glasser et al., 1994, 
Elstner et al., 1997). Additionally, secondary resistance to ATRA was seen in all 
patients who relapsed soon after withdrawal of ATRA, believed to be due to 
activation of a cytochrome P450 (CP450)-dependent enzyme. The use of CP450 
inhibitors, which include ketoconazole and liarozole, is being investigated, and the 
use of interferon-a in combination with ATRA has been proposed because interferon 
can inhibit the CP450 pathway (Fenaux & Degos, 1996). 
Combined therapy with ATRA and chemotherapy (daunorubicin and araC) is 
now regarded as the standard treatment for the APL variant (Bruserud et al., 2000, 
Fenaux et al., 1999, Fenaux, 2000). A follow-up of a long-term randomised trial by 
Fenaux (2000) has revealed that ATRA/daunorubicin/araC combined therapy results 
in significantly reduced relapse rates, and longer survival times compared with 
chemotherapy or ATRA alone. 
C) Phorbol Myristate Acetate 
The discovery that phorbol esters could restore a normal differentiation 
program in leukaemic cells represented one of the first examples for the potential of 
differentiation therapy (Huberman & CaHallam, 1979, Sachs, 1978, Koeffler et al., 
1980). Phorbol myristate acetate (PMA) binds with high affinity to PKC, activating 
the enzyme and subsequently induces various transcription factors involved in 
leukaemic cell differentiation, including PU.1 (Carey et al., 1996). PMA exposure is 
also associated with activation of the MEK/MAPK pathway (Hu et al., 2000), which 
in turn activates expression of p21 CipliWari (Jiang et al., 1994, Kharbanda et al., 1994, 
Zeng & el-Deiry, 1996). 
The use of PMA in the clinical setting is very limited because of its tumour 
promoting properties (Hecker, 1968, Baird & Boutwell, 1971). However, studies by 
Han et al. (1998a & 1998b) have demonstrated the feasibility of administering PMA 
to patients with refractory leukaemia concurrently receiving cytotoxic chemotherapy. 
In fact, the results from these studies reveal that PMA may attenuate the 
myelosuppressive effects of conventional chemotherapy, and as such Phase I trials 
are currently being conducted in the United States (Leszczyniecka et al., 2001). PMA 
treatment may also have a role as a modulator of cytotoxic drug action in leukaemia 
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as combined treatment with araC and gemcitabine with PMA results in increased 
apoptosis of human leukaemia cells (Vrana et al., 1999a). 
D) Dimethylsulfoxide 
Dimethylsulfoxide (DMSO) is a polar compound that has been shown to 
induce differentiation in a variety of transformed cell types. DMSO induces 
granulocytic maturation in HL60 promyelocytic cells (Collins et al., 1978, Santos-
Beneit & Mollinedo, 2000) and erythroid differentiation in MEL cells (Yamada et al., 
1997). DMSO-induced differentiation is associated with Go/G 1 cell cycle arrest, and 
the induction of p21 CiP l/Wari (Jiang et al., 1994). It is postulated that DMSO mediates 
differentiation via perturbations in PKC activity, intracellular Ca 2+, or protein 
tyrosine phosphorylation (Morley & Whitfield, 1993, Ginestier-Verne et al., 1996). 
Published evidence for the use of DMSO in the clinical arena is very limited, 
however peak plasma concentrations of approximately 20 mM have been achieved in 
patients undergoing peripheral blood stem cell transplantation (Egorin et al., 1998), 
suggesting the feasibility of use of DMSO as a differentiation-inducing agent in 
patients with haematological malignancies. 
E) Chromatin Remodelling Agents 
Interference with DNA methylation and histone deacetylases represents a 
logical target for therapeutic intervention as this process ultimately influences 
chromatin structure and chromosomal stability, in addition to gene expression 
(Hergersberg, 1991). DNA methylation status of genes is maintained by the enzyme 
cytosine DNA methyltransferase (Leonhardt & Bestor, 1993) and results in 
transcriptional repression and impaired induction of genes required for 
differentiation. Hypermethylation of leukaemia-specific tumour suppressor genes 
including calcitonin and p16 have been reported in leukaemic cells (Baylin et al., 
1987, Kamb, 1995). Hypermethylation of the p21Cip I /Waft gene promoter in bone 
marrow cells of ALL patients has been correlated strongly with decreased p21 CIP I/Wafl 
mRNA levels, which is highly predictive of a poor clinical outcome (Roman-Gomez 
et al., 2002). Several DNA demethylating agents have been identified, including the 
cytidine analogue 5-azacytidine (5-AC) which has been in clinical use since the mid 
1980s. Attention has been directed towards the 5-AC analogue, 5-aza-deoxycytidine, 
which is a potent inhibitor of DNA methylation and an effective inducer of 
leukaemic cell differentiation (Attadia, 1993). 5-aza-deoxycytidine has been effective 
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clinically in the treatment of acute leukaemia and MDS (Kantarjian et al., 1997, 
Wijermans et al., 1997). 
Histone deacetylases are enzymes that regulate the deacetylation of core 
nucleosomal histones, repressing the transcriptional activation of genes (Turner, 
1993, Ferrara et al., 2001). Suberoylanilide hyroxamic acid (SAHA) functions as an 
inhibitor of histone deacetylases, and may be used in the transcriptional activation of 
genes involved in the maturation process (Richon et al., 1998 & 2000, Licht, 2001), 
by reversing the aberrant repression of fusion proteins. SAHA is yet to be trailed in 
the clinical setting, although in vitro studies have shown its potential for use as an 
inducer of differentiation and apoptosis. SARA-induced differentiation is 
accompanied by an increase in p21 Cip1iWan and downregulation in c-Myb (Richon et 
al., 1996 & 1998, Vrana et al., 1999b) in MEL cells. In studies involving human 
cells (U-937 and HL60) however, SAHA induces an aberrant differentiation 
response, acting as a relatively weak inducer of maturation, but a potent inducer of 
apoptosis (Vrana et al., 1999b). 
The use of demethylating agents in combination with histone deacetylase 
inhibitors provides a promising new approach to differentiation therapy through 
modulation of gene expression (Chiurazzi et al., 1999). 
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1.5. Summary and Thesis Aims 
1.5.1. Summary of the Literature 
Leukaemia cells differ from their normal counterparts in that their cell 
division and differentiation are aberrantly regulated and the failure of these cells to 
properly regulate survival, proliferation, differentiation and apoptosis results in an 
altered phenotype and cancer. Understanding the molecular mechanisms controlling 
cell proliferation and developing therapeutic strategies to correct non-functional 
regulatory mechanisms is an emerging area of medical research (Bruserud et al., 
2000, Leszczyniecka et al., 2001). Current therapies halt the growth of aggressively 
multiplying leukaemic cells by killing them through the use of cytotoxic drugs or 
radiation therapy, a rather toxic and highly non-specific approach. Differentiation 
therapy represents a potentially less toxic form of cancer treatment involving the use 
of agents, that alone, or in combination, modify the state of differentiation and 
growth of leukaemic cells (Fenaux et al., 1999, Bruserud & Gjertsen, 2000, 
Waxman, 2000). This therapeutic protocol is based on the observation that many 
leukaemic subtypes display reversible alterations in the normal programs of growth 
control and that correction by appropriate treatment results in the resumption of both 
normal differentiation processes and susceptibility to apoptosis (Waxman, 2000). The 
promising results from laboratory studies that have investigated differentiation-
inducing agents are now beginning to show transitional promise in the clinical 
setting, in particular the use of ATRA in APL therapy. While the effectiveness of use 
of these agents is encouraging, their use is limited due to relapse (in ATRA-treated 
patients) or toxic side-effects (hypercalcaemia in vitamin D 3-treated patients), and the 
narrow scope of sensitive leukaemias that they act upon. Consequently, novel 
synthetic agents that can overcome these problems are required. 
Recent attention has been focussed on the second messenger sphingolipid, 
ceramide. Activation of the ceramide-signalling pathway by synthetic analogues of 
this second messenger presents a currently unexplored area of potential therapeutic 
development. Whilst many studies have addressed the involvement of ceramide in 
the apoptotic process (reviewed in Jarvis et al., 1996, Haimovitz-Friedman et al., 
1997, Hannun & Obeid, 1997, Kolesnick & Hannun, 1999), the differentiation-
inducing capability of this signalling pathway has been relatively ignored. Several 
lines of evidence suggest that signalling by ceramide possesses significant 
antiproliferative and differentiation-promoting capacity, as evidenced by its ability to 
induce: 
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• G0/G 1 cell cycle arrest via Rb dephosphorylation 
(Chao et al., 1992, Jayadev et al., 1995, Dbaibo et al., 1995, Mathias et al., 
1998) 
• transcriptional modification of cell cycle regulatory genes 
(Dobrowsky et al., 1992, Dobrowsky et al., 1993, Kolesnick & Golde, 1994, 
Wolff et al., 1994, Hannun, 1996, Ragg et al., 1998, Lee et al., 2000) 
• activation of the antiproliferative SAPK/JNK pathway 
(Westwick et al. 1995, Verheij et al., 1996, Pena et al., 1997, Ruvolo, 2001) 
• terminal differentiation 
(Okazaki et al., 1990, Kim et al., 1991, Dobrowsky et al., 1994, Ragg et al., 
1998) 
Consequently, manipulation of the ceramide-signalling pathway presents a 
novel therapeutic target for the treatment of diseases that lack control of growth and 
differentiation processes, such as leukaemia. However, the processes by which 
ceramide promotes these potentially therapeutic outcomes occur by mechanisms that 
are largely undefined. 
1.5.2. Thesis Aims 
The aim of this thesis is to define the ceramide-activated molecular 
mechanisms that result in growth arrest and differentiation of human leukaemic cells 
in order to assess the therapeutic potential of this second messenger and its signalling 
pathway. More specifically, the findings presented in this thesis aim to characterise 
the growth arrest and differentiation response of haemopoietic cell lines to ceramide 
signalling, to determine whether common responses and mechanisms are utilised, 
and to investigate the molecular mechanisms involved in ceramide-mediated growth 
arrest and differentiation. 
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2.1. Materials 
The reagents, antibodies, commercial kits, and disposables and equipment 
commonly used in this study, and the suppliers from which they were obtained, are 
listed in Tables 2.1.A., 2.1.B., 2.1.C. and 2.1.D. respectively. 
Table 2.1.A.: Commonly used reagents and suppliers. 
REAGENT SUPPLIER 
7-amino-actinomycin D (7-AAD) Sigma-Aldrich, USA 
Acetic acid (glacial) (AR Grade) BDH Chemicals, England 
40% Acrylamide-bis (19:1) Amresco, USA 
40% Acrylamide-bis (29:1) BIO-RAD Laboratories, USA 
Agarose (Molecular Biology Grade) BDH Chemicals, England 
Ammonium persulphate BIO-RAD Laboratories, USA 
Ampicillin powder (sodium salt) Sigma-Aldrich, USA 
Bacto-agar Oxoid Ltd., England 
Bacto-tryptone Oxoid Ltd., England 
Bacto-yeast extract Oxoid Ltd., England 
P-mercaptoethanol (13-ME) BDH Chemicals, England 
Boric acid Amresco, USA 
Bromophenol blue BDH Chemicals, England 
Bovine serum albumin (BSA) for restriction digests New England Biolabs, USA 
Calyculin A Sigma-Aldrich, USA 
C2-ceramide (N-Acetylsphingosine, D-erythro) BIOMOL Research Laboratories, Inc., USA 
Chloroform (AR Grade) BDH Chemicals, England 
dATP, dCTP, dGTP, dTTP (100 mM) Promega, USA 
dUTP (20 mM) Promega, USA 
D-glucose May & Baker, Australia 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, USA 
Ethylenediaminetetra acetic acid (EDTA) ICN Biochemicals, USA 
Ethanol (AR Grade) APS Chemicals Ltd., Australia 
Ethidium bromide Sigma-Aldrich, USA 
Extran MA03 Merck Pty. Ltd., Australia 
Foetal calf serum (FCS) CSL Limited, Australia 
Formaldehyde (40% w/v) May & Baker, Australia 
Formamide BDH Chemicals, England 
Gentamicin Pharmacia & Upjohn, Australia 
L-Glutamine JRH Biosciences, USA 
Glycerol (AR Grade) May & Baker, Australia 
Glycine Sigma-Aldrich, USA 
Methanol EM Science, USA 
NE Buffers 2 and 3 (for restriction digests) New England Biolabs, USA 
3-(N-morpholino) propane sulfonic acid (MOPS) Amresco, USA 
Nonidet P-40 (NP-40) Shell, USA 
Potassium acetate Sigma-Aldrich, USA 
Polyamp Duofitni Water For Injections BP (10 mL) ASTRA Pharmaceuticals Pty. Ltd., Australia 
Prestained SDS-PAGE broad range standards BIO-RAD Laboratories, USA 
Propan-2-ol (isopropanol) (AR Grade) BDH Chemicals, England 
Propidium iodide  Sigma-Aldrich, USA  
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Proteinase K Roche Diagnostics, USA  
Diversey, Australia  
Ambion, USA 
Pyroneg 
RNA loading buffer 
RNase A Roche Diagnostics, Germany  
JRH Biosciences, USA RPMI-1640 powdered media 
(w/o L-Glutamine, w/o NaHCO 3) 
Sheared salmon testes DNA Sigma-Aldrich, USA  
Bonlac Foods Ltd., Australia Skim milk powder 
Sodium acetate (CH 3COONa) Ajax Chemicals, Australia 
Sodium azide (NaN 3) Ajax Chemicals, Australia 
Sodium chloride (NaCl) Univar-Ajax Chemicals, Australia  
May & Baker, England Sodium citrate (C6H5Na307 .2H20) 
Sodium deoxycholate (C241-13904Na) BDH Chemicals, England 
Sodium dihydrogen orthophosphate 
(NaH2PO4 .2H20) 
Ajax Chemicals, Australia 
Sodium dodecyl sulphate (SDS) BDH Chemicals, England 
Sodium fluoride (NaF) Merck, Germany 
Sodium hydrogen carbonate (NaHCO 3) May & Baker, England 
Disodium hydrogen orthophosphate (Na2HPO4) 
anhydrous 
Ajax Chemical, Australia 
Sodium hydroxide (NaOH) Spectrum Chemical Mfg. Corp., USA 
SPP11EcoR I DNA-molecular weight marker Bresatec Pty. Ltd., Australia 
Sucrose Spectrum, USA 
TEMED (N,N,N',N'—tetra-methyl- 
ethylenediamine) 
BIO-RAD Laboratories, USA 
Tris base Merck, Germany 
Tris-HC1 Merck, Germany 
Tris-saturated phenol Amresco, USA 
Triton X-100 Sigma-Aldrich, USA 
Trypan blue Sigma-Aldrich, USA 
Tween 20 BDH Chemicals, England 
Urea Spectrum, USA 
X-vivo 15 serum-free media Biowhittaker, USA 
Xylene cyanole FF Sigma-Aldrich, USA 	' 
20 bp molecular ruler BIO-RAD Laboratories, USA 
100 bp PCR molecular ruler BIO-RAD Laboratories, USA 
[a-3211dATP dye-free NEN Life Science Products, Inc., USA 
[a-331]dATP dye-free NEN Life Science Products, Inc., USA 
[a-3311UTP dye-free NEN Life Science Products, Inc., USA 
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Table 2.1.B.: Antibodies used in the study. 
ANTIBODY SUPPLIER 
PRIMARY ANTIBODIES 
Goat polyclonal anti-Rb IgG (sc-50-G) Santa Cruz Biotechnology, USA 
Mouse monoclonal anti-p2l wanicIP l IgG (sc-817) Santa Cruz Biotechnology, USA 
SECONDARY CONJUGATED ANTIBODIES 
Anti-goat IgG HRP Santa Cruz Biotechnology, USA 
Anti-mouse IgG HRP Santa Cruz Biotechnology, USA 
IMMUNOPHENOTYPING ANTIBODIES 
Anti-CD 1 lb PE Becton-Dickinson, USA 
Anti-CD 14 PE Becton-Dickinson, USA 
Anti-CD34 PE Becton-Dickinson, USA 
Anti-glycophorin A PE Dako Corporation, USA  
Table 2.1.C.: Reagent kits used in the study. 
NAME OF KIT SUPPLIER 
AmpliTaq® PCR Kit 
AmpliTaq® DNA polymerase, 10X PCR buffer, 
MgCl2 
Roche Diagnostics, Germany 
Annexin V-FITC Apoptosis Detection Kit Pharmingen, USA 
Atlas 	Expression Array 
Human Cancer 1.2 
Clontech, USA 
Atlas 	Total RNA Labelling System Clontech, USA 
Complete, Mini Protease Inhibitor Cocktail Tablets Roche Diagnostics, Germany 
DNA-free 	treatment and removal Kit Ambion, USA 
Enhanced Chemiluminescence Detection Kit Amersham Life Science, England 
LightCycler capillaries Roche Diagnostics, Germany 
LightCycler RNA Master SYBR Green 1 real-time 
RT-PCR kit 
Roche Diagnostics, Germany 
PowerScript 	Reverse Transcriptase kit Clontech, USA 
RiboQuantr" Multi-Probe RNase Protection Assay 
System 
In vitro transcription kit and template 
PharMingen, USA 
RNeasy® Mini spin column kit 
RNA extraction, RNA cleanup 
QIAGEN, Germany 
SuperScript"' One-Step RT-PCR kit with 
SuperScript"' II RT and Platinum® Taq Mix 
Invitrogen Life Technologies, USA 
1.4 DNA ligase & 5X ligation buffer Gibco BRL, Australia 
QlAquick® Spin Kit 
PCR purification, nucleotide removal, gel extraction 	  
QIAGEN, Germany 
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Table 2.1.D.: Commonly used disposables, equipment and software. 
DISPOSABLES/EQUIPMENT/SOFTWARE SUPPLIER 
Biological safety cabinet class II Email Air Handling, Australia 
BioMax.'" MR film Eastman Kodak Company, USA 
Bottletop filters (0.2 plm) Nalgene, USA 
Cell culture incubator 37°C, 5% CO 2, water-jacketed 
3250 
Forma Scientific, USA 
Cell culture flasks (25 cm 2, 75 cm2 and 225 cm2) Iwaki, Japan 
Cell culture plates - 24 wells Iwaki, Japan 
CellQuest software package (V 3.3) Becton-Dickinson, USA 
Centrifuge (GS-15R) Beckman, Germany 
Centrifuge tubes (15 mL and 50 mL) Iwaki, Japan 
Densitometer calibrated (GS-800) BIO-RAD Laboratories, USA 
Dry block heater Selby, Australia 
Electrophoresis apparatus (DNA/RNA) BIO-RAD Laboratories, USA 
Electrophoresis power supply BIO-RAD Laboratories, USA 
FACScan flow cytometer Becton-Dickinson, USA 
FACS tubes (5 mL) Becton-Dickinson, USA 
GenomyxLe' programmable DNA sequencer Genomyx Corporation, USA 
Heat sealer — Futura-Jr. Audion Elektro® 
Hyperfilm 	autoradiography film Amersham Life Science, England 
Immun-Blot® polyvinyldifluoride (PVDF) membrane 
for protein blotting 
BIO-RAD Laboratories, USA 
Inverted light microscopes Wild Heerbrugg, Switzerland, and 
Leitz, Switzerland 
LightCycler Roche Diagnostics, Germany 
Light microscope Olympus, Japan 
Microfuge centrifuge (Force 7) Denver Instruments, USA 
Micro hybridisation incubator, Model 2000, and 
glass roller tubes 
Robbins Scientific, USA 
Micropipettes (2 1.1L, 10 pL, 20 pL, 200 gL, 10001AL 
Pipetman) 
Gilson, France 
Micropipette tips (10 IlL, 201AL, 2001AL and 
10004) 
Quantum Scientific Plastics, Australia 
Microscope camera (Vario-Orthomat) Leitz, Switzerland 
Microfuge tubes (0.2 mL, 0.6 mL, 1.5 mL and 2.0 
mL RNase/DNase Free) 
Quantum Scientific Plastics, Australia 
Microwave oven Sanyo, Singapore 
Milli-Q and Milli-RO water purification system Millipore Corporation, USA 
ModFit software package Becton-Dickinson, USA 
Oligonucleotide synthesis GeneWorIcs, Australia 
Pipetboy acu Integra Biosciences, Switzerland 
Polaroid black and white film (665) Polaroid, USA 
Polaroid MP-4 land camera Polaroid, USA 
Quantity One® quantitation software package (V4.0) BIO-RAD Laboratories, USA 
Scintillation counter (1214 Rackbeta) LKB Wallac, Finland 
SDS-PAGE electrophoresis apparatus and 
electrotransfer apparatus (XCell Ir. Mini-Cell and 
Blot Module) 
Novex, USA 
Spectrophotometer (BioPhotometer) & UVettes Eppendorf, Germany 
Syringe filters — Supor® Acrodisc® 25 (0.2[un) Gelman Sciences, USA 
Thermal cycler Eppendorf, Germany 
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Tissue culture flasks (25 cm2 and 75 cm2) Iwaki, Japan 
Ultracentrifuge (RC 5C Plus) Sorvall, USA 
UV transilluminator (Spectroline ®) Spectronics Corporation, USA 
VacuCap® 90 filters (0.2 rim) Gelman Sciences, USA 
Vacuum evaporator centrifuge (Centrivap 
Concentrator) 
Labconco, USA 
Vario MACS magnetic particle separator Miltenyi Biotech, Germany 
Vortex mixer (MS1 Minishaker) IICA Works, Malaysia 
Waterbath Grant Instruments, England  
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2.2. General Methods 
All solutions were stored and used at room temperature unless otherwise 
stated. Solutions that were required to be sterile were either autoclaved using a 
standard liquid autoclave cycle, or were aseptically filtered through a 0.22 pm filter 
into a clean bottle that had been previously sterilised by autoclaving at 121°C for 15 
minutes. Deionised ultrapure water was used to prepare all solutions and was 
obtained from a Milli-Q water purification system (Millipore Corporation, USA). All 
biological samples were considered biohazardous and as such were handled in a class 
11 biological safety cabinet. All DNA and RNA extractions, and subsequent 
manipulation of DNA and RNA, were performed using DNase/RNase-free solutions 
and filtered pipette tips whilst wearing clean gloves to ensure minimal degradation of 
the nucleic acids. 
2.2.1. Solutions 
7-amino-actinomycin D (7-AAD) Solution: 
1 mg 	7-AAD 
0.5 mL DMSO 
0.5 mL 	1X PBS 
Stock 7-AAD solution was prepared by dissolving the 7-AAD in DMSO and 
1X PBS. Gloves and a mask must be worn when preparing this solution due to the 
toxicity of 7-AAD. A working solution of 25 pg/mL 7-AAD was prepared by adding 
975 1AL 1X PBS to 25 pL stock 7-AAD solution. The solution was aliquotted into 
tubes and stored at -20°C. Working tubes were stored at 4°C. 
Agarose Gels (for cDNA/DNA): 
2.4 g 	agarose (for a 1.2% agarose gel) 
201AL 	10 mg/mL ethidium bromide (1 pg/mL) 
Agarose was added to 200 mL 1X TAE or TBE buffer and carefully heated in 
a microwave oven. The solution was gently swirled to dissolve the agarose and 
allowed to cool to handling temperature prior to pouring into a gel tray and allowing 
to set at room temperature with the appropriate gel comb in position. 
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2511M Calyeulin A Stock Solution: 
10 ps 	Calyculin A desiccate 
396.4 pt ethanol was added to an opened vial of Calyculin A and mixed 
carefully. Aliquots of 20 iaL volumes were dispended into sterile 0.6 mL tubes and 
were stored at -80°C. 
10 m1VI C2-ceramide Stock Solution: 
3.415 mg C2-ceramide 
C2-ceramide was carefully weighed out in an analytical balance in a 1.5 mL 
eppendorf tube and dissolved in 1 mL ethanol by vortexing. The solution was 
aliquotted into 100 !IL volumes in sterile 0.6 mL tubes and stored at -80°C for up to 6 
months. Working stocks of the solution were stored at -20°C. 
FACS Fixative: 
5 mL 	20X PBS 
2 g 	glucose 
0.67 mL 15% NaN3 
8 mL 	40% (w/v) formaldehyde 
The solution was adjusted to a final volume of 100 mL with Milli-Q water, 
filtered and stored at 4°C. 
Hypotonic Propidium Iodide (HPI) Solution: 
5 mg 	propidium iodide 
0.1 g 	sodium citrate 
0.1 mL 	Triton X-100 
As described previously by Nicoletti et al. (1991), propidium iodide and 
sodium citrate were dissolved in 100 mL Milli-Q water overnight at 4°C in the dark. 
Triton X-100 was added last to minimise frothing on the following day. The solution 
was stored at 4°C in the dark. 
2 X Laemelli Sample Buffer: 
2.5 mL 	0.5 M Tris-HC1 (pH 6.8) 
2 mL 	glycerol 
4 mL 	10% SDS 
0.5 mL 	0.1% bromophenol blue 
0.5 mL 	13-ME 
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Reagents were combined and volume adjusted to 10 mL with Milli-Q water. 
Luria-Bertani (LB) Media and LB Plate Preparation: 
10 g 	bacto-tryptone 
5 g 	bacto-yeast extract 
10 g 	NaC1 
The ingredients above were added to 950 mL Milli-Q water and stirred until 
dissolved. The pH was adjusted to 7.0 with 5M NaOH and final volume of the 
solution made up to 1 L with Milli-Q water. This solution was sterilised by 
autoclaving. If LB agar plates were needed, bacto-agar was added to the LB media at 
15 g/L and autoclaved to sterilise and to dissolve the agar. The LB media/agar 
solution was mixed gently to avoid air bubble formation, poured into Petri dishes and 
allowed to set in the biological safety cabinet (Sambrook et al., 1989). 
6X Loading Buffer for DNA: 
0.0125 g bromophenol blue (0.25%) 
0.0125 g xylene cyanole FF (0.25%) 
2 g 	sucrose (40% w/v) 
The sucrose was first dissolved in approximately 4 mL Milli-Q water, 
followed by the addition of bromophenol blue and xylene cyanole FF. The final 
volume was made up to 5 mL with Milli-Q water (Sambrook et al., 1989). 
Lysis Buffer for Nuclear Protein Extraction: 
201AL 	10% SDS 
25 !IL 	1 M Tris (pH 7.4) 
501.AL 	1M NaC1 
50 iL 	10% sodium deoxycholate 
50 iAL 	1 M NaF 
150 [IL 	protease inhibitor solution (final = 1 tablet/10 mL lysis solution) 
(stock = 1 tablet/1.5 mL water, 150 IAL aliquots stored at -20°C - 
CompleteTm, Mini Protease Inhibitor Cocktail, Roche Diagnostics, 
Germany) 
200 ;IL 	NP-40 
455 [IL 	Milli-Q water 
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As previously described by Chao et al. (1992), reagents were combined fresh 
on the day that the lysis solution was needed. The solution was stored overnight at 
4°C if needed on the subsequent day. 
Miniprep Plasmid Extraction (Alkaline Lysis) Solution 1: 
0.9 g 	glucose (50 mM) 
2.5 mL 	1 M Tris-HC1, pH 8.0 (25 mM) 
2 mL 	0.5 M EDTA, pH 8.0 (10 mM) 
The reagents were prepared in approximately 85 rnL Milli-Q water and once 
the glucose had dissolved, the pH was checked to ensure it was at 8.0. The solution 
was autoclaved and stored at 4°C. 
Miniprep Plasmid Extraction (Alkaline Lysis) Solution 2: 
40 pL 	5 M NaOH (200 rnM) 
100 jiL 	10% SDS (1%) 
The solution was made up to 1 mL with Milli-Q water. Solution 2 was 
prepared fresh on the day of the miniprep plasmid extraction. 
Miniprep Plasmid Extraction (Alkaline Lysis) Solution 3: 
29.44 g 	potassium acetate (3 M) 
11.5 mL glacial acetic acid 
The potassium acetate was dissolved in approximately 70 mL milli-Q water. 
The acetic acid was added and the final volume adjusted to 100 mL with Milli-Q 
water. 
10X MOPS Buffer: 
83.72 g MOPS (0.4 M) 
33.34 mL 3 M sodium acetate (100 mM) 
10 mL 	1 M EDTA, pH 8.0 (10 mM) 
The solution was made up in approximately 900 mL Milli-Q water prior to 
adjusting the pH to 7 with 5 M NaOH. The final volume was made up to 1 L with 
Milli-Q water and the solution was autoclaved, changing the colour of the buffer to 
yellow. The solution was stored at 4°C in the dark. 
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20X Phosphate Buffered Saline (PBS): 
170g 	NaC1 
21.4 g 	Na2HPO4 anhydrous 
7.8 g 	NaH2PO4 .2H20 
The above salts were dissolved in approximately 700 mL Milli-Q water by 
heating and stirring with a magnetic stirrer. The solution was allowed to cool to room 
temperature prior to adjusting to a final volume of 1 L with Milli-Q water and 
mixing. The solution was stored at room temperature without the need for 
sterilisation. 
PBS + 0.1% Azide + 1% FCS (PBS-A): 
25 mL 	20X PBS 
3.33 mL 15% NaN3 (0.1%) 
5 mL 	FCS (1%) 
The solution was made up to 500 mL with Milli-Q water, filtered to remove 
FCS debris and stored at 4°C. Working aliquots were taken as required. 
PBS + 0.1% Tween 20 (PBST): 
50 mL 20X PBS 
1 mL 	Tween 20 (0.1%) 
The 1X PBS solution was prepared (50 mL 20X PBS added to 950 mL Milli-
Q water) fresh on the day of use. The tip of a 1 mL disposable micropipette tip was 
cut off and a 1 mL volume of Tween 20 was dispensed into the PBS solution, tip 
ejected, and solution stirred using a magnetic stirrer until the tip had emptied of 
residual Tween 20. 
RNase A Solution (10 mg/mL stock): 
10 mg 	RNase A powder 
10mM 	Tris-HC1 (pH 7.5) 
15 mM NaC1 
As described by Sambrook et al. (1989), concentrated stock Tris-HC1 (pH 
7.5) and NaC1 solutions were used to prepare a 1 mL solution of 10 mM Tris-HC1 
(pH 7.5)115 mM NaC1 by adding 10 1.iL 1M Tris-HC1 (pH 7.5) and 15 111_, 1M NaCl 
to 975 [IL milli-Q water. The RNase A powder was dissolved in this solution by 
gentle vortexing and was heated at 100°C for 15 minutes and allowed to cool slowly 
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to room temperature. The solution was aliquotted into 100 1.IL volumes and stored at 
-20°C. 
RPM! Media Preparation: 
52 g 	RPM! 1640 powdered media (w/o L-glutamine, w/o NaHCO3) 
10 g 	NaHCO3 (2 g/L) 
The RPMI powder and NaHCO3 was added on top of approximately 4.5 L 
Milli-Q water and stirred with a magnetic stirrer to dissolve. The pH of the solution 
was then adjusted to 7.0 with concentrated HC1, and final volume made up to 5 L 
with Milli-Q water. The flask containing the solution was transferred into the 
biological safety cabinet and was filtered into sterile 500 mL screw cap bottles using 
a VacuCap® 90 vacuum filtration device. The bottles were stored at 37°C overnight 
for sterility confirmation. Media showing no signs of contamination were stored in 
the dark at room temperature until required. 
10X Running Buffer (for SDS-PAGE): 
29 g 	Tris base 
144 g 	glycine 
10 g 	SDS 
Reagents were combined and dissolved in 1 L Milli-Q water. The pH was 
checked to ensure it was at 8.3, and was not adjusted. This solution was re-used up to 
five times. 
20% SDS: 
100 g SDS was dissolved in 500 mL Milli-Q water and heated to 65°C to 
dissolve. 
20X SSC: 
175.3 g 	NaC1 
88.2 g 	sodium citrate 
The salts were dissolved in 900 mL Milli-Q water and the pH adjusted to 7.0 
if necessary with 1 M HC1. The solution was adjusted to a final volume of 1 L with 
Milli-Q water and stored at room temperature without the need for sterilisation. 
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50X Tris-Acetate Buffer (TAE Buffer): 
242 g 	Tris base 
57.1 mL glacial acetic acid 
100 mL 0.5 M EDTA, pH 8.0 
The Tris base was dissolved in approximately 700 mL Milli-Q water and the 
remaining reagents added. The final volume was adjusted to 1 L with Milli-Q water. 
TAE buffer was used as a lx working solution (Sambrook et al., 1989). 
5X Tris-Borate Buffer (TBE Buffer): 
54g 	Tris base 
27.5 g 	boric acid 
20 mL 	0.5 M EDTA, pH8.0 
Prepared as for Tris-Acetate buffer. Stock TBE buffer can form a precipitate 
when stored for a long period of time. When this occurred a new batch of TBE buffer 
was prepared. TBE buffer was used at a working strength of 0.5X for agarose gel 
electrophoresis, and 1X for polyacrylamide gel electrophoresis (Sambrook et al., 
1989). 
Tris-EDTA Buffer (TE Buffer): 
10 mL 	50 mM Tris-HC1, p118.0 (10 mM) 
100 pL 	0.5 M EDTA, pH8.0 (1 mM) 
Reagents were combined and the volume was adjusted to 50 mL with Milli-Q 
water (Sambrook etal., 1989). 
Transfer Buffer (for protein electrotransfer): 
100 mL 10X Running Buffer (for SDS-PAGE) 
200 mL methanol 
700 mL Milli-Q water 
This solution was de-gassed extensively prior to use and was re-used up to ten 
times. 
0.25% (w/v) Trypan Blue: 
2.5 mg 	trypan blue 
The trypan blue was dissolved in 10 mL Milli-Q water and filtered through a 
0.2 pm syringe filter into a 50 mL centrifuge tube. 
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Wash Solution 1 (for cDNA Arrays): 
100 mL 20X SSC (2X) 
50 mL 	20% SDS (1%) 
To prevent immediate precipitation of the SDS, the 20X SSC stock was 
diluted in approximately 800 mL Milli-Q water prior to the addition of 20% SDS. 
The solution was adjusted to a final volume of 1 L with Milli-Q water. If not used on 
the day of preparation, a precipitate would form which could be redissolved by 
heating. 
Wash Solution 2 (for cDNA Arrays): 
2 mL 	20X SSC (0.1X) 
10 mL 	20% SDS (0.5%) 
As for Wash Solution 1 (for cDNA Array), but the solution was adjusted to a 
final volume of 400 mL with Milli-Q water. 
2.2.2. Pipettes and Glassware 
Graduated glass culture pipettes and Pasteur pipettes were soaked overnight 
in 2% Extran MA03 (Merck Pty. Ltd., Australia) and washed in tap water for a 
minimum of 4 hours using a self-dumping pipette washer. Pipettes were then rinsed 5 
times in Milli-RO water, followed by 3 rinses in Milli-Q water. Cleaned pipettes 
were dried in a 50°C oven before being plugged with cotton wool and autoclaved at 
121°C for 15 minutes in copper pipette canisters and allowed to dry overnight in the 
50°C oven. 
All glassware used for storage of solutions or for reagent preparation, and 
Western blotting and electrophoresis equipment, was soaked in a water containing 
dissolved phosphate-free Pyroneg (Diversey, Australia) detergent for a minimum of 4 
hours and scrubbed. They were then rinsed thoroughly with tap water followed by 
several rinses with Milli-Q water and were left to dry. 
2.2.3. Maintenance and Treatment of Cell Cultures 
A) Maintenance Media 
RPMI media was prepared as described in Chapter 2.2.1. Supplementary 
components were added to the RPMI media to support the growth of the human 
leukaemic cell lines used in this study. These are as follows: 
500 mL RPMI media 
1.5 mL 	40 mg/mL gentamicin (120 ilg/mL) 
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5 mL 	200 mM L-glutamine (2 mM) 
50 mL 	foetal calf serum (10%) 
Gentamicin was stored in 2 mL aliquots at 4°C, L-glutamine was stored in 5 
mL aliquots at -20°C, and FCS were stored in 50 mL aliquots at -20°C and were 
thawed at 37°C prior to being aseptically added directly to the RPMI media. The 
media and additives were stored at 4°C between usage, and was pre-warmed to 37°C 
in a waterbath prior to addition to cell cultures. 
B) Cell Line Stocks 
All cell lines used in this study were originally obtained from the American 
Type Culture Collection, ATCC ® (University of Boulevard, Virginia, USA) and had 
been aseptically frozen down in liquid nitrogen in batches at 5 X 10 6/mL - 1 X 
107/mL and stored in an inventory system in the Department of Pathology, University 
of Tasmania. All human haemopoietic cell lines used, and their respective ATCC ® 
reference numbers and lineage type are given in Table 2.2. 
Table 2.2.: Human haemopoietic cell lines used in this study. 
Name of Cell Line ATCC® Reference Cell Lineage 
K562 CRL 243 Erythromyeloid, early granulocytic 
precursor 
KG-1 CCL 246 Myeloblastic and promyeloblastic 
KG-la CCL 246.1 Very 	young 	undifferentiated 
promyeloblastic (KG-1 variant) 
HL60 CCL 240 Promyelocytic 
Jurkat TIE 152 T Lymphocytic 
Raj i CCL 86 B Lymphocytic 
The characteristics of each cell line listed above, is provided in Table 1.5. 
C) Cell Culture Conditions 
Cells were grown in RPMI media described in Chapter 2.2.3(A). in vented 
capped tissue culture flasks, and were incubated at 37°C in a humidified atmosphere 
of 5% CO2. All cells were maintained at a density of 1-10 X 10 5 cell/mL, except 
KG-1 and KG-la cells which were maintained at a density of 2-20 X 10 5 cells/mL 
and 2-10 X 10 5 cells/rnL, respectively. All manipulations of cell lines were 
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performed in a class 11 biological safety cabinet. All items entering the cabinet were 
sterilised by swabbing with 70% ethanol. 
D) Treatment of Cell Cultures 
Experiments were conducted using unsynchronised cells in exponential 
growth phase. Prior to each experiment utilising cell cultures, cells were enumerated 
using a haemocytometer to determine the number of cells per millilitre of culture. 
The appropriate volume of cells for the experiment was transferred to a sterile 
centrifuge tube and cells collected by centrifugation at 400 x g for 5 minutes at room 
temperature. All cells were washed in sterile 1 X PBS and resuspended at 5 X 
105/mL in serum-free RPMI (SF-RPMI), except experiments using the HL60 cell line 
which were resuspended in SF-RPMI + 2% FCS, and experiments using Raji cells 
which were resuspended in X-Vivo serum-free medium (Biowhittaker, USA). SF-
RPMI was prepared as described in Chapter 2.2.3(A). except that FCS was omitted. 
Cells were pre-incubated in their respective treatment media (unless otherwise stated) 
for a further 2 hours, prior to the direct addition of vehicle (absolute ethanol), 
C2-ceramide or Calyculin A (concentrations used are stated in individual protocols) 
to the cell culture media. Treated cells were either plated out into 24-well cell culture 
plates at 1 mL/well, or transferred into cell culture flasks, depending on the volume 
of cells used in the experiment, for a specified period of time. Cells were harvested 
after designated time periods by centrifugation at 400 x g for 5 minutes and 
processed according to the desired protocol for a given experiment. All experiments 
included a 0 hour control time point unless otherwise specified. All experimental 
samples were accompanied by a time-matched, vehicle-treated (absolute ethanol) 
control sample. 
2.2.4. Flow Cytometry 
Fluorescent cells were enumerated and mean fluorescence intensity (MFI) of 
stained cells acquired using a FACScan flow cytometer (Becton-Dickinson, USA). 
Phycoerythrin (PE) and fluorescein isothiocyanate (FITC) was excited at 488 nm and 
by an air-cooled argon ion laser (Uniphase corporation, USA) at 15 mW. PE and 
FITC were collected using a 525 and 575 band-pass filter, respectively. 10,000 events 
were analysed for each sample and the data processed according to the specific 
experiment performed, using a Macintosh computer system. 
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2.2.5. 6.5% SDS-PAGE Gel Preparation for Rb Analysis 
The preparation of 6.5% SDS-polyacrylamide separating gels is outlined in 
Table 2.3. 
Table 2.3.: Preparation of 6.5% SDS-polyacrylamide separating gels. 
Reagent Volume 
40% Acrylamide-bis (29:1) 3.9 mL 
1 M Tris, pH8.8 9.4 mL 
10% SDS 250 ilL 
50% sucrose 4 mL 
Milli-Q water 6.8 mL 
50 mg/mL ammonium persulphate 
(made fresh) 
625 [IL 
TEMED 5 !IL 
Total = 25 mL 
All reagents except ammonium persulfate and TEMED were added in the 
order given in the above table and were extensively de-gassed to facilitate 
polymerisation of the gel. The ammonium persulphate was added and the solution 
mixed well but gently, followed by the addition of TEMED and gentle mixing. 
Approximately 4-5 mL volumes of the separating gel solution was quickly poured 
into upright empty gel cassettes, until the cassette was approximately % full. The 
cassette was very gently topped up with a layer of Milli-Q water such that the 
separating gel set level. 
The preparation of 4% SDS-polyacrylamide stacking gels is outlined in Table 
2.4. 
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Table 2.4.: Preparation of 4% SDS-polyacrylamide stacking gels. 
Reagent Volume 
40% Acrylamide-bis (29:1) 1.25 mL 
0.375 M Tris, pH6.8 4.15 mL 
Milli-Q water 6.6 mL 
50 mg/mL ammonium persulphate 
(made fresh) 
500 [IL 
TEMED 51.11_, 
Total = 12.5 mL 
As for the separating gel, all reagents except ammonium persulphate and 
TEMED were combined and de-gassed extensively. The Milli-Q water layer was 
removed from the top of the separating gel and the cassette allowed to drain. 
Ammonium persulphate was added to the stacking gel solution, followed by 
TEMED. The solution was mixed gently, but thoroughly, and was layered on top of 
the polymerised separating gel. A comb was inserted and the stacking gel allowed to 
set. Once polymerised, the gels could be stored in the gel cassettes for up to one week 
at 4°C in sealed plastic bags containing a small amount of Milli-Q water. 
2.2.6. 5% Polyacrylamide Gel Preparation For RNase Protection Assays 
56.25 mL 40% Acrylamide/Bis (19:1) 
50 mL 	10X TBE buffer 
238.8g 	Urea 
The 5% acrylamide gel solution was prepared by first dissolving the urea in 
approximately 100 mL Milli-Q water by heating. The remaining reagents were added 
and final volume adjusted to 500 mL with Milli-Q water. Bromophenol blue powder 
was added to the solution until the desired depth of colour was achieved. This 
solution was enough for the preparation of five 5% polyacrylamide gels for use in 
RNase protection assays. 
5% polyacrylamide gels were prepared as outlined in Table 2.5. 
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Table 2.5.: Preparation of 5% polyacrylamide gels. 
Reagent Volume 
5% Acrylamide gel solution 100 mL 
10% Ammonium persulphate 
(made fresh) 
7001AL 
TEMED 801AL 
Total = 100 
mL 
The ammonium persulphate was added to the 5% polyacrylamide gel 
solution, mixed well but gently, followed by the addition of TEMED and gentle 
mixing. The solution was immediately poured between two cleaned 61 cm glass 
plates with 0.4 mm spacers in place on a horizontal surface. The gel was allowed to 
polymerise with a sharks tooth comb in position. 
2.2.7. Extraction and Quantitation of Nucleic Acids 
A) Extraction of DNA 
Cells (2 X 10 6) were harvested by centrifugation at maximum speed in a 
benchtop microfuge, supernatant removed, and cells resuspended in 530 1AL 
proteinase K solution. Samples were incubated at 50°C for 2-3 hours and extracted 
by phenol/chloroform extraction. An equal volume of phenol and chloroform (530 
1AL of each) was added to the sample and the solution mixed by inversion. Samples 
were centrifuged at 10,000 x g and the upper aqueous layer removed to a new 
microfuge tube. A second phenol/chloroform extraction was performed as above. A 
1110 th  volume of 3M sodium acetate and 2 volumes of ice-cold absolute ethanol was 
added to the resulting upper phase from the second extraction. The samples were left 
at -20°C for a minimum of 2 hours and the precipitated DNA collected by 
centrifugation at 10,000 x g for 15 minutes at 4°C. The supernatant was carefully 
removed and washed with 70% and absolute ethanol respectively and the pellet air-
dried in a biological safety cabinet. The dried pellet was resuspended in 50 1AL 10 
mg/mL RNase buffer and incubated for 15 minutes at 37°C followed by 30 minutes 
at room temperature. 
For some applications, the RNase-treated DNA (or PCR products) was re-
precipitated by adding 40 [IL deionised water and 160 [LL 95% ethanol, vortexing 
briefly, and incubating at room temperature for 15 minutes. The samples were then 
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centrifuged at maximum speed for 20 minutes at 4°C, the resulting pellet washed in 
250 1.11, 70% ethanol, and the samples re-centrifuged at maximum speed for 10 
minutes at 4°C. The pellets were air-dried as described previously and resuspended in 
20 [IL deionised water or TE buffer, depending on the application. 
DNA was stored at -20°C for an indefinite period of time. 
B) Analysis of DNA by Agarose Gel Electrophoresis 
A 1.2% agarose gel containing 1 [1.g/mL ethidium bromide was prepared as 
described in Chapter 2.2.1. and placed in an electrophoresis tank filled with 1 X TAE 
or TBE buffer. The DNA or RT-PCR/PCR products were prepared by adding 6X 
DNA loading buffer (to 1X final), and 20 [iL was loaded onto the gel. Additionally, 
molecular weight markers were run alongside the sample DNA to provide a 
reference. The gel was run at 60V constant for approximately 2 hours and DNA 
visualised on a UV transilluminator. Photographic evidence was obtained using a 
Polaroid MP4 land camera and black and white Polaroid film. 
C) Extraction of RNA 
Cells (1 X 107) were harvested by centrifugation at 400 x g for 5 minutes at 
4°C, supernatant removed, and RNA extraction performed using the RNeasy® Mini 
spin column kit (QIAGEN, Germany). Briefly, cells were lysed in Buffer RLT (600 
[LL Buffer RLT + 6 pL I3-ME) by pipetting up and down and vortexing thoroughly. 
The lysate was passed through a 20G needle 5 times, 1 volume (600 1AL) of 70% 
ethanol added, and the solution was mixed by pipetting. The sample was loaded onto 
an RNeasy® Mini spin column sitting in a 2 mL collection tube and centrifuged at 
8,000 x g for 15 seconds. 700 [IL of Buffer RW1 was applied to the column and the 
column centrifuged at 8,000 x g for 15 seconds. 500 lit Buffer RPE was loaded into 
the column and the column centrifuged at 8,000 x g for 15 seconds followed by 
another addition of 500 lit Buffer RPE and centrifugation at maximum speed for 2 
minutes to dry the column membrane. The column was carefully transferred to a 1.5 
mL microfuge tube and 50 [IL RNase-free water applied directly to the membrane. 
The column was left at room temperature for 2 minutes and centrifuged at 10,000 x g 
for 3 minutes to elute the RNA. The resulting RNA was immediately transferred to - 
80°C for storage. 
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D) DNase Treatment of RNA 
RNA was treated to ensure the removal of contaminating DNA using the 
DNA-free treatment and removal kit protocol (Ambion, USA). Briefly, 3.5 
pL 10X buffer and 2 pL DNase 1 was added to 45 pL RNA in a 0.6 mL PCR 
microfuge tube and incubated at 37°C for 30 minutes in a thermal cycler. The DNase 
inactivation reagent was resuspended and 5 [IL was added to the DNase-treated RNA 
and incubated for 2 minutes at room temperature. The RNA was stored at -80°C, and 
was centrifuged at 10,000 x g for 1 minute to pellet the DNase inactivation reagent 
prior to use. 
E) Determination of RNA Integrity 
A 1.2% RNA mini denaturing gel was prepared by dissolving 0.6 g agarose in 
50 mL 1X MOPS buffer by heating in a microwave. After allowing the gel solution 
to cool to handling temperature, 9 mL 40% (w/v) formaldehyde was added in a fume 
cabinet. The solution was poured into a mini gel tray, comb placed into position and 
the gel allowed to set at room temperature. RNA samples were prepared as follows: a 
master-mix containing 8 pL 10X MOPS buffer, 40 pL formamide, and 14.4 pL 40% 
(w/v) was prepared. 7.8 pL of the master-mix solution was added to 2.5 pL RNA (1- 
2 pg), heated to 65-70°C for 15 minutes, and cooled on ice. 4 [IL 0.5 mg/mL 
ethidium bromide and 4 1AL RNA loading buffer (Ambion, USA) was added to the 
denatured RNA sample and the total volume loaded onto the gel. The gel was run at 
50V constant for approximately 2 hours and RNA visualised on a UV 
transilluminator. Photographic evidence was obtained using a Polaroid MP4 land 
camera and black and white Polaroid film. 
Total human RNA appeared as two distinct bands at approximately 4.5 and 
1.9 kb, correlating to 28s and 18s rRNA respectively. The ratio of intensities of the 
28s and 18s rRNA bands was estimated and should be 1.5-2.5:1 indicating minimal 
RNA degradation. Additional bands appearing below the 18s rRNA band could 
occasionally be seen which corresponded with 5s rRNA and tRNA. If any 
contaminating DNA was present it could be seen as smear remaining in the well. 
RNA that demonstrated degradation or DNA contamination was discarded and new 
RNA extracted and analysed for integrity. 
F) Quantitation and Determination of Nucleic Acid Purity 
The concentration and purity of DNA and RNA was determined by measuring 
the absorbance at 260 nm (A260) and at 280 nrn (A280) using a spectrophotometer. 
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Generally, 2 1AL DNA or RNA (typically 1-5 mg) was diluted in 58 pi, RNase-free 
water to give a dilution factor of 30 (60+2). The diluted sample was then transferred 
into a clean RNase-free cuvette (UVette — Eppendorf, Germany) which was placed 
into a spectrophotometer (BioPhotometer — Eppendorf, Germany) and absorbance 
measured. The readings obtained were based on a blanked absorbance reading taken 
from water. 
An absorbance of 1 unit at 260 nm corresponds to 50 lAg/mL DNA and 40 
[tg/mL RNA prior to taking the dilution factor into account. The ratio of A260/A280 
gives an estimate of purity and should be above 1.8. Nucleic acid demonstrating a 
ratio below 1.8 was excluded from use in further applications in this study. 
Concentration (.1,g/mL) = A260 x [50 (for DNA) or 40 (for RNA)] x dilution factor 
2.2.8. RNase Protection Assays 
RNase protection assays were performed as per the protocol and reagents 
provided in the RiboQuantTM Multi-Probe RNase Protection Assay System 
(PharMingen, USA), using DNase-treated RNA (refer to Chapter 2.2.7.). A brief 
summary of the protocol is provided below. 
A) Probe Synthesis 
Necessary precautions and routines were followed when handling and 
disposing radioactive substances, as outlined in the National Health and Medical 
Research Council's regulations (1985, 1995a, 1995b). The radiolabelled RNA probe 
was synthesised by adding the RiboQuant TM kit components in the order shown in 
Table 2.6. to a 1.5 mL microfuge tube, gently mixing by pipetting, and incubating for 
1 hour at 37°C. 
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Table 2.6.: Synthesis of radiolabelled RNA riboprobes. 
Reagent Amount/Volume 
40 U/IAL RNasin 1 4 
GACU pool mix (2.75 mM G, A, and C; 61 mM U) 1 4 
100 mM DTT 2 4 
5X Transcription buffer 4 4 
RPA template set 1 4 
[a-33NUTP, dye-free (3000 Ci/mmol, 10 ii.Ci/IAL) 10 !IL 
20 U/4 T7 RNA polymerase 1 4 
Total = 204 
Following the probe synthesis incubation, 2 4 RNase-free DNase was added 
to the reaction and was incubated for a further 30 minutes at 37°C. A 
phenol/chloroform extraction was performed by adding 26 4 20 mM EDTA, 25 lit 
Tris-saturated phenol, 25 4 chloroform/isoamyl alcohol (50:1), and 2 4 yeast 
tRNA to the DNase-treated probe mixture. The solution was vortexed into an 
emulsion, and centrifuged for 5 minutes at maximum speed in a bench-top 
microfuge. The upper aqueous phase was transferred to a new microfuge tube and 50 
4 chloroform/isoamyl alcohol solution added and mixed by vortexing, followed by 
another separation of phases by centrifugation for 2 minutes at maximum speed. 50 
4 4 M ammonium acetate and 250 1AL ice-cold absolute ethanol was added to the 
resulting upper aqueous phase and the tube was inverted to mix, and incubated for 1 
hour at -80°C. The tube was centrifuged for 15 minutes at 4°C at maximum speed, 
the supernatant carefully removed and the pellet washed with 100 4 ice-cold 90% 
ethanol, followed by centrifugation for 5 minutes at 4°C. All supernatant was 
removed and the pellet air-dried and solubilised in 50 [IL hybridisation buffer by 
gentle vortexing. The activity of the resulting probe was measured using a Rackbeta 
liquid scintillation counter (LKB Wallac, Finland) and the probe stored at -20°C until 
needed. 
B) RNA Preparation and Hybridisation 
5 lug aliquots of experimental sample RNA were frozen at -80°C for 15 
minutes. The frozen RNA samples, plus additional samples of 5 lig HeLa RNA and 4 
!_tg yeast tRNA, included as positive and negative controls respectively for the RPA 
protocol, were dried using the Centrivap vacuum evaporation centrifuge (Labconco, 
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USA) at room temperature. Samples were solubilized in 8 tL hybridisation buffer by 
gentle vortexing. 2 ill, probe was added to each RNA sample and the RNA/probe 
mix overlaid with 60 uL mineral oil. The tubes were placed into a dry block heater 
pre-warmed to 90°C. The heat block temperature was immediately adjusted to 56°C 
and the samples incubated overnight. Prior to removing the samples, the heat block 
temperature was adjusted to 37°C, and having attained this temperature, the samples 
were incubated for a further 15 minutes. 
C) RNase Treatment and Purification of Hybridised Probe 
An RNase cocktail was prepared by combining 1.25 mL RNase buffer and 3 
[LL RNase A + Ti mix into a microfuge tube (enough for 10 samples). 100 j.tL of this 
mix was added directly underneath the oil layer into the hybridisation solution for 
each sample to degrade any unhybridised, and thus single-stranded RNA. Samples 
were incubated for 45 minutes at 30°C. A proteinase K cocktail was prepared by 
combining 195 pL proteinase K buffer, 15 111., proteinase K, and 15 iL yeast tRNA in 
a 1.5 mL microfuge tube. 
The RNase digests were extracted from underneath the oil layer, added to an 
18 ;AL aliquot of proteinase K solution, and incubated for 15 minutes at 37°C. The 
RNA:RNA hybrids were extracted by adding 65 p.L Tris-saturated phenol and 65 [IL 
chloroform/isoamyl alcohol (50:1), vortexing into an emulsion, and separation of the 
phases by centrifugation for 5 minutes at maximum speed. The upper aqueous phase 
(120 [IL) was transferred to a new microfuge tube and 120 1AL 4 M ammonium 
acetate and 650 lit ice-cold absolute ethanol added. The solution was mixed by 
inversion and incubated for 1 hour at -80°C. RNA:RNA hybrids were pelleted by 
centrifugation for 15 minutes at 4°C. The supernatant was carefully removed and 
pellets washed with 1000, ice-cold 90% ethanol, and collected by centrifugation for 
5 minutes at 4°C. Following removal of the supernatant, the pellets were air-dried 
and solubilized in 2.5 uL 1X loading buffer by vortexing. Loading buffer was also 
added to 2 1AL of an appropriate dilution of undigested probe (usually 1/20). The 
samples were prepared for loading onto a gel by heating for 3 minutes at 90°C and 
placed immediately on ice. 
D) Gel Resolution of Protected RNA:RNA Hybrids 
A 5% polyacrylamide gel was prepared as described in Chapter 2.2.6. Excess 
gel was scraped away from the glass plates. The gel was positioned in the 
GenomyxLe programmable DNA sequencer (Genomyx Corporation, USA) and 
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pre-run for 45 minutes at 40W constant with 0.5X TBE in the upper buffer chamber, 
and IX TBE buffer in the lower chamber. The 2.5 1AL RNA:RNA hybrid samples 
(including HeLa RNA and yeast tRNA controls) and undigested probe mixed with 
1X loading buffer were loaded onto the gel and the gel run at 50W constant until the 
dye front reached approximately 30 cm. The top glass plate was removed and the gel 
was dried, rinsed well with Milli-Q water. This was repeated two more times. The gel 
was dried thoroughly for a final time and was exposed to BioMax me film 
(Eastman Kodak Company, USA), and developed after a sufficient exposure period. 
E) RNase Protection Assay Analysis 
Using the undigested probe as a marker, the identity of the "RNase-protected" 
bands in the experimental samples and HeLa and yeast tRNA control samples was 
determined. The autoradiogaphs were scanned using a GS-800 calibrated 
densitometer (BIO-RAD Laboratories, USA) and analysed using the Quantity One ® 
quantitation software package (BIO-RAD Laboratories, USA). Pixel volumes 
(optical density/mm2) data were obtained and normalised between samples using the 
data obtained from house-keeping gene analysis. Generally, all raw data was 
normalised using the 0 hr Control sample for GAPDH. Analysis was performed on 
various exposure times to enable accurate normalisation to the 0 hr Control sample, 
and to allow a more complete and accurate collection of data for the genes being 
expressed. Fold changes between the samples were calculated for each gene analysed 
where a signal was detectable. 
2.2.9. cDNA Arrays 
cDNA array analysis was performed using the protocol and reagents provided 
in the AtlasTm Pure Total RNA Labelling System, and Atlas Cancer 1.2 
cDNA Expression Array kits (Cat . # K1038-1 and # 7851-1 respectively, Clontech, 
USA). A summary of the protocol, including alterations made for the purpose of this 
study, is provided below. 
A) Poly A+ RNA Enrichment 
Extracted RNA was purified for Poly A+ RNA only, using the protocol and 
reagents provided in the Atlas TM Pure Total RNA Labelling System kit (Clontech, 
USA). The streptavidin-conjugated magnetic beads were resuspended and 15 pL per 
probe synthesis (usually two probes were synthesised per experiment) was aliquotted 
into a 0.6 mL microfuge tube. The beads were separated using a Vario MACS 
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magnetic particle separator (Miltenyi Biotech, Germany) and - the supernatant 
removed. The beads were washed in 150 1X binding buffer and separated on the 
magnetic particle separator. This was repeated three times and the beads were finally 
resuspended in 15 pL 1X binding buffer per probe, and kept on ice until needed. 
Up to 50 [is of RNA was transferred into a 0.6 mL microfuge tube for each 
sample (Control and Ceramide; 2, 8, or 24 hours post-treatment). RNase-free water 
was added to the sample to bring the volume to 45 4. 1 [IL biotinylated oligo(dT) 
was added and mixed with the RNA and the tubes were immediately incubated for 2 
minutes at 70°C on a preheated thermal cycler, and allowed to cool at room 
temperature for 10 minutes. 45 pt 2X binding buffer was then added and mixed by 
pipetting. The beads were resuspended and 15 pi, was added to each Poly A+ RNA 
sample. The Poly A+ RNA/beads solution was continually mixed for 30 minutes at 
1500 rpm on a MSI Minishaker vortexer (IKA Works, Malaysia) at room 
temperature. The beads were separated, supernatant was removed, and the beads 
were resuspended in 50 1.tI, 1X wash buffer. The beads were separated and 
resuspended a second time in IX wash buffer. The beads were separated, supernatant 
removed, and the beads were resuspended in 50 1A1 1X, reaction buffer. The beads 
were again separated, supernatant was removed, and the beads were resuspended in 3 
RNase-free water and kept on ice until needed. 
B) cDNA Probe Synthesis 
Necessary precautions and routines were followed when handling and 
disposing radioactive substances, as outlined in the National Health and Medical 
Research Council's regulations (1985, 1995a, 1995b). A master mix (Table 2.7.) for 
synthesis of the radiolabelled cDNA probes was prepared at room temperature (to 
make 2 probes + 1 extra). 
Table 2.7.: cDNA probe synthesis master mix. 
Reagent Volume 
5X Reaction buffer 12 III, 
10X dNTP mix (for dATP label) 6 iiL 
[a-321]dATP, dye-free (3000 Ci/mmol, 10 pfi/IAL) 151AL 
100 mM DTT 1.51AL 
Total = 34.5 lit 
(11.5 threaction) 
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The Poly A+ RNA/beads solution was resuspended. 4 tiL CDS primer mix 
(specific for the human cancer 1.2 array) was added to the beads, mixed well by 
pipetting, and incubated for 2 minutes at 65°C in a preheated thermal cycler. The 
temperature was reduced to 50°C and the tubes incubated for a further 2 minutes. 
During this incubation, 6 tit PowerScript ml Reverse Transcriptase (Clontech, USA) 
(2 .t.L per reaction) was added to the master mix at room temperature and was gently 
mixed by pipetting. After the completion of the 50°C incubation, 13.5 IA, master mix 
was added to each reaction tube and the contents mixed thoroughly. The reaction 
tubes were immediately returned to 50°C and incubated for 25 minutes, followed by 
the addition of 2 lit 10X termination mix. 
C) cDNA Probe Purification 
All procedures performed and reagents used from this point onwards were 
from the Atlas TM Human Cancer 1.2 cDNA Expression Array kit (Clontech, USA). 
Radiolabelled cDNA probes were purified by column chromatography. Briefly, the 
probe synthesis reactions (approximately 20 1.t.L each) were diluted in 180 tiL Buffer 
NT2 and loaded into a NucleoSpin extraction spin column sitting in a 2 mL 
collection tube. The columns were centrifuged for 1 minute at maximum speed in a 
bench-top microfuge and the flow-through discarded as liquid radioactive waste. The 
columns were transferred into new collection tubes and 400 121, Buffer NT3 was 
added. The columns were centrifuged for 1 minute at maximum speed and the flow-
through discarded. This was repeated two more times. The columns were then 
transferred into labelled 1.5 mL microfuge tubes and 100 vt.L Buffer NE was added 
directly to the membrane and allowed to soak for 2 minutes. The tubes with columns 
in place were centrifuged for 2 minutes at *maximum speed to elute the purified 
probes and the activity of the probes measured by scintillation counting on a 
Rackbeta liquid scintillation counter (LKB Wallac, Finland). The probes were stored 
at -20°C until needed. 
D) Hybridisation of cDNA Probe to Atlas Array 
The ExpressHyb hybridisation solution was prewarmed to 68°C to dissolve 
any precipitates. 100 1AL 10 mg/mL (0.5 mg per probe synthesis) sheared salmon 
testes DNA was heated for 5 minutes at 100°C, and then immediately chilled on ice. 
A prehybridisation solution was prepared by adding 50 4, (0.5 mg) of the denatured 
salmon testes DNA to 5 mL of the prewarmed ExpressHyb solution. This was kept at 
68°C until used. 
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Two Human Cancer 1.2 array blots (one for each control and ceramide 
sample) were placed into separate cleaned glass hybridisation bottles using forceps, 
ensuring that they were orientated with the correct side facing inwards and that no air 
pockets were present between the glass surface and the blots. This step was 
performed quickly to prevent drying of the array membranes. The 5 mL 
prehybridisation solution was added to the bottles containing the array blots and the 
arrays were prehybridised for 30 minutes at 68°C with continuous agitation in a 
Model 2000 Micro Hybridisation Incubator (Robbins Scientific, USA). 
The cDNA probes were prepared for hybridisation by adding 5 !IL C ot-1 DNA 
and incubating for 2 minutes at 100°C, followed by an immediate incubation on ice 
for 2 minutes. Once the prehybridisation incubation was completed, each of the probe 
solutions were then pipetted directly into the prehybridisation solution in the bottles 
containing the array blots. Hybridisation bottles were labelled according to the probe 
(control or ceramide) they contained. Blots were hybridised with the probe overnight 
with continuous agitation at 68°C. 
The next day, the hybridisation solution was discarded and blots were washed 
four times with approximately 200 mL prewarmed Wash Solution 1 (2X SSC; 1% 
SDS) for 30 minutes at 68°C with continual agitation. A 30 minute wash was then 
performed in prewarmed Wash Solution 2 (0.1X SSC; 0.5% SDS) at 68°C, and a 
final wash was performed in 2X SSC at room temperature. The array membranes 
were removed from the hybridisation bottles, excess solution was briefly drained 
without allowing the blots to dry, and the blots were wrapped in plastic wrap and 
mounted on a sheet of blotting paper in the correct orientation. The array blots were 
exposed to BioMax Tm MR film (Eastman Kodak Company, USA) using an 
intensifying screen at -80°C for 6 hours, 24 hours and 3-10 days depending on the 
activity of the probe and the resulting signal intensity, and the film was developed. 
E) Atlas"' Array Analysis 
The developed films were scanned using a GS-800 calibrated densitometer 
(BIO-RAD Laboratories, USA) and analysed using the Quantity One ® quantitation 
software package (BIO-RAD Laboratories, USA). Optical density values per mm 2 
were obtained and were normalised between samples using the data obtained from 
expression analysis of the house-keeping genes included on the array. Fold changes 
between the samples were calculated for each gene analysed. Analysis was performed 
on the various exposures to enable a more complete and accurate collection of data 
for the genes being expressed. 
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F) Stripping of cDNA Probe From Atlas Array 
The array blots were reused for subsequent or confirmatory experiments after 
exposure to the film by stripping the probe from the membrane. Briefly, the blots 
were placed in a boiling solution of 500 mL 0.5% SDS for 5-10 minutes. The 
solution was then removed from the heat source and allowed to cool at room 
temperature for 10 minutes. The blots were then rinsed in Wash Solution 1 (2X SSC; 
1% SDS), wrapped in plastic wrap, and exposed to film at -80°C to check the 
efficiency of the stripping procedure. If no signal was detected, the blots were stored 
at -20°C until needed in a subsequent experiment. 
2.2.10. Primer Design and Standard RT-PCR Testing 
A) Primer Design 
Oligonucleotides @rimers) for use in reverse transcription-polymerase chain 
reaction (RT-PCR) applications were designed according to the guidelines discussed 
by Persing (1993), and only amplified intron-spanning regions of the specific target 
gene as a precaution to prevent amplification of potentially contaminating DNA. It 
was ensured that the chosen primer sequences were not self-complementary such that 
interprimer annealing could not occur. Furthermore, a Blast search (National Centre 
for Biotechnology Information, N1E1) was performed on all primer sequences to 
ensure they were only complementary with the desired human target gene of interest. 
Primer sequences were designed using the GenBank nucleotide sequence database 
(National Centre for Biotechnology Information, N1H) with the accession numbers 
provided in the AtlasTM Human Cancer 1.2 cDNA Expression Array handbook for 
each specific gene of interest. All primer sequences were designed to have an 
optimum annealing temperature at 60°C, and amplified a ,:--, 400-500 bp RT-PCR 
product. These conditions were chosen such that the efficiency of amplification of all 
transcripts was similar for each primer set. All primers used in this study were 
synthesised by GeneWorks (Adelaide, Australia) and were RPC purified. The primer 
sequences used for confirmation of the cDNA array results are given in Table 2.8. 
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Table 2.8.: Details of the primer sets designed for confirmation of cDNA array results. 
Target Gene Name GenBank 
Accessn No. / 
cDNA Array 
Posn. 
Sequence (5' to 3') RT-PCR 
Product 
Size 
Preferentially 
expressed antigen of 
melanoma 
(PRAME) 
U65011 / 
C08c 
Sense: 
437 bp ACTCTTCATGGCAGCCTTTG 
Antisense: 
CGCTTCACTTTCTCAATGAGGT 
Proliferating cell/cyclic 
nuclear antigen 
(PCNA) 
M15796 / 
C13e 
Sense: 
396 bp CGGATACCTTGGCGCTAGTA 
Antisense: 
TGAGTGTCACCGTTGAAGAGA 
Macrophage inhibitory 
cytokine 1 
(MIC1) 
AF019770 / 
E09e 
Sense: 
391 bp CTCAGAGTTGCACACCGAAG 
Antisense: 
AGATTCTGCCAGCAGTTGGT 
Growth arrest & DNA- 
damage-inducible 
protein 153 
(GADD153) 
S40706 / 
CO5d 
Sense: 
473 bp GCCTTTCTCTTCGGACACTG 
Antisense: 
TCACCATTCGGTCAATCAGA 
Glyceraldehyde 3- 
phosphate 
dehydrogenase 
(GAPDH) 
X01677 / 
G27 
Sense: 
443 bp TTCATTGACCTCAACTACAT 
Antisense: 
GTGGCAGTGATGGCATGGAC 
B) One-Step RT-PCR and Product Detection 
The primer sequences described in Chapter 2.2.10.(A). were tested by RT-
PCR using the SuperScriptTM One-Step RT-PCR kit (Invitrogen Life Technologies, 
USA). A standard protocol described in the SuperScript TM One-Step RT-PCR kit 
package insert was adopted. The reagents and reaction conditions used are listed in 
Tables 2.9(A). and 2.9(B). respectively. 
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Table 2.9(A).: SuperScriptl' One-Step RT-PCR reagent set-up. 
Reagent Volume per 
Reaction 
Final 
Concentration/Amount 
2X Buffer (containing 400 mM 
each GACU & 2.4 mM MgSO4) 
12.5 	.t1_, 1X (200 mM each dNTP & 
1.2 mM MgC12) 
3 tiM Sense primer 1.71AL 0.2 uM 
31AM Antisense Primer 1.7 pL 0.2 uM 
SuperScriptTM 11 RT enzyme / 
Platinum® Taq mix 
0.5 pi. Unknown 
(assuming 1U each) 
1001.1g/pL RNA Sample 2 [IL 200 ug 
RNase-free water 6.6 	.LI., (Final volume to 25 [IL) 
Total = 25 tiL 
Table 2.9(B).: SuperScripC One-Step RT-PCR reaction conditions. 
Temperature Time 
50°C 20 minutes 
94°C 2 minutes 
94°C 30 seconds 
40 cycles 60°C 30 seconds 
72°C 45 seconds 
72°C 5 minutes 
4°C co 
All components of the One-Step RT-PCR reaction were stored at -20°C. The 
SuperScript RT and Platinum Taq enzyme mix was stored at -20°C until needed and 
kept on ice while out of the -20°C freezer in order to maintain their fidelity. 
Additionally, the enzymes were only mixed very gently on all occasions. Reagents 
were combined in a 0.2 mL PCR tubes on ice, and the reaction performed using an 
Eppendorf thermal cycler (Eppendorf, Germany). Negative control samples (water 
instead of RNA) were included with each sample reaction. GAPDH was amplified 
simultaneously with each amplification run to monitor the validity of the reaction. 
RT-PCR products were analysed by agarose gel electrophoresis as described 
in Chapter 2.2.7(B), using a 100 bp PCR molecular ruler to provide a reference size 
marker. The products were visualised on the UV transilluminator. 
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2.2.11. Real-Time RT-PCR Optimisation 
The parameters optimised in the real-time RT-PCR include primer 
concentration, Mn(0Ac)2 concentration, template concentration, and the temperature 
for measuring SYBR Green I fluorescence. Primer, Mn(0Ac)2, and template 
concentrations were optimised by performing real-time RT-PCR using various 
concentration ranges. The optimal conditions were concluded as that which produced 
the most specific and intense product as determined by real-time RT-PCR analysis 
and by agarose gel electrophoresis. The optimal temperature for fluorescence 
detection was determined to be the temperature that was below the product melting 
point (Tm) and above primer-dimer product if it existed. 
The optimal primer concentration was found to 0.3 1.1.M for each of the 
primers tested. Optimal Mn(0Ac)2 concentrations varied between the primer sets 
tested and are provided in Table 2.10. A template concentration of 1 i.tg per reaction 
was found to be optimal for all primer sets tested. The optimal temperature for 
measurement of SYBR Green I fluorescence was found to be 78°C for the PCNA 
primer set, and 81°C for all other primer sets tested. 
Table 2.10.: Optimised real-time RT-PCR Mn(0Ac) 2 concentrations for each of the designed primer 
sets. 
Primer Set Volume per 101.1L Reaction 
(50 mM Stock 
Final Mn(0A02 
Concentration 
PRAME 0.74 3.5 mM 
PCNA 0.5 1AL 2.5 mM 
MIC1 0.5 IlL 2.5 mM 
GADD153 0.5 iaL 2.5 mM 
GAPDH 0.7p1 3.5 mM 
The final optimised real-time RT-PCR reaction set-up and conditions are 
provided in Table 2.11. and Tables 2.12(A).-2.12(E)., respectively. 
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Table 2.11.: Final optimised real-time RT-PCR reagent set-up. 
Reagent Volume per 
Reaction 
Final 
Concentration/Amount 
RNase-free water Final volume to 101.1.L 
50 mM Mn(0Ac) 2 Refer to Table 5.3. 
3 ii,M Sense and Antisense Primers liAL  
3.75 jaL 
0.3 I_IM 
1X 2.7X LightCycler mix 	(containing 
Tth DNA polymerase, GACU mix & 
SYBR Green I) 
500 ng/pL RNA Sample 21AL 11.ig 
Total = 10 
Table 2.12(A).: Program 1: Reverse Transcription - Final optimised real-time RT-PCR reaction 
conditions. 
Program Parameter Value 
Cycles 1 
Time 25 minutes 
Temperature 61°C 
Temperature transition rate 20°C/second 
Analysis Mode None 
Acquisition Mode None 
Table 2.12(B).: Program 2: Denaturation - Final optimised real-time RT-PCR reaction conditions. 
Program Parameter Value 
Cycles 1 
Time 3 minutes 
Temperature 95°C 
Temperature transition rate 20°C/second 
Analysis Mode None 
Acquisition Mode None 
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Table 2.12(C).: Program 3: Amplification - Final optimised real-time RT-PCR reaction conditions. 
Program Parameter Value 
Cycles 50 
Analysis Mode Quantification 
Segment 1 Segment 2 Segment 3 
Time 5 seconds 7 seconds 13 seconds 
Temperature 95°C 60°C 72°C 
Temperature transition 
rate 
20°C/second 20°C/second 2°C/second 
Acquisition Mode None None Single (78°C for 
PCNA, 81°C for 
others) 
Table 2.12(D).: Program 4: Melting Curve Analysis - Final optimised real-time RT-PCR reaction 
conditions. 
Program Parameter Value 
Cycles 1 
Analysis Mode Melting Curve 
Segment 1 Segment 2 Segment 3 
Time 5 seconds 15 seconds 0 seconds 
Temperature 95°C 65°C 95°C 
Temperature transition 
rate 
20°C/second 20°C/second 0.1°C/second 
Acquisition Mode None None Continuous 
Table 2.12(E).: Program 5: Cooling - Final optimised real-time RT-PCR reaction conditions. 
Program Parameter Value 
Cycles 1 
Time 30 seconds 
Temperature 40°C 
Temperature transition rate 20°C/second 
Analysis Mode None 
Acquisition Mode None 
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All components of the real-time RT-PCR were stored at -20°C in aliquots and 
were thawed as required. The LightCycler mix was stored at -20°C until needed and 
kept on a cool block in the dark when out of the -20°C freezer in order to maintain 
fidelity of the enzyme and SYBR Green I fluorescence. Reagents were combined in 
glass capillaries, and the reaction performed using a LightCycler (Roche Diagnostics, 
Germany). A negative control sample (water instead of RNA) was included with the 
sample reactions. GAPDH was amplified simultaneously with each amplification run 
to monitor the validity of the reaction. 
Real-time RT-PCR product size could be confirmed by collecting the product 
from the LightCycler capillary into a 1.5 mL microfuge tube by brief centrifugation 
and analysis by agarose gel electrophoresis as described in Chapter 2.2.7(B), using a 
100 bp PCR molecular ruler to provide a reference size marker. The products were 
visualised on the UV transilluminator. 
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3.1. Introduction 
The sphingomyelin (SM) pathway has emerged as an important regulator of 
cellular growth, differentiation and apoptosis in human leukaemia cells. Studies into 
ceramide action upon human haemopoietic cells have predominantly concentrated on 
three cell lines: HL60 promyelocytic, U-937 monocytic, and MOLT-4 T lymphocytic 
cells. 
The first noted cellular effect of ceramide was its ability to induce monocytic 
differentiation of HL60 cells (Okazaki et al., 1989, Okazaki et al., 1990, Kim et al:, 
1991), thus mimicking the action of TNFcc and IFNy on these cells. In fact it has been 
shown that ligation of the TNFoc and IFNy receptors causes significant SM 
hydrolysis, resulting in ceramide generation. Similarly, treatment of HL60 cells with 
vitamin D3, an inducer of monocytic differentiation, caused a rapid time-dependent 
hydrolysis of SM (Okazaki et al., 1989), which led these researchers to believe that 
the growth inhibitory effects of vitamin D3 was mediated by the SM cycle. In 
contrast, agonists such as retinoic acid or DMSO, which induce granulocytic 
differentiation, or phorbol esters, which promote macrophage-like differentiation, 
failed to stimulate SM hydrolysis in HL60 cells (Kim et al., 1991, Hannun, 1994). It 
was concluded from this work that ceramide generation results in a specific 
differentiation response. 
A significant majority of the reports in the literature have focussed on the 
ability of ceramide to mediate apoptosis. The ability of ceramide to induce apoptosis 
was first reported in U-937 cells by Obeid et al., 1993. Exposure to C2-ceramide 
mimicked the effect seen following the treatment of this cell line with TNFoc, leading 
to the postulation that ceramide may act as a "death messenger" in apoptosis 
induction. From these and subsequent findings by other researchers it was concluded, 
rather simplistically, that ceramide generation was an obligatory step in the apoptotic 
process, a conclusion that became well accepted and which dominated SM signalling 
research for many years. Doubts as to the role of ceramide in initiating Fas apoptosis 
originally arose following the finding that ceramide generation occurred downstream 
of caspase activation, and was indeed blocked by inhibition of CPP32 (Gamen et al., 
1996, Sillence & Allan, 1997). Tepper et al. (2000) subsequently revealed that 
ceramide generation occurred specifically during the execution phase of apoptosis, 
rather than being involved in the initiation events. Recent studies have shown that 
ceramide causes the release of cytochrome c from the mitochondria, with subsequent 
activation of the executor caspases, thus demonstrating that ceramide has a role in the 
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amplification, rather than the initiation of apoptosis (Ghafourifar et al., 1999, Ito et 
al., 1999, Cuvillier et al., 2000, Hearps et al., 2002). 
Despite the intense interest in ceramide signalling during the past decade, 
very few studies have followed up on the original observation that ceramide 
signalling could induce growth arrest and haemopoietic differentiation. 
Serum starvation of MOLT-4 cells caused significant Go/G1 cell cycle arrest 
that was associated with an accumulation of endogenous ceramide, via activation of a 
magnesium-dependent SMase. Furthermore, the addition of exogenous ceramide (C6- 
ceramide) mimicked the dramatic Go/G1 cell cycle arrest comparable to the effects 
observed with serum withdrawal. This cell cycle arrest was subsequently associated 
with the activation (dephosphorylation) of Rb (Dbaibo et al., 1995), and the addition 
of exogenous C6-ceramide (at levels comparable to that achieved with serum 
withdrawal) or C2-ceramide (Chao et al., 1992, Pushkareva et al., 1995) resulted in a 
concentration- and time-dependent dephosphorylation of Rb in MOLT-4 cells 
(Dbaibo et al., 1995), thus forming the mechanistic link between ceramide 
production and cell cycle arrest. Interestingly, the addition of exogenous ceramide 
had little activity in causing growth suppression of cells that lack a functional Rb 
gene (Dbaibo et al., 1995), whilst cells transfected with either SV40 T antigen or 
ElA adenoviral protein, which bind and sequester Rb, showed an inability to undergo 
ceramide-induced cell cycle arrest. Although interfering with Rb activity abrogated 
ceramide-induced cell cycle arrest, it did not prevent ceramide-induced apoptosis 
(Dbaibo et al., 1995), which is evidence that ceramide-induced cell cycle arrest and 
apoptosis are separate mechanisms. 
A study by Ragg et al. (1998) demonstrated that treatment of U-937 cells with 
a sub-apoptotic dose of C 2-ceramide induced terminal differentiation and cell cycle 
arrest with up to 80% of cells in G 0/G 1 phase by 24 hours. Ceramide-induced G0/G 1  
cell cycle arrest was also accompanied by Rb dephosphorylation and increased 
p21Cipl/Wafl expression. This was the first report of a ceramide-induced effector 
mechanism linking cell cycle inhibition, Rb activation, and stable expression of 
p2l ciP uwan with ceramide treatment of cells. This study also demonstrated that cell 
cycle regulatory mechanisms could be activated in a p53-independent manner, as U-
937 cells lack a functional p53 gene. In addition to the above findings, C2-ceramide-
treatment of U-937 cells activated the JNK MAP kinase, leading to the postulation 
that activation of the JNK pathway and its subsequent pathways may control 
transcription of the p2l ciP "Wafi gene (Ragg et al., 1998). 
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While extensive effort has been invested in investigating the relationship 
between ceramide signalling and apoptosis, the growth arrest and differentiation-
inducing effects of ceramide are relatively understudied. With the proposed role of 
ceramide as an initiator of apoptosis now discredited, it is time to direct attention 
back towards gaining a greater understanding of the ability of ceramide to mediate 
growth arrest and differentiation, as these outcomes hold significant therapeutic 
potential. Studies to date have predominantly examined three cell lines, and have 
only assessed limited outcomes (e.g. cell cycle and Rb status) with no attempt to 
determine the extent or consistency of responses with other cell lines. A larger screen 
of cell lines, from different human haemopoietic cell lineages is needed to determine 
which type(s) of cells respond to ceramide, to characterise the response, and 
determine the consistency in terms of outcome and magnitude of ceramide-
responsive cells. 
This chapter will investigate and characterise the response of haemopoietic 
cell lines to ceramide signalling in terms of viability/growth rates, cell cycle status, 
Rb activation, p2l ciP l/wall expression, and phenotype, and seek to determine whether 
common responses and mechanisms are utilised. 
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3.2. Methods 
3.2.1. Experimental Plan 
Preliminary dose-response experiments were conducted to determine the 
optimal concentration of C2-ceramide, and the most suitable culture conditions for 
each cell line. Experiments were conducted using exponentially growing cells. The 
optimal concentration of C2-ceramide was defined as being a dose that was high 
enough to induce maximal growth arrest while minimising the apoptosis observed at 
higher concentrations. As such, the concentrations of C 2-ceramide used in a majority 
of the experiments conducted in this study for each cell line were as follows: 5 IIIVI: 
K562 and Jurkat; 7.5 1.1M: KG-I, KG-1 a, and HL60; 20 pLM: Raji. Where the 
concentration of C2-ceramide used varies from that provided above, the appropriate 
concentration will be stated in the individual section protocols of this thesis. 
It was critical that the culture conditions used during an experiment were such 
that cells were only minimally affected (or not at all) by the culture conditions alone, 
as serum-free conditions have been noted to induce ceramide generation, cell cycle 
arrest, Rb dephosphorylation, and apoptosis in some cell lines (Dean et al., 1986, 
Kim et al., 1991, Howard et al., 1993, Shichiri et al., 1993, Dbaibo et al., 1995, 
Jayadev et al., 1995). The optimal experimental treatment culture conditions 
determined for this study are stated in Chapter 2.2.3(D). Treatment conditions that 
vary from those outlined in Chapter 2.2.3(D). are stated in the individual protocols. 
Cellular responses were investigated following the treatment of cells with C2- 
ceramide. This included the analysis of ceramide-induced cell cycle arrest, growth 
arrest, and differentiation. Enumeration and viability studies were performed using 
trypan blue staining to demonstrate whether ceramide causes growth arrest in the 
various human haemopoietic cell lines. Hypotonic PI staining and flow cytometry 
was used to investigate the ability of ceramide to induce cell cycle arrest. The 
phosphorylation status of Rb following C2-ceramide treatment was studied by 
Western blotting. RNase protection assays were used to investigate the expression of 
p21 Cm 1 /Wafl following C2-ceramide treatment, and changes in cell surface marker 
expression were analysed by immunophenotyping using flow cytometry. 
3.2.2. Determination of Cell Viability 
Cell lines were treated with vehicle or C2-ceramide and were plated at 5 X 10 5 
cells/mL in 24 well culture dishes and incubated at 37°C/5% CO 2. A 10 ilL volume 
of cells were harvested at various timepoints and mixed with an equal volume of 
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0.25% (w/v) trypan blue by gentle pipetting. The cell suspension was pipetted into a 
haemocytometer and the number of viable cells enumerated. Cells were considered 
viable if they had not taken up the trypan blue stain. 
3.2.3. Cell Cycle Analysis 
All cell lines were treated with C 2-ceramide and were plated at 5 X 10 5 
cells/mL (1 mL/well) in 24 well culture dishes and incubated at 37°C15% CO2. Time-
matched controls were treated with an equivalent volume of the ethanol vehicle. 
Cells (1 X 106 cells/sample) were harvested by centrifugation in 5 mL FACS tubes at 
predefined timepoints. The supernatant was removed and the cells were resuspended 
in 300 tit hypotonic propidium iodide (HPI) solution, and left for at least 2 hours at 
room temperature or overnight at 4°C in the dark (Nicoletti et al., 1991, Ragg et al., 
1998). 
Raji cells were washed with 1X PBS, fixed with 1.5 mL 70% ethanol/1X PBS 
for 30 minutes at 4°C, and treated with RNase prior to staining with HPI solution. 
The removal of RNA from these cells produced a more satisfactory coefficient of 
variation when analysed. 
DNA content data were acquired using a FACScan flow cytometer (Becton-
Dickinson, USA) and subsequent cell cycle analysis was performed using ModFit 
software (Becton-Dickinson, USA) to model the linear red fluorescence signal area 
(FL2-Area). The proportion of cells in each phase of the cell cycle was noted for each 
sample analysed and the percentage change calculated between C2-ceramide-treated 
and vehicle-treated, time-matched control samples. Apoptosis was identified as a 
sub-G0/G 1 peak. Aggregates were excluded from the analysis by use of a doublet 
discrimination module and subsequent gating on the linear red fluorescence area and 
width parameters. 
3.2.4. Preparation of Total Cellular Protein Extracts 
The Rb phosphorylation status was investigated by Western blotting. Cellular 
protein extracts were prepared from 2 X 10 6 harvested cells by lysis of the pelleted 
cells in 50-100 [IL freshly prepared lysis buffer (described in Chapter 2.2.1.) and 
cleared by centrifugation at 18000 x g for 15 minutes at 4°C. Lysates were prepared 
for gel electrophoresis by boiling for 7 minutes in an equal volume of 2X Laemelli 
sample buffer (also described in Chapter 2.2.1.) followed by incubation on ice. 
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3.2.5. Western Blot Analysis of Rb Phosphorylation Status 
A 6.5% separating gel and a 4% stacking gel were prepared as described in 
Chapter 2.2.5. Following polymerisation of the stacking gel, the comb was removed 
and the wells were thoroughly flushed out with Milli-Q water to remove any 
unpolymerised gel. The gel cassette was placed into position in an XCell II Mini-Cell 
(Novex, USA) electrophoresis apparatus and the upper and lower compartments 
filled with lx running buffer. The wells of the gel were flushed with 1X running 
buffer. 
Prepared cellular protein samples (30 114 and a prestained, broad-range 
SDS-PAGE standard (BIO-RAD Laboratories, USA) sample were loaded onto the 
gel and the proteins run through the stacking gel by electrophoresis at 80V constant 
until the dye front had progressed into the separating gel. The voltage was then 
increased to 120V constant until the dye front had reached the bottom of the 
separating gel. Proteins were transferred to an Immun-Blot ® PVDF membrane (BIO-
RAD Laboratories, USA) in a Novex electrotransfer blot module for 2 hours at 25V 
in 1X transfer buffer. 
Following protein transfer, the membrane was blocked for 1 hour at room 
temperature, or overnight at 4°C, in 5% skim milk powder in PBST, washed three 
times in PBST, and incubated by rocking overnight in 0.5 fig/mL anti-Rb goat 
antibody in PBST at 4°C. The blot was washed three times in PBST and incubated 
for 2 hours in 0.2 1.tg/mL anti-goat HRP-conjugated antibody in PBST at room 
temperature, followed by another three washes in PBST. Detection of Rb was 
performed using Enhanced Chemiluminescence and Hyperfilm (Amersham, 
England). 
3.2.6. RNase Protection Assays - p21 CipllWafl Expression Analysis 
All cell lines were treated with vehicle or C2-ceramide at 5 X 105 cells/mL in 
serum-free RPMI media, except HL60 cells which were treated in RPMI + 2% FCS, 
and Raji cells which were treated in X-Vivo media (Biowhittaker, USA) + 2% FCS. 
The treated cells were transferred to 75 cm2 cell culture flasks and incubated at 
37°C/5% CO2. Cells (1 X 107 cells/sample) were harvested at 0, 4 and 8 hours post-
treatment, and RNA extracted, DNase-treated and quantitated as outlined in Chapter 
2.2.7. 
RNase protection assays were performed using the extracted RNA, and 
analysed exactly as described in Chapter 2.2.8. using the human stress-1 (hStress-1) 
template (Cat. # 45351P, PharMingen, USA). The hStress-1 template contains, 
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among others, riboprobes directed towards human p2.1 ciP 1lwaf1  RNA transcripts, and 
the house-keeping gene transcripts L32 and GAPDH. 
3.2.7. Immunophenotyping 
Myeloid cell lines (K562, KG-1, KG-la and HL60) were treated with vehicle 
or C2-ceramide, plated at 5 X 105 cells/mL in 24 well culture dishes and incubated at 
37°C/5% CO2. Harvested cells (5 x 10 5 cells/sample) were washed twice, 
resuspended in 100 [IL PBSA + 1% FCS and incubated with 10 pL PE-conjugated 
anti-human CD 11 b and CD 14 antibodies for 15 minutes at room temperature in the 
dark. K562 cells were also incubated with anti-glycophorin A, and KG-1 and KG-la 
with anti-CD34 antibodies, as these represent specific lineage maturation markers for 
these cell lines. In addition, all cells were simultaneously incubated with 10 111, of a 
25 pig/mL isotonic 7-amino-actinomycin D (7-AAD) solution thus providing a means 
for dead cell exclusion from the final analysis (Gill et al., 1975, Waggoner, 1990). 
Stained cells were washed twice with PBSA + 1% FCS prior to fixation in 300 [1,1, 
FACS Fixative. Cells were immediately analysed by flow cytometry (described in 
Chapter 2.2.4.) using the CellQuest software package (Becton-Dickinson, USA). 
1mmunophenotype profiles were generated and the percentage change in Mean 
Fluorescence Intensity (MFI) for ceramide-treated cells relative to the time-matched 
vehicle-treated controls was calculated. 
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3.3. Results 
3.3.1. Effect of Ceramide Treatment on Growth Rate and Viability 
Figure 3.1. shows histograms demonstrating the dramatic effect of C2- 
ceramide treatment on cell viability. Cell viability was measured using trypan blue 
staining and the subsequent enumeration of cells at various timepoints. The change in 
viable cell numbers was determined by calculating the number of remaining viable 
cells at each timepoint compared with the number of viable cells at the 0 hour 
timepoint. Compared with the vehicle-treated, time-matched control cells, a 
considerable reduction in the number of viable cells was noted following ceramide 
treatment for all cell lines investigated. Similarly, the percentage of viable cells (i.e. 
the number of viable cells relative to the total cell count) in the ceramide-treated cell 
populations was shown to decrease over time. 
Treatment of K562 cells with C 2-ceramide caused a slight reduction in the 
number of viable cells during the first 24 hours (Figure 3.1.) which contrasted the 
observed continued growth of the time-matched control culture at this time point. 
The rate of loss of viable ceramide-treated cells accelerated after 24 hours of 
exposure such that only 15% of the original number of viable cells were present after 
72 hours. In comparison, the time-matched, vehicle-treated control cells had 
proliferated to some 300% of the original inoculum, despite serum-free conditions. 
The changes in the percentage of viable cells (Figure 3.2.) in the ceramide-treated 
culture reflects the growth rate pattern observed for K562 cells shown in Figure 3.1. 
During the first 24 hours the percentage of viable cells decreased to approximately 
60% and continued to decrease at a similar rate throughout the remainder of the 
experiment, such that a large majority of cells were dead by 72 hours (13% viability). 
In contrast, the percentage viability in the time-matched control culture was 
consistently >90% throughout the timecourse. 
Ceramide-treated HL60 cells showed a steady decrease in cell numbers during 
the first 48 hours, which countered the increase in cell numbers observed in the time-
matched control culture during this period (Figure 3.1.). Viable HL60 cell numbers 
had more than halved by 48 hours following ceramide treatment, compared with a 
150% increase in numbers observed in the control cell culture at the same timepoint. 
Between 48-72 hours the number of viable cells had stabilised, while there was a 
significant decrease in viable cell numbers during the 48-72 hour period in the 
control cell culture, bringing the number of viable cells equal to that in original 
inoculum. Figure 3.2. reveals that at 24 hours, a majority of the ceramide-treated 
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Figure 3.1.: Human haemopoietic cell viability curves demonstrating the number of viable 
cells per mL of culture, at various timepoints, using trypan blue staining following treatment 
with either vehicle or C 2-ceramide. A single representative set of results from at least four 
repeated experiments is shown. 
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HL60 cells were viable (76% viability), while approximately half of the observed 
cells were viable by 48 hours, decreasing further to 30% viability by 72 hours. 
Following the initial 24 hours of culture at which point 99% of cells remained viable, 
the control culture showed a decreasing percentage viability, although the percentage 
of viable cells in the control culture was consistently greater than that observed in the 
ceramide-treated cell population at the remaining matched timepoints. 
The KG-1 and KG-la cell cultures exhibited very similar growth rate patterns 
over a 48 hour time period (Figure 3.1.). The reduction in viable cell numbers was 
very dramatic for both cell lines following ceramide treatment. By 24 hours post-
treatment, only 30% of the original count of KG-1 cells, and 13% of KG-la cells 
remained viable. The number of viable cells continued to decrease during the 
proceeding 24 hours, and by 48 hours the number of viable cells was almost 
negligible. The KG-1 control cell culture exhibited a slight increase in proliferation 
over the 48 hour period, whilst the number of viable cells in the KG-la control cell 
culture remained effectively unchanged throughout the experiment. Figure 3.2. shows 
that the observed decrease in growth rates for both KG-1 and KG-la cell lines 
following ceramide treatment was due to increased cell death as these percentage 
viability curves closely resemble the growth rate curves shown in Figure 3.1. 
Following exposure to ceramide for 24 hours, the percentage of viable cells had 
rapidly decreased to 31% and 20% for KG-1 and KG-la cells respectively. By 48 
hours, the percentage viability had further reduced to 6% and 3% for KG-1 and KG-
1a cells respectively. The control KG-1 culture showed a slight decrease in 
percentage viability, with 66% of cells remaining viable by 48 hours. There was 
negligible change in percent viability in the KG-la control culture from the 0 hour to 
24 hour timepoint (94% viability at both), and only a slight decrease by 48 hours to 
approximately 84% viability. 
Jurkat T lymphocyte cells displayed the most dramatic loss in viable cell 
numbers (Figure 3.1.), with the rate of cell loss following ceramide treatment far 
exceeding that observed by the other cell lines investigated. Because of this sudden 
reduction in viable cell numbers, data could not be obtained for this cell line beyond 
24 hours of continuous culture following ceramide treatment. As early as 2 hours 
post-treatment, the number of viable cells decreased from 5 X 10 5/mL to 1.8 X 
105/mL. By 8 hours the number of viable cells had decreased further, such that only 
18% of the original viable cell number remained in culture, which was sustained up 
to the 24 hour timepoint. In comparison, the time-matched control cells showed a 
gradual increase in cell numbers due to proliferation in the _first 12 hours, with the 
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number of viable cells slightly decreasing at 24 hours. The changes in the percentage 
of viable cells (Figure 3.2.) reflects the observed growth rate pattern, whereby there 
was a dramatic decrease in the percentage of viable cells during the first 8 hours, 
such that only 17% of cells remained viable by this timepoint, while the percentage 
of viable cells in the control population remained >80% throughout the experiment. 
Raji cells exhibited a relatively low susceptibility to loss in viability following 
ceramide treatment over a 48 hour period compared with the other cell lines studied. 
As seen in Figure 3.1., the number of viable ceramide-treated cells remained 
relatively constant up to the 24 hour timepoint, similar to that observed in the control 
culture. At 48 hours, however, a slight decrease in viable cell numbers had occurred. 
In contrast, the control Raji cell population exhibited a 50% increase in cell numbers 
during the 24-48 hour period, such that the number of viable cells had more than 
doubled by 48 hours. The change in the percentage of viable cells (Figure 3.2.) in the 
ceramide-treated culture paralleled that observed in the control culture by the 24 hour 
timepoint (approximately 90% viability for both). At 48 hours the percentage 
viability observed for the ceramide-treated cell population had decreased to 79%, 
while the control population had increased marginally to 95% viability. 
3.3.2. Cell Cycle Analysis 
To determine whether C2-ceramide treatment consistently resulted in 
withdrawal from the cell cycle, changes in the proportion of cells in each phase of the 
cell cycle was investigated. Asynchronous cultures of logarithmically growing cells 
were treated and harvested at various timepoints, stained with a hypotonic solution of 
propidium iodide, and subsequent flow cytometric analysis performed. DNA content 
histograms from representative experiments at 24 hours post-treatment are provided 
in Figures 3.3.A. and 3.3.B. Changes in cell cycle kinetics were evident by 24 hours 
post-treatment with ceramide. The histograms are accompanied by quantitative data, 
which identify the proportion of cells in each phase of the cell cycle after gating for 
only the cycling population of cells. 
Following ceramide treatment, a 34% increase in the proportion of K562 cells 
in G0/G 1 phase of the cell cycle was demonstrated at 24 hours (27% and 41% in the 
control and ceramide-treated cultures respectively) when compared with time-
matched, vehicle-treated control cells (Figure 3.3.A.). Accompanying this increase in 
G0/G 1 was a 20% decrease in the proportion of cells in S phase (from 53% in the 
controls to 41% in the ceramide-treated culture). This is indicative of an inability to 
cross the G1-S transition, a hallmark of G0/G 1 cell cycle arrest. At 48 hours, a 60% 
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Figure 3.3.A.: DNA histograms demonstrating C 2-ceramide-induced cell cycle arrest in 
human haemopoietic cells. All histograms represent samples taken 24 hours after C2- 
ceramide treatment. Single representative results from at least four repeated experiments are 
shown. 
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increase in G0/G 1 phase cells was seen, which was accompanied by a 34% decrease 
in S phase. Similarly, a 20% increase in G 0/G 1 phase cells and a 24% decrease in the 
proportion of cells in S phase was demonstrated in HL60 cells by 24 hours. In 
contrast to K562 cells however, a sub-G 0/G1 population was particularly evident by 
24 hours in the ceramide-treated HL60 cell preparations. 
An early increase in the proportion of KG-1 cells in the G0/G 1 phase 
following ceramide treatment is not evident at 24 hours post-treatment. Although a 6- 
10% increase in G0/G1 was consistently demonstrated by 24 hours (Figure 3.3.A.), a 
25% increase in the proportion of KG-1 cells in G0/G 1 , accompanied by a 35% 
decrease in S phase events, was observed at 48 hours (Figure 3.4.). A more 
significant G0/G 1 increase was demonstrated in KG-la cells by 24 hours, increasing 
from 52% in the control cell population to 67% in the ceramide-treated population (a 
22% increase) (Figure 3.3.B.). A 33% decrease in S phase KG-la cells was shown at 
24 hours. By 48 hours, this became a 41% increase in Go/G1, and a 61% decrease in S 
phase (Figure 3.4.). Sub-Go/G 1 peaks were evident in both KG-1 and KG-la cells 
following ceramide treatment. 
After 24 hours of ceramide treatment, a significantly large sub-G 0/G1  
population of Jurkat cells was consistently seen. This sub-G 0/G1 peak, which 
accounted for an estimated 55%-60% of all events collected in the 24 hour ceramide-
treated Jurkat cell population, masked the G0/G 1 population thus making it difficult 
to accurately measure the true proportion of cells in the G0/G1 phase of the cell cycle. 
Raji B cells showed a 28% increase in the proportion of cells in G0/G 1 phase, 
and a 44% decrease in the proportion of cells in S phase by 24 hours post-treatment. 
In contrast to the Jurkat cells, few sub-Go/G 1 events were noted. 
3.3.3. Analysis of Rb Phosphorylation Status 
To determine the mechanism for ceramide-induced cell cycle arrest, the 
phosphorylation status of the Rb tumour suppressor protein was investigated by 
Western blotting, probing for both the hyper- and hypophosphorylated forms of Rb. 
Representative Western blot results for K562, HL60, KG-1, KG-la, Jurkat and Raji 
cell lines are shown in Figure 3.5. SDS-PAGE and Western blotting takes advantage 
of the fact that the faster migrating hypophosphorylated (RbhYP°) forms of Rb can be 
distinguished from the slower migrating hyperphosphorylated (Rb hYPer) forms. In all 
vehicle-treated sample preparations, a band corresponding to ,=-- , 105 kDa, representing 
inactive hyperphosphorylated Rb, was observed. The appearance of the lower Mr 
hypophosphorylated Rb form was indicative that Rb had become activated. 
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Figure 3.4.: DNA histograms demonstrating C 2-ceramide-induced cell cycle arrest in KG-1 
and KG-la human haemopoietic cells at 48 hours after C2-ceramide treatment. Single 
representative results from at least four repeated experiments are shown. 
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Activation of Rb was observed as early as 4 hours post-treatment in K562 
cells treated with ceramide. The Rb hYPer band remained prominent at this timepoint 
and throughout the experiment. By 24 hours, the intensity of the bands began to 
decrease presumably due to the reduced number of viable cells harvested. In contrast, 
RbhYP° was not apparent in ceramide-treated HL60 cells until 24 hours post-treatment 
and remained visible at 48 hours. 
The transformation of RbhYPer into the Rbh"° form by ceramide was very 
dramatic and an early event in both KG-1 and KG-la cell lines. By 4 hours post-
treatment, only the RbhYP° form of the TS protein could be visualised, while the 
RbhYPer band was clearly visible in the vehicle-treated control cell preparations at all 
timepoints during the experiment. No protein bands could be seen by 24 hours, again 
most likely due to the insufficient numbers of viable cells harvested. 
Activation of Rb was not seen in the Jurkat T cell line until 24 hours post-
treatment with ceramide, at which time the number of viable cells had diminished 
greatly, accounting for the lower level of protein seen compared with the earlier 
timepoints. Although a band corresponding to RbhYPer was seen at all timepoints in 
the vehicle-treated control Jurkat cell extracts, the lower Mr RbhYP° band was absent 
in the control extracts throughout the experiment. 
Logarithmically growing, vehicle-treated Raji B lymphocytic cells exhibited a 
slightly different Rb pattern from protein extracts from other cell lines in that more 
than two phosphorylation isoforms of Rb were observed. Following C2-ceramide 
exposure, an additional lower Mr band, representing fully hypophosphorylated Rb, 
became clearly apparent. This band was visible as early as 4 hours post-treatment 
with ceramide, and became more intense as the experiment progressed through to the 
8 and 24 hour timepoints, increasing incrementally in intensity in proportion to the 
intensity of the two higher M r RbhYPer bands. A hypophosphorylated isoform of Rb 
was identifiable in time-matched, vehicle-treated cell extracts, however an additional 
lower Mr hypophosphorylated Rb band was observed as early as 4 hours after 
ceramide treatment. This third isoform was not observed until 24 hours of culture for 
the time-matched, vehicle-treated controls. 
3.3.4. Expression ofp21ciPlfirafl Following Ceramide Treatment 
The expression of the cyclin-dependent kinase inhibitor p2l ciPilwqa following 
treatment with vehicle or C2-ceramide was investigated at 4 and 8 hours post-
treatment in K562, HL60, KG-1, KG-la, Jurkat and Raji cells by RNase protection 
assay (RPA) using the RiboQuantTM RPA System and hStressl template 
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(PharMingen, USA). An additional 2 hour timepoint was analysed for the Jurkat cell 
line. Enlarged sections of the un-normalised RPA blots from analysis of each cell 
line, showing the expression of p2PP"w`i1/ in RNA extracts from ceramide-treated 
cells and time-matched, vehicle-treated controls is shown in Figures 3.6.A. and 
3.6.B. The raw optical density data generated from image analysis were normalised 
to the expression of housekeeping genes included in the template set (Table 3.1.A.) 
and fold changes in expression between time-matched, vehicle-treated control cells 
and C2-ceramide-treated cells for each of the genes subsequently calculated (Table 
3.1.B.). Multiple exposures of varying times were used to overcome pixel saturation 
for normalisation purposes, and only one exposure time is shown in the results 
figures in this thesis for representative purposes. 
The expression of p21 CiP liWafi was demonstrated to increase significantly 
following ceramide treatment compared with the time-matched, vehicle-treated 
controls for each of the cell lines studied. This was apparent for a majority of the cell 
lines analysed by observing the raw RPA blots presented in Figures 3.6.A. and 
3.6.B., particularly for the K562, HL60 and KG-1 cell lines (Figure 3.6.A.). The 
increase in expression was however more clearly evident after normalisation of the 
optical density data to the GAPDH RPA control and presenting the data in numerical 
form as shown in Table 3.1.A. An increase of approximately 3 fold was calculated by 
4 hours post-treatment with ceramide in K562 cells compared with the time-matched 
controls, and increased further to greater than 4 fold by 8 hours post-treatment. HL60 
cells demonstrated an increase in expression of greater than 4 fold by 4 hours post-
treatment, compared with the time-matched controls, although the change in 
expression was relatively negligible by 8 hours post-treatment. Similarly, KG-la cells 
demonstrated a significant increase (>6 fold) in p21 ciP liWafleXpression by 4 hours 
post-treatment, although this increase appeared to have stabilised somewhat by 8 
hours post-treatment to less than a 2 fold increase in expression. This increase is not 
clearly apparent in Figure 3.6.B. for this cell line, due to slight overloading of RNA 
on the polyacrylamide gel, hence the importance of normalising data to the GAPDH 
control. 
A trend of increasing p21 ciP ifivanexpression was observed in KG-1 cells over 
the timecourse following ceramide treatment, whereby an increase of approximately 
3 fold was evident by 4 hours, and almost 4 fold by 8 hours post-treatment compared 
with time-matched controls. Less significant changes in p2l ciP liWafieXpression was 
demonstrated for both Jurkat and Raji cells, although an increase was clearly 
apparent at the timepoints examined. By 4 hours post-treatment with ceramide no 
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change was observable for the Raji cell line, and only a relatively slight increase was 
calculated for Jurkat cells (<1.5 fold increase). By 8 hours post-treatment, an increase 
of almost 2 fold, and 2.5 fold, was demonstrated in Jurkat and Raji cell RNA 
extracts, respectively. 
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Figure 3.6.A.: Enlarged sections of un-normalised RNase protection assay blots for K562, 
HL60 and KG-1 haemopoietic cell lines, highlighting changes in p2IciP I/Wafl RNA 
expression at 4 and 8 hours following treatment with either vehicle or C2-ceramide, 
accompanied by the respective GAPDH and L32 controls for each blot. RPAs were 
performed using the RiboQuant RNase protection assay with the hStress 1 template 
(Pharmingen, USA). C 2-ceramide concentration used were as follows: 5 MM: K562; 7.5 MM: 
HL60 20 MM: KG-1. 
With the exception of the results obtained for the HL60 cell line, all RPA results presented in 
this figure were obtained in our laboratory by Joanna Burrows and Anna Hearps, and are 
used with permission. 
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Table 3.1.A.: Table of p2/ aP liwai7 expression data obtained from image analysis of RPA blots for 
K562, HL60, KG-1, KG-la, Raji and Jurkat cells (shown in Figures 3.6.A. and 3.6.B.) using the 
hStressl RiboQuant template (PharMingen, USA) at 4 and 8 hours post-treatment with vehicle or C2- 
ceramide. All optical density data presented in the table are normalized to the 0 hr Control GAPDH 
housekeeping gene to allow the determination of fold change in expression of p2/ ciP16v47 at each 
timepoint. The raw data given in the table has been adjusted to subtract background. With the 
exception of the results obtained for the HL60 cell line, all data were calculated from RPA 
experiments conducted in our laboratory by Joanna Burrows and Anna Hearps, and these results are 
used with permission. The data provided in this table is representative of data obtained from at least 
three repeated experiments. 
p2PPI/w42 Volume Normalised to 0 hour Control GAPDH 
(optical density/mm2) 
Cell Line 0 hr Control 
4 hr 
Control 
4 hr 
C2-ceramide 
8 hr 
Control 
8 hr 
C2-ceramide 
K562 31.109 27.589 83.262 20.986 89.321 
HL60 12.082 24.754 120.546 108.025 84.000 
KG-1 268.766 76.587 223.176 78.120 303.084 
KG-la 545.999 106.391 728.733 511.367 929.388 
Jurkat 14.450 91.020 117.710 30.930 59.440 
Raji 353.273 412.348 434.719 331.267 799.965 
Table 3.1.B.: Fold change in p21 0191/Wafl expression relative to time-matched controls. 
Cell Line 4 hours 8 hours 
K562 3.02 4.26 
HL60 4.87 0.78 
KG-1 2.91 3.88 
KG-la 6.85 1.82 
Jurkat 1.29 1.92 
Raji 1.05 2.42 
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3.3.5. Changes in Cell Surface Marker Expression in Myeloid Cell Lines 
Myeloid cell lines that were responsive to ceramide-induced cell cycle 
alterations were investigated for changes in cell specific surface marker expression to 
determine if ceramide was inducing haemopoietic differentiation. Cells were stained 
with PE-conjugated antibodies, and analysed by flow cytometry in conjunction with 
the dead cell discriminant dye 7-AAD. Expression profiles representative of each cell 
line investigated, at 48 hours post-treatment for KG-1 and KG-1 a cells, and at 72 
hours for K562 and HL60 cells, are shown in Figure 3.7. Histograms of the 
percentage change in MFI of C 2-ceramide-treated cells relative to vehicle-treated 
time-matched control cells using results from a series of experiments are shown in 
Figures 3.8.A. and 3.8.B. 
A small increase in CD1 lb and CD14 expression was observed in all myeloid 
cell lines studied over the course of the experiments following exposure to C2- 
ceramide (Figures 3.8.A and 3.8.B.). Ceramide treatment of K562 cells induced a 
slight increase in CD1 lb and CD14 expression, as evidenced by the right shift in the 
fluorescence profile relative to the time-matched, vehicle-treated controls (Figure 
3.7.). After treatment with ceramide, K562 cells exhibited an 11% increase (± SE) in 
CD1lb expression at 24 hours, a 30% increase by 48 hours, and a 46% increase in 
expression by 72 hours relative to time-matched, vehicle-treated control cells. A 4% 
increase in CD14 was observed at 24 hours, which increased to a 12% increase by 48 
hours and to 20% by 72 hours (Figure 3.8.A.). In contrast to the myeloid markers, 
expression of glycophorin A dramatically decreased following ceramide treatment 
(Figure 3.7.), such that a 104% decrease in MFI was readily observed as early 24 
hours post-treatment, relative to the time-matched control cells. This became even 
more apparent at later timepoints, with a 187% decrease in MFI by 48 hours, and a 
366% decrease in expression by 72 hours (Figure 3.8.A.). 
HL60 cells, however, exhibited a more striking increase in CD1 lb and CD14 
expression as revealed by the right shift of the fluorescence profiles in Figure 3.7. 
following ceramide treatment. A 34% and 46% increase in MFI for CD1 lb was 
observed by 48 and 72 hours respectively relative to the control cells, and an 11%, 
55%, and 71% increase in CD14 at 24 hours, 48 hours and 72 hours respectively 
(Figure 3.8.A.). Interestingly, the CD1 lb expression profile for the HL60 cell line 
(Figure 3.7.) identifies a subpopulation of cells responsive to ceramide, which may 
account for the apparent increase in the proportion of CD1 lb positive events seen in 
this cell line. 
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Figure 3.7.: Immunophenotype expression profiles of human myeloid cells at 48 hours 
(KG-1 and KG-la cells) and 72 hours (K562 and HL60 cells) post-treatment with C2- 
ceramide demonstrating changes in maturation marker expression. A single representative 
set of results from at least four repeated experiments is shown. 
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Figure 3.8.A.: Histograms demonstrating changes in maturation marker expression in 
human myeloid cells at various timepoints post-treatment with C2-ceramide. Data are 
expressed as a percentage change in the mean fluorescence intensity, relative to vehicle-
treated control cells, and are combined from at least four individual experiments. 
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human myeloid cells at various timepoints post-treatment with C 2-ceramide. Data are 
expressed as a percentage change in the mean fluorescence intensity, relative to vehicle-
treated control cells, and are combined from at least four individual experiments. 
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Figure 3.8.B. shows that there was a negligible increase in CD1 lb expression 
in KG-1 cells at 24 hours post-treatment with ceramide, although this rapidly 
increased to a 54% increase in MFI by 48 hours, relative to the time-matched, 
vehicle-treated control cells. Similarly, CD14 expression increased from a 5% 
increase at 24 hours to a 64% increase by 48 hours (Figure 3.8.B.), relative to the 
controls. In contrast, a dramatic decrease in CD34 expression was observed in KG-1 
cells, as evidenced by a significant left shift in the fluorescence profile for ceramide-
treated cells in Figure 3.7. At 24 hours post-treatment, a 60% decrease in MFI for 
CD34 was observed for ceramide-treated cells, which increased to a 198% decrease 
in CD34 by 48 hours exposure to ceramide (Figure 3.8.B.). 
Similarly, ceramide induced an increase in CD1lb and CD14 in KG-la cells, 
as evidenced by a right shift in the fluorescence profiles for these markers in Figure 
3.7. Following 24 hours of ceramide treatment, a 46% increase in CD1 lb MFI was 
observed relative to the time-matched, vehicle-treated control cells. By 48 hours, this 
was even further amplified to a 60% increase (Figure 3.8.B.). CD14 expression 
increased during the first 24 hours with a 32% increase in MFI relative to the control 
cells, and remained stable at this expression level through to the 48 hour timepoint 
(34% increase) (Figure 3.8.B.). Ceramide-treated KG-la cells also exhibited a 
dramatic decrease in CD34 expression shown by the significant left shift in the CD34 
fluorescence profile in Figure 3.7. Relative to the time-matched control cells, a 69% 
decrease in MFI was observed at 24 hours, and a 136% decrease in CD34 MFI was 
observed at 48 hours, relative to the control cells (Figure 3.8.B.). 
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3.4. Discussion 
Treatment of human leukaemia cell lines with ceramide results in the 
induction of cell cycle arrest, differentiation, and apoptosis (Okazaki et al., 1989, 
Okazaki et al., 1990, Kim et al., 1991, Jayadev et al., 1995, Bettaieb et al., 1996, 
Ragg et al., 1998). To date, research into these ceramide-induced responses has 
focussed predominantly on three leukaemia cell lines; HL60, U937 and MOLT-4, 
and a comprehensive study to investigate whether these responses are common to 
other cell types is lacking in the literature. Instead, a number of individual research 
papers have been published which investigate these responses rather simplistically 
and in isolation. The present study has extended these observations by performing a 
screen of myeloid and lymphoid cell lines, and the capacity for ceramide to induce 
cell cycle and growth arrest, differentiation and apoptosis was investigated for each 
cell line in an attempt to highlight whether common cellular responses were elicited. 
The phosphorylation status of Rb was investigated for those cell lines exhibiting 
ceramide-induced cell cycle arrest, as a possible effector mechanism for this event. 
All cell lines studied were responsive to ceramide, although the 
responsiveness to ceramide treatment varied in magnitude. The findings presented 
demonstrate that ceramide commonly induces cell cycle arrest, differentiation, and 
some degree of apoptosis in a variety of human leukaemia cell lines. 
Although one would suggest experiments to study the effect of ceramide on 
growth rates and viability would be fundamental to the study of other cellular 
responses to ceramide, comprehensive published data is limited. As such, six cell 
lines, which broadly represent the myeloid and lymphoid haemopoietic lineages, 
were treated with C2-ceramide and the number of viable and dead cells enumerated 
as part of this study. Cell viability was judged by the ability to exclude trypan blue 
dye. In the experiments performed, the time-matched, vehicle-treated control cell 
culture showed continual proliferation or, in the case of KG-la cells, were 
maintained at an equal number to that in the original inoculum. 
Investigations into the ability of ceramide to cause growth arrest revealed 
consistent outcomes in all cell lines studied. Following treatment with ceramide, all 
cell lines underwent a decrease in viable cell numbers, although the degree and rate at 
which this decrease took place varied considerably between the different cell types 
studied, demonstrating the pleiotropic nature of ceramide. Cell loss was particularly 
evident in Jurkat T cells, and also in the myeloblastic and promyeloblastic KG-1 and 
KG-1a cells. K562, HL60 and Raji cells were somewhat less susceptible to a loss in 
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viable cells upon treatment with ceramide. By 24 hours post-treatment a majority of 
the ceramide-treated cells remained viable for these cell lines, particularly in the Raji 
B cell culture which showed the number of viable cells remained unchanged by this 
timepoint. Growth arrest was, however, clearly evident by 48 hours in each of these 
cell lines. The viability results obtained for the HL60 cell line supports the published 
findings by Okazaki et al. (1990), where it was observed that ceramide causes a dose-
dependent inhibition of HL60 cell growth. Moreover, this study has demonstrated 
that a reduction in viable cell numbers, relative to the time-matched, vehicle-treated 
controls, is a common feature of ceramide treatment. 
The observed decrease in viable cell numbers was paralleled by an increase in 
cell death in all cell lines studied, however the rate and magnitude of cell death 
varied significantly between each cell type. It is important to note that the number of 
dead cells may have been underestimated, particularly at the later timepoints, as cells 
that had been dead for a long period of time could not always be distinguished from 
the surrounding debris in the cell culture. In most instances, the rate of decrease in 
percentage viability reflected the rate of viable cell loss. A dramatic rate of cell death 
was observed in the Jurkat cell line during the first 8 hours of culture, and this has 
been attributed to apoptotic cell death. Studies in our laboratory have demonstrated 
this by showing an externalisation of phosphatidylserine residues on the cell 
membrane within 2 hours of exposure to C2-ceramide, by double labelling with 
Annexin V-FITC and Propidium Iodide (Hearps et al., 2002) (see Appendix A). 
Furthermore, it was revealed that ceramide-treated cells bearing this early apoptotic 
marker had a reduced mitochondrial transmembrane potential that was preceded by 
the release of cytochrome c from the mitochondria, and subsequent activation of the 
execution caspase, caspase 3, in Jurkat T cells (Hearps et al., 2002). These findings 
collectively support the recently accepted notion (Ghafourifar et al., 1999, Ito et al., 
1999, Cuvillier et al., 2000, Tepper et al., 2000) that ceramide activates distal 
caspases via mitochondrial cytochrome c release. 
Cell death was also observed in the time-matched control cultures, however 
the absolute number of viable cells continued to increase for all cell lines 
investigated. That is, the growth rate always exceeded the rate of cell death. This 
was, however, never observed in ceramide-treated cell populations as the death rate 
always exceeded the rate of growth. The observed cell death in the vehicle-treated 
controls was presumably associated with the serum-free culture conditions, as other 
authors have also noted that culturing in serum-free media can result in cell death 
(Howard et al., 1993). Regardless, ceramide-treated cells consistently showed a more 
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significant rate of cell death/loss in viable cell numbers, which was consistently 
observed earlier than in the time-matched controls at each timepoint, demonstrating 
that the effects observed were not due to serum-withdrawal alone. 
This study has demonstrated that induction of cell cycle arrest, defined as an 
increase in the proportion of cells in the G0/G1 phase of the cell cycle thus preventing 
progression into S phase (Jayadev et al., 1995), is a consistent outcome of ceramide 
signalling in all of the cell lines studied. Ceramide-induced G 0/G 1 cell cycle arrest 
has been previously demonstrated in other cell lines (Dbaibo et al., 1995, Jayadev et 
al., 1995, Ragg et al., 1998, Lee et al., 2000). Both myeloid and lymphoid 
haemopoietic cell lines included in this study underwent Go/th cell cycle arrest 
following C2-ceramide treatment, with the degree of arrest varying between cell lines. 
The degree of apparent responsiveness to ceramide-induced cell cycle arrest reflects 
the pleiotropic nature of diverse responses associated with the ceramide-signalling 
pathway. The diversity of responses is most probably a result of ceramide engaging 
different downstream effectors depending on the cellular microenvironment (Mathias 
et al., 1998), the phase of the cell cycle in which the signal was initiated, or the 
magnitude in generation of ceramide metabolites that may enhance or antagonise 
ceramide-activated signalling mechanisms (Spiegel et al., 1998b). 
KG-1 and KG-1a cells showed delayed cell cycle arrest in response to 
ceramide treatment compared with the other cell lines investigated. Although G0/G 1  
arrest was demonstrable at 24 hours post-treatment in both cell lines, a more 
significant accumulation of G0/G1 events was not clearly apparent until 48 hours after 
treatment. Thus, despite the extended timeframe, ceramide treatment still initiated 
G0/G1 cell cycle arrest, as observed in the other cell lines examined. 
In most cases, it was clearly apparent that the observed accumulation of G 0/G 1  
phase cells was accompanied by a reduction in the proportion of cells in both the S 
and G2/M phases of the cell cycle. This suggests that cell are able to move through 
the S and G2/M phases and into the G0/G1 phases, but are prevented from traversing 
the G 1 to S phase transition, thus supporting the findings by Jayadev et al. (1995). 
These results further support the hypothesis that ceramide signalling plays an 
important role in regulating significant components of the cell cycle, specifically at 
the restriction point where expression of cyclin-dependent kinases and regulation of 
Rb is of extreme importance. 
C2-ceramide-induced cell cycle arrest was usually accompanied by some 
degree of apoptosis, with the magnitude varying between cell lines and with dosage. 
A presence of a sub-Go/Gi (hypodiploid) peak in a DNA histogram has been 
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attributed to cells undergoing apoptotic death by many researchers (Nicoletti et al., 
1991, McCloskey etal., 1994, Banker etal., 1997, Mangiarotti et al., 1998), although 
this is still in some dispute by other authors (Qian et al., 1995, Darzynkiewicz et al., 
1997). The presence of a sub G 0/G1 peak was noted in this study to indicate general 
cell death, whether by an apoptotic or necrotic mechanism, as ceramide-induced non-
apoptotic killing has been noted (Mengubas et al., 1999). Regardless, the presence of 
a hypodiploid peak in ceramide-treated populations is consistent with the results 
obtained from viability experiments performed in this study, which show cell death 
in association with ceramide exposure. It is interesting to note that cell lines that had 
comparatively minimal hypodiploid peaks (K562 and Raji cells) generally showed 
more pronounced G0/G 1 cell cycle arrest. This finding may indicate that cell death is 
occurring primarily in cells that are trapped in the G0/G 1 phase, hence lowering the 
apparent number of G0/G 1 events by selective killing. Therefore, where significant 
cell death was demonstrated in this study, in particular in the Jurkat cell line, the 
proportion of cells that have undergone cell cycle arrest in response to ceramide 
would have been underestimated. Other authors have also demonstrated the selective 
killing of cells in the G0/G 1 phase of the cell cycle following treatment with C6' 
ceramide (Spinedi et al., 1998) and after drug treatment or activation (Luciano et al., 
1996, Vial et al., 1997, Mangiarotti et al., 1998, Mongini et al., 1998). As mentioned 
previously, ceramide-induced cell death in Jurkat cells has been confirmed as 
apoptosis in our laboratory using Annexin V-FITC/PI staining (Appendix A) and the 
demonstration of caspase 3 activation. Apoptotic death was well advanced by 24 
hours post-treatment, which accounts for the significant sub-G 0/G1 population 
observed in the respective Jurkat DNA histogram. 
Research into the mechanisms by which ceramide induces cell cycle arrest has 
shown that dephosphorylation of Rb is almost certainly always involved (Chao et al., 
1992, Jayadev etal., 1995, Dbaibo etal., 1995). Ceramide-induced activation of Rb 
has been demonstrated in MOLT-4 (Chao et al., 1992, Dbaibo et al., 1995, Jayadev 
et al., 1995), U-937 (Ragg et al., 1998), and WI38 (Venable et al., 1995) cells. 
Furthermore, MOLT-4 cells that are partially deficient in Rb, or express proteins that 
sequester the Rb protein, are resistant to ceramide-induced cell cycle arrest (Mathias 
et al., 1998). To obtain further insight into the mechanism of C 2-ceramide-induced 
growth and cell cycle arrest, the phosphorylation status of the Rb protein was 
determined by taking advantage of the fact that SDS-polyacrylamide gel 
electrophoresis and Western blotting can resolve the faster migrating 
hypophosphorylated forms of Rb from the slower migrating hyperphosphorylated 
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form. The inactive hyperphosphorylated Rb (RbhYPer) was consistently observed in the 
vehicle-treated, time-matched control protein extracts. However, in the ceramide-
treated protein extracts, and additional band of lower molecular weight, 
corresponding to the active, hypophosphorylated (Rb h"°) form of the Rb protein, was 
observed. Therefore it has been demonstrated that ceramide can induce Rb activation 
in all cell lines studied. 
Rb activation is shown to occur very rapidly in all cell lines, except HL-60 
and Jurkat cells where Rb activation was first observed at 24 hours post-treatment. In 
fact, the presence of an additional Rb hYP° band was observed as early as 4 hours post-
treatment with ceramide in extracts from the K562, KG-1, KG-la and Raji cell lines. 
It is interesting to note Rb activation in the Jurkat cell line, which exhibited an 
extreme initial apoptotic response. This would suggest that a significant proportion of 
the Jurkat cell population undergo apoptosis, leaving a viable sub-population, which 
are proposed to be resistant to such ceramide-induced cell death. It is reasonable to 
presume that the remaining sub-population of Jurkat cells would undergo G0/G 1 cell 
cycle arrest as a result of ceramide-induced Rb activation. It was not possible to 
detect Rb in the KG-1 and KG-la 24 hour post-ceramide-treated samples, 
presumably due to the loss of cells to apoptosis, which is consistent with the results 
from viability studies performed in this study. Regardless, activated Rb was clearly 
demonstrated in earlier timepoints for these cell lines following ceramide treatment, 
indicating that Rb activation is an early ceramide-induced event. Raji protein extracts 
displayed a different Rb phosphorylation pattern to that observed in all other cell 
extracts, in that more than two isoforms of Rb were observed in the vehicle-treated 
control extracts. However, a third, lower molecular weight band corresponding to 
fully hypophosphorylated Rb was clearly apparent in the ceramide-treated extracts 
throughout the experiment. 
It is important to mention that although Rb hYP° was observed in vehicle-treated 
control protein extracts of some of the cell lines investigated (presumably due to the 
serum-free conditions), this form of the protein was always seen in greater 
proportions to the RbhYPer band in extracts from ceramide-treated cells, compared 
with the corresponding time-matched control cell extracts. Furthermore, RbhYP° was 
consistently observed at earlier timepoints for cells treated with ceramide, than in the 
time-matched, vehicle-treated controls. 
Expression of the CKI p21ciP//Waf/ i s transcriptionally regulated in a p53- 
dependent manner in normal cells. As such, p21 c4iliwan expression can be induced in 
response to stimuli that induce activation of the p53 tumour suppressor, including 
116 
Chapter 3: Ceram ide-Mediated Cellular Effects 
DNA damaging agents (el-Deiry et al., 1994, Akashi et al., 1995, Russo et al., 1995). 
Over the last decade a number of investigators have demonstrated an increase in 
pE ciP ifivaii expression in a p53-independent manner using mitogenic stimuli 
(Michieli et al., 1994), immunosuppressive agents (Khanna & Hosenpud, 1999), 
cytokines (Datto et al., 1995, Robson et al., 1999), and a variety of differentiating 
agents (Jiang et al., 1994, Steinman et al., 1994, Zhang et al., 1995, Liu et al., 1996a, 
Zeng & el-Deiry, 1996, Brown et al., 1997, Ragg et al., 1998). The finding that 
p21 c1P uwan is a target for p53 has generated considerable interest in the regulation of 
its expression, as p53 mutations and deletions are common in cancers. p53- 
independent pathways of p21 00/Wan induction could represent alternative 
approaches to control aberrant proliferation resulting from a nun-functional or absent 
p53 gene (Steinman et al., 1994). RNase protection assays were utilised in this study 
to demonstrate whether ceramide could induce p2l ciP 1/Wan expression as part of a 
coordinated cell cycle arrest response. An increase in p2/ ciP liWan expression was 
shown in all cell lines analysed, and is consistent with findings reported by other 
authors who have shown similar results in other cell lines (Ragg et al., 1998, Lee et 
al., 2000). The upregulation in p2l ciP ilWan expression at the transcriptional level was 
shown to occur as early as 4 hours post-treatment, further confirming that this is an 
immediate early response to ceramide signalling. Interestingly, the kinetics observed 
for upregulated p21 CiP 1lWan message parallel those observed for accumulation of 
activated Rb following ceramide treatment, although the onset of ceramide-mediated 
p2l cw ifivafi expression proceeded ceramide-induced Rb activation. Jiang et al. (1994) 
found a close relationship between induction of p2 1 ciP uwan and differentiation, as a 
delay in p21 c1P uwan induction was observed in HL60 cells resistant to TPA induced 
growth arrest and differentiation. Similarly, Rots et al. (1999) have shown that 
vitamin D3-induced cell cycle arrest in myeloid cells always precedes differentiation, 
and involves the induction of p21 Cip1/Waf1. Taken together, these findings further 
identifyp2l ciP"Wan as a candidate gene linking differentiation signals to G0/G 1 arrest 
and Rb hypophosphorylation in a number of cell lines. This p53-independent 
induction of expression of p2/ ciP l/Wan is of great importance as a future target for 
leukaemia therapy. Roman-Gomez et al. (2002) have recently demonstrated 
hypermethylation of the p2/ ciP //wafi gene promoter in bone marrow cells of ALL 
patients, which correlated strongly with decreased p21 CiP liWall rnRNA levels, and was 
highly predictive of a poor clinical outcome. 
Haemopoiesis is a multistage developmental process in which .a pluripotent 
haempoietic stem cell gives rise to monocytes, granulocytes, lymphocytes, 
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megakaryocytes, and erythrocytes. As multipotent progenitor cells undergo 
monocytic development, they sequentially differentiate into proliferating monoblasts, 
promonocytes, monocytes, and finally macrophages. Granulocytic development 
involves the differentiation of progenitors into myeloblasts, promyelocytes, 
myelocytes and then neutrophils. 
Specific markers can be used to distinguish monocytic and granulocytic cells 
at particular stages of maturation. Changes in expression of these cell surface 
markers are used, not only to demonstrate the normal haemopoietic process, but also 
to show how haemopoietic cells differentiate in response to treatment with various 
agents, such as ceramide analogues. The CD1 1 b leukocyte integrin subunit is initially 
expressed at the monoblastic and myelocytic stages of development but expression 
increases during monocytic and granulocytic differentiation (Griffin et al., 1981, 
Rosmarin et al., 1989, Lubbert et al., 1991, Grande et al., 2001). It comprises part of 
the adhesion molecule CD1 1 b/CD18 (also called Mo 1 or Mac-1), and is involved in 
binding a complement component as well as promotion of homotypic granulocyte 
adhesion and adhesion of granulocytes and monocytes to endothelial cells during host 
defence and immune response (Lubbert et al., 1991). Expression of CD1 lb mRNA 
has been shown to be sharply upregulated during induction of granulocytic or 
monocytic differentiation of HL60 cells. This included an increase in the number of 
CD1lb molecules per cell as well as the number of CD11b-positive cells (Hickstein 
et al., 1989, Rosmarin et al., 1989). The CD14 cell surface antigen is expressed in 
mature monocytes (Lubbert et al., 1991). 
Haemopoietic differentiation was only assessable in the myeloid cell lines. 
The ability of ceramide to induce myeloid differentiation has been noted by several 
other authors (Okazaki et al., 1990, Bielawska et al., 1992, Ragg et al., 1998), 
although all studies to date have been confined to HL60 and U-937 cells. The results 
presented in this thesis confirm that ceramide has the ability to induce myeloid 
maturation, and extends these studies by providing evidence of ceramide-induced 
differentiation in other myeloid cell lines. Haemopoietic differentiation was 
demonstrated by changes in the expression of the myeloid cell surface markers 
CD1 lb and CD 14, and the cell-specific surface markers glycophorin A for K562 
cells, and CD34 for KG-1 and KG-la cells. 
Treatment of erythromyeloid K562 cells with ceramide resulted in a small 
increase in CD1 lb and CD14 expression by 24 hours, and continued to increase over 
the proceeding 48 hours, whereby a 46% increase in CD1 lb expression and a 20% 
increase in expression were noted by 72 hours post-treatment, relative to the time- 
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matched, vehicle-treated controls. In order to further characterise ceramide-induced 
differentiation in K562 cells, changes in expression of a third surface marker, 
glycophorin A (glyA), was assessed. It has been well documented in the literature 
that parental K562 cells strongly express the glyA cell surface marker (Andersson et 
al., 1979, Koeffler & Go1de, 1980). Differentiation of K562 cells along the erythroid 
line has been demonstrated in the presence of sodium butyrate (Hoffman, 1979, 
Andersson et al., 1979), and these cells produce embryonic haemoglobin when 
cultured with hemin (Koeffler & Go1de, 1980). The dramatic downregulation in glyA 
expression, taken together with the increase in CD1 lb and CD14 expression, is 
consistent with ceramide-induced differentiation of this cell line towards the 
granulocytic/macrophage lineage, and away from the erythroid lineage. 
An increase in CD1lb and CD14 expression was more clearly evident in 
HL60 cells, particularly at the 48 and 72 hour timepoints. These results confirm those 
published by Okazaki et al. (1990) and Bielawska et al. (1992). Okazaki et al. (1990) 
found that ceramide alone (at 1-6 [tM concentrations) was sufficient to induce HL60 
monocytic differentiation. Further, the differentiation response noted mimicked that 
observed when HL60 cells were treated with vitamin D3 alone, a well-known inducer 
of HL60 cell maturation. The present study identified a subpopulation of HL60 cells 
staining positive for CD1lb that are responsive to ceramide treatment, which is 
suggestive that a heterogeneous subpopulation exists within the homogeneous cell 
line. It is proposed therefore that the cellular response to ceramide treatment is 
dependent on a number of factors, including the state of the microcellular 
environment, the presence of co-stimulatory factors, and most likely the phase of the 
cell cycle, thus further confirming the pleiotropic nature of ceramide as a second 
messenger. 
Ceramide-treated KG-1 cells showed a delayed increase in both CD1 lb and 
CD14 expression relative to the other cell lines studied. An increase in expression of 
these surface markers was not demonstrated until 48 hours post-treatment, although 
the change in expression by this timepoint was very convincing. Similarly, a 
significant change in CD1 lb expression was not observed in KG-la cells until 48 
hours post-treatment, although an increase in CD14 was clearly apparent from the 24 
hour timepoint onwards. Changes in expression of the CD34 surface antigen was also 
investigated for ceramide-induced differentiation studies involving the KG-1 and 
KG-la cell lines as this surface marker is expressed on parental KG-1 and KG-la 
cells (Satterthwaite et al., 1990, Pasternak & Pasternak, 1994). CD34 is expressed on 
very immature cells (e.g. stem cells and myeloid progenitor cells in the bone 
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marrow), and expression of CD34 decreases as these cells differentiate (Berenson et 
al., 1988 & 1991). CD34 mRNA downregulation associated with induced 
macrophage differentiation has been shown previously in KG-1 cells by Satterthwaite 
et al. (1990) using TPA and ionomycin. A significant decrease in CD34 expression 
was observed in both these cell lines by 24 hours post-treatment with ceramide. 
Downregulation in expression of this very primitive cell surface marker is a 
convincing indication of cell maturation towards the granulocytic lineage in these 
two cell lines. 
Together with the immunophenotyping results presented here, it is possible to 
conclude that ceramide can induce haemopoietic differentiation in K562, HL60, KG-
1 and KG-1 a cells, thus further extending the published findings by other 
investigators in this field of research. 
Treatment of the various cell lines included in this study with the ceramide 
analogue, C 2-ceramide, has resulted in a number of common responses. All cell lines 
showed a decrease in the number of viable cell numbers, which was accompanied by 
an increase in cell death, presumed to be apoptotic in nature. All cells underwent 
concomitant cell cycle arrest in the G0/G 1 phase of the cell cycle, presumably via 
activation of the Rb tumour suppressor protein. In parallel with Rb activation, 
induction of p2/ ciP //wafi expression was demonstrated which in turn was associated 
with haemopoietic differentiation into a more mature phenotype for each of the 
myeloid cell lines studied. Taken together, this chain of events is consistent with an 
alteration in the balance within the cell from being strongly proliferative to anti-
proliferative as a result of ceramide-signalling. Although common outcomes are 
described, it is interesting to note that the kinetics of the responses observed varied 
quite considerably from one cell line to the next, seemingly depending upon the 
cellular context, thus confirming the pleiotropic nature of ceramide. 
The rate of loss in cell viability, and the kinetics involved in the decrease of 
percent viable cells observed in this study, indicates an initial apoptotic response. 
However, not all cells are initially killed, or the apoptotic response is not completed 
in a subset of the cell population. This is particularly true in the Jurkat cell line, 
whereby a significant majority of cells initially underwent apoptosis, although a 
remaining small subpopulation remained viable, presumably entering G0/G1 arrest via 
Rb activation. Many explanations might be plausible for this phenomenon. It is 
feasible to suggest that within the homogenous cell populations used as a model for 
this study, exists heterogenous cell subsets, in a similar way that subpopulations are 
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observed in vivo. Since asynchronous culture were used for the current study, a more 
feasible postulation might be that the rate of response to ceramide varies significantly 
depending upon the phase of the cell cycle the cells are in at the time of initial 
exposure. Delivery of a differentiation signal by ceramide at an inappropriate stage of 
the cell cycle, or in conflict with an existing proliferative signal may result in 
apoptosis being initiated. Okazaki et al. (1990) suggest that the loss of viable cells 
may be partly due to the induction of cell differentiation by ceramide, rather than to 
simple toxicity. Regardless, ceramide-induced apoptosis has been extensively 
demonstrated by a number of authors (Obeid et al., 1993, Sakakura et al., 1996). 
The type of response a cell demonstrates following exposure to exogenous 
ceramide appears to be entirely dependent upon the stage of differentiation it is at, at 
the time of ceramide addition. Again, this is particularly evident in the Jurkat cell 
line, which are fully differentiated T lymphocyte cells. The addition of ceramide to 
this cell line appears to force the cells into terminal differentiation, the final outcome 
of terminal differentiation being cell death. Because these cells are already at such a 
late stage of differentiation, the immediate ceramide-induced response is apoptotic 
death. 
Cells that survived the initial apoptotic response underwent changes 
consistent with the imposition of an anti-proliferative phenotype. Cell cycle arrest 
was demonstrated in all cell lines, and activation of the Rb tumour suppressor protein 
and upregulation of the CKI p21 CIP I /Wan are potentially common mechanisms for this 
event. Since the cell lines used in this study are p53nun,  the results presented here 
have demonstrated the activation of cell cycle regulatory elements in a p53- 
independent manner. Because the inactivation of p53 in cancer has been associated 
with poor survival, refractory disease and chemoresistance (Lowe et al., 1993, Soini 
et al., 1993, Marks et al., 1996, Dive 1997), it is reasonable to assume that restoring 
the function of p53 in cancer cells may have considerable implications in cancer 
treatment. Thus, manipulation of the ceramide-signalling pathway may be beneficial 
in the treatment of proliferative disorders such as leukaemia, where regaining control 
of the cell cycle in the absence of a functional p53 gene is fundamental. Therefore, 
further elucidation into the mechanisms by which Rb is activated by ceramide is 
warranted. 
This study presents what is believed to be the first demonstration of ceramide-
induced differentiation in K562, KG-1 and KG-la cells. Ceramide-induced HL60 
differentiation has been confirmed in the current study. Since p21 Cipl /Wan i s 
considered to play a significant role in terminally differentiating cells such as muscle, 
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and in cells treated with differentiating agents to force them to become fully matured 
(Halevy et al., 1995, Parker et al., 1995, Flink et al., 1998), and p21aPilwaf1  
expression is induced by ceramide in all cell lines investigated in this study, it is 
feasible to conclude that ceramide is inducing terminal differentiation in K562, 
HL60, KG-1 and KG-la cells. Ceramide-induced differentiated myeloid cells have a 
lowered proliferative capacity and eventually die of apoptosis, presumably as a result 
of terminal differentiation. If cellular differentiation is blocked at a proliferative 
stage, then blastic leukaemia may eventuate (Testa et al., 1993). Based on the present 
study, it is possible to hypothesise that ceramide signalling can push leukaemia cells 
past this blockage, resulting in a non-proliferative, terminally differentiated cell that 
undergoes normal apoptosis. The ability to change aggressively growing cancer cells 
into mature, less proliferative cells that then die by programmed cell death forms the 
fundamental qualities of a potential cancer therapy. 
Ceramide-mediated myeloid cell differentiation is most likely to involve a 
transcriptionally-activated pathway as this study has demonstrated alterations in the 
expression profiles of CD1 lb, CD14 and the cell-specific glycophorin A and CD34 
cell surface markers. Many authors have shown activation of the protooncogenes c-
fos and c-jun following treatment with ceramide (Kim & Kim, 1998, Ragg et al., 
1998, Ruvolo, 2001), whose protein products can heterodimerise to form the AP-1 
transcription factor complex. AP-1 has been previously shown to have a role in 
ceramide-mediated apoptosis (Sawai et al., 1995) but as yet has not been linked to 
ceramide-induced differentiation. As an increase in CD 14 expression following 
ceramide treatment has been demonstrated, and the CD 14 gene promoter has recently 
been shown to have multiple AP-1 binding sites (Liu et al., 2000), it is suggested that 
ceramide-induced AP-1 activation is a potential mechanism for ceramide-induced 
differentiation. 
In summary, activation of the sphingomyelin signalling pathway by 
exogenous addition of a synthetic ceramide analogue causes common outcomes in a 
variety of cell types, which are mediated via common mechanisms. The overall 
outcome is growth arrest, Rb activation, p21aP 17Wafl upregulation, terminal 
differentiation and apoptosis. Each of these processes results in a reduction in the 
number of aggressively growing cancer cells, which is the primary aim of cancer 
therapies. Since maturation and proliferation are linked events, it is proposed that the 
growth of aggressively proliferating leukaemia cells is greatly diminished by 
ceramide-initiated cellular maturation and Rb activation. The results presented in this 
chapter, demonstrate the potential for ceramide in initiating cell cycle regulatory 
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mechanisms and terminal differentiation of haemopoietic cells into a mature, less 
proliferative phenotype. Further investigations into the molecular basis of growth 
arrest and differentiation mechanisms mediated by the ceramide-signalling pathway 
and their manipulation for therapeutic purposes are warranted. 
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4.1. Introduction 
Despite the retinoblastoma (Rb) tumour suppressor protein being one of the 
few identified downstream effectors of ceramide signalling, very little is known as to 
how ceramide activates Rb. The relationship, if any, between ceramide-induced Rb 
activation and differentiation remains unexplored. 
Rb is a nuclear phosphoprotein that is regulated by phosphorylation during 
normal progression through the cell cycle (Mihara et al., 1989, Ludlow et al., 1990, 
Riley et al., 1994, Chen et al., 1995a, Weinberg, 1995). It plays an essential role at 
the Restriction Point of the cell cycle, where it functions to modulate members of the 
E2F transcription factor family (Nevins, 1992, Helin et al., 1993, Lees et al., 1993). 
The E2F proteins in turn transactivate genes whose products are important for S 
phase entry (Neuman et al., 1994, Buchmann et al., 1998). When Rb is in its 
inactivated form (hyperphosphorylated), the bound E2Fs are released and progression 
through the S phase is permitted. Hypophosphorylation of Rb prevents the release of 
E2F complexes, converting them to repressors that prevent expression of E2F target 
genes (Weintraub et al., 1992). 
Rb remains in an inactivated form during cell cycle progression via 
phosphorylation by cyclin-dependent kinases, in particular by cyclin D-dependent 
kinase complexes (Ewen et al., 1993, Kato et al., 1993, Sherr, 1994). Ludlow et al. 
(1990) demonstrated that in normal proliferating cells Rb is found in its 
dephosphorylated form in G 1 phase of the cell cycle, and becomes phosphorylated at 
the beginning of S and remains phosphorylated through S and G2 phases. Rb is then 
completely dephosphorylated between the end of G2 and the beginning of G1 phases 
of the cell cycle. Rb has been shown to be in its activated form in non-cycling, 
terminally differentiated cells (Furukawa et al., 1990). An understanding of the 
molecular mechanism or mechanisms that enable Rb to remain in the 
dephosphorylated/activated form is becoming more apparent. 
To date, two effector mechanisms for Rb activation have been determined. 
The first is via an indirect method, whereby cyclin-dependent kinase (CDK) 
complexes are inhibited from phosphorylating Rb. CDKs are catalytic proteins whose 
activity requires interaction with regulatory subunits termed cyclins (Pines, 1995). 
The Rb protein is specifically phosphorylated by cyclin D-complexed CDK4 and 
CDK6 (Sherr, 1996). Cyclin-dependent kinase inhibitors (CKIs) function to prevent 
this cyclin-CDK complex from forming by binding to the CDK in place of the cyclin 
subunit. The INK4 CKIs (p16 INK4a, p 15INK4b, p 18 INK4c, and p  19INK4d) have been 
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shown to directly block cyclin D-dependent kinase activity and cause GI arrest 
(Serrano et al., 1993, Kamb et al., 1994, Hirai et al., 1995). In addition, p27 KiP I , 
p571(1 P2 , and p21 ciP uwan inhibit cyclin D-dependent kinases. p27 KiP 1 and p21 CiP I/Wari 
are involved in cell cycle control at the Restriction Point of the cell cycle (Harper et 
al., 1993, Harper et al., 1995, Toyoshima & Hunter, 1994, Niculescu et al., 1998). Of 
particular interest, however, is p21 Cip 1 lWafl as extensive studies have revealed that this 
CKI is the critical determinant in blocking cell cycle progression by inactivation of 
Rb (Harper et al., 1993, Harper et al., 1995, Niculescu et al., 1998). 
The best-defined mechanism for Rb activation, however, is by direct removal 
of phosphate groups from the Rb protein via activation of protein phosphatases (PP) 
(Alberts et al., 1993, Durfee et al., 1993, Ludlow et al., 1993, Schonthal & 
Feramisco, 1993, Dou et al., 1995, Berndt et al., 1997, Nelson et al., 1997). 
Mammalian protein phosphatases are represented by four distinct prototypes: PP1, 
PP2A, PP2B, and PP2C (Ingebritsen & Cohen, 1983). To date, two protein 
phosphatases have been attributed to the enzymatic dephosphorylation of Rb, PP1 
(Durfee et al., 1993, Ludlow et al., 1993, Nelson et al., 1997) and PP2A (Dobrowsky 
& Hannun, 1992, Dobrowsky et al., 1993, Dobrowsky & Hannun, 1993, Hannun, 
1996). Both classes of protein phosphatases direct their activity towards the serine 
and threonine amino-acid residues of the retinoblastoma protein (Cohen, 1989). 
Ceramide has been shown to activate a cytosolic serine/threonine protein 
phosphatase, which has been named the ceramide-activated protein phosphatase 
(CAPP) (Dobrowsky & Hannun, 1992, Dobrowsky et al., 1993, Dobrowsky & 
Hannun, 1993, Hannun, 1996) belonging to the PP2A subfamily of protein 
phosphatases (Dobrowsky et al., 1993, Galadari et al., 1998). CAPP is believed to be 
involved in a range of cellular activities, but it has been postulated that one of its 
major roles is to dephosphorylate Rb via CDK2 inhibition, thus leading to G0/G 1 cell 
cycle arrest (Lee et al., 2000). Another protein phosphatase, belonging to the PP1 
subfamily of protein phosphatases, is also believed to dephosphorylate Rb and can be 
activated by long chain ceramides (Chalfant et al., 1999). PP1 appears to play a 
major role in Rb dephosphorylation during exit of the mitosis phase of the cell cycle 
(Alberts et al., 1993, Durfee et al., 1993, Ludlow et al., 1993, Berndt et al., 1997, 
Nelson et al., 1997), as opposed to PP2A, which has been shown to play a role in 
preventing entry into mitosis (Kinoshita et al., 1990, Lee et al., 2000). The role of 
protein phosphatases in cell cycle regulation via Rb activation has been studied using 
PP1 and PP2A inhibitors including okadaic acid, Calyculin A, and phosphatidic acid 
(Ishihara et al., 1989, Kishikawa et al., 1999). The phosphatase inhibitor Calyculin A 
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has been previously identified as a potent inhibitor of the catalytic subunit of both 
type 1 and 2A protein phosphatase families (Ishihara et al., 1989, Song and Lavin, 
1993) and has been reported to be equally effective against both PP1 and PP2A 
(Ishihara et al., 1989, Li et al., 1993), as opposed to other protein phosphatase 
inhibitors including okadaic acid and cantharidin which are more effective against 
PP2A (Morana et al., 1996). The discovery that inhibition of these protein 
phosphatases causes changes in cell growth regulation led to the suggestion that PP1 
and PP2A could function as tumour suppressors in mammalian cells (Cohen & 
Cohen, 1989, Haystead et al., 1989). 
The exact role of p2l ciP uwan and protein phosphatases in ceramide-mediated 
cell cycle regulation and differentiation is still largely debatable. Other authors have 
demonstrated that expression of p21CiP liWaf7 is increased following treatment with 
exogenous ceramide (Ragg et al., 1998, Lee et al., 2000), and it is accepted that 
p2 Cip 1 /Wafl plays a crucial role in both Rb dephosphorylation and terminal 
differentiation (Harper et al., 1993, Harper et al., 1995, Halevy et al., 1995, 
Liebermann et al., 1995, Parker et al., 1995, Steinman et al., 1994, Flink et al., 1998, 
Niculescu et al., 1998). Similarly, it is well established that ceramide can activate 
cytosolic protein phosphatases (Dobrowsky & Hannun, 1992, Dobrowsky et al., 
1993, Dobrowsky & Hannun, 1993, Hannun, 1996), and these appear to be important 
in mediating Rb dephosphorylation (Lee et al., 2000). There is, however, limited 
knowledge of whether these two cellular factors play equally important roles or 
whether one is most important in regulating cell cycle control, and the other in 
terminal differentiation. In the previous chapter, ceramide has been shown to induce 
'ial/Wafl both Rb activation and terminal differentiation that is associated with p21 C- c 
transcriptional activation. It is yet to be determined whether Rb activation and 
terminal differentiation utilise the same or independent upstream ceramide-signalling 
pathways, and/or whether they are dependent upon each other. 
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4.2. Methods 
4.2.1. Experimental Plan 
Effector mechanisms for Rb activation by ceramide were investigated in 
representative ceramide-responsive cell lines. K562, KG-1, KG-la and Raji cells 
were treated with C2-ceramide and with the potent protein phosphatase inhibitor 
Calyculin A to determine the role of protein phosphatases in ceramide-induced Rb 
activation. The phosphorylation status of Rb was determined by Western blotting. 
Additionally, the role for protein phosphatases in ceramide-induced myeloid 
differentiation was determined. This was achieved with K562 cells by measuring 
changes in glycophorin A cell surface marker expression following Calyculin A 
treatment by flow cytometry. The relative toxicity associated with Calyculin A 
treatment of KG-1 and KG-la cells, however, required that another more sensitive 
technique be utilised to allow an early timepoint to be analysed in these cell lines. As 
such, an RNase protection assay (RPA) using a custom template was adopted for 
analysing changes in cell marker RNA levels in KG-1 and KG-la cells. 
4.2.2. Rb Phosphorylation Analysis Following Protein Phosphatase Inhibition 
K562, KG-1, KG-la, and Raji cell lines were treated with the C 2-ceramide 
concentrations outlined in Chapter 3.2.1., using treatment culture media as previously 
discussed in Chapter 2.2.3(D)., to induce Rb activation. Additional cells were also 
treated with C2-ceramide + 25 nM Calyculin A. Cells were plated out at 5 X 105 
cells/mL (1 ml/well) in 24 well cell culture dishes and were incubated at 37°C/5% 
CO2. Cells (2 X 106 cells/sample) were harvested (described in Chapter 2.2.3(D)). At 
various timepoints, nuclear protein extractions were performed (described previously 
in Chapter 3.2.4.). Proteins were separated on 6.5% SDS-polyacrylamide gels and 
Western blotting was performed to demonstrate the phosphorylation status of Rb, as 
described in Chapter 3.2.5. 
4.2.3. Immunophenotyping Following Protein Phosphatase Inhibition 
K562 cells were treated with 51.1M C 2-ceramide or with C2-ceramide + 25 nM 
Calyculin A in serum-free RPMI media and plated out at 5 X 10 5 cells/mL in 24 well 
culture dishes and incubated at 37°C/5% CO2. Cells (5 X 10 5 cells/sample) were 
harvested at 0 and 12 hours post-treatment, washed, stained with PE-conjugated anti-
human glycophorin A antibodies, washed again, fixed as described previously in 
Chapter 3.2.8. Cells were analysed by flow cytometry (described in Chapter 2.2.4.) 
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using CellQuest software (Becton-Dickinson, USA). Immunophenotype profiles were 
generated and changes in MFI values between vehicle-treated, C2-ceramide-treated, 
Calyculin A-treated, and C2-ceramide + Calyculin A-treated cells calculated. 
4.2.4. RNase Protection Assays — CD11b, CD14, CD34 Expression Analysis 
KG-1 and KG-la cells were treated with 7.511M C2-ceramide or with C2 - 
ceramide + 25 nM Calyculin A in serum-free RPMI media and transferred to 75 cm2 
cell culture flasks and incubated at 37°C/5% CO2. Cells (1 X 10 7 cells/sample) were 
harvested at 0 and 12 hours post-treatment, and RNA extracted, DNase-treated and 
quantitated as outlined in Chapter 2.2.7. 
RPAs were performed using the protocol and reagents provided in the 
RiboQuantTM Multi-Probe RNase Protection Assay System (PharMingen, USA) as 
described in Chapter 2.2.8., with a custom template designed to include riboprobes 
directed towards human CD11b, CD14 and CD34 RNA transcripts and the house-
keeping gene transcripts L32 and GAPDH (Cat. # 559721-16464, PharMingen, 
USA). Statistical analyses of the change in expression levels were performed using 
the Students' two-tailed paired t-test. 
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4.3. Results 
4.3.1. Effect of Calyculin A on Ceramide-Induced Rb Activation 
The role of protein phosphatases in ceramide-induced Rb activation was 
investigated by inhibiting protein phosphatase activity with the use of Calyculin A in 
K562, KG-1, KG-la and Raji cell lines. Cells previously shown to undergo 
ceramide-induced Rb activation were treated with C2-ceramide and with a 
combination of C2-ceramide and Calyculin A. SDS-PAGE and Western blotting 
investigated the phosphorylation status of the Rb tumour suppressor protein in cell 
extracts at various timepoints after the treatment. Representative Western blot results 
from this study are provided in Figure 4.1. 
Each of the blots presented in Figure 4.1. confirm the results observed in 
Chapter 3.3.3. of this thesis. That is, following C2-ceramide treatment, Rb is rapidly 
activated as indicated by the presence of a lower molecular weight band 
corresponding to hypophosphorylated Rb. In fact, this event can be seen as early as 2 
hours post-treatment with ceramide in the KG-1 and Raji cells. However, only the 
hyperphosphorylated Rb band can be seen following co-treatment with C 2-ceramide 
and Calyculin A for all cell lines studied, demonstrating that Calyculin A prevented 
ceramide-induced Rb activation. 
Due to the biological toxicity of Calyculin A, and the synergistically 
detrimental effects of combined C2-ceramide and Calyculin A treatment, protein 
concentration was considerably lower for the later timepoint of 24 hours post-
treatment, except for K562 cells which appeared to be more resistant to these toxic 
effects. Therefore Rb could not be detected by Western blotting for KG-1, KG-la or 
Raji cell lines at the 24 hour timepoint following combined C2-ceramide and 
Calyculin A treatment. 
4.3.2. Effect of Calyculin A on Ceramide-Induced Differentiation 
The role of protein phosphatases in ceramide-induced differentiation was 
investigated by analysing changes in cell surface marker expression of K562, KG-1 
and KG-la cells. Cells were treated with vehicle, C 2-ceramide, Calyculin A, or with a 
combined treatment of C 2-ceramide and Calyculin A over a 12 hour timecourse. 
K562 cells were stained with anti-glycophorin A PE-conjugated antibodies 
and analysed by flow cytometry. The resulting immunophenotype expression profiles 
are shown in Figure 4.2. The percentage change in mean fluorescent intensity (MFI) 
was calculated and the results show that vehicle-treated cells exhibit a strongly 
129 
Figure 4.1.: Western blot analysis of the retinoblastoma (Rb) phosphorylation status in 
human haemopoietic cells following treatment with either C 2-ceramide alone, or C2- 
ceramide + Calyculin A. A single representative set of results from at least four repeated 
experiments is shown. 
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Figure 4.2.: Immunophenotype expression profiles of K562 erythromyeloid cells at 12 hours 
post-treatment with vehicle, C 2-ceramide alone, Calyculin A alone, or C 2-ceramide + 
Calyculin A, demonstrating changes in glycophorin A expression. A single representative set 
of results from at least four repeated experiments is shown. 
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positive glycophorin A expression profile, while a left-shift in the expression profile 
is identified in the ceramide-treated cells. K562 cells treated with Calyculin A alone 
gave an expression profile that very closely resembled that exhibited by the vehicle-
treated cells. Treatment with both ceramide and Calyculin A caused a decrease in 
glycophorin A expression, similar to that shown in cells treated with ceramide alone, 
indicating that inhibition of phosphatase activity had very little effect. 
The combined flow cytometry data histograms from four replicate 
immunophenotyping experiments are presented in Figure 4.3. This graph verifies the 
significant down-regulation in glycophorin A expression in both the ceramide-treated 
and the ceramide + Calyculin A-treated K562 cell populations by a dramatic negative 
percentage change in MFI relative to the time-matched control. In contrast, cells 
treated with Calyculin A alone did not exhibit a significant change in MFI compared 
with the vehicle-treated control cells. These findings indicate that Calyculin A alone 
does not affect glycophorin A cell surface marker expression in K562 cells, and 
combined treatment with C2-ceramide and Calyculin A does not inhibit the 
downregulated glycophorin A expression indicative of ceramide-induced K562 
differentiation. 
The significant toxicity of Calyculin A in KG-1 and KG-la cells by 12 hours 
post-treatment precluded an immunophenotype analysis of differentiation, hence a 
novel approach for analysing the role of protein phosphatases in ceramide-induced 
differentiation was required in these cell lines. KG-1 and KG-la cell lines were 
treated as described above and at 12 hours post-treatment, RNA was extracted and 
analysed for changes in CD11b, CD14 and CD34 expression levels using a RPA. 
Representative RPA blots from these experiments are shown in Figures 4.4. and 4.6., 
respectively. The raw data from image analysis of the blots presented in Figures 4.4 
and 4.6. were normalised to the expression of housekeeping gene transcripts for each 
sample, and fold changes in CD11b, CD14 and CD34 expression were calculated. 
These are presented in Tables 4.1. and 4.2. for KG-1 and KG-la cells, respectively. 
The expression of CD1lb for KG-1 cells had not altered by 12 hours post-treatment 
with ceramide. CD1lb or CD14 expression was extremely weak and meaningful data 
could not be extracted for either KG-1 or KG-la cells. 
Analysis of CD34 RNA expression showed that at 12 hours post-treatment, a 
significant downregulation in CD34 expression was clearly visible for both KG-1 and 
KG-la cells (2.6 and 1.8 fold decrease in expression relative to the 12 hour control 
for KG-1 and KG-la cells respectively) following C2-ceramide treatment alone. For 
both cell lines, the intensity of the bands representing CD34 essentially remained 
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unchanged between the 0 hour vehicle-treated control and the 12 hour control. 
Calyculin A treatment alone resulted in CD34 expression levels that paralleled those 
seen in the 12 hour vehicle-treated controls (p = 0.369 and 0.382 for KG-1 and KG-
1a cells, respectively). Combined treatment with C 2-ceramide and Calyculin A, 
however, induced a significant downregulation in CD34 expression, similar to that 
seen following treatment with C 2-ceramide alone (p = 0.088 and 0.010 for KG-1 and 
KG-la cells, respectively). The normalised CD34 data from image analysis of a 
minimum of four separate RPA experiments are represented in histogram form in 
Figures 4.5. and 4.7. to show the fold change in CD34 band volume, relative to the 
12 hour vehicle-treated control, following ceramide and/or Calyculin A treatment for 
KG-1 and KG-la cells respectively. These histograms demonstrate that Calyculin A 
alone does not induce a significant change in CD34 expression, whereas ceramide 
treatment alone, and ceramide + Calyculin A treatment results in a significant 
downregulation in CD34 RNA levels by 12 hours post-treatment. 
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Figure 4.4.: Analysis of CD11b, CD14 and CD34 RNA expression in KG-1 
myeloblastic/promyeloblastic cells at 12 hours post-treatment with either vehicle, C2 - 
ceramide alone, Calyculin A alone, or C 2-ceramide + Calyculin A. Results were obtained by 
performing RNase protection assays using a custom RiboQuantm template set (Pharmingen, 
USA). The RPA blot is provided in its entirety for comparison of expression of housekeeping 
genes between each sample. A single representative set of results from four repeated 
experiments is shown. 
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Figure 4.5.: Histogram demonstrating changes in CD34 expression for KG-1 
promyeloblastic cells at 12 hours post-treatment with vehicle, C 2-ceramide alone, Calyculin 
A alone, or C2 -ceramide + Calyculin A. Data are expressed as a fold change in the CD34 
band volume relative to the 12 hour vehicle-treated control, and are combined from four 
individual experiments. 
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Figure 4.6.: Analysis of CD11b, CD14 and CD34 RNA expression in KG-la 
promyeloblastic cells at 12 hours post-treatment with either vehicle, C 2-ceramide alone, 
Calyculin A alone, or C2-ceramide + Calyculin A. Results were obtained by performing 
RNase protection assays using a custom RiboQuant' template set (Pharmingen, USA). The 
RPA blot is provided in its entirety for comparison of expression of housekeeping genes 
between each sample. A single representative set of results from three repeated experiments 
is shown. 
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Figure 4.7.: Histogram demonstrating changes in CD34 expression for KG-la 
promyeloblastic cells at 12 hours post-treatment with vehicle, C 2-ceramide alone, Calyculin 
A alone, or C2-ceramide + Calyculin A. Data are expressed as a fold change in the CD34 
RPA band volume relative to the 12 hour vehicle-treated control, and are combined from 
three individual experiments. 
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Table 4.1.: Table of raw data and final normalised results obtained from image analysis of the RPA 
blot shown in Figure 4.4. for KG-1 myeloblastic/promyeloblastic cells, showing the calculated fold 
changes in expression of CD1 lb, CD14 and CD34. The raw data given in the table has been adjusted 
to subtract background. The data provided in this table is representative of data obtained from four 
repeated experiments. 
N.R. = No result obtained (signal absent or too weak for quantitation). 
* Normalised Volume = Raw volume data normalised to the 0 hour Control GAPDH raw volume 
value. 
Volume (optical density/nun2) 
Gene 
0 hr 
Control 
12 hr 
Control 
12 hr 
C2-ceramide 
12 hr 
Calyculin A 
12 hr 
C2-ceramide + 
Calyculin A 
GAPDH 
Raw Volume 
(0D/mm2) 
66.350 51.916 38.061 63.649 31.191 
*Normalised Volume 
(0D/mm2) 
1.000 0.783 0.574 0.959 0.470 
CD1lb 
Raw Volume 1.575 1.431 1.021 1.889 0.737 
*Normalised Volume 1.575 1.829 1.779 1.969 1.568 
CD14 
Raw Volume N.R. N.R. N.R. N.R. N.R. 
*Normalised Volume N.R. N.R. N.R. N.R. N.R. 
CD34 
Raw Volume 11.181 10.137 2.867 12.279 2.419 
*Normalised Volume 11.181 12.946 4.995 12.804 5.147 
Fold chance in ex ression relative to the 12 hr control: 
CD11b 1.0 1.0 1.08 0.86 
CD14 N.R N.R N.R N.R 
CD34 1.0 0.4 1.0 0.4 
p = 0.369 
	I 	I 
p = 0.088 
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Table 4.2.: Table of raw data and final normalised results obtained from image analysis of the RPA 
blot shown in Figure 4.5. for KG-la promyeloblastic cells, showing the calculated fold changes in 
expression of CD11b, CDI4 and CD34. The raw data given in the table has been adjusted to subtract 
background. The data provided in this table is representative of data obtained from three repeated 
experiments. 
N.R. = No result obtained (signal absent or too weak for quantitation). 
* Normalised Volume = Raw volume data normalised to the 0 hour Control GAPDH raw volume 
value. 
Volume (optical density/mm 2) 
Gene 
0 hr 
Control 
12 hr 
Control 
— 
12 hr 
C2-ceramide 
12 hr 
Calyculin A 
12 hr 
C2-ceramide + 
Calyculin A 
GAPDH 
Raw Volume 
(0D/mm2) 
163.079 154.562 167.395 154.921 169.410 
*Normalised Volume 
(0D/mm2) 
1.000 0.948 1.027 0.950 1.039 
CD1lb 
Raw Volume N.R. N.R. N.R. N.R. N.R. 
*Normalised Volume N.R. N.R. N.R. N.R. N.R. 
CD14 
Raw Volume N.R. N.R. N.R. N.R. N.R. 
*Normalised Volume N.R. N.R. N.R. N.R. N.R. 
CD34 
Raw Volume 16.215 15.782 9.522 16.170 9.690 
*Normalised Volume 16.215 16.651 9.277 17.022 9.325 
Fold chance in ex ression relative to the 12 hr control: 
CD11b N.R N.R N.R N.R 
CD14 N.R N.R N.R N.R 
CD34 1.0 0.56 1.0 0.56 
p = 0.382 
p = 0.010 
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4.4. Discussion 
The purpose of this chapter was to identify whether protein phosphatase 
activity could account for ceramide-induced Rb activation and to determine if a link 
existed between ceramide-induced Rb activation and the induction of myeloid 
differentiation. K562, KG-1, KG-1a and Raji cell lines were used as representative 
ceramide-responsive cell lines to investigate whether ceramide-induced Rb activation 
could be prevented by inhibiting protein phosphatase activity. These cell lines gave 
the most profound Rb activation responses in experiments in the previous chapter of 
this thesis. The findings presented demonstrate that Rb activation is dependent, at 
least initially, on phosphatase activity. However differentiation, as evidenced by 
alterations in cell surface marker expression, is independent of phosphatase activity. 
The phosphatase inhibitor Calyculin A is a well characterised inhibitor of the 
catalytic subunit of both type 1 and 2A protein phosphatase families (Ishihara et al., 
1989, Song & Lavin, 1993) and has been used extensively in studies of haemopoietic 
differentiation and apoptosis (Song & Lavin, 1993, Morana et al. 1996, Kishikawa et 
al., 1999, Lee et al., 2000). A number of investigators have shown that a ser/thr 
phosphatase (CAPP), belonging to the type 2A subfamily, is a direct target of 
ceramide signalling (Dobrowsky & Hannun, 1992, Dobrowsky et al., 1993, Wolff et 
al., 1994). CAPP was first identified by Dressler et al. (1992) as a result of initial 
studies into the sphingomyelin cycle in T9 glioma cells, as protein phosphorylation 
was known to be a key component of cell signalling. Since these early studies, other 
investigators have shown that CAPP may serve to mediate the cellular action of 
ceramide. Wolff et al. (1994) suggest that CAPP appears to be partly responsible for 
ceramide-mediated downregulation of c-myc in HL60 cells. Further, there is evidence 
to show that CAPP plays a role in protein kinase C4-induced translocation of 
preformed nuclear factor-KB from the cytosol to the nucleus (Dressler et al., 1992, 
Dbaibo et al., 1993, Lozano et al., 1994, Muller et al., 1995), and in ceramide-
mediated activation of JNK and the subsequent expression of c-jun (Verheij et al., 
1996, Reyes et al., 1996). 
It has been shown in this thesis that ceramide can rapidly induce activation of 
the Rb tumour suppressor protein in the absence of a functional p53 gene. Ceramide-
treated K562, KG-1, KG-1a and Raji cells all exhibited the presence of a 
hypophosphorylated Rb band as early as 4 hours post-treatment, and even as early as 
2 hours in the KG-1 and Raji cell lines. Thus ceramide-induced Rb activation is a 
rapid and early event. On treatment with the protein phosphatase inhibitor Calyculin 
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A, however, ceramide-induced Rb activation was abrogated even at the earliest 
timepoints analysed. To date, a clear link between ceramide-induced phosphatase 
activation and subsequent intracellular events had not been established. The results 
presented here provide a link between ceramide-induced phosphatase activity and the 
activation of the retinoblastoma protein and subsequent cell cycle arrest. 
Supporting the notion that PPs are primarily responsible for Rb 
dephosphorylation, are the findings presented by Dou et al. (1995) who demonstrated 
that treatment of HL60 cells with araC resulted in the activation of Rb, although 
p21 c1P 1iwan could not be detected. However, araC-induced Rb dephosphorylation was 
inhibited by the addition of Calyculin A or okadaic acid, and therefore it was 
concluded from these experiments that protein phosphatases are predominantly 
responsible for Rb dephosphorylation, rather than induction of p21 CiPYWafl 
expression. Interestingly, addition of these protein phosphatase inhibitors reproduced 
the growth arrest-specific Rb dephosphorylation seen following araC treatment, 
under cell-free conditions. 
What remains to be determined is the exact type and species of protein 
phosphatase that is involved in ceramide-induced Rb activation. Although the 
substrates of CAPP remain largely undetermined, this phosphatase has been 
demonstrated to differentially modulate activity of cyclins and CDKs, namely CDK2 
(Lee et al., 2000). The possibility exists that Rb is also a likely candidate as a direct 
substrate for CAPP due to the rapidity of action demonstrated in this study, a notion 
that is further supported by other investigators (Voorhoeve et al., 1999, Rubin et al., 
1998 & 2001). As Calyculin A is capable of inhibiting both PP1 and PP2A protein 
phosphatase family members, subsequent investigations into the characterisation of 
the identity of the protein phosphatase induced by C2-ceramide are warranted, 
perhaps with the use of Okadaic acid which specifically inhibits PP2A phosphatase 
members only. It is worthy of mentioning however, that Lee et al. (2000) 
demonstrated that ceramide activates both protein phosphatases 1 and 2A, which 
provided the reasoning for the choice of Calyculin A used in the present study. 
Cyclins associate with their respective catalytic partners, CDKs, and function 
to regulate the passage of cells through the cell cycle via phosphorylation of their 
substrate, which in the case of CDK4 and CDK6 is the Rb protein (Ewen etal., 1993, 
Kato et al., 1993, Sherr, 1994 & 1996). CDK activity is in turn regulated by 
phosphorylation and dephosphorylation events, as well as interactions with specific 
inhibitors, named cyclin-dependant kinase inhibitors (CKIs), which include 
p2 1 wan/cIP I . This CKI is crucial in inhibiting cyclin-CDK4 and CDK6 complex 
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formation and thus regulation of the phosphorylation status of Rb (Harper et al., 
1993, Harper et al., 1995, Niculescu et al., 1998). 
An increase in p21 Wafl/Cipl expression was also demonstrated as a ceramide-
mediated event in all cell lines investigated. While Rb activation via induction of 
p21 Wafl/Cip I expression requires transcriptional activation and subsequent translation, 
phosphatase-mediated Rb activation is transcription-independent and is therefore 
expected to occur much more rapidly than p21 Wafl/Cipl -mediated Rb activation. This 
is consistent with the findings presented by Zeng & el-Deiry (1996), and the results 
demonstrated in the present chapter, where distinct Rb activation is shown to occur 
as early as 2 hours post-treatment with C2-ceramide. However, only a weak increase 
in p21 Wafl /OP] expression was observable by 4 hours, becoming more evident by 8 
hours post-treatment with ceramide. Thus the ability of Calyculin A to prevent 
ceramide-induced Rb activation suggests that ceramide-induced activation of Rb is 
primarily mediated via protein phosphatase activity and not by transcriptional 
activation ofp21 Wall/CIPI . Therefore it is postulated that ceramide-induced expression 
of p2l wa P 1 is most likely a coincidental finding in relation to Rb activation, and is 
instead perhaps part of the differentiation response noted by others (Liu et al., 1996a, 
Ragg et al., 1998), or part of a redundant pathway. 
The previous chapter used flow cytometry to assess changes in surface marker 
expression that arise from ceramide-induced myeloid differentiation, however, most 
cell lines did not exhibit changes measurable by flow cytometry until at least 24-48 
hours post-treatment. The notable exception was K562 cells, where a significant 
downregulation in glycophorin A expression was observed as early as 12 hours post-
treatment. The toxicity of Calyculin A confounded attempts to analyse CD34 
downregulation by immunophenotyping, as CD34 surface marker downregulation in 
KG-1 and KG-la cells is not significant until 24 hours post-treatment. As such, a 
different approach for analysing these early changes in CD34 downregulation was 
necessary. A custom designed RNase protection assay permitted the examination of 
changes in CD34 RNA levels at a 12 hour timepoint. 
On treatment with vehicle alone, the resulting immunophenotype expression 
profiles at 0 and 12 hours post-treatment demonstrated that K562 cells strongly 
express the glycophorin A cell surface marker, as reported by other authors 
(Andersson et al., 1979, Koeffler & Golde, 1980), and confirming the results 
obtained in the previous chapter of this thesis. A significant left-shift in the 
expression profile was demonstrated following treatment with ceramide, also 
confirming the finding that ceramide induces glycophorin A downregulation in K562 
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cells which is consistent with the induction of a myeloid differentiation response. 
Calyculin A treatment alone resulted in an expression profile paralleling that 
produced by treatment with the vehicle alone. This demonstrates an important finding 
in this study, that Calyculin A treatment alone is not sufficient to induce any degree 
of differentiation in K562 cells, as determined by alterations in glycophorin A surface 
marker expression. Combined treatment with both ceramide and Calyculin A caused 
a significant left shift in the expression profile, equivalent in proportion to that seen 
after treatment with ceramide alone. Thus, the inhibition of protein phosphatase 
activity, and hence ceramide-induced Rb activation, has little or no effect on 
ceramide-induced K562 differentiation. 
With the use of a custom designed RPA template set, which included 
riboprobes directed towards CD11b, CD14 and CD34 RNA transcripts, the same 
overall findings as that observed in K562 cells was demonstrated in KG-1 and KG-la 
cells. Although conclusive results could not be obtained for CD1lb and CD14 
analysis, the inclusion of the CD34 riboprobe in the RPA template set proved to be 
very useful in demonstrating the effect of Calyculin A treatment on KG-1 and KG-1a 
differentiation. Expression of CD1lb and CD14 is a late maturation event, which 
would account for the absence in RNA signals at the 12 hour timepoint. A band 
corresponding to CD34 was observed at both 0 and 12 hours in the vehicle-treated 
cell RNA extracts, thus confirming that parental KG-1 and KG-la cells strongly 
express the CD34 surface marker as noted by other authors (Satterthwaite et al., 
1990, Pasternak & Pasternak, 1994). Treatment with ceramide reduced CD34 
expression compared with the time-matched Calyculin A-treated control, thus 
indicating differentiation towards a more mature phenotype (Berenson et al., 1988 & 
1991). Calyculin A treatment alone did not alter the expression of CD34 compared 
with the vehicle-treated control, and combined treatment with ceramide and 
Calyculin A resulted in a lower intensity CD34 band that paralleled that seen after 
treatment with ceramide alone. It is evident, therefore, that inhibiting protein 
phosphatase activity in KG-1 and KG-la cells does not prevent ceramide-induced 
differentiation. 
Although it was not observed in the present study using C2-ceramide, it is 
interesting to note that inhibition of ser/thr protein phosphatases has been shown to 
augment myeloid differentiation in other models. Uzunoglu et al. (1999) have 
demonstrated that inhibition of PP1 and PP2A using Calyculin A and okadaic acid 
augmented methylprednisolone-induced granulocytic differentiation of HL60 cells 
and monocytic differentiation of K562 cells. Yuksel et al. (2002) also demonstrated 
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improved methylprednisolone-induced granulocytic and monocytic differentiation of 
HL60 and K562 cells, respectively. Morita et al. (1992) showed that treatment of 
HL60 cells with Calyculin A and okadaic acid lead to enhanced ATRA-induced 
granulocytic differentiation, although TPA-induced differentiation toward the 
macrophage lineage was unchanged. Similarly, no change was noted in arsenic 
trioxide-induced differentiation of HL60 and K562 cells. Downregulation of PP2A 
activity has been reported during ATRA-induced granulocytic differentiation of 
HL60 cells (Tawara et al., 1993). 
Although such reports of enhanced differentiation responses using a variety of 
differentiation agents (methylprednisolone and ATRA) following inhibition of 
protein phosphatase activity exist, this does not appear to be the case for ceramide. 
On its own, Calyculin A treatment was unable to induce myeloid maturation in the 
cell lines used in this study. In addition, Calyculin A did not prevent, or even appear 
to alter, the ceramide-induced differentiation response in K562, KG-1 or KG-la cells. 
Therefore it can be concluded that ceramide and methylprednisolone/ATRA are 
involved in different signalling pathways. 
In contrast to Rb dephosphorylation, the addition of the protein phosphatase 
inhibitor, Calyculin A, does not prevent ceramide-mediated differentiation in K562, 
KG-1 and KG-la cells. These findings suggest that although Rb activation is 
essential for initiating cell cycle arrest, it is not required for ceramide-mediated 
myeloid differentiation. Furthermore, it can be concluded that ceramide-induced 
differentiation occurs via an independent signalling pathway to ceramide-induced Rb 
activation. Other authors (Rots et al., 1999, Dimberg et al., 2002) have suggested that 
cell cycle arrest and differentiation occur simultaneously and must therefore be 
linked to a common regulatory mechanism. Rots et al. (1999) report that a number of 
genes are upregulated by vitamin D3 during myeloid differentiation, including the 
CKIs p21C1111/Wafl and p 27KiP1 However, the authors did not examine Rb activation, 
and thus failed to discuss the interdependence of Rb activation and differentiation. 
Rots et al. assumed that the expression of CKIs was entirely responsible for cell cycle 
arrest, and did not consider CKI-independent mechanisms such as protein 
phosphatase activation. The results from the present study clearly indicate that Rb 
activation and myeloid differentiation are independently regulated by ceramide. 
Regardless of the interdependence of these two cellular responses, it is important to 
remember that both cell cycle arrest and differentiation are crucial in the process of 
regaining control of immature leukaemia cells. Cell cycle arrest reduces the rate of 
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appearance of new cancer cells, and terminal differentiation increases the rate of 
removal of these cells via eventual apoptosis. 
Taken together, the results from the present study, and those from the 
previous chapter of this thesis suggest that ceramide-signalling in haemopoietic cells 
simultaneously activates two independent pathways; the phosphatase-dependent 
activation of Rb, and the phosphatase-independent initiation of myeloid 
differentiation involving p2l ciP lAvan . As Rb activation is an early event following 
ceramide treatment (as early as 2 hours post-treatment in KG-1 and Raji cell lines), it 
is feasible to suggest that the direct removal of phosphate groups, or 
dephosphorylation of Rb via CDIC2 inactivation (Lee et al., 2000), by protein 
phosphatase activity are more likely to be mechanisms for Rb activation than 
transcriptional activation ofp2I ciPilwafi . The subsequent indirect activation of Rb by 
inhibition of CDKs by CKIs would take a considerably greater period of time to 
occur than the rapid activation observed here. It is proposed therefore that protein 
phosphatases are primarily responsible for ceramide-induced Rb activation, and that 
CDK inactivation by p21 CipllWafl is most likely to be part of the terminal 
differentiation response, and/or perhaps plays a secondary role in ceramide-induced 
Rb activation. It is possible that protein phosphatases provide the initial early 
response to activate Rb and halt the cell cycle, and the expression and subsequent 
translation ofp21 CiP ilWafi occurs later as part of the terminal differentiation response 
to lock the cell into a non-proliferative state. 
Supporting the notion that PPs are primarily responsible for Rb 
dephosphorylation, are the findings presented by Dou et al. (1995) who demonstrated 
that treatment of HL60 cells with araC resulted in the activation of Rb, although 
p21' an could not be detected. However, araC-induced Rb dephosphorylation was 
inhibited by the addition of Calyculin A or okadaic acid, and it was also therefore 
concluded from these experiments that protein phosphatases are predominantly 
responsible for Rb dephosphorylation, rather than induction of p21 Cipl/Waf1 
expression. Interestingly, addition of these protein phosphatase inhibitors reproduced 
the growth arrest-specific Rb dephosphorylation seen following araC treatment, 
under cell-free conditions. 
In conclusion, ceramide-signalling initiates at least two signalling pathways 
that independently regulate Rb activation and differentiation. As such, ceramide-
induced Rb activation and myeloid differentiation are not dependent events. 
Inhibition of protein phosphatases 1 and 2A completely abolished ceramide-induced 
activation of the Rb protein, but did not alter the ability of ceramide to induce 
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myeloid differentiation. This highlights a key role for protein phosphatases in 
ceramide-mediated regulation of the cell cycle, and presents a novel target for 
directed therapy of leukaemia. 
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5.1. Introduction 
The three major fates of haemopoietic cells, proliferation, differentiation and 
death, are closely intertwined. For example, cell proliferation and cell death are 
carefully balanced under normal circumstances. Similarly, induction of 
differentiation is usually associated with a loss in proliferative capacity, and cell 
death is associated with the latter stages of haemopoietic cell differentiation 
(Leszcyniecka et al., 2001). A crucial prerequisite for haemopoietic cell terminal 
differentiation is cell cycle arrest (Freytag, 1988, Furukawa, 1997, 1998, & 2002), 
and a number of genes must be tightly regulated for correct progression through each 
phase. Given the complexities of the interrelations between haematopoietic cell 
proliferation, differentiation and death, it is not surprising that leukaemic 
transformation is related to deregulation of these processes. A greater understanding 
of these specific changes in gene expression that give rise to cancer may present an 
opportunity for future therapies. 
The factors that regulate haemopoietic cell differentiation remain 
incompletely understood. It has become clear, however, over the last decade that 
changes in the expression levels of a plethora of genes occur in a programmed 
manner during the differentiation process. Early studies investigated intracellular 
signalling following the binding of haemopoietic growth factors to their appropriate 
receptor on the external surface of the cell. Since then, many single-gene studies have 
been performed to investigate the role of cell cycle regulators, transcription factors, 
and signal transduction pathways in the differentiation process. 
Increased expression of p2/ ciPliwaf1 following differentiation induction by 
phorbol esters has been reported by a number of authors (Jiang et al., 1994, 
Kharbanda et al., 1994, Zeng & el-Deiry, 1996), and this is now an accepted feature 
of terminally differentiated cells (Halevy etal., 1995, Liebermann etal., 1995, Parker 
et al., 1995, Flink et al., 1998). Cell cycle arrest has been linked with the activation 
of TFs factors via differentiation-associated signalling. TFs shown to be triggered by 
differentiation stimuli in haemopoietic cells include PU.1 (Olson et al., 1995, Simon 
et al., 1996, Bellon et al., 1997, DeKoter et al., 1998, Anderson et al., 1999, Oikawa - 
et al., 1999), c-jun (Adunyah et al., 1992 & 1995), AP-1 (Liebermann et al., 1998, 
Rosson & O'Brien, 1998), substance P-1 (Laurenzi et al., 1989, Bost & Pascual, 
1992, Pascual et al., 1992), and downregulation in c-myc (Nguyen et al., 1995a, 
Lerga et al., 1999, Lin etal., 2000). 
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The results from the studies presented in the previous chapter showed that 
ceramide-induced myeloid differentiation and Rb activation utilise independent 
pathways, and protein phosphatases are primarily responsible for ceramide-mediated 
Rb activation. Haemopoietic cell differentiation requires specific changes in gene 
expression, and to date very few studies have investigated the effect of ceramide on 
gene expression in relation to the differentiation process. As with the majority of 
studies that have investigated gene expression changes following treatment with 
various differentiating agents, research into ceramide-induced haemopoietic cell 
differentiation has primarily focussed on single gene studies, with particular focus on 
p21 cipliwap expression (Ragg et al., 1998, Lee et al., 2000), c-myc and c-jun 
expression, and activation of the JNK/SEK MAPK pathway members (Sawai et al., 
1995, Westwick et al., 1995, Verheij et al., 1996, Ragg et al., 1998, reviewed by 
Okazaki et al., 1998). A comprehensive screen of genes known to play a role in the 
three major cellular fates (proliferation, differentiation, and cell death), genes that are 
often deregulated in malignancies such as leukaemia, is clearly absent from the 
literature. 
There are a number of techniques available for conducting small-scale gene 
expression screening in a cell population. The ribonuclease protection assay (RPA) is 
a highly sensitive and specific method for the detection and quantitation of mRNA 
species. This assay utilises a DNA-dependent RNA polymerase from the T7 
bacteriophage in constructing RNA probes from a DNA template containing the T7 
promoter. PharMingen has developed a series of multi-probe RPA template sets, 
which have been assembled into biologically relevant groups, to be used in 
conjunction with their RiboQuant TM Multi-Probe RPA System (PharMingen, USA). 
Within each set are a number of DNA templates, each of distinct length and each 
representing a sequence in a distinct mRNA species. Having synthesised 
radiolabelled RNA probes from the DNA template set, the probes are hybridised in 
excess to target RNA from experimental samples. Any free probes and single-
stranded RNA that has not hybridised to the probes are digested with RNases and the 
remaining "RNase-protected" probes are purified, resolved on denaturing 
polyacrylamide gels, and the quantity of each mRNA species is determined by 
autoradiography of by phosphorimaging with normalisation to housekeeping gene 
expression (included in each template set). The distinct advantage of the RPA 
approach is that several mRNA species can be simultaneously quantitated in a single 
sample of total RNA (PharMingen, USA), in contrast to other methods such as 
Northern blotting and semi-quantitative RT-PCR. 
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There has been an explosive increase in the knowledge of genes at the 
sequence level over the last decade, especially since the commencement of the 
human genome project (Aaronson et al., 1996, Hillier et al., 1996). The rapid 
increase in sequence information has required corresponding improvements in the 
following steps of genetic analysis. Existing approaches to genetic analysis focus on 
individual analysis of particular genes and do not provide a means for high-
throughput implementation. There are numerous other methods available to detect 
and quantify differential gene expression. Differential display (Liang & Pardee, 
1992) and its variants provide an efficient way to identify genes that are differentially 
expressed between two tissues or cell types, or between a control and experimental 
sample. It does not, however, give quantitative expression information. Systematic 
cDNA sequencing (Okubo et al., 1992) will provide quantitative results, but is a very 
tedious technique when investigating genes with low expression levels. The SAGE 
(serial analysis of gene expression) method (Velculescu et al., 1995) diminishes 
sequencing requirements but the method is complicated and statistical limitations 
still apply (Jordan, 1998). 
Recently, a hybridisation technique has become available for simultaneous 
expression analysis of hundreds to tens of thousands of genes, a method known as 
cDNA expression array analysis. In contrast to previous techniques available for gene 
expression analysis, hybridisation methods use complex probes and large arrays of 
targets, and derive their power from the fact that each individual experiment provides 
a very large amount of information. They appear unrivalled for large-scale 
measurement of gene expression (Jordan, 1998) and provide an accurate and 
sensitive evaluation of the magnitude of gene expression changes occurring between 
two target cell populations (Leszcyniecka et al., 2001). Quantitative use of cDNA 
arrays for expression measurement using high-density membranes was pioneered by 
Hans Lehrach's group (Gress et al., 1992), and full implementation of this technique 
was later published by several authors (Nguyen et al., 1995b, Zhao etal., 1995, Pietu 
et al., 1996). Three main types of cDNA arrays have been developed (high-density 
nylon membranes, glass slide microarrays, and oligonucleotide chips), and differ 
primarily in the way they are analysed and more significantly in the number of genes 
they permit analysis of. In each design type, plasmid DNA, PCR products, or 
oligonucleotides are immobilised to a solid support, and complex cDNA probes 
derived from poly A÷ RNA labelled with radioactive or fluorescent nucleotides are 
hybridised. 
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High-density membrane cDNA arrays, or nylon filter arrays, have been used 
by a number of groups for RNA expression analysis (Dunne etal., 1992, Maier etal., 
1994, Nguyen et al., 1995b, Bernard et al., 1996, DeRisi et al., 1996, Gress et al., 
1996, Lanfranchi et al., 1996, Pietu et al., 1996, Sehgal et al., 1998). Robotics have 
made possible the generation of high-density arrays capable of producing results for 
analysis of nearly 60,000 genes in a 22 X 22 cm 2 area. Generally, high-density nylon 
arrays keep a niche for relatively small-scale work, for investigating specific sets of 
genes of interest (Jordan, 1998), and are usually limited to 500 - 2,000 known genes. 
Blots are hybridised with 33P or 32P-labelled cDNA isolated from test and control 
tissue or cell samples. Data can be captured on phosphorimager screens or by 
exposure to X-ray film and subsequent image analysis is performed to determine the 
relative optical intensity for each gene producing a signal. Hybridisation conditions 
must give low background (since signals are quite small) and ensure equivalent 
hybridisation rate over the whole membrane. Long hybridisation times are often used 
to maximise the signal intensity that increase linearly with probe concentration and 
hybridisation duration. This approach has been found to yield highly reproducible 
results by many investigators (Baldwin et al., 1999), although it is accepted that 
semi- or fully-quantitative methods such as RT-PCR, Northern blotting or real-time 
RT-PCR should be used to confirm candidates identified on filter arrays. The aims of 
this chapter were firstly to investigate the changes in gene expression of nine genes 
involved in cell cycle regulation, DNA damage and apoptosis in cells induced to 
differentiate using ceramide using an RPA, incorporating the hStress 1 RiboQuant TM 
template set (PharMingen, USA). This preliminary genetic screen was then expanded 
with the application of Atlas TM Human Cancer 1.2 cDNA Expression Arrays 
(Clontech, USA) as a method of mass screening for changes in expression of genes 
that are known to be involved in a variety of malignancies to investigate the response 
of other cancer-related genes following ceramide treatment. 
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5.2. Methods 
5.2.1. Experimental Plan 
A screen of cell cycle-, DNA damage-, and apoptosis-related genes was 
performed in a ceramide-responsive cell line using the hStress 1 RiboQuantTM 
template and the RiboQuantTM Multi-Probe RNase Protection Assay System 
(PharMingen, USA). HL60 cells were used for this preliminary screen, as this was 
the first cell line shown to differentiate in response to ceramide treatment (Okazaki et 
al., 1989, Okazaki et al., 1990, Kim et al., 1991) and this model has been utilised 
extensively to investigate aspects of ceramide-mediated changes at the morphological 
and protein level. HL60 cells were treated with C2-ceramide and RNA was extracted 
at various timepoints and analysed by RPA. This allowed for a rapid screen of the 
involvement of various human genes known to play a role in cell cycle regulation, 
DNA damage repair, and apoptosis, following ceramide treatment in this cell line, 
and this provided the proof of principle for a more comprehensive study to follow. 
These genes include the p53 tumour suppressor, the growth arrest and DNA-damage-
inducible protein 45 (GADD45), the differentiation- and proliferation-related 
transcription factor c-fos, and the CKI . Included in the template set are 
the anti-apoptotic members bcl-2 and the closely related bc/-XL , and mc/-/, and the 
pro-apoptotic members bcvc and bcl-X8 (Oltvai et al., 1993, Lincz, 1998, Minn et al., 
1998, Pellegrini & Strasser, 1999). 
Clontech has produced high-density nylon membrane arrays, such as the 
AtlasTM Human Cancer 1.2 cDNA Expression Array, which includes 1,176 genes that 
are known to be involved in human cancers. The various DNA targets are arrayed 
onto nylon membranes into functional classes including tumour suppressors and 
oncogenes, cell cycle regulators, signal transduction modulators and effectors, 
apoptosis effectors, DNA damage repair proteins, transcription factors, growth 
factors and chemokines and their receptors, stress response proteins, proteins 
involved in metabolic pathways, and cytoskeleton and motility proteins. Plasmid and 
bacteriophage DNA is included as negative controls to confirm hybridisation 
specificity, along with DNA for several housekeeping genes, which act as positive 
controls and provide a means for normalising mRNA abundance. GenBank (NCB', 
USA) accession numbers are provided for all gene targets included on all Atlas TM 
arrays. 
The Atlas TM Human Cancer 1.2 cDNA expression array system (Clontech, 
USA) was used in the current study to investigate the changes in RNA expression of 
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1,176 genes known to be involved in human cancer. As only purified cDNA is 
spotted onto AtlasTM arrays, the sensitivity is regarded to be higher than commercially 
available filter arrays spotted with lysed bacterial colonies available from other 
sources (Bowtell, 1999). AtlasTM arrays have been extensively used for a range of 
applications including the demonstration of differentially expressed genes following 
stimulation of B and T lymphocytes (011ila & Vihinen, 1998), and differentially 
expressed genes in nasopharyngeal carcinoma (Xie et al., 2000). Negative controls 
consisting of plasmid and bacteriophage cDNA spots are included to confirm 
hybridisation specificity, along with several housekeeping cDNAs which act as 
positive controls for normalising mRNA abundance. cDNAs for the genes of interest 
are arrayed into functional classes that represent specific areas of research, in the case 
of the 1.2 Human Cancer array, genes that are known to be involved in human 
cancers. The known genes on this array are divided into 25 main categories: cell 
surface antigens, transcription, cell cycle, cell adhesion receptors/proteins, immune 
system proteins, extracellular transport/carrier proteins, oncogenes and tumour 
suppressors, stress response proteins, membrane channels and transporters, 
extracellular matrix proteins, trafficking/targeting proteins, metabolism, post-
translational modification/protein folding, translation, apoptosis associated proteins, 
RNA processing turnover and transport, DNA binding and chromatin proteins, cell 
receptors (by ligands), cell signalling/extracellular communication proteins, 
intracellular transducers/effectors/modulators, protein turnover, cell receptors (by 
activities), cytoskeleton/motility proteins, functionally unclassed, and DNA synthesis 
recombination and repair. 
The results from previous chapters have shown that the erythromyeloid K562 
cell line was the most responsive cell line (in terms of magnitude and rate) to 
ceramide-induced growth arrest and differentiation, while resulting in only minimal 
cell death relative to the other cell lines studied. As the focus of the final section of 
the current study was to be directed towards the growth arrest and differentiation-
inducing ability of ceramide in cells of the myeloid lineage, the K562 cell line was 
chosen to be utilised for cDNA array analysis in order to perform a mass screen of 
"cancer-related" gene expression following ceramide-induced differentiation. Cells 
were treated with vehicle or C2-ceramide and RNA was extracted at early (2 hours 
post-treatment), intermediate (8 hours post-treatment) and late (24 hours post-
treatment) timepoints. Radiolabelled cDNA probes were generated from this RNA 
and were hybridised to Atlas TM Human Cancer 1.2 cDNA Expression Arrays 
(Clontech, USA). A comparison was then made between the expression of genes 
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following treatment with C2-ceramide and gene expression in the time-matched, 
vehicle-treated control cells. 
5.2.2. RNase Protection Assays 
HL60 cells were treated with vehicle or C 2-ceramide (7.5 1.tM) at 5 X 10 5 
cells/mL in RPMI + 2% FCS. The treated cells were transferred to 75 cm 2 cell culture 
flasks and incubated at 37°C/5% CO2. Cells (1 X 10 7 cells/sample) were harvested at 
0, 4 and 8 hours post-treatment, and RNA extracted, DNase-treated and quantitated 
as outlined in Chapter 2.2.7. 
RNase protection assays were performed on the prepared RNA, and were 
analysed as described in Chapter 2.2.8., using the human stress-1 (hStress-1) 
template (Cat. # 45351P, PharMingen, USA). The hStress-1 template contains 
riboprobes directed towards human bcl-XL, bcl-Xs, p.53, GADD45, c-fos, , 
bax, bcl-2 and mc/-/ RNA transcripts, and the house-keeping gene transcripts L32 
and GAPDH. 
5.2.3. cDNA Array Analysis 
K562 cells were treated with vehicle or 5 1.1.M C2-ceramide in serum-free 
RPMI media at 5 X 105 cells/mL, and were not pre-incubated prior to their addition. 
Cells were transferred to 75 cm 2 cell culture flasks and incubated at 37°C. Cells (1 X 
107 cells/sample) were harvested at 2, 8 and 24 hours post-treatment and RNA was 
extracted, DNase-treated and quantitated as detailed in Chapter 2.2.7. 
cDNA array analysis was performed using the protocol and reagents provided 
in the AtlasTM Pure Total RNA Labelling System, and AtlasTm Human Cancer 1.2 
cDNA Expression Array kits (Cat. # K1038-1 and # 7851-1 respectively, Clontech, 
USA). Refer to Chapter 2.2.9. for an outline of the cDNA array experimental 
procedure performed. 
5.2.4. Confirmation of Array Results 
The results obtained from cDNA array analysis were confirmed by Sandrine 
Chopin in our laboratory by performing real-time RT-PCR analysis on four 
representative genes that were included on the Atlas Human Cancer 1.2 cDNA 
Expression Array. These genes only were chosen because they represent different 
expression patterns and can be taken as specific 'random' examples to confirm the 
reliability of the AtlasTM cDNA array hybridisation. The genes chosen for 
confirmation purposes were PRAME (preferentially expressed antigen of melanoma), 
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PCNA (proliferating cell/cyclin nuclear antigen), MIC1 (macrophage inhibitory 
cytokine 1), and GADD153 (growth arrest and DNA-damage-inducible protein 153). 
A primer set directed towards glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(an endogenous house-keeping control gene that is in abundant levels and remains 
constant at all timepoints and following treatment) was also designed. GAPDH was 
amplified simultaneously with the amplification of the confirmatory genes, to ensure 
the validity of each run, and to enable calculation of concentrations in each of the 
RNA samples. The same RNA that was extracted from vehicle- and C2-ceramide-
treated K562 cells at 2, 8, and 24 hours and used in the array experiments was also 
used for all confirmation experiments. 
Primer sets were designed for each of the gene sequences, and conditions 
were optimised for amplification of the genes using standard RT-PCR as outlined in 
Chapter 2.2.10. Primer sequences and optimised standard RT-PCR conditions can be 
found in Tables 2.8. and 2.9(A). and (B), respectively. 
Real-time RT-PCR was performed to confirm the cDNA array results using 
the LightCycler system, and LightCycler RNA Master SYBR Green I real-time RT-
PCR kit and capillaries (Roche Diagnostics, Germany). Optimisation of the 
conditions for real-time RT-PCR was performed for each primer set as outlined in 
Chapter 2.2.11. 
Amplification curves and melting curves were generated using the software 
included with the LightCycler system (Roche Diagnostics, Germany) for each 
confirmatory gene. The amplification curve and the corresponding crossing point (the 
point at which SYBR Green I fluorescence was detected above background 
fluorescence) for each gene was compared for each sample to enable the 
determination of their relative expression levels between vehicle- and C2-ceramide-
treated samples. The melting curve was generated to check the specificity of the 
primer sets and to ensure the SYBR Green I fluorescence was being measured at a 
temperature that was below the Tm and above primer-dimer (if present). 
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5.3. Results 
5.3.1. Expression of Cell Cycle-, DNA-Damage- and Apoptosis-Related Genes 
Following Ceramide Treatment 
The RNase protection assay blot obtained for HL60 promyelocytic cells 
following treatment with vehicle and C2-ceramide at 4 and 8 hours post-treatment is 
presented in Figure 5.1. Multiple exposures of varying times were used to overcome 
pixel saturation for normalisation purposes, and only one exposure time is shown in 
the results figure in this thesis for representative purposes. The raw optical density 
data generated from image analysis was normalised to the expression of 
housekeeping genes included in the template set and fold changes in induced gene 
expression between time-matched, vehicle-treated control cells and C 2-ceramide-
treated cells were calculated and are presented in Tables 5.1.A and 5.1.B. 
A significant change in expression was considered to be a 1.5 fold 
increase/decrease after normalisation of the data, as suggested by the manufacturer of 
the RPA kit. A significant change in expression was exhibited for bc1-XL, GADD45, 
c-fos, p2l ciPuwafi , and bc1-2 in HL-60 cells following ceramide treatment. A 1.7 fold 
increase in bc/-XL was demonstrated by 4 hours post-treatment with ceramide, and 
this increased expression continued up to the 8 hour timepoint (1.9 fold change in 
expression). Although a strong p53 band was easily observable in the HeLa control 
lane, no bands were detectable in any of the HL60 RNA extracts, presumably as 
HL60 cells lack a functional p53 gene. Strong basal expression of GADD45 was 
identified in HL60 cells, and a 1.6 fold increase in expression was demonstrated at 4 
hours following ceramide treatment, however, no change in expression was noted at 
8 hours. A 1.5 fold increase in c-fos expression was seen at 4 hours post-treatment 
with ceramide, which decreased to near basal levels by 8 hours for both the vehicle-
and ceramide-treated cells. 
p2iCipl/Wafl expression showed the greatest degree of change, with a 4.9 fold 
increase in expression at 4 hours, rapidly returning to an expression level slightly 
above that of basal levels in ceramide-treated cells by 8 hours. A 1.5 fold increase in 
expression was seen for both c-fos and bc1-2 at 4 hours post-treatment, however, no 
significant changes was noted by 8 hours for either gene. Although bax and mc/-/ 
were shown to be strongly expressed in HL60 control cells at 0 hours, only a slight 
increase in expression was observed for these genes at 4 hours post-treatment (1.3 
fold increase), although these changes were not considered significant. No significant 
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change in expression was seen at 8 hours post-treatment with ceramide for either bax 
or mc/-/ . 
No bands were observable on the autoradiograph in the yeast tRNA negative 
species sensitivity control lane, while the full complement of genes were seen in both 
the undigested probe and the HeLa positive control. 
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Figure 5.1.: Analysis of cell cycle, DNA damage, and apoptosis-related gene expression in 
HL60 promyelocytic cells at 4 and 8 hours post-treatment with either vehicle or C 2-ceramide 
using the RiboQuant RNase protection assay with the hStressl template (Pharmingen, 
USA). The RPA blot is provided in its entirety for comparison of expression of housekeeping 
genes between each sample. A single representative set of results from at least three repeated 
experiments is shown. 
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Table 5.1.A.: Table of final normalised data obtained from image analysis of the RPA blot for HL60 
promyelocytic cells (shown in Figure 5.1.) using the hStressl RiboQuant template (PharMingen, USA) 
at 4 and 8 hours post-treatment with vehicle or 7.5 jiM C 2-ceramide. All optical density data presented 
in the table are normalized to the 0 hour Control GAPDH housekeeping gene to allow the 
determination of fold change in expression of the various genes investigated at each timepoint (Table 
5.1.B.), where a signal was detectable. The raw data given in the table has been adjusted to subtract 
background. The data provided in this table is representative of data obtained from at least three 
repeated experiments. 
N.R. = No result obtained (signal absent or too weak for quantitation). 
. 	Volume 
0 hr Control 
Normalised 
4 hr 
Control 
(optical 
to 0 hour 
density/mm2) 
4 hr 
C2-ceramide 
Control GAPDH 
8 hr 
Control 
8 hr 
C2-ceramide 
Gene 
GAPDH 1.000 1.020 1.084 1.120 1.138 
bc/-XL 156.749 256.786 438.054 530.663 997.732 
bc1-Xs N.R. N.R. N.R. N.R. N.R. 
p53 N.R. N.R. N.R. N.R. N.R. 
GADD45 546.589 579.095 935.688 1034.631 1104.791 
c-fos 436.146 132.583 193.520 263.639 " 	219.854 
oiCipl/Wafl 12.082 24.754 120.546 108.025 84.000 
bax 1142.935 1191.150 1550.615 2169.471 1854.850 
bc1-2 755.740 845.926 1271.414 1873.553 1567.238 
mc// 1588.427 1584.709 2052.006 2781.280 2453.099 
Table 5.1.B.: Fold change in gene expression relative to time-matched controls. 
Gene 4 hours 8 hours 
bc/-XL 1.71 ---1.88 
bcl-Xs N.R. N.R. 
p53 N.R. N.R 
GADD45 1.62 1.07 
c-fos 1.46 0.83 
p2/ciPmvail 4.87 0.78 
box 1.30 0.86 
bc1-2 1.50 
u 
0.84 
mc// 1.30 0.88 
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5.3.2. Screen of Cancer-Related Genes by cDNA Array Analysis 
K562 cells were treated with vehicle or C 2-ceramide and RNA extracted at 2, 
8 and 24 hours post-treatment and hybridised to Atlas TM Human Cancer 1.2 cDNA 
Expression Arrays. Figures 5.2.A., 5.3.A. and 5.4.A. show the resulting blots that 
were obtained from cDNA array hybridisation experiments at 2, 8 and 24 hours post-
treatment respectively. Differential expression is shown in Figures 5.2.B., 5.3.B. and 
5.4.B. by false colouring the blot images (control blot performed in the red channel, 
and C2-ceramide blot performed in the green channel), and overlaying both blots 
from each respective timepoint. As such, genes that are more highly expressed on the 
control array will appear as red spots (downregulated following C 2-ceramide 
treatment), and genes that are more highly expressed on the C2-ceramide array will 
appear as green spots (upregulated following C2-ceramide treatment). Those genes 
that do not change in expression appear as yellow spots. This technique provides a 
means for rapid screening of the array to determine which genes are differentially 
expressed. 
Genes demonstrating a 1.3 fold change or greater in relative pixel density 
were considered differentially expressed, as suggested by the manufacturer of the 
array and a figure that has been adopted in previously published studies using this 
filter array kit (01lila & Vihinen, 1998, Xie et al., 2000). Genes that were shown to 
be significantly differentially expressed at one or more timepoints following C2- 
ceramide treatment are compiled in Table 5.2. Image analysis was performed on the 
cDNA array blots shown in Figures 5.2.A., 5.3.A. and 5.4.A. to generate optical 
density data which was then normalised to the expression of housekeeping genes 
included on the array. Included in Table 5.2. are the individual images of spots for 
each respective gene, taken from the blot overlays (Figures 5.2.B., 5.3.B. and 5.4.B.) 
at each timepoint for direct qualitative comparison. 
While spot saturation is a common feature of nylon filter arrays, this problem 
was overcome using multiple exposure times ranging from 5 hours up to 11 days. 
Only one exposure time is shown in the results figures in this thesis for representative 
purposes. Image analysis of the results was conducted using densitometry and 
specialised pixel volume image analysis software. This technique was somewhat 
subjective, although it was sufficient for the determination of general trend in gene 
expression changes. As such the investigator suggests that that fold changes 
calculated and presented in this thesis for each gene should be considered 
approximate only, and not necessarily an absolute reflection of the exact result, hence 
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the need for further confirmation experiments using techniques such as real-time RT-
PCR. 
A large number of genes were shown to be altered in expression following 
ceramide treatment. The categories of genes that were generally upregulated include 
those involved with negative cell cycle and growth control, DNA damage, 
differentiation, and cytoskeletal genes, while downregulated genes include those that 
are involved in cell proliferation and regulating metabolic pathways. A significant 
increase in the transcription factor-related oncogene c-jun (AP-1 TF complex) 
expression was seen at 8 and 24 hours (6.1 and 5.2 fold increases, respectively) while 
a decrease in c-myc expression was seen at both 2 (3.3 fold decrease) and 24 (1.8 fold 
decrease) hours. An increase of 1.5 fold at 8 hours and 3.9 fold at 24 hours was 
demonstrated for c-jun N-terminal kinase 2 (INK2), which is consistent with the 
increase in c-jun expression. However, a decrease in expression of the jun activation 
domain binding protein was demonstrated at the later timepoints analysed, with a 2.2 
fold decrease seen at 8 hours and a 1.6 fold decrease at 24 hours. 
There was an increase in expression of other transcription factors including 
the TISI1B protein (EGF response factor 1), the early growth response protein 1 
(hEGR1), and the cAMP-responsive element modulator I alpha protein (HCREM). 
Changes were noted in the expression of cell cycle-related genes including the 
G WS-specific cyclin D3, cyclin H, the CDK regulatory subunit 1, p2]''' and 
p57KiP2 . There was a very significant increase in the expression of growth inhibitory 
factor (8.8 fold at 24 hours), and a decrease in cell cycle regulatoryprotein D123 (2.3 
fold at 2 hours and 2.5 fold at 24 hours) and cell cycle protein P38-2G4 homolog. A 
decrease in expression of proliferating cyclic/cell nuclear antigen (PCNA) was 
demonstrated at all timepoints, with a 1.6 fold decrease at 2 hours, extending to a 1.9 
fold and 2.6 fold decrease by 8 and 24 hours, respectively. A significant increase in 
expression (5.2 fold at 8 hours, and 4.1 fold at 24 hours) was seen for the dual-
specificity  protein phosphatase 8, a tyrosine phosphatase. 
Changes were noted in genes known to play a role in apoptosis, including an 
increase in expression of the Bel family member induced myeloid leukaemia cell 
differentiation protein mc1-1. A significant increase in expression of the growth 
arrest and DNA-damage-inducible protein 153 (GADD153) was seen at 8 hours (1.5 
fold) and increased further to a 9.0 fold change by 24 hours. In addition, an increase 
in expression of GADD45 was seen at 24 hours (1.8 fold). 
There were changes in expression of signal-transduction-related genes 
including an increase in expression of the G proteins transforming protein rho B, and 
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ras-related C3 botulinum toxin substrate 1 and 2. A decrease in expression was 
demonstrated for the calcium-binding proteins calmodulin 1 and calvasculin, while 
there was an increase in expression of the signal transduction modulators and 
effectors zyxin + zyxin-2, junction plakoglobin, and decrease in expression of other 
signal transduction modulators and effectors including guanylate kinase and the B-
cell receptor-associated protein. Decreases in a number of stress response proteins, 
including cytosolic superoxide dismutase 1 (SOD 1), microsomal glutathione 5- 
transferase II (microsomal GSTI1), and GST homolog were demonstrated. 
Increases in expression of the genes translated into DNA-binding and 
chromatin proteins, including high mobility group protein 1 (HMG-1) and DNA-
binding protein CPBP (8.2 fold at 8 hours, and 9.1 fold at 24 hours) were seen, while 
a decrease was demonstrated for HMG-2, HMG-17, and the chromatin assembly 
factor 1 p48 subunit (also known as the retinoblastoma-binding protein 4 [RBBP4]). 
An initial decrease in expression (2.2 fold) was seen for the cell surface 
antigen preferentially expressed antigen of melanoma (PRAME), while only a slight 
increase (1.5 fold) in expression was noted by 8 hours, and no significant change was 
seen by 24 hours. An increase in expression was demonstrated for the cell adhesion 
receptors and proteins integrin alpha E precursor and integrin beta 8 precursor. 
Changes (an increase in expression by 24 hours) were seen in expression levels of 
various growth factors, cytokines, and other extracellular communication proteins, 
including the macrophage inhibitory cytokine 1 (MIC1). Contrary to this was the 
expression of macrophage migration inhibitory factor (MIF), which was consistently 
shown to be downregulated at all timepoints (1.6 fold). 
There was a decrease in expression of a number of genes known to be 
involved in regulation of metabolic pathways, including nucleoside-diphosphate 
kinase, inosine-5'-monophosphate dehydrogenase 2, thymidylate synthase, L-lactate 
dehydrogenase M subunit, and ornithine decarboxylase. Each of these genes 
demonstrated little or no change at the initial 2 hour timepoint. Fatty acid synthase 
was the only member of this family of genes that demonstrated an increase in 
expression. 
There was initial downregulation in expression of a number of cytoskeletal 
proteins including vimentin, desmin, and two cytokeratin genes, which was followed 
by an increase in expression at the 8 and 24 hour timepoints. 
A downregulation in expression of the haemoglobin alpha subunit was 
demonstrated at both the 8 and 24 hour timepoints. An initial decrease in another 
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trafficking protein, the TRAM protein, changed to an increase in expression by 24 
hours. 
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Figure 5.2.A.: Demonstration of differential expression of "cancer-related" genes using the 
Atlas' Human Cancer 1.2 cDNA Expression Array (Clontech, USA) for K562 
erythromyeloid cells at 2 hours post-treatment with vehicle (A) and 5 uM C 2-ceramide (B). 

Figure 5.2.B.: K562 2 hour cDNA array blots from Figure 5.2.A., overlaid and false-
coloured. Genes that are upregulated in expression following C 2-ceramide treatment are 
represented as green spots, while genes that are downregulated are represented by red spots. 
Genes that have no change in expression appear as yellow spots. 
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Figure 5.3.A.: Demonstration of differential expression of "cancer-related" genes using the 
Atlas' Human Cancer 1.2 cDNA Expression Array (Clontech, USA) for K562 
erythromyeloid cells at 8 hours post-treatment with vehicle (A) and 5 i.tM C2 -ceramide (B). 

Figure 5.3.B.: K562 8 hour cDNA array blots from Figure 5.3.A., overlaid and false-
coloured. Genes that are upregulated in expression following C 2-ceramide treatment are 
represented as green spots, while genes that are downregulated are represented by red spots. 
Genes that have no change in expression appear as yellow spots. 
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Figure 5.4.A.: Demonstration of differential expression of "cancer-related" genes using the 
Atlas Human Cancer 1.2 cDNA Expression Array (Clontech, USA) for K562 
erythromyeloid cells at 24 hours post-treatment with vehicle (A) and 5 tM C2-ceramide (B). 

Figure 5.4.B.: K562 24 hour cDNA array blots from Figure 5.4.A., overlaid and false-
coloured. Genes that are upregulated in expression following C 2-ceramide treatment are 
represented as green spots, while genes that are downregulated are represented by red spots. 
Genes that have no change in expression appear as yellow spots. 
MOD ••• CID ••• CEI 	••• 
• Orientation Marks 
CI Human Genotnic DNA 
Negative Controls 
El House-Keeping Genes (Positive Controls) 
Ke), : 
A 
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Table 5.2.: Table of qualitative (and final normalised semi-quantitative) results for significantly (1.3 
fold change at any timepoint) differentially expressed genes in K562 erythromyeloid cells at 2, 8 and 
24 hours post-treatment with 5 uM C 2-ceramide, using the Atlas ."' Human Cancer 1.2 cDNA 
Expression Array (Clontech, USA). The individual spots for each respective gene, taken from the 
array overlay analysis (from Figures 5.2.B., 5.3.B. and 5.4.B.), is provided for direct qualitative 
comparison between timepoints. Genes that are upregulated in expression following C 2-ceramide 
treatment are represented as green spots, while red spots represent genes that are downregulated. 
Genes that have no change in expression appear as yellow spots. Fold changes were obtained by 
normalising the original optical density data to the housekeeping genes on each of the arrays 
(following initial background subtraction). Final normalised changes in gene expression between 
vehicle- and C2-ceramide-treated cells is provided (numerical value shown below qualitative results) 
for those genes with .1.3 fold change at one or more timepoints. Where no change in expression was 
demonstrated (1.3 fold change), a numerical value has not been provided. 
Gene (Position on Atlas 	Human 1.2 cDNA Array) Timepoint  
Post-Treatment 
2 hrs 8 hrs 24 hrs 
TUMOUR SUPPRESSORS & RELATED PROTEINS: 
prohibitin (PHB) (A06b) r 
0.39 0.77 0.28 
TRANSCRIPTION FACTOR-RELATED ONCOGENES: 
r 	1 
c-jun proto-oncogene; transcription factor AP-1 (A01c) ii. .4 
6.1 5.2 
c-myc oncogene (A03c)  
r 1 
0.30 0.56 
INTRACELLULAR SIGNAL TRANSDUCTION-RELATED ONCOGENES: 
transforming protein rhoA H12 (RH012; ARH12; ARHA) (A13c) .. 	A 
:.. j 
410 
0.59 1.7 
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CYCLINS: 
GUS-specific cyclin D3 (CCND3) (A081) [ 	.  
0.59 0.42 
cyclin H (CCNH); M015-associated protein (Al Ii) 9 ii 
0.56 0.63 
CELL CYCLE REGULATING KINASES: 
kinase regulatory subunit 1 (CKS1) (A10k) Lcyclin-dependent L  Li 
0.63 0.77 
CDK INHIBITORS: 
cyclin-dependent kinase inhibitor IC (CDKN1C); p57-KIP2 (A081) 
cyclin-dependent 	kinase 	inhibitor 	1 	(CDKN1A); 	melanoma 	differentiation- 
associated protein 6 (MDA6); CDK-interacting protein I (CIP1); WAF1 (A091) 
0.37 
0.59 
3.1 
5.7 
0.71 
OTHER CELL CYCLE REGULATORS: 
protein D123 (A08m) 
growth inhibitory factor; metallothionein-RI (MT-III) (A02n) 
0.44 0.4 
1.4 8.8 
cell cycle protein P38-264 homolog; HG4-1 (A08n) r 
0.71 0.67 
SYMPORTERS & ANTIPORTERS: 
..-- , I," 	• 
ADP/ATP carrier protein (B02a) L. 	• . 
0.4 1.3 0.53 
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ATPase TRANSPORTERS: 
ATP synthase coupling factor 6 mitochondrial precursor (F6) (BOO) 
r--4 
A 
E • 
0.63 0.67 
RECEPTOR-ASSOCIATED PROTEINS & ADAPTERS: 
alpha-2-macroglobulin 	receptor-associated 	protein 	precursor 	(alpha-2-MRAP; 
A2MRAP); low density lipoprotein receptor-related protein- associated protein 1 
(LRPAPI) (B03b) _A • 
0.63 2.6 
INTRACELLULAR KINASE NETWORK MEMBERS: 
c-jun N-terminal kinase 2 (JNK2); JNK55 (B10c) Li 
1.5 3.9 
TYROSINE PHOSPHATASES: 
dual-specificity protein phosphatase 8; hVH5 (B08i) 
5.2 4.1 
G PROTEINS: 
transforming protein rhoB; ARHB; ARH6 (B110 II 
ras-related C3 botulinum toxin substrate 1; p21-rac I; ras-like protein TC25 (B131) 
5.2 2.8 
0.59 1.9 
ras-related C3 botulinum toxin substrate 2; p21-rac2; small G protein (B12j) L L 
guanine nucleotide-binding protein G(I)/G(S)/G(0) gamma-10 subunit (B13j) 
1.4 1.7 
41 
0.59 1.6 
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CALCIUM-BINDING PROTEINS: 
calmodulin 1; delta phosphorylase kinase (BOS1) • Li 
placental calcium-binding protein; calvasculin; S100 calcium-binding protein A4; 
0.44 0.67 0.59 
MTS1 protein (B071) 0.63 0.56 
KINASE SUBSTRATES & INHIBITORS: 
hint protein; protein kinase C inhibitor I (PKCI1) (B02m) L is • 
0.56 1.3 0.77 
OTHER INTRACELLULAR SIGNAL TRANSDUCTION MODULATORS & 
EFFECTORS: 
zyxin + zyxin-2 (B07m) 
Liii Li 
0.77 2.7 2.1 
junction plakoglobin (RJP); desmoplakin III (DP3) (B10m) L • 
2.7 
guanylate kinase (GMP kinase) (B12m) 110 • 
0.77 0.56 0.59 
B-cell receptor-associated protein (hBAP) (B04n) • [ 
0.63 0.67 
Bel FAMILY: 
induced myeloid leukaemia cell differentiation protein mc1-1 (C07c) 
3.1 1.7 
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OTHER APOPTOSIS-ASSOCIATED PROTEINS: 
growth arrest & DNA-damage-inducible protein 153 (GADD153); DNA-damage-
inducible transcript 3 (DDIT3); C/EBP homologous protein (CHOP) (CO5d) 
C • 
1.5 9.0 
PDCD2 (CI4d) • 
0.71 0.29 0.67 
DNA POLYMERASES, REPLICATION FACTORS & RECOMBINATION 
PROTEINS: 
proliferating cyclic/cell nuclear antigen (PCNA); cyclin (C13e) r.1 LA • 
0.63 0.53 0.39 
DNA DAMAGE REPAIR PROTEINS, LIGASES & HELICASES: 
mutL protein homolog; DNA mismatch repair protein MLH1; COCA2 (C08g) • IIlk 
RAD5IC truncated protein (C12h) 
0.56 0.35 
ri 
0.63 
0.33 
OTHER DNA SYNTHESIS, REPAIR & RECOMBINATION PROTEINS: 
growth arrest & 	DNA-damage-inducible protein (GADD45); 	DNA-damage- 
inducible transcript 1 (DD1T1) (C09i) 110 
1.8 
TRANSCRIPTION FACTORS: 
TISI1B protein; EGF response factor I (ERF I) (Cl2i) r r 1 • 
1.4 2.6 2.0 
jun activation domain binding protein (C14i) * U 
0.46 0.63 
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early growth response protein I (hEGR1); transcription factor ETR103; KROX24; ril • 
zinc finger protein 225; AT225 (Cl2j) 
cAMP-responsive element modulator 1 alpha protein (HCREM) (C14k) 
1.9 2.7 2.0 
major histocompatibility complex enhancer-binding protein MAD3 (C111) 
1.7 1.7 
3.3 
TAXI-binding protein 151 (TXBP151) (C10m) U 
0.63 1.5 
DNA-BINDING & CHROMATIN PROTEINS: 
CA r - high mobility group protein (HMG-I) (D08a) • 
2.7 1.4 
chromatin assembly factor I p48 subunit (CAF1 p48 subunit); retinoblastoma- 1110 
binding protein 4 (RBBP4); RBAP48; rnsil protein homolog (D12a) 0.44 0.56 
DNA-binding protein CPBP (D03b) 
nonhistone chromosomal protein HMG17 (D06b) 
1.3 
r 
8.2 9.1 
0.5 
ge-1 
0.67 
high mobility group protein HMG2 (D07b) Ilb-41 L... 
0.4 0.71 0.71 
CELL SURFACE ANTIGENS: 
e r preferentially expressed antigen of melanoma (PRAME) (DO8c) & I, 	. 
0.46 1.5 
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CELL ADHESION RECEPTORS & PROTEINS: 
integrin alpha E precursor (ITGAE); mucosal lymphocyte-1 antigen; hm1-1 antigen; 
CD103 antigen (D06d) 2.1 
integrin beta 8 precursor (ITGB8) (D07d) C 
2.1 
OTHER RECEPTORS: 
Transmembrane protein sex precursor (DO1m) 
3.1 2.7 
STRESS RESPONSE PROTEINS: 
cytosolic superoxide dismutase 1 (SODI) (D06m)  
pP-.1 
0.63 0.63 
microsomal glutathione S-transferase 11 (microsomal GSTII) (D08m) IE 
0.59 0.5 
glutathione-S-transferase (GST) homolog (D09m)  
.. r • 
0.59 
GROWTH FACTORS, CYTOKINES & CHEMOKINES: 
vascular endothelial growth factor precursor (VEGF); vascular permeability factor 
(VPF) (E09b) • L2 
platelet-derived growth factor A subunit precursor (PDGFA; PDGF I) (E08c) 
1.3 2.5 
delta-like protein precursor (DLK) (E12c) 
1.4 3.2 
0.67 0.77 1.8 
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macrophage inhibitory cytokine 1 (MIC1) (E09e) • • 41 
2.7 3.5 3.9 
OTHER EXTFtACELLULAR COMMUNICATION PROTEINS: 
macrophage migration inhibitory factor (M1F); glycosylation-inhibiting factor (GIF) 
. 	, 
0 	 I 
(E07h) 0.63 0.63 0.63 
PROTEIN TURNOVER: 
metalloproteinase inhibitor 1 precursor (TIMP1); erythroid potentiating activity 
1' 	• 
■ 	• • • 
(EPA); fibroblast collagenase inhibitor (E10j) 0.71 1.8 1.7 
IMMUNE SYSTEM PROTEINS: 
78-kDa glucose regulated protein precursor (GRP 78); inununoglobulin heavy chain LI • 
binding protein (BIP) (E02n) 0.71 2.4 
METABOLIC PATHWAYS: 
nria23-H4; 	nucleoside-diphosphate 	kinase; 	nucleoside 	5'-diphosphate k 	. • e 
phosphotransferase (NDK) (F09b) 0.35 0.5 
inosine-5'-monophosphate dehydrogenase 2 (IMP dehydrogenase 2; IMPD2) (FlOc) • • • 
0.77 0.77 
thymidylate synthase (TYMS; TS) (F03d) ri • 
0.67 0.56 0.4 
L-Iactate dehydrogenase M subunit (LDHA) (F05d) • 
0.56 0.46 0.44 
fatty acid synthase (F03e) . 
L 
1.7 
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omithine decarboxylase (F05e) 
0.63 0.67 
• 
0.46 
CYTOSKELETON & MOTILITY PROTEINS: 
type I cytoskeletal 18 keratin; cytokeratin 18 (K18) (F08f) r-.. • 
type]] cytoskeletal 8 keratin (KRT8); cytokeratin 8 (K8; CK8) (F03g) 
2.4 
0.59 1.4 2.4 
't • vimentin (VIM) (F04g) • 
desmin (DES) (F05g) 
0.77 1.8 1.5 
0.5 2.5 
TRAFFICKING PROTEINS (ENDOCYTOSIS & EXOCYTOSIS): 
TRAM protein (F09h) 
0.56 0.4 1.9 
haemoglobin alpha subunit (F03i) 4111 41 
0.71 0.77 
RNA PROCESSING, TURNOVER & TRANSPORT: 
• arginine/serine-rich splicing factor 7; splicing factor 9G8 (F10i) r • 
0.67 0.42 0.71 
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Increased 	in 	1(562 	cells 	following 	PMA-induced 
hVH5 - 5.2 4.1 differentiation (Johnson etal., 2000). Highly expressed 
in regions of the body where you would expect to find 
differentiated 	cells, including the brain, 	heart, and 
skeletal 	muscle (Martell et al., 	1995, Ogata et al., 
1995). 
racl increased in HL60 cells induced to differentiate 
racl - 0.59 1.9 along 	the 	neutrophil 	lineage, 	while 	differentiation 
induction in both HL60 and U937 cells results in an 
rac2 - 1.4 1.7 increase in rac2 transcript (Didsbury etal., 1989). 
Zyxin exhibits three copies of the LIM motif, a double 
zyxin 0.77 2.7 2.1 zinc-finger domain found in many proteins that play a 
central role in the regulation of cell differentiation 
plakoglob in - - 2.7 (Sadler et at., 1992, Macalma et at., 1996, Beckerle, 
1997). 	Involved 	in 	pathways 	important 	for 	cell 
cytokeratin 8 0.59 1.4 2.4 differentiation (Beckerle, 1997). 
An increase in expression of cytoskeletal-related genes 
cytokeratin 18 - 2.4 is an indication of cellular stabilisation and changes in 
the 	mechanical 	properties 	of the 	cell, 	which 	is 
vimentin 0.77 1.8 1.5 consistent with cell maturation and tumour suppression 
(Dellagi et al., 1983, Sadler etal., 1992, van der Ven 
desmin 0.5 - 2.5 et at., 	1992, Macalma et at., 1996, Witcher et al., 
1996, Beckerle, 1997). 
A reduction in metabolic pathway gene transcripts can 
nucleoside-d i phosphate kinase - 0.35 0.5 be correlated with a reduced growth rate. 
IMP dehydrogenase - 0.77 0.77 
thymidylate synthase 0.67 0.56 0.4 
L-lactate dehydrogenase M subunit 0.56 0.46 0.44 
Decrease suggests differentiation of erythromyeloid 
haemoglobin alpha subunit - 0.71 0.77 cells away from the erythroid lineage and towards the 
granulocytic/macrophage lineage. 
5.3.3. Confirmation of cDNA Array Results by Real-Time RT-PCR 
The cDNA array results were confirmed by a semi-quantitative real-time RT-
PCR method. RNA (2, 8 and 24 hours post-treatment) used for the cDNA array 
analysis was amplified using designed primer sets targeted towards transcripts of four 
representative genes included in the Atlas TM Human Cancer 1.2 cDNA Expression 
Arrays. Sandrine Chopin performed all confirmation work, and the results from these 
experiments are provided in Appendix B & C. Melting curves were generated to 
ensure that the real-time RT-PCR products were specific and to determine the 
temperature at which fluorescence of SYBR Green I would be measured. The 
resulting melting curves for each primer set for a single representative real-time RT-
PCR run are presented in Appendix B. 
The concentrations of transcript present in the original sample for each of the 
confirmatory genes at each timepoint was calculated based on the determined 
crossing points from the amplification curve (the point at which SYBR Green I 
fluorescence was detected above background fluorescence), relative to a 10 pg 
GAPDH control RNA sample that was amplified simultaneously. Appendix B shows 
the amplification curves for RNA from vehicle and ceramide-treated cells, and the 
corresponding negative control (water) that were generated from representative real- 
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time RT-PCR assays for each gene analysed. The raw data from the real-time RT-
PCR assays are presented in Appendix C, which shows the calculated concentrations 
determined from a GAPDH standard curve (generated from amplification curves 
provided in Appendix D). The fold change in expression for each gene at 2, 8, and 24 
hours post-treatment with ceramide was then calculated relative to GAPDH 
expression in the same RNA samples and these are also provided in Appendix C. 
A left shift was demonstrated in the PRAME amplification curve for RNA 
from ceramide-treated cells at 24 hours, which identifies an increase in expression 
following ceramide expression. Although the amplification curves at 2 and 8 hours 
show neither a noticeable left or right shift following ceramide treatment, significant 
changes in expression were calculated relative to GAPDH expression. A 1.8 fold 
decrease in PRAME expression was seen at the 2 hour timepoint following ceramide 
treatment. By 8 hours, a 2.8 fold increase in expression was determined, and a 3.2 
fold increase was calculated for the 24 hour timepoint. 
The PCNA amplification curves show a right shift of the ceramide curve at 8 
and 24 hours, which demonstrate a decrease in PCNA expression on treatment with 
ceramide. Negligible shift is shown between the control and ceramide curves at 2 
hours, although relative to GAPDH expression, a 3.3 fold decrease in expression was 
calculated by this early timepoint. At 8 hours, a 1.5 fold decrease in PCNA 
expression was calculated, which was reduced slightly to a 1.2 fold decrease in 
expression by 24 hours post-treatment with ceramide. 
A 1.3 fold decrease in M/C/ expression was calculated at 2 hours post-
treatment with ceramide relative to GAPDH expression. This was further increased to 
a 2.3 fold decrease in expression by 8 hours, however, by 24 hours a 2.9 fold increase 
in M/C/ expression was demonstrated. The increase in expression at 24 hours is 
accompanied by a significant left shift in the amplification curve for the RNA from 
ceramide-treated cells. 
A fold change in expression of GADD153 could not be calculated at the 2 and 
24 hour timepoints, presumably due to insufficient amplification of the target 
GADDI 53 template. Although very low amounts of GADD153 product were 
amplified, it was however possible to calculate a 10.8 fold increase in GADD153 at 
the 8 hour timepoint relative to GAPDH expression. This result may be somewhat 
unreliable however due to the low amount of amplicon produced. 
Table 5.4. provides a summary of the results obtained from gene expression 
analysis using both cDNA array and real-time RT-PCR methods for comparison 
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purposes. The results obtained from the real-time RT-PCR assays support the results 
obtained from cDNA array analysis for each of the four selected genes. 
Table 5.4.: Summary table comparing the fold change in expression by cDNA array analysis (shown 
in Table 5.2.) with the fold change in expression as determined by real-time RT-PCR (shown in 
Appendix C) for the following representative genes using RNA from K562 erythromyeloid cells at 2, 8 
and 24 hours post-treatment with 51.1M C2-ceramide: PRAME, PCNA, MICI and GADD I 53. 
N.C. = No change in expression - 	fold change (as determined from cDNA array analysis). 
N.R. = No result obtained - unable to determine fold change (as determined from real-time RT-PCR 
analysis). 
Gene Timepoint 
(hours) 
Normalised Fold Change 
(cDNA array analysis) 
Normalised Fold Change 
(real-time RT-PCR) 
PRAME 2 0.46 0.53 
8 1.5 2.78 
24 N.C. 3.24 
PCNA 2 0.63 0.31 
8 0.53 0.65 
24 0.39 0.83 
MIC1 2 2.7 0.77 
8 3.5 0.44 
24 3.9 2.90 
GADD153 2 N.C. N.R. 
8 1.5 (10.78) 
24 9.0 N.R. 
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5.4. Discussion 
Studies over the last decade have revealed that haemopoietic differentiation 
engages a complex pattern of changes in expression of numerous genes. The previous 
chapters in this thesis demonstrate that a number of gene products are involved in 
ceramide-induced cell cycle arrest and the subsequent maturation of haemopoietic 
cells including the Rb tumour suppressor protein, protein phosphatases, and the CKI 
p21CipliWari . A number of studies have concentrated on the changes in expression of 
individual genes during haemopoietic differentiation. However, comprehensive 
studies, simultaneously examining the expression of multiple genes, including genes 
known to have oncogenic potential, and discussions on the inter-relationships to one 
another are lacking from the literature. 
Further elucidation of the signalling pathway utilised by ceramide to induce 
differentiation, in particular the changes in gene expression, is required to gain a 
better understanding of the key molecular mechanisms involved. RNase protection 
assays (RPAs) provide a rapid and relatively simple approach to genetic screening 
and provide a "proof-of-principle" for justifying the application of larger, more 
involved techniques. RPAs incorporate a set of gene templates for the simultaneous 
investigation of changes in expression of a number of key genes of interest. The RPA 
method, incorporating the hStressl multi-probe template, was adapted in this study to 
provide an efficient way of investigating the ceramide-signalling pathway. 
The hStress 1 set contains probe templates for eleven genes (including two 
housekeeping genes), and permits expression analysis of cell cycle regulatory 
elements, DNA-damage repair genes, and apoptosis-related genes. The cell cycle 
regulatory genes included in the set include p.53 which is known to be either absent 
or non-functional in most leukaemia cell lines, and p2/ ciPuwall whose protein product 
plays a crucial role in inhibiting cyclin D-dependent kinases, thus preventing 
dephosphorylation of the Retinoblastoma tumour suppressor protein (Harper et al., 
1993, Harper et al., 1995), and has been reported to play a role in ceramide-mediated 
terminal differentiation (Ragg et al., 1998). The transcription factor c-fos is a critical 
component of the stress-activated protein kinase pathway, activation of which is 
proposed to be a necessary event in the induction of apoptosis (Verheij et al., 1996). 
The hStress 1 template set also includes riboprobes for studying the mRNA 
expression of the apoptosis-related genes bcl-XL, bcl-Xs, bc1-2, bax and mc/-/, and 
the growth arrest and DNA-damage-inducible protein 45 (GADD45). 
169 
Chapter 5: Other Genes Induced by Ceramide 
In this study, RPAs using the hStressl template were performed on the 
promyelocytic HL60 cell line at 4 and 8 hours post-treatment with ceramide. The 
HL60 cell line was chosen for the preliminary RPA study, as it was with the use of 
these cells that the first link was made between ceramide and differentiation 
(Okazaki et al., 1989, Okazaki et al., 1990, Kim et al., 1991). Subsequently this 
model has been used extensively for investigations into ceramide-mediated growth 
regulation and differentiation by a number of authors. A significant change in 
expression was determined to be 1.5 fold of greater for the purposes of this study, as 
suggested by the manufacturer of the RPA kit. Greater than 1.5 fold changes were 
demonstrated for five of the nine genes included in the template set. As expected, no 
band was observable for p.53 in any of the experimental RNA samples, as HL60 cells 
lack a functional p53 gene (Wolf & Rotter, 1985). A band corresponding to p53 was, 
however, clearly seen in the HeLa control sample. The most significant change in 
expression was demonstrated for p2l ciP ilwafi , with almost a 5-fold increase at 4 
hours, returning to basal expression levels by 8 hours. This further confirms the 
findings presented in previous chapters of this thesis, and results published by other 
authors (Ragg et al., 1998, Lee et al., 2000). Furthermore, it supports the hypothesis 
that ceramide treatment results in the terminal differentiation of immature leukaemia 
cells (Steinman et al., 1994, Halevy et al., 1995, Liebermann et al., 1995, Parker et 
al., 1995, Flink et al., 1998). 
The significant increase in GADD45 expression at both timepoints following 
ceramide treatment is consistent with cell cycle arrest and differentiation in HL60 
cells, as shown previously in this study. GADD45 is a DNA-damage-inducible gene 
that is translated into a nuclear protein and is expressed in a cell cycle-regulated 
manner (Carrier et al., 1994, Kearsey et al., 1995) and appears to play a role in co-
ordinating aspects of DNA repair and replication. GADD45 expression is elevated in 
response to DNA damaging agents such as ionising radiation, nutrient deprivation, 
and during growth arrest and differentiation (Fornace et al., 1988 & 1989, 
Papathanasiou et al., 1991, Price & Calderwood, 1992, Zhan et al., 1994). It is 
transcriptionally activated via p53 (Kastan et al., 1992, Zhan et al., 1993, Carrier et 
al., 1994, Gujuluva etal., 1994) and interacts with p2/clwafi and PCNA (Fornace et 
al., 1989, Smith et al., 1994, Hall et al., 1995, Kearsey et al., 1995). Hence, a p53- 
independent mechanism for the expression of GADD45 in HL60 cells has been 
demonstrated in the current study. 
It seems likely that c-fos contributes to ceramide-mediated regulation of the 
cell cycle and differentiation as the expression of the c-fos gene was shown to be 
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upregulated following ceramide treatment, and has been shown in previous studies to 
be involved with negative regulation of the cell cycle (Balsalobre & Jolicoeur, 1995). 
Okada et al. (1999) have shown that overexpression of c-fos prevents progression of 
primitive stem cells through the cell cycle, rendering them dormant in the G 0/G 1 
phase. Similarly, overexpression of c-fos in splenic B cells leads to enhanced p27KiP 1 
expression, and thus cell cycle arrest (Kobayashi et al., 1997). However, it is now 
well accepted that c-fos in association with c-jun comprise the transcription factor 
complex AP-1 which is responsible for regulating the transcription of genes involved 
in both cell survival and death (Okada et al., 1999). Sawai et al. (1995) propose that 
AP-1 is a requirement for apoptosis in HL60 cells, and that this TF complex is 
activated via ceramide signalling. c-fos knockout mice display a greatly reduced rate 
of apoptosis to stress stimuli such as ionising radiation (Pruschy et al., 1997) 
indicating the importance of c-fos in the apoptotic pathway. c-fos has also been 
shown to be associated with numerous other physiological responses, including 
mitogenesis (Okada et al., 1999), and differentiation (Sawai et al., 1995). Studies 
conducted in our laboratory have demonstrated that c-fos and c-jun expression is a 
pre-requisite for ceramide-induced myeloid differentiation (McQuestin, 2001). Taken 
together, the findings from each of these studies are consistent with the increase in c-
fos expression seen in ceramide-treated HL60 cells in the current study, in 
association with the G0/G1 cell cycle arrest, myeloid differentiation and viability 
results presented in the previous chapters of this thesis. 
Expression of a number of Bc1-2 protein family members was also 
investigated at the transcriptional level as these genes play a crucial role in the 
regulation of cell death, and function in coordination with each other to determine the 
susceptibility of a cell to undergo apoptosis (Pellegrini & Strasser, 1999). The 
expression of bc1-2 is high in myeloid cells, and is regulated in a differentiation-
linked manner such that levels of bc1-2 mRNA decrease dramatically and rapidly 
during differentiation of HL60 cells induced by PMA and other agents, including 
vitamin D3 and RA (Delia et al., 1992, Xu et al., 1993, Park et al., 1994, Naumovski 
& Cleary, 1994, Blagosklormy et al., 1996). Surprisingly, although HL60 cells did 
demonstrate strong bc1-2 basal expression levels, a 1.5 fold increase in bc1-2 
expression was exhibited at the early timepoint following ceramide exposure. 
However, a slight decrease in bc1-2 expression was shown at 8 hours, although this 
was not considered to be significant (<1.5 fold change). The significant increase in 
the anti-apoptotic bc/-XL demonstrated at 4 and 8 hours, the slight increase in 
expression of mc// at 4 hours (<1.5 fold change), and the slight increase (<1.5 fold 
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change) in the pro-apoptotic member bax, tend to suggest that ceramide treatment 
leads to the protection of HL60 cells from apoptosis due to the significant induction 
of expression of anti-apoptosis genes such as bc1-2 and bc/-XL . This is in contrast to 
the findings from previous chapters where HL60 cell death was clearly demonstrated 
following ceramide treatment. It is likely that post-translational interactions, rather 
than transcriptional mechanisms, between Bc1-2 family members are responsible for 
the increased sensitivity to apoptosis as indicated by the study conducted by El-
Assaad et al. (1998). In this study it was demonstrated that over-expression of bc/-XL 
did not protect MCF7 breast carcinoma cells from ceramide-induced apoptosis, and 
the fact that bc1-2 mRNA levels are not necessarily predictive of bc1-2 protein levels 
(Blagosklonny et al., 1996). It is the ratio of anti-apoptotic to pro-apoptotic members 
that is considered to be one of the determining factors as to whether survival or death 
will occur following an apoptotic signal (Korsmeyer et al., 1993, Oltvai et al., 1993). 
The activation of expression of cell cycle regulatory and differentiation-
associated genes including p2l ciP liwall , GADD45 and c-fos demonstrated from RPA 
analysis, together with the results from protein studies presented in previous chapters, 
suggest a myriad of genes are playing a role in ceramide-mediated cell cycle arrest 
and subsequent terminal differentiation of haemopoietic cells. As such, it was 
considered justified to perform a large-scale screen of ceramide-induced genes, 
particularly as studies of this nature are absent from the literature, in order to further 
elucidate the relevant genes and potential mechanisms involved in regulating growth, 
differentiation and death following ceramide treatment. 
RNA from K562 cells were used for the cDNA array experiments, as K562 
cells were considered to be representative of the other myeloid ceramide-responsive 
cell lines, and distinctly demonstrated ceramide-induced cell cycle arrest and 
differentiation, while demonstrating only a small amount of cell death relative to the 
other cell lines investigated. The focus of this section of the study was to be directed 
towards the growth arrest and differentiation-inducing ability of ceramide in cells of 
the myeloid lineage. As such, the K562 cell line was chosen as the model for use in 
cDNA array analysis to investigate the expression changes in "cancer-related" genes 
following ceramide treatment. 
For the purpose of this study, genes demonstrating a 1.3 fold change or 
greater in relative pixel density were considered differentially expressed as this figure 
is suggested by the manufacturer of the array, has been adopted in previously 
published studies using this filter array kit (011ila & Vihinen, 1998, Xie et al., 2000), 
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and provides a reasonable starting point for estimating which genes are differentially 
expressed as a basis for further investigative work. 
In the categories of cell cycle and growth regulators, the downregulation of 
G I/S-specific cyclin D3, P38-2G4 and protein D123 following ceramide treatment 
indicates negative regulation of the cell cycle and is consistent with cell cycle arrest 
at the G0/G1 phase of the cell cycle. The cell cycle protein P38-2G4, a homolog of 
murine p38-2G4 (Lamartine et al., 1997, Radomski & Jost, 1995), is a cell cycle-
specifically modified and proliferation-associated nuclear protein in mammals 
(Radomski & Jost, 1995). Protein D123 has been proposed as being necessary for 
phase entry into the cell cycle, and a decrease in this protein results in G 1 arrest 
(Onisto et al., 1998). Downregulation of each of these genes further supports the 
roles for ceramide in cell growth inhibition and G 0/G 1 cell cycle arrest. 
A significant increase in expression was demonstrated for p21 ciP liWafi at 8 
hours post-treatment with ceramide, while other timepoints were difficult to analyse 
due to low signal levels. This is consistent with the results obtained from RPA 
studies on all cell lines investigated in this thesis, and further confirms ceramide-
induced p53-independent G0/G1 cell cycle arrest and terminal differentiation in K562 
cells. Overexpression of PCNA has been related to tumour size and poor prognosis, 
and PCNA is inhibited by p21 cIP1/Waf1  expression during cell cycle arrest (Flores-
Roses et al., 1994, Waga et al., 1994, Chen et al., 1995b, Luo et al., 1995, Warbrick 
et al., 1995, Zhou et al., 1998). Thus, overexpression ofp2I ciP l/Wafi inhibits PCNA, 
resulting in the inhibition of PCNA-dependent DNA replication and prevention of 
cell proliferation (Flores-Roses et al., 1994, Li et al., 1994, Waga et al., 1994). 
Downregulation of PCNA, as demonstrated in the array experiments in the current 
study, is therefore consistent with an upregulation in p2l ciP liWan expression, which 
would result in a reduction in growth rate, cell cycle arrest and subsequent terminal 
differentiation. 
In the categories of apoptosis and DNA synthesis and repair-related proteins, 
significant increases in expression were demonstrated for GADD153 and GADD45. 
The increase in GADD45 expression also further confirms the results from the RPA 
study presented in this thesis. GADD45 transcript is elevated in cells that have been 
growth arrested or after DNA damage. (Fornace et al., 1988 and 1989), and 
furthermore, has been shown to bind PCNA in vivo (Smith et al., 1994), further 
assisting in the p21aP"wafi-induced inhibition of PCNA-driven cell proliferation. 
An upregulation was seen in mc/-/ expression, which is consistent with 
haemopoietic cell cycle arrest, differentiation and apoptosis. mc//, a homologue of 
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Bc1-2, was isolated from the ML-1 human myeloblastic cell line (Kozopas et al., 
1993), and is rapidly induced in response to signals for cell differentiation and death, 
but not to signals for cell proliferation. ML-1 cells induced to differentiate into 
monocyte/macrophage cells demonstrated an early increase in expression of mc// 
(Kozopas et al., 1993, Yang et al., 1996). It is considered a potential target for 
inhibiting cancer development and inducing differentiation and apoptosis in tumour 
cells (Craig, 2002). Interestingly, mcll has also been shown to play a role in cell 
cycle progression, and has a binding site for PCNA. A mutant of mc// that lacks 
PCNA binding was not capable of inhibiting cell cycle progression as effectively as 
wild-type mc// (Fujise et al., 2000). Taken together, an increase in ofp2/ ciPuwafi , c-
fos, and mc// expression is consistent with a decrease in PCNA levels and 
subsequent cell cycle arrest. 
In the category of transcription factor-related oncogenes, c-jun was found to 
be highly upregulated, while c-myc was downregulated in response to ceramide 
treatment. c-jun is a key member of the SAPK/JNK pathway (reviewed by Karin et 
al., 1997) and has been shown to be upregulated in HL60 cells (Sawai et al., 1995), 
and activated by phosphorylation in U937 cells upon treatment with C2-ceramide 
(Ragg et al., 1998). In association with c-fos (to form the transcription factor AP-1), 
c-jun is known to elicit a variety of cellular responses including proliferation, 
differentiation and apoptosis, depending on the original stimulus, cell type and 
microenvironment of the cell. The level of c-jun transcript has been reported to 
increase during HL60 cell differentiation along the macrophage lineage (Lord et al., 
1993). It is interesting to note also that c-jun has been implicated as being a 
downstream target for CAPP in A431 cells (Reyes et al., 1996), which correlates 
with the results presented in a previous chapter of this thesis. Consistent with an 
increase in c-jun mRNA levels is an upregulation in expression at both the 8 and 24 
hour timepoints for c-jun N-terminal kinase 2 (JNK2). 
The product of transcription factor and proto-oncogene c-myc strongly 
stimulates cellular proliferation, inducing cells to exit G0/G 1 and enter the cell cycle 
via transcriptional regulation of myc-target genes. c-myc expression is rapidly 
suppressed by p53 upon induction of growth arrest and apoptosis (Guillouf et al., 
1995). Therefore a decrease in c-myc expression, as demonstrated in the current study 
following treatment with ceramide, is consistent with cells undergoing G0/G 1 cell 
cycle arrest. c-myc expression has also been shown by various authors to be 
dramatically suppressed after the induction of myeloid terminal differentiation in 
HL60, U937, HEL, ML-1 and K562 cells (Collins, 1987, Larsson et al., 1988 & 
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1994, Liebermann & Hoffman-Liebermann, 1989, Gomez-Casares et al., 1993, 
Nguyen et al., 1995a, Lerga et al., 1999). Kim et al. (1991) have reported early and 
specific ceramide-induced downregulation of c-myc in HL60 cells, resembling results 
from an earlier study seen after treatment with TNFa (Kronke et al., 1987). Further 
work has led this group of researchers to speculate that c-myc downregulation by 
ceramide in HL60 cells is a result of activation of CAPP (Wolff et al., 1994). Several 
lines of investigation have revealed that there is also a close association between c-
myc and GADD45, and c-myc and GADD153. Results from these studies identify 
that c-myc is capable of suppressing the induction of both these DNA damage and 
growth arrest-related proteins, suggesting that a coordinate downregulation of 
GADD45 and GADD153, and other GADD genes, is one mechanism by which c-myc 
can circumvent growth arrest (Marhin et al., 1997, Amundson et al., 1998). Thus an 
increase in GADD45 and GADD153 in consistent with a downregulation in c-myc, as 
demonstrated from the array analysis results in the present study, which further 
correlates with cells undergoing cell cycle arrest. 
The primary aim of this study was to investigate the ceramide-induced 
changes in expression of differentiation-associated genes in a representative myeloid 
cell line. CDNA array analysis provides a very effective means for conducting a 
study of this kind. However, use of the Atlas"' Human Cancer 1.2 array also provides 
supportive data to indicate the involvement of other genes reported to be involved in 
human cancer. A selection of the remainder of genes analysed, which are categorised 
into a variety of different gene families contained within the cDNA array, are 
discussed further. These genes were chosen for discussion, as they appear to be of 
relative significance in the process of ceramide-induced differentiation. One such 
gene is the ADP/ATP carrier which demonstrated a decrease in expression at both 
the 2 and 24 hour timepoints following ceramide treatment, and has been shown also 
to decrease in HL60 cells during the differentiation response to phorbol ester and 
retinoic acid treatment (Battini etal., 1987). 
inRNA levels for the dual-specificity protein phosphatase 8 (h VHS) gene 
were shown in the present study to be significantly increased at the later timepoints 
by ceramide, which is consistent with a study recently conducted by Johnson et al. 
(2000), who found upregulation in expression of hVH5 in K562 cells following 
PMA-induced differentiation. This demonstrates activation of a protein phosphatase 
other than the CAPP, which may be playing a regulatory role in the ceramide-
signalling pathway. Interestingly hVH5 is highly expressed in regions of the body 
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where you would expect to find differentiated cells, including the brain, heart, and 
skeletal muscle (Martell et al., 1995, Ogata et al., 1995). 
An increase in expression of the genes for both ras-like proteins (G proteins), 
racl and rac2, were demonstrated in the array experiments at the 24 hour timepoint. 
Overexpression of these genes is also consistent with differentiation into a mature 
phenotype. mRNA levels of ras increase with the terminal differentiation of 
haemopoietic cells into granulocytes, and this is specific to cells of the haemopoietic 
lineage (Shirsat et al., 1990). racl transcript has been shown to be increased in HL60 
cells induced to differentiate along the neutrophil lineage, while differentiation 
induction in both HL60 and U937 cells results in an increase in rac2 transcript 
(Didsbury et al., 1989). Interestingly, neither rac mRNAs are present in Jurkat cells, 
which suggests that rac proteins are only important in myeloid differentiation. 
Zyxin is a component of adhesion plaques that are proposed to perform 
regulatory functions at the plasma membrane (Macalma et al., 1996), and displays 
features of an intracellular signal transducer (Beckerle, 1997). This protein exhibits 
three copies of the LIM motif, a double zinc-finger domain found in many proteins 
that play a central role in the regulation of cell differentiation (Sadler et al., 1992, 
Macalma et al., 1996, Beckerle, 1997). Together with its partners, zyxin is capable of 
directing nuclear proteins to the cytosol (Nix & Beckerle, 1997), and is involved in 
the spatial control of actin filament assembly as well as in pathways important for 
cell differentiation (Beckerle, 1997). zyxin expression was found to be upregulated 
following ceramide treatment at the later timepoints. Together with an increase in 
expression of other cytoskeletal-related genes such as plakoglobin, cytokeratin 8 and 
18, vimentin and desmin, an increase in expression of zyxin is an indication of 
cellular stabilisation and changes in the mechanical properties of the cell, which is 
again consistent with cell maturation and tumour suppression (Dellagi et al., 1983, 
Sadler et al., 1992, van der Ven et al., 1992, Macalma et al., 1996, Witcher et al., 
1996, Beckerle, 1997). 
All of the genes coding for components of metabolic pathways that 
demonstrated differential expression were consistently downregulated in expression. 
It is justifiable to propose that a reduction in metabolic pathway gene transcripts can 
be correlated with a reduced rate of growth as demonstrated in growth curves 
presented in a previous chapter of this thesis. Finally, it has been proposed that 
ceramide treatment results in the differentiation of K562 cells away from the 
erythroid lineage and towards the granulocytic/macrophage lineage due to the 
demonstrated decrease in glycophorin A cell surface marker expression. This is in 
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fact consistent with the downregulation in haemoglobin alpha subunit expression 
shown in the array experiments in the present study. 
Real-time PCR is used to monitor the fluorescence emitted during an 
amplification reaction as an indicator of amplicon production during each PCR cycle 
as opposed to endpoint detection by conventional quantitative PCR methods. It is 
possible to monitor the amplification reaction during the exponential phase where the 
first significant increase in the amount of PCR product correlates to the initial 
amount of target template (known as the crossing point). Real-time RT-PCR is 
considered a very suitable technique for validation of array results (Rajeevan et al., 
2001), and was utilised to support the expression profile obtained for four genes at 
each of the timepoints investigated in the cDNA array experiments. These genes only 
were chosen as they represent different expression patterns and can be taken as 
examples to demonstrate the reliability of array hybridisation. As shown in Table 
5.4., these genes showed similar expression patterns using real-time RT-PCR 
compared with the expression profiles obtained from array hybridisation 
experiments. The only exception being GADD153, for which real-time RT-PCR 
analysis was not possible due to inefficient Sybr Green I intercalation into the 
amplified product, resulting in apparent low levels of GADD153 target amplification. 
Inefficient Sybr Green I addition resulting in weak signals have been associated with 
amplicons of long length (Dorak, 2001), although the GADD153 product (473 bp) is 
not especially large relative to the product sizes of the other genes tested. In spite of 
the absence in GADD153 expression confirmation, the results of the differential array 
hybridisation can be considered reliable. 
The use of a cDNA filter array has provided a simple, relatively non-
expensive, and high-throughput approach to comparing differential expression of 
genes that are known to be involved in cancer following ceramide treatment in the 
ceramide-responsive myeloid cell line K562. From the results presented in this 
chapter, it may be deduced that ceramide signalling activates a highly complex, but 
coordinated, set of changes in gene expression. Furthermore, the overall pattern of 
changes in expression of the various gene families following ceramide treatment in 
K562 myeloid cells is indicative of cells undergoing growth and cell cycle arrest, 
induction of terminal differentiation, and evidence of death by apoptosis (as 
summarised in Table 5.3.). These results provide important information with regards 
to communication between genes involved in the ceramide-signalling pathway, and 
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provide a basis for which further confirmation work should be done. Subsequent 
follow-up investigations into the roles these differentially expressed genes are 
playing in ceramide-signalling pathway is well justified, and could potentially 
provide target genes for the successful treatment of leukaemia. 
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6. General Discussion 
It has become apparent that the regulation of normal development and tissue 
function is the result of mechanisms regulating cell division, differentiation and cell 
death. Proliferation, differentiation, and apoptosis are tightly regulated during 
haemopoiesis, allowing amplification along specific lineages while preventing 
excessive proliferation of immature cells. Inhibition of apoptosis, disruption of 
growth regulatory mechanisms, and the inability of non-functional clones of 
immature cells to differentiate into a mature phenotype are all characteristics of 
cancer, including leukaemia. Current treatment protocols aim to halt the growth of 
aggressively multiplying cells using non-selective cytotoxic drugs or radiation 
therapy. This approach is, however, associated with considerable toxicity (Mokyr & 
Dray, 1987, Pai & Nahata, 2000). Advances in the understanding of the biochemical 
events involved in cell growth regulation, differentiation and apoptosis may lead to 
the development of selective pharmacological interventions to improve the outcome 
in the treatment of leukaemia. Recently, significant attention has been directed 
towards a less toxic approach that targets cellular growth and differentiation 
pathways to alter the proliferative potential of cancer cells, while limiting 
cytotoxicity to healthy neighbouring cells, a strategy known as 'differentiation 
therapy' (Sachs, 1978, Fisher et al., 1985, Waxman, 1996, Leszczyniecka et al., 
2001, Spira & Carducci, 2003, Gomez-Vidal et al., 2004). The interest in 
differentiation therapy lies in the fact that differentiated tumour cells can be 
reprogrammed to result in the loss of proliferative capacity and induction of terminal 
differentiation into mature non-dividing cells (Sachs, 1978, Fisher et al., 1985, 
Waxman, 1996), which ultimately results in removal of these cells by apoptosis 
(Martin etal., 1990) as part of a normal haemostatic mechanism. 
The search for suitable differentiation-mediating drugs has come under 
intense investigation over the last decade. Many drugs have been trialled, but only a 
small number, including vitamin D3 and all-trans retinoic acid, have exhibited 
potential in the clinical setting to overcome maturation defects found in leukaemia 
cells. But even the use of these compounds has been associated with some clinical 
limitations, including associated toxicity (hypercalcaemia in vitamin D 3 -treated 
patients), disease relapse and fatality (Laubenthal et al., 1975, Castaigne et al., 1990, 
Chen et al., 1991, Glasser et al., 1994, Elstner et al., 1997, Fenaux & Debotton, 
1998, Nagpal et al., 2001, Mehta & Mehta, 2002). Consequently, only a minority of 
differentiation-inducing drugs are still in clinical use today. 
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The failure to utilise a number of these differentiation agents has meant the 
search for suitable alternatives has to be widened. New differentiation agents will 
inevitably arise from studies that gain a greater understanding of normal cellular 
processes linked to cellular maturation. One such pathway is the sphingomyelin (SM) 
pathway, which is an ubiquitous, evolutionarily conserved signalling system initiated 
by hydrolysis of the plasma membrane phospholipid sphingomyelin to generate the 
second messenger ceramide (Pena et al., 1997). Okazaki and colleagues (1989) first 
proposed that sphingolipids were biologically active after demonstrating Vitamin D3- 
induced turnover of SM in HL60 cells. Sphingolipids have now been shown to be a 
diverse class of molecules, that play an important role as second messengers within 
the cell (Kolesnick et al., 1994), producing a diverse range of stress-related cellular 
responses including cell cycle arrest, apoptosis, and cell senescence (Kolesnick and 
Golde, 1994, Hannun, 1996). The central component of the SM pathway, the second 
messenger ceramide, is highly pleiotropic in nature and is capable of instigating a 
range of anti-proliferative cellular responses including proliferation, differentiation, 
growth arrest and apoptosis (Mathias et al., 1998). The extent of such responses 
depends on the cell type and the initial stimuli presented to the external surface of the 
cell, and also the amount and location of ceramide generation (Perry & Hannun, 
1998). Multiple direct targets of ceramide have been identified, and include a proline-
directed ceramide-activated protein kinase (Mathias et al., 1991, Dressler et al., 
1992, Joseph et al., 1993), a serine/threonine ceramide-activated protein phosphatase 
(Dobrowsky & Hannun, 1992 & 1993, Dobrowsky et al., 1993, Hannun, 1996), 
members of the stress-response kinase cascade (SAPK/JNK) and components of the 
mitogen-activated protein kinase cascade (MAPK) (reviewed by Testi, 1996, Riboni 
et al., 1997 and Gomez-Munoz, 1998). Therefore, ceramide is a multi-functional 
molecule that does not have a single defined function within the cell. 
A greater understanding of the events that take place following ceramide 
treatment will be of therapeutic benefit in the treatment of neoplastic diseases such as 
leukaemia. By exposing the individual components of the SM pathway it is possible 
that novel therapeutic targets will be found. A synthetic ceramide, available as a cell 
permeable, biologically active analogue (C 2-ceramide), has been shown to effectively 
mimic the action of an extracellular stimulus (Levade & Jaffrezou, 1999). C2- 
ceramide provides an ideal model molecule for investigating ceramide-mediated 
effects in the laboratory setting. To evaluate the biological effects of ceramide in 
vitro, immortal human haemopoietic leukaemic cell lines, which are blocked at 
different stages of maturation, were utilised as a model for investigating biological 
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responses following ceramide treatment. They allow the study of a homogenous 
population of neoplastic cells (Koeffler, 1983), as well as providing a renewable 
source of material for characterisation of cell surface markers and receptors and 
mRNA for analysis of gene expression. 
To date, research into ceramide-induced responses has predominantly 
focussed on only a few human leukaemic cell lines, primarily HL60 (Okazaki et al., 
1989, Okazaki et al., 1990, Kim et al., 1991, Raines et al., 1993, Hannun, 1994), U-
937 (Obeid et al., 1993, Ragg et al., 1998) and MOLT-4 (Chao et al., 1992, Dbaibo 
et al., 1995, Pushkareva et al., 1995). A number of individual research papers have 
been published which investigate these responses in isolation, although a thorough 
study has not been undertaken. The results presented in this thesis provide the 
outcomes of the first comprehensive study to investigate whether responses to 
ceramide are consistent in both lymphoid and myeloid cell lineages. 
As shown in Chapter 3, the biological effects exhibited by all myeloid and 
lymphoid cell lines investigated (K562, KG-1, KG-la, HL60, Jurkat and Raji) 
following ceramide treatment were generally universal. Exposure to ceramide 
consistently resulted in activation of the Rb tumour suppressor protein, as determined 
by Western blotting. This was accompanied by a reduction in total cell numbers and 
G0/G 1 cell cycle arrest. An interesting result was shown for Jurkat T cells, which 
underwent rapid apoptosis before G 0/G 1 arrest could be demonstrated. These cells are 
fully differentiated along the T cell lineage, and exposure to ceramide forced them 
into terminal differentiation, the final outcome of this being cell death, thus 
supporting the proposal that the cellular response at the time of ceramide addition is 
highly dependant on the stage of differentiation of the treated cell population. 
Cell cycle arrest was accompanied by a degree of apoptosis in all cell lines 
examined, which was comparatively lower in cells showing greater G 0/G 1 phase 
accumulations in cell cycle studies, suggesting that apoptosis is occurring primarily 
in cells that are trapped in the G0/G 1 phase, hence lowering the apparent number of 
G0/G1 events by selective killing. It can be concluded that ceramide-induced Rb 
activation and cell cycle arrest are linked events and are key events in the repression 
of uncontrolled cellular growth. Of significance is the fact that this response occurred 
in a p53-independent manner, as the cell lines examined in this study lack a 
functional p53 gene. This demonstrates the ability of ceramide treatment to regain 
control of the cell cycle in the absence of genes that function to regulate progression 
through the cell cycle and subsequent proliferation in normal, healthy cell 
populations. Manipulation of this important regulatory mechanism will be beneficial 
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in future treatment of cancer, as the p.53 gene is recognised as the most commonly 
mutated tumour suppressor gene in human cancer (Nigro et al., 1989, Levine et al., 
1991, Hollstein etal., 1991 & 1994, Greenblatt etal., 1994). 
Interestingly, although the ceramide-mediated effects were consistent, the 
degree to which ceramide was able to elicit cellular responses varied between cell 
lines, thus reflecting the range of responses associated with the ceramide-signalling 
pathway. This further confirms that the final outcome of signals transmitted by 
ceramide could depend on the phase of the cell cycle in which signalling was 
initiated, the engagement of different downstream effectors in different cell types 
(Mathias et al., 1998), or the generation of ceramide metabolites that may enhance or 
antagonise ceramide-activated signalling mechanisms. 
Another common finding as a result of ceramide treatment was the induced 
expression of the cyclin-dependent kinase inhibitor gene p21 CiP "Wan , as demonstrated 
in Chapter 3 using RNase protection assays. It has been previously proposed 
(Steinman et al., 1994) that p53-independent pathways of p21 c1P liwan induction could 
represent alternative approaches to control aberrant proliferation resulting from a 
non-functional or absent p.53 gene. An increase in p2l ciP "Wafi expression was shown 
in all cell lines analysed, and is consistent with findings reported by other authors 
who have shown similar results in other cell lines (Ragg et al., 1998, Lee et al., 
2000). The upregulation in p2/aP wall expression was shown to be an immediate 
early response to ceramide signalling. Interestingly, the kinetics observed in the 
detection of p2/ ciPlman message paralleled that observed for accumulation of 
activated Rb following ceramide treatment. It would therefore appear that activation 
of the Rb tumour suppressor protein and upregulation of the CKI p2 YWafl are 
common mechanisms for ceramide-induced cell cycle arrest. 
Induction of myeloid haemopoietic differentiation was demonstrated by a 
general increase in the maturation markers CD1 lb and CD 14, and a decrease in 
glycophorin A in K562 cells and a decrease in CD34 in KG-1 and KG-la cells using 
immunophenotyping experiments. Investigation of differentiation was only 
assessable for the myeloid cell lines, as cells of this lineage possess cell-specific 
surface markers, which make this study possible. An increase in p21 ciP ilwail 
expression and the subsequent induction of cell differentiation is consistent with an 
alteration in the balance within the cell from being strongly proliferative to anti-
proliferative as a result of ceramide-signalling. Although immunophenotyping was 
not possible for investigation of ceramide-mediated lymphoid differentiation, an 
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increase in p21 a0I/Wan expression in the lymphoid cell lines studied indicates these 
cells are undergoing differentiation in response to ceramide treatment. 
Expression of p2/ ciP llwafi is considered to be conclusive evidence that cells 
are differentiating into a mature phenotype. Rots et al. (1999) have shown that 
vitamin D3-induced cell cycle arrest in myeloid cells always precedes differentiation, 
and involves the induction of p21 Cip1iWari. These findings identify p21aP "Wan as a 
candidate gene linking differentiation signals to G01G1 arrest and Rb 
hypophosphorylation in a number of cell lines. The upregulated expression of 
p21 CiP I/Wafi in response to ceramide-treatment in the current study indicates terminal 
differentiation induction, since p21 ciP 1iwan is considered to play a significant role in 
terminally differentiating cells such as muscle and in cells treated with differentiating 
agents to force them to become fully matured (Halevy et al., 1995, Parker et al., 
1995, Flink et al., 1998). Jiang et al. (1994) found a close relationship between 
induction of p2l ciP liwan and differentiation, as a delay in p21 CiP l/Wafi induction was 
observed in HL60 cells resistant to TPA induced growth arrest and differentiation. 
Taken together with the cell cycle analysis results, it can be concluded that 
ceramide-treated cells have a lowered proliferative capacity and consequently die of 
apoptosis, as a result of terminal differentiation. The significance of this can be 
appreciated from the findings that the presence of blastic leukaemic cells arises as a 
result of a blockage in a differentiating ability (Testa et al., 1993). The results 
presented in Chapter 3 of this thesis support the hypothesis that ceramide signalling 
halts the growth of proliferating leukaemic cells at the G0/G 1 phase of the cell cycle, 
and are forced past a differentiation blockage, resulting in a non-proliferative, 
terminally differentiated cell that undergoes apoptosis and subsequent removal from 
the population. 
To further characterise the SM pathway, the mechanism by which ceramide 
could mediate Rb activation was investigated. Two possible effector mechanisms for 
Rb activation have been postulated in the literature thus far; the inhibition of CDK 
complexes by CKIs such as p2 1 ciP uwan (Serrano et al., 1993, Kamb et al., 1994, 
Hirai et al., 1995, Harper et al., 1993, Harper et al., 1995, Toyoshima & Hunter, 
1994, Niculescu et al., 1998), and, the direct removal of phosphate groups from the 
Rb protein via activation of protein phosphatases (Alberts et al., 1993, Durfee et al., 
1993, Ludlow et al., 1993, Schonthal & Feramisco, 1993, Dou et al., 1995, Berndt et 
al., 1997, Nelson etal., 1997). 
From the results presented in Chapter 4 together with the results from the 
preceding chapter, it was determined that the primary mechanism for ceramide- 
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induced activation of Rb was via activation of protein phosphatases in the cell 
[presumably the ceramide-activated protein phosphatase (CAPP)], which is 
consistent with the findings published by Dou et al. (1995). Treatment with the 
protein phosphatase inhibitor Calyculin A totally eliminated the presence of 
dephosphorylated Rb resulting from ceramide treatment, even at the earliest 
timepoints analysed. The results from these protein-phosphatase inhibition 
experiments provide a clear link between ceramide-induced phosphatase activation 
and subsequent activation of the retinoblastoma protein, leading to cell cycle arrest. 
Ceramide-induced Rb activation was demonstrated in Chapter 3 to be a rapid 
and early event, and was shown to precede induction of p2] '-t' expression in all 
cell lines investigated. Rb activation via induction of p21 Wafl/Cipl expression would 
require transcriptional activation and subsequent translation of the p21 Cip I /Waft 
protein. Conversely, phosphatase-mediated Rb activation is transcription-
independent and would therefore occur much more rapidly than p21 waniciP l -mediated 
Rb activation, a notion that is consistent with the findings presented by Zeng & el-
Deiry (1996). Thus, the kinetics involved in ceramide-mediated Rb activation, and 
the demonstration that Calyculin A prevents ceramide-induced Rb activation 
suggests that ceramide-induced activation of Rb is primarily mediated via protein 
phosphatase activity and not by transcriptional activation of p2/ waivciPi . These 
results therefore imply that ceramide-induced expression of p21Wafl/Opl is, instead, 
most likely involved in the differentiation response noted by others (Jiang et al., 
1994, Liu et al., 1996a, Ragg et al., 1998). 
Although Calyculin A completely prevented ceramide-induced Rb activation, 
it did not prevent ceramide-induced myeloid differentiation. This would suggest that 
ceramide-induced cell cycle arrest (presumably via Rb activation) and ceramide-
induced differentiation occur by two independent but simultaneous pathways: the 
phosphatase-dependent activation of Rb and subsequent cell cycle arrest and the 
phosphatase-independent initiation of myeloid differentiation involving activation of 
p21 cIP"wan expression. The activation of Rb by protein phosphatase activity 
functions to halt the cell cycle, and transcriptional activation of p2I CIPI/Waf1  occurs 
later as part of the terminal differentiation response to lock the cells into a non-
proliferative state. Further elucidation as to the type/s of protein phosphatases 
activated by ceramide may present a novel target for directed therapy of leukaemia. 
RNase-protection assays provided a preliminary means for examining 
transcriptional activation of a variety of cell cycle regulatory and apoptosis-
associated genes. RPA experiments were conducted using the promyelocytic HL60 
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cell line treated with ceramide as the first link between ceramide and differentiation 
was first discovered using these cells (Okazaki et al., 1989, Okazaki et al., 1990, 
Kim et al., 1991) and provided an ideal model for subsequent genetic screening for 
investigations into ceramide-mediated growth regulation and differentiation. As 
demonstrated in Chapter 5, expression of p53 was not detected as HL60 cells lack a 
p53 gene (Wolf & Rotter, 1985). An upregulation of pilCipl/Wafl was demonstrated, 
which further confirms the findings presented in Chapter 3 and results published by 
other authors (Ragg et al., 1998, Lee et al., 2000), and supports the hypothesis that 
ceramide treatment results in the terminal differentiation of immature leukaemia cells 
(Steinman et al., 1994, Halevy et al., 1995, Liebermann et al., 1995, Parker et al., 
1995, Flink et al., 1998). An increase in both GADD45 and c-fos expression 
following ceramide treatment is consistent with cell cycle arrest (Balsalobre & 
Jolicoeur, 1995, Kobayashi et al., 1997, Okada et al., 1999) and also differentiation 
(Sawai etal., 1995) in HL60 cells. 
These experiments clearly identified that the ceramide-signalling pathway 
involves a complex pattern of changes in gene expression that were consistent with 
cell cycle arrest, differentiation and apoptosis, and justified the need for a large-scale 
study of the genes involved in ceramide signalling. A comprehensive screen of 1,176 
genes known to be involved in cancer was conducted on the ceramide-responsive 
erythromyeloid cell line, K562, using a commercially available cDNA filter array. 
The demonstrated downregulation in the cell cycle-regulated GI/S-specific 
cyclin D3, P38-2G4 and protein D123 genes following ceramide treatment illustrates 
that ceramide-treated K562 cells are undergoing cell cycle arrest, specifically at the 
Go/G1 phase of the cell cycle, which is consistent with the results shown in Chapter 3. 
Similarly, a downregulation in PCNA expression indicates an anti-proliferative 
response following ceramide treatment (Flores-Roses et al., 1994, Li et al., 1994, 
Waga et al., 1994), and is consistent with an increase in p21 CiPI/Wafl expression 
(Flores-Roses et al., 1994, Waga et al., 1994, Chen et al., 1995b, Luo et al., 1995, 
Warbrick et al., 1995, Zhou et al., 1998). The increase in mc/-/ expression is also 
strongly indicative of cells undergoing cell cycle arrest, differentiation and apoptosis 
(Kozopas et al., 1993). c-jun was shown to be upregulated, which is consistent with 
an increase in c-fos expression demonstrated in the HL-60 cells, as these 
transcription factors form the AP-1 complex, which is known to be involved in 
differentiation and apoptotic responses (Lord et al., 1993, Sawai et al., 1995, Pruschy 
et al., 1997). The downregulation in c-myc expression also demonstrates cell cycle 
arrest, as this gene is rapidly suppressed by p53 upon induction of growth arrest and 
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apoptosis (Guillouf et al., 1995) in normal, healthy cells. Furthermore, c-myc 
expression is known to be dramatically reduced during myeloid terminal 
differentiation in a variety of cell types (Collins, 1987, Larsson et al., 1988 & 1994, 
Liebermann & Hoffman-Liebermann, 1989, Gomez-Casares et al., 1993, Nguyen et 
al., 1995a, Lerga etal., 1999). 
cDNA array analysis also revealed some novel findings that are worthy of 
mentioning here, including the upregulation in expression of a protein phosphatase 
(hVH.5) other than the CAPP. Also, expression of genes whose products are known to 
be involved in forming and co-ordinating assembly of the components of the 
cytoskeleton of the cell (zyxin, plakoglobin, cytokeratin 8 and 18, vimentin and 
desmin) were upregulated following ceramide treatment. This is an indication of 
cellular stabilisation and demonstrates that changes are occurring in the mechanical 
properties of the cell. Features that support the hypothesis that ceramide can induce 
cell maturation and tumour suppression (Dellagi et al., 1983, Sadler et al., 1992, van 
der Ven et al., 1992, Macalma et al., 1996, Witcher et al., 1996, Beckerle, 1997). 
While an enormous amount of data was generated from the cDNA array 
analysis of ceramide-treated K562 cells, the results from these experiments can be 
summarised in the following general terms. Genes that are known to be involved in 
suppressing progression through the cell cycle and genes involved in the 
differentiation response were upregulated, while the expression of proliferation-
related genes were downregulated. These findings are consistent with the hypothesis 
that ceramide lowers the proliferative potential of leukaemic cells, and induces 
terminal differentiation of these cells into a mature phenotype. 
Supplementary investigation of the genes shown to be differentially expressed 
in this cDNA array analysis was outside the scope of the current study, but is to be 
examined as part of a future study for the purpose of further characterising the 
ceramide-signalling pathway. Results from the array experiments were extremely 
valuable in confirming • changes in genes involved in cell cycle arrest and 
differentiation, but also revealed unexpected changes in other novel genes. It is 
feasible to suggest that differentially expressed genes represent potential targets for 
defining cancer susceptibility to specific treatment protocols, for the development of 
new drugs for improved therapy, and for the development of genetic reagents for 
gene-based therapy (e.g. modulation of gene promoter activity) of cancer. 
Specifically, it may be possible to determine the responsiveness of a patient to a 
ceramide-related therapy by investigating the pattern of gene expression after 
treatment in vitro from a sample of circulating leukaemic cells. The identification of 
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sets of genes that change during differentiation therapy would create a molecular 
profile, and represents an important diagnostic tool. A high-density microarray 
containing a complete or relevant repertoire of genes, whose expression change as the 
cells revert to a more normal state by differentiation therapy with ceramide of a 
component of the SM pathway, could be used to define the effectiveness of such 
therapy and to monitor disease progression. 
With the use of cDNA expression arrays, it is possible to monitor the 
differential expression in human genes, allowing changes in expression to be 
detected as a function of cell type, tissue source, physiological state or genetic 
background. cDNA arrays could also serve as a rapid method for identifying changes 
in expression that accompany treatment of human cells with drugs, hormones, 
inhibitors, elicitors and a host of other molecules (Schena, 1996). Extensive patient 
screening with cDNA arrays may allow the identification of informative patterns in 
gene expression in subsets of human populations, and thus it may also be possible in 
the future that cDNA arrays will be utilised in the diagnosis of human disease. 
Although filter arrays are limited to the number of genes that can be 
investigated at any one time, this technology was considered novel at the time this 
study was performed, and provided an immense amount of useful data. More 
comprehensive arrays, which utilise similar methods to those used for filter array 
analysis, are now available for large-scale gene expression investigations, including 
glass slide microarrays and oligochip arrays. Glass slide microarray analysis of gene 
expression is a considerably more expensive method than nylon filter array analysis, 
and requires specialised equipment and software packages. Furthermore, multiple 
exposure times are possible with nylon filter arrays which utilise radioactive 
detection techniques such as that used for Atlas TM arrays for obtaining results for less 
abundant transcripts or preventing spot saturation. In general, applications utilising 
detection of radioactive sources also provide greater sensitivity over fluorescent-
based assays, and AtlasTM arrays use low complexity and high purity arrayed PCR 
amplified DNA as opposed to lysed bacterial colonies which is thought to further 
increase the sensitivity of these filters (Bowtell, 1999). 
Differentiation therapy relies on the fact that neoplastic cells display 
alterations in normal programs of differentiation and growth control that can be 
overcome by appropriate treatment (Leszczyniecka et al., 2001). For an agent to be 
successfully used in differentiation therapy it must possess certain fundamental 
qualities. It must be capable of tumour reprogramming by modifying the state of 
differentiation, leading to a concomitant loss in proliferative capacity of cancer cells 
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by apoptosis. Furthermore, as is the case with any therapeutic, it must be well 
tolerated, capable of being delivered via a suitable administration route, biologically 
available to the target cell population, and, ideally, its effects must be stable and 
prolonged. 
Two differentiation-mediating drugs have shown promise as differentiation 
agents. All-trans retinoic acid (ATRA) has the ability to reduce the proliferative 
activity of APL cells, and induce granulocytic differentiation and subsequent 
apoptosis of these neoplastic cells (Chen et al., 1991, Drach et al., 1994, Fenaux & 
Degos, 1996, Shiohara et al., 1999, Gianni et al., 2000, Hansen et al., 2000). ATRA 
continues to be used today in the clinical treatment of APL, and overcomes many 
side effects commonly seen with conventional therapies used in treating APL (Kawai 
et al., 1994). ATRA treatment is commonly used in combination with conventional 
chemotherapeutics (daunorubicin and araC) as the standard treatment for APL 
(Bruserud et al., 2000, Fenaux et al., 1999, Fenaux, 2000) as 
ATRA/daunorubicin/araC combined therapy results in significantly reduced relapse 
rates, and longer survival times compared with chemotherapy or ATRA alone 
(Fenaux, 2000). Restricting its use however, is the fact that it is only effective in cells 
displaying the t(15;17) chromosomal translocation, which encodes for the PML-RAR 
fusion promyelocytic leukaemia protein (Degos, 1992, Li et al., 1997), which can be 
overcome with supraphysiologic concentrations of ATRA (Grignani et al., 1998). 
Additionally, ATRA treatment is associated with a potentially fatal syndrome (ATRA 
syndrome) involving a significant increase in leukocyte count (Fenaux & De Botton, 
1998). 
Vitamin-D3 (1a,25-dihydroxyvitamin D 3), like ATRA, exhibits the 
fundamental features necessary for its use as a differentiation therapy. Koeffler and 
colleagues (1984) were first to publish findings that this agent was capable of 
inducing myeloid differentiation and mediate cell cycle arrest at the G0/G 1 , and 
possible the G2/M phases of the cell cycle. Clinical trials involving vitamin-D3 are 
still in their infancy, although its use appears to be severely hampered by its 
associated toxicity, namely hypercalcaemia, at a concentration required to suppress 
cancer cell proliferation (Laubenthal et al., 1975, Nagpal et al., 2001, Mehta & 
Mehta, 2002). 
The current study has demonstrated that ceramide also displays the 
fundamental qualities of a differentiation therapeutic, at least in the in vitro model. 
Treatment with the ceramide analogue, C 2-ceramide, results in a reduction in viable 
cell numbers, halts cellular proliferation via the induction of Go/G1 cell cycle arrest, 
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and initiates terminal differentiation in myeloid cells which is followed by cell death 
by apoptosis. What remains to be demonstrated is how circulating leukaemic cells 
respond to ceramide treatment in vivo. Being of lipid composition, it could be 
assumed that ceramide would be sufficiently available to, and easily taken up by, the 
target leukaemic cells. In fact, a study published by Venable et al. (1995) 
demonstrated that 16% of total radiolabelled ceramide is taken up by WI-38 
fibroblast cells within the first hour of treatment, 44% by 24 hours, and 63% of total 
ceramide is taken up by the cells by 48 hours. A point considerably worthy of 
mention is that all ceramide treatments performed in this study were conducted in 
serum-free culture conditions. Bielawska et al. (1992) have reported that serum 
attenuates the effect of ceramide in HL60 cells, resulting in a 10-fold increase in the 
IC50% due to the presence of lipid-binding proteins. As such, further investigations 
into the effect of ceramide uptake in the presence of serum are warranted to ascertain 
the validity, of administering ceramide in vivo. Although in vitro results are 
promising, limited data is available in the literature as to how well ceramide is 
tolerated in vivo, and to address this concern, and the concerns of administration 
route and the longevity of its effects in vivo, future experiments using an animal 
model are well justified. 
It must be considered that ceramide itself may not be a suitable therapeutic, 
for reasons including bioavailability and possible intolerance in vivo. This study has 
aimed to provide a greater understanding into the molecular mechanisms involved in 
the ceramide-signalling pathway, and has revealed a number of potential key 
molecules that are worthy of consideration for the target-directed therapy of 
leukaemia. Thus, it may be more feasible to target a component of this signalling 
pathway, than focus on ceramide itself as a differentiation therapeutic. Additionally, 
as is the case with ATRA and its combined use with araC and daunorubicin, it is 
important to consider that a novel therapy utilising one or more components of the 
ceramide-signalling pathway could be used in combination with conventional 
chemotherapeutics, perhaps as a means of sensitising neoplastic cells through 
induction of terminal differentiation to overcome their differentiation blockage. 
To further investigate the ability of ceramide to induce terminal 
differentiation, and in the search for potential new therapeutic targets, investigations 
into the expression of transcription factors (TFs) known to be differentially expressed 
in terminally differentiated cells are warranted. Examples include PU.1, GATA-1 & - 
2, SCL, and Id2. Expression of the Spi-11Spf-1 gene (PU.1) is required for terminal 
differentiation of myeloid cells (Chen et al., 1995c, Olson et al., 1995, Simon et al., 
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1996), but is not expressed in mature erythroid cells (Galson et al., 1993, Hromas et 
al., 1993). Similarly, 1d2 expression is markedly increased in terminally 
differentiated myeloid cells (Ishiguro et al., 1996). GATA-1, GATA-2, and SCL 
expression is high in totipotent precursor cells before they undergo commitment and 
remains high as cells mature towards the erythroid lineage, and is specifically 
repressed during differentiation to the monocytic lineage (Green et al., 1991, 
Mouthon et al., 1993, Shimamoto et al., 1994, Murrell & Green, 1995, Shimamoto et 
al., 1995). Thus, it is proposed that examination of these TFs during ceramide 
treatment of myeloid cells would confirm induction of terminal differentiation by 
ceramide, and would be useful in confirming the lineage-specific differentiation of 
K562 cells. 
In summary, the results presented in this thesis demonstrate that the 
sphingomyelin-signalling pathway plays a fundamental role in regulating cell growth, 
differentiation and death. The central component of this signalling pathway, 
ceramide, is capable of activating cellular regulatory elements in a p53-independent 
manner, which is of particular interest, as p53 is the most disrupted gene in cancer 
(Nigro et al., 1989, Levine et al., 1991, Hollstein et al., 1991 & 1994, Greenblatt et 
al., 1994). The ability to change aggressively growing leukaemic cells into mature, 
less proliferative cells that then die by programmed cell death are the fundamental 
attributes of a potential candidate for use as a differentiation therapeutic. It is 
therefore proposed that components of this ubiquitous, highly conserved signalling 
pathway, or its downstream effectors, may be manipulated for the purpose of 
inducing terminal differentiation in abnormally proliferating cell populations, and 
thus potentially becoming a novel therapy in the treatment of leukaemia. 
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Appendix A 
Annexin V-FITC/propidium iodide (Armexin V/PI) analysis to confirm C 2-ceramide-induced 
apoptosis in Jurkat T lymphocytic cells at 2 and 8 hours post-treatment with 5 uM C2 — 
ceramide. The live (Annexin V-/ PI-), apoptotic (Annexin V+/PI-) and dead (Annexin 
V+/PI+) populations can be readily identified. Taken from Hearps et al., 2000. 
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Real-time RT-PCR melting curves generated using the LightCycler software package (Roche 
Diagnostics, Germany) for the PRAME (preferentially expressed antigen of melanoma) 
primer set at 2, 8 and 24 hours post-treatment with vehicle or 5 uM C2-ceramide, to 
demonstrate the specificity and Tm of the primer set. 
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Real-time RT-PCR amplification curves generated using the LightCycler software package 
(Roche Diagnostics, Germany) for the PRAME (preferentially expressed antigen of 
melanoma) primer set at 2 hours (A), 8 hours (B) and 24 hours (C) post-treatment with 
vehicle or 5 viM C 2-ceramide, using the same RNA as that used in the cDNA array 
experiments with K562 erythromyeloid cells. 
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Real-time RT-PCR melting curves generated using the LightCycler software package (Roche 
Diagnostics, Germany) for the PCNA (proliferating cell/cyclic nuclear antigen) primer set at 
2, 8 and 24 hours post-treatment with vehicle or 5 nN4 C 2-ceramide, to demonstrate the 
specificity and Tm of the primer set. 
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Real-time RT-PCR amplification curves generated using the LightCycler software package 
(Roche Diagnostics, Germany) for the PCNA (proliferating cell/cyclic nuclear antigen) 
primer set at 2 hours (A), 8 hours (B) and 24 hours (C) post-treatment with vehicle or 5 1.1M 
C2-ceramide, using the same RNA as that used in the cDNA array experiments with K562 
erythromyeloid cells. 
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Real-time RT-PCR melting curves generated using the LightCycler software package (Roche 
Diagnostics, Germany) for the MIC1 (macrophage inhibitory cytokine 1) primer set at 2, 8 
and 24 hours post-treatment with vehicle or 5 1..1M C 2-ceramide, to demonstrate the 
specificity and Tm of the primer set. 
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Real-time RT-PCR amplification curves generated using the LightCycler software package 
(Roche Diagnostics, Germany) for the MIC 1 (macrophage inhibitory cytolcine 1) primer set 
at 2 hours (A), 8 hours (B) and 24 hours (C) post-treatment with vehicle or 5 IAM C2- 
ceramide, using the same RNA as that used in the cDNA array experiments with K562 
erytluomyeloid cells. 
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Real-time RT-PCR melting curves generated using the LightCycler software package (Roche 
Diagnostics, Germany) for the GADD153 (growth arrest & DNA-damage-inducible protein 
153) primer set at 2, 8 and 24 hours post-treatment with vehicle or 5 11M C 2-ceramide, to 
demonstrate the specificity and Tm of the primer set. 
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Real-time RT-PCR amplification curves generated using the LightCycler software package 
(Roche Diagnostics, Germany) for the GADD153 (growth arrest & DNA-damage-inducible 
protein 153) primer set at 2 hours (A), 8 hours (B) and 24 hours (C) post-treatment with 
vehicle or 5 IAM C2-ceramide, using the same RNA as that used in the cDNA array 
experiments with K562 erythromyeloid cells. 
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Table of real-time RT-PCR array confirmation data for PRAME, PCNA, MIC I and 
GADD153 using K562 RNA used in the cDNA array analysis experiments. GAPDH was co-
amplified at each individual timepoint for normalisation purposes. All data presented in the 
table was obtained by Sandrine Chopin in our laboratory. 
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Gene Timepoint Crossing 
Point 
Calculated 
Conc. (ng) 
Normalised Fold 
Change 
(relative to GAPDH) 
FRAME Vehicle 2hr (GAPDH Vehicle 2hr) 
16.82 
(19.09) 
5.896 X 10-2 
(7.049 X 10 -3) 0.53 
C2-ceramide 2hr 
(GAPDH C2-ceramide 2hr) 
16.29 
(17.36) 
4.963 X 10-2 
(1.115 X 10 -2) 
Vehicle 8hr 
(GAPDH Vehicle 8hr) 
16.92 
(18.26) 
1.293 X 10 -2 
(5.827 X 10 -3 ) 2.78 
C2-ceramide 8hr 
(GAPDH C2-ceramide 8hr) 
17.31 
(18.07) 
1.270 X 10 -2 
(2.057 X 10 -3 ) 
Vehicle 24hr 
(GAPDH Vehicle 24hr) 
17.06 
(17.97) 
2.351 X 10 -2 
(2.165 X 10 -3) 3.24 
._ 
C2-cerarnide 24hr 
(GAPDH C2-ceramide 24hr) 
16.53 
(22.89) 
4.055 X 10 -2 
(1.149 X 1013) 
PCNA Vehicle 2hr (GAPDH Vehicle 2hr) 
18.54 
(16.85) 
1.528 X 10 -3 
(4.077 X 10-3) 0.31 
C2-ceramide 2hr 
(GAPDH C2-ceramide 2hr) 
18.51 
(14.78) 
1.556 X 10 -3 
(1.350 X 10 -2) 
Vehicle 8hr 
(GAPDH Vehicle 8hr) 
19.28 
(17.73) 
9.956 X 104 
(2.439 X 10 -3 ) 0.65 C2-ceramide 8hr 
(GAPDH C2-ceramide 8hr) 
18.85 
(16.56) 
4.826 X 10-3 
(9.956 X 10 -3) 
Vehicle 24hr 
(GAPDH Vehicle 24hr) 
19.76 
(17.65) 
7.501 X 104 
(2.557 X 10 -3) 0.83 C2-ceramide 24hr 
(GAPDH C2-ceramide 24hr) 
20.30 
(17.86) 
5.492 X 104 
(2.259 X 10 -3) 
MIC1 Vehicle 2hr (GAPDH Vehicle 2hr) 
30.63 
(21.34) 
7.162 X 10-6 
(1.047 X 10-3) 0.77 
C2-ceramide 2hr 
(GAPDH C2-ceramide 2hr) 
30.80 
(21.00) 
6.551 X 10-6 
(1.258 X 10-3) 
Vehicle 8hr 
(GAPDH Vehicle 8hr) 
30.86 
(20.28) 
6.319 X 10-6 
(1.845 X 10) 0.44 C2-ceramide 8hr 
(GAPDH C2-ceramide 8hr) 
33.30 
(21.28) 
1.714 X 10 -6 
(1.081 X 10-3) 
Vehicle 24hr 
(GAPDH Vehicle 24hr) 
30.83 
(22.04) 
6.443 X 10-6 
(7.191 X 104) 2.90 C2-ceramide 24hr 
(GAPDH C2-ceramide 24hr) 
30.12 
(23.30) 
9.420 X 10-6 
(3.649 X 104) 
GADD153 Vehicle 2hr (GAPDH Vehicle 2hr) 
NR 
(6.93) 
NR 
(1.465 X 104) NR 
C2-ceramide 2hr 
(GAPDH C2-ceramide 2hr) 
37.98 
(9.50) 
1.719 X 10-9 
(3.230 X 10-2) 
Vehicle 8hr 
(GAPDH Vehicle 8hr) 
40.47 
(7.57) 
3.967 X 1046 
(1.003 X 104 ) (10.78) C2-ceramide 8hr 
(GAPDH C2-ceramide 8hr) 
37.30 
(8.44) 
2.566 X 10-9 
(6.017 X 10 -2) 
Vehicle 24hr 
(GAPDH Vehicle 24hr) 
NR 
(18.50) 
NR 
(1.672 X 10) NR C2-ceramide 24hr 
(GAPDH C2-ceramide 24hr) 
5.424 
(5.424) 
3.551 X 10-1 
(3.551 X 104 ) 
N.R. = No result obtained (unable to determine fold change). 
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Real-time RT-PCR amplification curves generated using the LightCycler software package 
(Roche Diagnostics, Germany) for the GAPDH primer set using a range of GAPDH RNA 
template concentrations for generation of a standard curve for determining relative 
concentrations of the confirmatory genes. 
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Background: Leukaemia cells differ from their normal 
counterparts in that their ability to properly regulate sur-
vival, proliferation, differentiation, and apoptosis is aber-
rant. Understanding the molecular mechanisms control-
ling cell proliferation and developing therapeutic 
strategies to correct nonfunctional regulatory mechanisms 
are emerging areas of medical research. Ceramide, a me-
tabolite of membrane sphingomyelin hydrolysis, has re-
cently emerged as a key regulator of cellular proliferation, 
differentiation, and apoptosis in leukaemia cells. 
Methods: Leukaemia cell lines were treated with a bio-
logically active analogue of ceramide, C 2-ceramide. Cell 
cycle status was assessed flow cytometrically using pro-
pidium iodide. Induction of apoptosis was confirmed by 
annexin V staining of externalised phosphatidylserine and 
retinoblastoma activation was determined by Western 
blotting. 
Results: C2-ceramide induced activation of retinoblas-
toma tumour suppressor protein, Go/G, cell cycle arrest, 
or apoptosis in leukaemia cell lines. In addition, these 
effects differed depending upon cell type, thus confirming 
the pleiotropic nature of the ceramide signalling pathway. 
Most cells studied responded to exogenous C 2-ceramide 
by entering growth arrest, evidently resulting from activa-
tion of retinoblastoma protein, and by displaying some 
degree of apoptosis. 
Conclusions: Taken together, these findings suggest that 
signalling via ceramide has novel therapeutic applications 
for treatment of leukaemia. Cytometry 43:164 -169, 
2001. © 2001 Wiley-Liss, Inc. 
Key terms: ceramide; retinoblastoma; cell cycle arrest; 
apoptosis; leukaemia 
Defects in cell cycle regulatory mechanisms can re-
sult in uncontrolled proliferation and, when this occurs 
in haematopoietic cells, cancers such as leukaemia or 
lymphoma may arise. Halting the growth of aggressively 
multiplying leukaemic cells is the primary aim of ther-
apies designed to treat this cancer, and most treatment 
protocols achieve this by killing the leukaemic cells 
through the use of cytotoxic drugs or by radiation 
therapy. Another, as yet underused approach to halting 
the growth of leukaemic cells is to promote their de-
velopment into a more mature cell type that does not 
divide, a process called differentiation therapy (1). The 
interest in differentiation therapy lies in the fact that 
the differentiated cells lose their proliferative capacity; 
hence, the abnormal growth of leukaemic cells can be 
inhibited by inducing them to develop into mature 
nondividing cells. 
In recent years, the sphingomyelin pathway has 
emerged as an important regulator of cellular growth 
control mechanisms (2). The sphingomyelin pathway is a 
ubiquitous, evolutionary conserved signalling system that 
is initiated by hydrolysis of the plasma membrane sphin-
golipid, sphingomyelin, to generate the second messenger 
ceramide. As such, the sphingomyelin pathway is analo-
gous to conventional signalling systems such as cyclic 
AMP and phosphoinositide pathways. Sphingomyelin hy-
drolysis results from action of acidic or neutral sphingo-
myelinase isoforms (3), or ceramide can be generated de 
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novo by ceramide synthase (4). Multiple direct targets of 
ceramide have been identified, including a proline-di-
rected ceramide-activated protein kinase (5), a serine/ 
threonine ceramide-activated protein phosphatase (CAPP) 
(6), protein kinase Ct (7), and the proto-oncogenes Vav 
(8) and c-Raf-1 (9). In addition, ceramide interacts with 
several signalling cascades including mitogen-associated 
protein kinase, JNK, caspase and mitochondrial signalling 
systems (reviewed in 10). 
Ceramide is pleiotropic in its effects and, depending 
upon the cell type, can modulate differentiation, growth 
arrest, proliferation, and apoptosis. This diversity of re-
sponse is most probably a result of ceramide engaging 
different downstream effectors depending upon the cel-
lular microenvironment, the phase of the cell cycle, and 
the magnitude of ceramide generation and its source (10). 
In a recent study we demonstrated that ceramide caused 
terminal differentiation of the U937 monoblastic leukae-
mia cells that was characterised by cell cycle arrest and 
activation of the retinoblastoma nuclear tumour suppres-
sor phosphoprotein (Rb). We postulated that this induc-
tion of tumour suppressor genes could be exploited for 
therapeutic purposes (11). This present study further in-
vestigates the therapeutic potential of ceramide by inves-
tigating whether cell cycle arrest and Rb tumour suppres-
sor protein activation are common features of ceramide-
induced growth arrest of human haematopoietic cell lines. 
MATERIALS AND METHODS 
Reagents 
The synthetic, cell-permeable ceramide analogue C 2- 
ceramide was purchased from BioMol Research Laborato-
ries (Plymouth Meeting, PA, USA), dissolved in absolute 
ethanol, and stored at —80°C. 
Cell Lines and Culture Conditions 
The human leukaemia cells used in this study were from 
the monocytic 1J937, KG1, KG1a, promyelocytic HL-60, 
erythromyelocytic K562, and lymphocytic Jurkat and Raji 
cell lines. All cells were maintained at a density of 1-10 X 
105 cells/ml, except KG1 cells, which were maintained at 
2-20 X 105 cells/ml. Cells were cultured in RPMI-1640 
medium ORH Biosciences, Lenexa, KS, USA), supple-
mented with 2 mM L-glutamine ORH Biosciences), 5-10% 
fetal bovine serum (CSL Limited, Parkville, Victoria, Aus-
tralia), and 100 U/ml gentamicin (Pharmacia & Upjohn, 
Perth, WA, Australia) and incubated at 37°C in a humidi-
fied atmosphere of 5% CO2 . 
Experiments were conducted using exponentially 
growing cells in serum-free medium, except experiments 
using HL-60 cell lines, which were conducted using RPMI 
+2% foetal bovine serum and Raji cells treated in X-Vivo 
serum-free medium (Biowhittaker, Wallcersville, MD, 
USA). Before treatment, cells were washed in phosphate 
buffered saline (PBS) and resuspended at 5 X 10 5 cells/ml 
in medium, and incubated in serum-free medium for an-
other 2 h before the addition of C 2-ceramide. Cells were 
treated with the following concentrations of C2-ceramide:  
5.0 p,M: U937, K562, and Jurkat; 7.5 p,M: HL-60; 20 AM: 
KG1, KG1a, and Raji. These doses of C 2-ceramide were 
selected for each cell line based upon maximal growth 
arrest and minimising the apoptosis observed at higher 
concentrations. 
Cell Cycle Analysis 
Cells (1 X 106) were harvested by centrifugation, resus-
pended in hypotonic propidium iodide (PI) solution 
(0.1%[w/v] sodium citrate, 0.1% [v/v] Triton X-100, 0.05 
mg/ml PD, and left overnight at 4°C in the dark (11,12). 
Because the coefficients of variation were unsatisfactory 
with the method described in the previous section, Raji 
cells were washed with PBS, fixed with 70% ethanol/PBS, 
and treated with RNase before staining with PI. Cell cycle 
data were acquired using a FACScan flow cytometer (Bec-
ton-Dickinson, Sunnyvale, CA, USA) and subsequent cell 
cycle analysis was performed using ModFit software (Bec-
ton-Dickinson) to model the linear red fluorescence signal 
area. Apoptosis was identified as a sub-Go/G, peak and 
confirmed in separate experiments by annexin V staining 
of exposed phosphatidylserine groups (Annexin V-FITC 
Apoptosis Detection Kit, BD Pharmingen, San Diego, CA, 
USA). Aggregates were excluded from the cell cycle anal-
ysis by use of the doublet discrimination module and 
subsequent gating on the linear red fluorescence area and 
width parameters. 
Western Blot Analysis of Rb 
Phosphorylation Status 
Cellular protein extracts were prepared from 2 X 106 
harvested cells by lysis of the pelleted cells in 50-100 p,1 
freshly prepared lysis buffer (25 mM Tris [pH 7.4], 50 rnM 
NaC1, 50 mM NaF, 0.5% sodium deoxycholate, 2% Nonidet 
P40, 0.2% sodium dodecyl sulphate [SDS], Complete pro-
tease inhibitor [Roche Diagnostics, Mannheim, Germany]) 
and cleared by centrifugation at 18,000g for 15 min at 4°C. 
Lysates were prepared for gel electrophoresis by boiling 
for 7 min in an equal volume of 2X Laemelli sample buffer 
(0.125 M Tris-HCL [pH 6.8], 20% [v/v] glycerol, 4% SDS, 
0.005% bromophenol blue, 5% [v/v] 2-mercaptoethanol). 
Samples (30 AO were loaded onto a 6.5% SDS-polyacryl-
amide gel and proteins were separated by electrophoresis. 
Proteins were transferred to Immun-Blot polyvinyldifluo-
ride membrane (Bio-Rad Laboratories, Hercules, CA, USA), 
and the membrane was blocked for 1 h at room temper-
ature in 5% skim milk in PBST (PBS + 0.1% TWeen 20), 
washed 3 X in PBST, and incubated overnight at 4°C with 
0.5 jig/m1 anti-Rb- goat antibody (Santa Cruz Biotechnol-
ogy, Inc., Santa Cruz, CA, USA) in PBST. The blots were 
washed 3X in PBST and incubated for 2 h at room tem-
perature in 0.2 jig/m1 anti-goat- horseradish peroxidase 
antibody (Santa Cruz Biotechnology, Inc.), followed by 
another three washes in PBST. Detection of Rb was per-
formed using Enhanced Chemiluminescence and Hyper-
film (Amersham Life Science, Buckinghamshire, UK). 
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FIG. I. DNA histograms (propidium iodide, FL2 area) demonstrating 
Cz-ceramide-induced cell cycle arrest in K562 erythroleukaemia cells, 
Raji B cells, HL-60 myeloid cells, U937 myeloid cells, KG1 myeloid cells, 
and apoptosis in Jurkat T cells. All histograms represent samples taken 
24 h after C2-ceramide treatment. Single representative results from at 
least four repeat experiments are shown. 
RESULTS 
Induction of Cell Cycle Arrest by C 2-Ceramide 
A variety of haematopoeitic cell lines were examined to 
determine whether C 2-ceramide treatment consistently re-
sulted in withdrawal from the cell cycle. Asynchronous 
cultures of logarithmically growing cells were treated and 
harvested at various times for cell cycle analysis. Cell cycle 
arrest was determined by examining for an increased 
proportion of events in Go/G, and a concurrent decrease 
in the proportion of events in S phase when compared 
with time-matched, vehicle-treated controls. This is indic-
ative of an inability to cross the G 1 -stransition that is a 
hallmark of cell cycle arrest. Figure 1 shows DNA histo- 
Control 
	
C2-CeramIde 
Annexin V - FITC 
FIG. 2. Confirmation of the rapid onset of apoptosis in Ceceramide-
treated Jurkat T cells by demonstration of externalised phosphatidylserine 
residues. Apoptotic (annexin+/propidium iodide—), dead (annexin+/ 
propidium iodide +), and live (annexin—/propiodium iodide—) popula-
tions are readily identified. A single representative result from four repeat 
experiments is shown. 
grams depicting the results obtained for cell lines K562, 
Raji, HL-60, U937, KGI, and Jurkat after 24 h of treatment 
with C2-ceramide. Th K562, Raji, HL-60, and U937 cells 
showed evidence of substantial cell cycle arrest (increased 
Go/G,/decreased S phase), whereas KG1, Jurkat, and 
KGla (not shown) cells exhibited slight to negligible cell 
cycle arrest. Interestingly, although Jurkat cells did not 
undergo evident cell cycle arrest, their histograms indi-
cated the presence of large amounts of broken DNA and 
debris indicative of apoptosis. Apoptosis of Jurkat cells 
was confirmed by annexin V-fluorescein isothiocya-
nate/PI staining (Fig. 2) and was evident as early as 2 h 
after adding ceramide. This apoptosis and associated DNA 
degradation were well advanced by 24 h, accounting for 
the left shift of the Jurkat sub-Go/G, apoptotic peak in 
Figure 1. Many cell lines that entered cell cycle arrest in 
response to C2-ceramide also exhibited slight to moderate 
levels of apoptosis as determined by a similar sub-Go/G, 
apoptotic peak. 
Activation of Rb Tumour Suppressor Nuclear 
Phosphoprotein by C2-Ceramide 
Rb is a 110-kDa nuclear phosphoprotein that is consid-
ered to be a tumour suppressor because loss or inactiva-
tion of both copies of the RBI gene results in unrestrained 
malignant growth (13). Hypophosphorylated Rb is the 
active form, and dephosphorylation of the Rb protein has 
been associated with growth arrest, the G o/G, phase of 
the cell cycle, and the differentiated phenotype of haema-
topoietic cells (14-16). To obtain further insight into the 
mechanism of C2-ceramide-induced growth and cell cycle 
arrest, the phosphorylation status of the Rb protein was 
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FIG. 3. Western blot analysis of retinoblastoma phosphorylation status 
after C2-ceramide treatment of K562 erythroleukaemia cells, Raji B cells, 
I1I,60 myeloid cells, Jurlcat T cells, KG!, and KGla myeloid cells. Single 
representative results from at least four repeat experiments are shown. 
determined by taking advantage of the fact that SDS-
polyacylamide gel electrophoresis and Western blotting 
can resolve the faster migrating hypophosphorylated 
forms of Rb from the slower migrating hyperphosphory-
lated forms. Cells were treated with C 2-ceramide and har-
vested at different times, and lysates were subjected to 
SDS-polyacylamide gel electrophoresis and Western blot-
ting (Fig. 3). In vehicle-treated samples, a band of A4,. 
110 kDa, representing inactive hyperphosphorylated Rb 
(Rbhwer), was observed. However, in K562, Raji, 111-60, 
Jurkat, KG!, and KG 1 a cells treated with C 2-ceramide, 
additional, faster migrating bands of M,. — 105 kDa were 
noted as soon as 4 h posttreatment. The lower 114 r  band 
represented the appearance of hypophosphorylated (ac-
tive) forms of Rb (Rbhm"), thus demonstrating that C2- 
ceramide induced Rb activation. Logarithmic growing, 
untreated Raji cells exhibited a slightly different Rb pat-
tern from other cells in that two hyperphosphorylated 
bands were observed; after ceramide exposure, an addi-
tional lower M,. band, representing hypophosphorylated 
Rb, was apparent. In KG1 and KG1 a cell lines, it was not 
possible to detect Rb in 24-h post-C 2-ceramide samples, 
presumably due to the loss of cells to apoptosis; however, 
activated Rb was clearly demonstrated in earlier points. 
Interestingly, Jurkat T cells exhibited a Rb hYP° band only at 
24 h posttreatment. 
DISCUSSION 
We investigated cell cycle arrest and Rb nuclear tumour 
suppressor phosphoprotein activation in haematopoietic 
cell lines treated with the synthetic lipid analogue C 2- 
ceramide. Rb activation was a common feature of all 
ceramide-responsive cell lines, and this was accompanied 
by G, cell cycle arrest or apoptosis. These findings also 
suggested that modulation of the sphingomyelin pathway 
and the resultant inactivation of cellular proliferation can 
be exploited for therapeutic purposes in cancer. 
The majority of haematopoietic cells tested exhibited 
G, cell cycle arrest, with the degree of arrest varying 
between cell lines. Similar growth arrest after exposure of 
cell lines to synthetic ceramide analogues has been re-
ported (11,17,18), some of which have been confirmed in 
the present study. The degree of apparent responsiveness 
to ceramide-induced cell cycle arrest may reflect the pleio-
tropic nature of responses associated with this signalling 
pathway. The final outcome of signals transmitted by 
ceramide could depend on the phase of the cell cycle in 
which signalling was initiated, the engagement of differ-
ent downstream effectors in different cell types (10), or 
the generation of ceramide metabolites that may enhance 
or antagonise ceratnide-activated signalling mechanisms 
(19). With the exception of Jurkat  T cells, which under-
went apoptosis before any G, arrest could be noted, this 
study showed that induction of cell cycle arrest in leukae-
mic cells is a consistent outcome of ceramide signalling. 
C2 ceramide-induced cell cycle arrest was usually ac-
companied by a degree of apoptosis, the extent of which 
differed between cell lines and with dosage. Cells lines 
that had comparatively lower or minimal apoptosis gen-
erally showed greater G, phase accumulations in cell 
cycle studies. This observation may indicate that the apo-
ptosis is occurring primarily in cells that are trapped in the 
G, phase, hence lowering the apparent number of G, 
events by selective killing. If this is the case, then the 
proportion of cells that have undergone cell cycle arrest in 
response to Crceramide will have been underestimated in 
this study. This possibility is supported by the finding that 
C6-ceramide-induced apoptosis occurred primarily in the 
G ,/S phases of human neuroepithelioma cells (20). Other 
studies have reported similar selective apoptosis of G 1 - 
arrested cells after drug treatment  or activation (21-24). 
There is presently great controversy as to the role, if any, 
of ceramide in directly initiating apoptosis because of the 
lack of data demonstrating a direct link between the ef-
fectors of ceramide and the primary components of the 
apoptotic machinery (caspases and BcI-2 family mem-
bers). Although these direct links remain to be estab-
lished, studies on the kinetics of ceramide formation 
(25,26) and modulation of ceramide levels using synthetic 
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analogues have provided supporting evidence of a close 
relationship between ceramide and apoptosis. 
Rb has a well-documented role in regulating the cell 
cycle at the G 1 -S phase transition (27), with its activity 
regulated by phosphorylation state, the hypophosphory-
lated form being active. Rb activation was the common 
feature of C2-ceramide responsive cells in this study, indi-
cating that Rb may be a key target or effector of ceramide 
signalling. Other studies have similarly reported Rb acti-
vation after addition of synthetic ceramide analogues 
(11,18,28), and the present studies strengthen and extend 
these findings. Rb activation was an early event after 
ceramide treatment and most likely was the effector of the 
observed C2 ceramide-induced G, cell cycle arrest. The 
fact that Rb was activated by dephosphorylation makes it 
a likely candidate for a target of ceramide signalling be-
cause CAPP, a type 2A protein phosphatase (6), is one of 
the few recognised effectors of the sphingomyelin path-
way. Rb has been well documented as a substrate for 
phosphatases, and its activity can be modulated by these 
enzymes (28). Rb activity can also be affected by a family 
of cell cycle regulatory proteins termed cyclin-dependent 
kinase inhibitors (CKIs) (27). Rb is maintained in the 
phosphorylated state by the actions of cyclin-dependent 
kinases that in turn are negatively regulated by CKIs. We 
recently demonstrated that cell cycle arrest and Rb acti-
vation in C 2 ceramide-treated U937 cells was associated 
with the rapid induction of expression of p2 1 cm' (11), a 
CKI with a key role in mediating cell cycle arrest during 
differentiation (29) and whose expression has been asso-
ciated with Rb dephosphorylation and growth arrest of 
leukaemia cells in response to differentiation-inducing 
agents (30,31). Future studies will concentrate on defining 
the roles of phosphatase activity and CM expression in 
activating Rb after ceramide treatment. 
The ability of ceramide to promote differentiation and 
maturation of different cell types is often overlooked be-
cause of the recent intense scrutiny upon its role in apo-
ptotic signal transduction. Signals transduced by ceramide 
may in fact be maturation/differentiation in nature rather 
than directly apoptotic, and this notion has been sup-
ported by several lines of investigation including the find-
ings that synthetic ceramides induce morphologic 
changes characteristic of maturation and terminal differ-
entiation in HL-60 (32), U937 (11), K562 (unpublished 
observations), and T9 glioma cells (33). The recent finding 
that Crceramide induces expression of the CKI p2 laPi is 
further evidence (1 1), as expression of this protein has a 
well-characterised role in mediating cell cycle arrest dur-
ing terminal differentiation (29,34). In haematopoietic 
cells, terminal differentiation culminates in apoptosis and 
removal from the circulatory pool. A failure to maintain 
the balance between cytogenesis in the bone marrow and 
peripheral terminal differentiation results in a disease state 
such as leukaemia or lymphoma. Delivery of a differenti-
ation signal by ceramide at an inappropriate stage of the 
cell cycle or in conflict with an existing proliferative signal 
may result in apoptosis being initiated. If cellular differen-
tiation is blocked at a proliferative stage, then blastic  
leukemia may eventuate (35), and we are currently exam-
ining the hypothesis that ceramide signalling can push 
leulcaemic cells past this blockade, resulting in a nonpro-
liferative phenotype or a terminally differentiated cell that 
undergoes normal apoptosis. 
The common outcome from treatment of leukaemic cell 
lines with synthetic ceramide analogues is growth arrest 
or apoptosis. Both processes result in a reduction in the 
number of aggressively proliferating cancer cells, which is 
the primary aim of cancer therapies. Ceramide has already 
been shown to induce apoptosis in vitro in non-dividing B 
chronic lymphocytic leukemic cells (36), highlighting the 
potential of ceramide as a novel treatment strategy. How-
ever, further investigations into the molecular basis of cell 
growth mechanisms controlled by the sphingomyelin 
pathway and their manipulation for therapeutic purposes 
are warranted. 
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Mitochondrial cytochrome c release precedes 
transmembrane depolarisation and caspase-3 
activation during ceramide-induced apoptosis 
of Jurkat T cells 
A. C. Hearps, J. Burrows, C. E. Connor, G. M. Woods, R. M. Lowenthal and S. J. Ragg 
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Whilst the role of ceramide, a second messenger of the 
sphingolipid family, in the Initiation of receptor-mediated 
apoptosis Is controversial, a growing body of evidence 
is emerging for a role of ceramide In the amplification 
of apoptosis via mitochondrial perturbations that culmi-
nate in the activation of execution caspases. Treatment 
of Jurkat T cells with the cell-permeable analog, C2- 
ceramide, resulted in the rapid onset of apoptosis as 
evidenced by Annexin V-FITC staining of externalised 
phosphatidylserine residues. Cells bearing this early 
apoptotic marker had a reduced mitochondrial trans-
membrane potential (6.11m) that was preceded by the 
release of cytochrome c from mitochondria. Subsequent 
activation of caspase-3 provides the link between these 
ceramide-induced mitochondrial changes and execution 
caspases that ultimately result in the physical destruction 
of the cell. Collectively these results demonstrate that 
ceramide signalling results In caspase-mediated apopto-
sis via mitochondrial cytochrome c release and are further 
supportive of the role of ceramide in the amplification of 
apoptosis. 
Keywords: apoptosis; caspase-3; ceramide; cytochrome c; 
mitochondrial transmembrane depolarisation. 
Introduction 
Apoptosis is an evolutionary conserved mechanism of pro- 
grammed cell death that has a critical role in the main- 
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tenance of homeostasis and the removal of obsolete cells. 
Defects in its induction and execution form the basis of 
many diseases, in particular, cancers such as leukaemia 
and lymphoma. Understanding the mechanisms and reg-
ulation of apoptosis is an area of research that has the 
potential to result in novel and improved therapies for 
these diseases. 
The sphingolipids are a diverse class ofeukaryotic lipids 
that have a structural function in cell membranes as well 
as playing a role as second messengers within the ce11. 1 
Ceramide, a second messenger generated from sphingom-
yelin by the activation of a sphingomyelinase, has been '- 
implicated in apoptosis induced by a broad range of apop-
totic stimuli, in particular by the ligation of the Fas or 
TNFa receptors." Whilst numerous studies have high-
lighted the potential role of ceramide in the regulation of 
Fas-mediated apoptosis 3-5 the proposal that ceramide is a 
primary initiator has been recently under strong scrutiny. 
Doubts as to the role of ceramide in initiating Fas apopto-
sis were initially cast by the findings that ceramide gener-
ation occurred downstream of caspase activation and was 
blocked by inhibition of CPP32.6,7 Subsequent findings 
that Fas treatment resulted in apoptosis without any de-
tectible changes in cellular ceramide species 7-9 and that 
a number of antagonists of apoptosis attenuated or pre-
vented ceramide, but not Fas, induced apoptosis7 ,8, 10-12  
has lead a number of authors to conclude that ceramide 
is not involved in the initiation of Fas apoptosis but 
rather may have a role in the amplification or execution 
phases. 1° • 11,13 
Nevertheless, the fact remains that exogenous short 
chain synthetic ceramides, such as C2-ceramide, initiate 
apoptosis in a number of cell lines 14 • 15 and recent reports 
have indicated that the mitochondria may be central in 
this phenomenon. Modulation of mitochondria function 
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by ceramide in mainly cell-free systems has been detailed 
in a number of studies. I6-19 However, the findings that 
ceramide induced the release of cytochrome c from isolated 
mitochondria2° and enhanced cytoplasmic cytochrome c 
levels prior to caspase activation21 • 22 raises the possibil-
ity that cytochrome c released to the cytoplasm can ac-
tivate caspases (in particular caspases-9 and -3) during 
C2 -ceramide-induced apoptosis. Such a mechanism would 
provide the link between ceramide signalling and execu-
tion caspases. 
The present study investigated alterations in mitochon-
drial transmembrane potential (6, cytochrome c 
content and caspase-3 activation that arise during C2- 
ceramide-induced apoptosis of Jurkat T cells, using in-
tact cells and direct visualisation in contrast to previously 
reported isolated organelles and subcellular fractions. 20-22 
We report that cells in the early phase of apoptosis have 
decreased Atlim that is preceded by mitochondrial release 
of cytochrome c with subsequent caspase-3 activation and 
conclude that the apoptogenic properties of C 2 -ceramide 
are primarily due to its interaction with the mitochondria. 
Materials and methods 
Cell culture and induction of apoptosis 
The Jurkat human T cell leukaemia cell line was main-
tained in RPMI 1640 media supplemented with 10% 
foetal calf serum, 2.0 mM L-glutamine and 120 Ag/mL 
gentamicin at 37 ° C in a humidified, 5% CO2 atmo-
sphere. Experimental procedures were performed in 
serum-free conditions at a cell density of 1 x 106 /mL. 
Apoptosis was induced either via the addition of 5 AM 
C2-ceramide (BioMol) dissolved in ethanol with controls 
treated with an equivalent volume of the vehicle, or by 
addition of 100 ng/ml anti-Fas antibody (CH-11, Upstate 
Biotechnology). 
Confirmation of apoptosis by Annexin 
V/PI staining 
Externalised phosphatidylserine residues were detected 
using the reagents and protocols from the Annexin V-
FITC Apoptosis Detection Kit II (PharMingen). Briefly, 
1 x 106 cells were pelleted, washed in cold PBS and re-
suspended in 500 AL Annexin binding buffer. A 100 AL 
aliquot (2 x 10 5 cells) was taken, 5 AL each of Annexin 
V-FITC and PI added and cells were incubated for 15 min-
utes at RT in the dark. 400 AL of binding buffer was added 
and samples were acquired on a FACScan flow cytome-
ter (Becton Dickinson) and analysed using CELLQuest 
software within 1 hour. 
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Detection of cytochrome c release 
Cytochrome c release was detected via immunohistochem-
istry as previously described 23 with minor modification. 
Briefly, treated cells were harvested, washed once in PBS 
and resuspended in PBS at a density of 2 x 10 6 /mL. 
100 AL of cell suspension (2 x 10 5 cells) plus 50 AL FCS 
was cytospun onto slides, fixed in 1:1 methanol/acetone 
for 2 minutes and air-dried. Fixed slides were incubated 
in 1:50 dilution of mouse anti-cytochrome c Ab (clone 
6H2.B4, PharMingen) in PBS/3% BSA for 2 hours at 
37 ° in a humidified chamber. Slides were washed 3 times 
in PBS for 5 minutes prior to incubation in 1:100 dilution 
of Alexa-488 conjugated goat anti-mouse secondary Ab 
(Molecular Probes) for 1 hour at RT in the dark. Slides 
were washed 3 times in PBS for 5 minutes and mounted 
using Permafluor aqueous mounting solution. Slides were 
analysed on a Leitz Dialux 22EB fluorescent microscope 
fitted with a 488 nm laser. A diffuse, homologous stain-
ing pattern was determined to be indicative ofcytoplasmic 
cytochrome c. Quantitative data was obtained by calculat-
ing the percentage of cells exhibiting cytochrome c release 
from 8 randomly selected fields per sample at 50x mag-
nification. Confocal microscopy images were also captured 
from the above mentioned slides at 100 x magnification 
via the use of an OptiScan Omnichrome Series 43 confocal 
microscope. 
Measurement of Atiirn alterations 
Alterations to the Tin were detected using the 
sensitive dye MitoTracker Red (Molecular Probes) and 
flow cytometry. 20 minutes prior to the conclusion of 
the incubation period, 500 AL (5 x 10 6 cells) was ex-
tracted and volume made up to 1 mL with serum free 
medium. 50 nM MTR was added and cells returned to 
37 ° C for the remaining 20 minutes. At the conclusion 
of the incubation period, cells were washed once in PBS 
and resuspended in 150 p.I Annexin V binding buffer. 
5 AL Annexin V-FITC was added and cells incubated for 
10 minutes at RT prior to the addition of 100 AL binding 
buffer and analysis via flow cytometry. 
Analysis of caspase -3 activation 
Intracellular detection of caspase-3 activation was per-
fo-rmed using the IntraStain Fix and Perm kit (Dako). 
Briefly, 1 x 106 cells were resuspended in 100 AL of fix-
ing reagent and incubated for 15 minutes at RT prior 
to the addition of 2 mL of PBS and centrifugation at 
300 g for 5 minutes. The cell pellet was resuspended 
in 100 AL permeabilising reagent plus 20 AL of PE-
conjugated anti-active caspase 3 Ab (Pharmingen) and 
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incubated for 15 minutes at RT in the dark. 2 mL PBS 
was again added and cells centrifuged as above. 300 pi of 
FACSFix was added and cells acquired immediately on a 
FACScan flow cytometer and analysed as describe above. 
Results 
C2-ceramide induces apoptosis of Jurkat T cells 
Externalisation of membrane phosphatidylserine residues 
is an early event in apoptosis and was visualised by double 
labelling of cells with Annexin V-FITC and Propidium Io-
dide (PI) with the stepwise transition from Annexin - /P1 
(viable) to Annexin+/PI- (early apoptotic) to Annexin+/ 
PI+ (dead) demonstrating apoptosis. Annexin V/PI stain-
ing of C2 -ceramide treated Jurkat cells shows that a sig-
nificant population of these cells become Annexin V+ 
within 2 hours of treatment (Figure 1). This population 
peaked at 4 hours post-treatment and, by 8 hours, many 
of these early apoptotic cells had progressed to PI + and 
had thus died. Anti-Fas mAb treated cells demonstrated 
a more dramatic and rapid transition to apoptosis whilst 
the majority of vehicle-treated cells remained viable. 
Ceramide induces cytochrome c release and caspase activation 
Reduced mitochondrial tI'm occurs only in cells 
with externalised phosphatidylserine residues 
following C2-ceramide induced apoptosis 
MitoTracker Red stains mitochondria in a A Wm-
dependent manner and when combined with Annexin 
V-FITC and flow cytometry, the A tlirn of the apoptotic 
population can be independently assessed. Following treat-
ment with C 2 -ceramide, flow cytometry plots were gen-
erated which depicted viable (Annexin V - ) or apoptotic 
(Annexin V+) populations of cells (Figure 2). After 
2 hours of C 2 -ceramide treatment, approximately 10% of 
cells were Annexin V+ and this population of apoptotic 
cells was readily observable by 3 and 4 hours post treat-
ment. Analysis of the MitoTracker Red fluorescence of this 
apoptotic population revealed that it was significantly re-
duced compared to the viable cells in that sample (p = 
0.002, paired t-test). This reduction was evident as early 
as 2 hours post addition of C 2 -ceramide and the statisti-
cal significance increased with the later timepoints. Im-
portantly, apoptotic cells in C 2 -ceramide-treated samples 
always had a significantly reduced A klim compared to the 
spontaneous apoptotic population in the time-matched 
controls. Thus cells in the execution phase of C 2 -ceramide 
Figure 1. Confirmation of the rapid onset of apoptosis in Jurkat T cells following treatment with ethanol vehicle, C2-ceramide or anti-
Fas antibody by demonstration of externalised phosphatidylserine residues. Apoptotic (Annexin+/P1 - ), dead (Annexin+/P1 -1- ) and alive 
(Annexin- /PI - ) populations are readily identified. A single representative result from 4 repeat experiments is shown. 
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Figure 2. Determination of changes in Atlim following treatment 
with C2-ceramide. Cells were loaded with the mitochondrial per-
meability dye, MitoTracker Red and apoptotic cells identified by 
Annexin V staining of externalised phosphatidylserine residues. A 
decrease in MitoTracker Red fluorescence is indicative of reduced 
Agirn. A single representative result from 6 repeat experiments is 
shown. 
C2-ceramide 
2 Hrs 
3 Hrs 
4 Hrs 
displayed intense punctuate cytoplasmic staining which 
is in agreement with its localisation in the mitochondria. 
After apoptosis initiation by C 2 -ceramide, the majority 
of cells exhibited homogenous and diffuse cytochrome c 
staining that is consistent with its translocation from the 
mitochondria to the cytoplasm. Quantitation of cells ex-
hibiting cytochrome c release following treatment with ei-
ther vehicle or C 2 -ceramide demonstrated that over 60% 
of C2-ceramide treated cells had released cytochrome c 
from their mitochondria to the cytoplasm as early as 
2 hours post-treatment compared to less than 10% of con-
trol cells (Figure 4). Taken together, these results clearly 
demonstrate that release of mitochondrial cytochrome c 
into the cytoplasm is an early event in C 2 -ceramide me-
diated apoptosis of Jurkat T cells. 
Activation of caspase -3 by C2 -ceramide 
Detection of effector caspase activation in Jurkat T cells 
during ceramide-mediated apoptosis was performed by 
probing cells that had been treated with either vehi-
cle, C2 -ceramide or anti-Fas mAb with a phycoerythrin-
conjugated antibody to the active form of caspase-3. 
C2-ceramide treatment caused activation of caspase-3 in 
Jurkat T cells as evidenced by a right shift in fluores-
cence (Figure 5). Activation of caspase-3 was very weak to 
negligible at 2 hours post-treatment with C 2 -ceramide, 
however more than 30% of C2-ceramide-treated cells had 
activated caspase-3 by 4 hours post-treatment. In com-
parison, negligible caspase-3 activation was observed in 
time-matched, vehicle- treated cells whereas Fas ligation, 
which is known to execute apoptosis via caspase-3, pro-
duced significant caspase-3 activation. This data clearly 
shows that activation of the effector caspase, caspase-3, 
occurs during C2 -ceramide-induced apoptosis. 
Discussion 
Annexin V - FITC 
induced apoptosis had reduced iWm relative to both in-
ternal and external controls. 
C2-ceramide induces release of cytochrome c 
from mitochondria 
To investigate whether C 2 -ceramide caused the release of 
cytochrome c from the mitochondria to the cytoplasm, 
the cellular localisation of cytochrome c was examined by 
confocal immunofluorescence microscopy (Figure 3). In 
untreated and vehicle-treated Jurkat cells, cytochrome c 
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The present study demonstrates that C 2 -ceramide initi-
ated apoptosis ofJurkat T cells is associated with an early 
release of mitochondrial cytochrome c with subsequent 
mitochondrial depolarisation and activation of effector 
caspases. This report strengthens the hypothesis that ce-
ramide signalling initiates apoptosis by directly targeting 
the mitochondria, leading to activation of distal caspases 
and hence cellular destruction. 
Recent investigations have highlighted the critical role 
of mitochondria in the apoptogenic processes (reviewed 
by 24,25 ). The release of cytochrome c from mitochondria 
into the cytoplasm is widely accepted as a critical and 
decisive initial event of chemically-induced apoptosis. 26 
This study has demonstrated, using direct visualisation 
by confocal immunofluorescence microscopy, that release 
• Vehick 
• C2-Ceraglide 
Ceramide induces cytochrome c release and caspase activation 
Figure 3. Cytochrome c release visualised by confocal immunofluorescence microscopy. Immunolocalised cybochrome c (green) is 
shown in untreated, vehicle-treated and C2-ceramide-treated Jurkat cells. Cells were incubated for 2 hours with the indicated reagents 
followed by harvesting and staining. A single representative result from 5 individual experiments is shown. 
Untreated Vehicle C2-ceramide 
41. 
Figure 4. Quantitation of cytochrome c release in Jurkat T cells 
after 2 hours treatment with vehicle or C2-ceramide. A change in 
the staining pattern from intense punctuate to diffuse homologous 
was determined to be indicative of release of cytochrome c from 
the mitochondria to the cytoplasm. Data was enumerated from 8 
randomly selected fields per sample. Result shown is the Mean ± 
SE of 5 individual experiments. 
0 	 2 
Time Post - Treatment (Hours) 
of mitochondrial cytochrome c into the cytoplasm occurs 
in the very early stages of apoptosis induction. More than 
60% of cells had released cytochrome c within 2 hours of 
C2 -ceramide treatment, at which timepoint phosphatidy-
lserine extemalisation and caspase-3 activation were non-
existent or only weakly present in around 10-20% of cells. 
This finding of ceramide-induced cytochrome c release us-
ing intact cells confirms recent studies that used isolated 
mitochondria2° or subcellular fractionation2I to demon-
strate this effect. Earlier studies 27 • 28 demonstrated that 
a 6 hour incubation with synthetic ceramide analogues 
increased the cytoplasmic concentration of cytochrome c, 
however, as apoptosis is well advanced by this timepoint 
it is impossible to state with certainty whether such accu-
mulation is a cause, or result, of apoptosis. By examining 
earlier timepoints and demonstrating cytochrome c release 
in cells yet to show signs of apoptosis, the present study 
overcomes the deficiencies of this previous work by show-
ing that cytochrome c release from the mitochondria is an 
early event in C2 -ceramide induced apoptosis. 
Reductions in A klim suggest that mitochondrial per-
meability has been compromised and that intermembra-
neal proteins such cytochrome c are released, however the 
relationship between A Wm, mitochondrial release of cy-
tochrome c and initiation of apoptosis is controversial with 
studies showing that cytochrome c release can occur before, 
A coincidentally, or independently of 4im. 19,20,23,26 The  
present study utilised a flow cytometry based assay that 
allowed the A Wm of cells that were in the early stages of 
apoptosis (i.e. Annexin V+) to be assessed independently 
of non-apoptotic cells, thus excluding the confounding 
effects of viable cells from the analysis. Externalisation 
of phosphatidylserine is characteristic of the execution 
phase of apoptosis and results from changes to plasma 
membrane phospholipid symmetry. 29 Our data showed 
that apoptotic cells had significantly reduced A Wm com-
pared to viable cells, however, it is apparent that re-
duced A Wm accompanies phosphatidylserine externali-
sation as decreased MitoTracker Red fluorescence was ob-
served only in Annexin V+ cells. Thus decreased A Wm is 
observed only in cells committed to the execution phase, 
which occurs post-activation of caspase-3. 3° Furthermore, 
given that more than 60% of cells exhibited released cy-
tochrome c, but only 10-20% had reduced A Wm, it can 
be concluded that cytochrome c release occurs prior to 
the collapse in A Wm and phosphatidylserine external-
isation during C2 -ceramide induced apoptosis, placing 
C2-ceramide-mediated cytochrome c release upstream of 
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Figure 5. Activation of caspase-3 in Jurkat T cells after treatment with C2-ceramide. The active form of caspase-3 was detected using a 
monoclonal antibody and flow cytometry. A right shift in PE fluorescence is indicative of active caspase-3. A PE positive region (bar) was 
established from the 0 hour control histogram and this region was transposed to all other histograms. The percentage of cells staining 
positive for active caspase-3 PE was established by determining the number of cells which exhibited PE fluorescence within this region. 
Cells incubated with anti-Fas antibody were used as a positive control to confirm the position of positive events. These histograms are 
representative of 4 separate experiments. 
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the execution phase. This contradicts a recent study which 
showed that reduced A klim occurred without cytochrome 
c release in C2 -ceramide treated Rat-1 fibroblasts31 despite 
evidence of PARP cleavage. However, given the lengthy 
exposure to high doses of ceramide (50 AM for 6 hours), 
and the somewhat low levels of apoptosis observed in that 
study (<50% after 12 hours), the sensitivity of the Rat-1 
cell line to ceramide-mediated apoptosis must be ques-
tioned. Our finding that C2 -ceramide induced cytochrome 
c release occurs prior to A xlim reduction is supported 
by others who utilised isolated mitochondria in cell-free 
systems. 19,2o  
Cytochrome c was released from coupled mitochondria, 
as the decrease in A Wm was observed after the event, a 
finding that is in keeping with other models of apoptosis. 
Reduced A Wm was not observed until after DNA frag-
mentation in staurosporine-treated HeLa cells 23 whereas 
exposure of cells to etoposide resulted in cytochrome c 
release that also preceded losses in A Wm. 31 Moreover, 
it is evident that C2 -ceramide-mediated cytochrome c 
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release does not require the opening of the mitochondrial 
permeability transition (MPT) pore, a dynamic multipro-
tein complex that is located at the contact site between the 
outer and inner mitochondrial membranes whose opening 
has been implicated in cell death induced by reactive oxy-
gen species, hepatotoxins, calcium and anoxia. 32 It is more 
likely that interaction between ceramide signalling and 
the Bc1-2 family is mediating the mitochondrial effects 
given the ability of Bc1-2 to inhibit C2-ceramide mediated 
cytochrome c release2° and the resistance of Bc1-2 over-
expressing cells to ceramide-induced apoptosis. 28 ' 33 The 
recent finding that cell-permeable exogenous ceramides 
induced downregulation of Bc1-2, increased the Bax/Bc1-2 
ratio followed by release of cytochrome c and activation 
of caspases-9 and -3 in C6 glioma cells 34 further supports 
this notion. 
Ceramide signalling appears to result in activation of 
distal caspases, such as caspases 9 and 3, but not the prox-
imal caspases (2, 8 and 10) thus placing sphingomyeli-
nase activation downstream of the proximal caspases with 
subsequent ceramide generation leading to activation of 
the distal caspases. 35 . 36 In the present study, C2-ceramide 
resulted in activation of the distal caspase-3, placing ce-
ramide signalling upstream of the effector caspases. Such a 
finding is supported by other studies 22 • 36 ' 37 and provides 
the link between ceramide signalling and the mechanical 
destruction of the cell as a result of apoptosis. It is well 
established that released cytochrome c activates caspase-9 
in concert with the cytoplasmic factors ATP and Apaf- 1 , 
and as a result, consequently activates caspase- 3. 38 In the 
present study, caspase-3 activation occurred at timepoints 
later than cytochrome c release and hence the caspase acti-
vation can be considered to be distal to the mitochondrial 
events. 
Conclusion 
Early studies into the mechanism of receptor-mediated 
apoptosis highlighted generation of ceramide as the sec-
ond messenger linking receptor activation and the initi-
ation of cell death. 2-5 However, that ceramide formation 
was dependent upon activation of proximal caspases, 39 
the failure of ceramide signalling to activate proximal 
caspases4° and the elucidation of the FADD/MORT1 
death domain signalling pathways 4I lead to the demise 
of this notion with several authors postulating that ce-
ramide generation was either an artefact or consequence 
of apoptosis rather than an initiator. 8-11 '42 
This study clearly demonstrates that ceramide activates 
the distal executioner caspases by causing the release of 
cytochrome c from the mitochondria to the cytoplasm of 
intact cells. When taken in concert with other studies 
which showed that Bc1-2 prevented apoptosis whilst not 
inhibiting ceramide generation 39 and that Fas-mediated 
Ceramide induces cytochrome c release and caspase activation 
ceramide generation occurred independently of the ef-
fector stage of apoptosis, 43 ceramide accumulation and 
signalling is clearly prior to the effector phase of apopto-
sis and proximal to the distal caspases. The generation of 
ceramide, whether by receptor-associated sphingomyeli-
nase,2 or membrane changes induced by chemotherapeu-
tic agents,44 ' 45 causes the activation of distal caspases, 
thus amplifying the response to the initial apoptotic sig-
nal. Ceramide-induced cytochrome c release is therefore 
an additional mechanism for caspase-3 activation, com-
plementary to the proximal caspases, which acts to ensure 
the death of the cell by distal caspases. 
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